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" Recognizing that we have the kind of internal environment we have 
because we have the kind of kidneys that we have, we must 
acknowledge that our kidneys constitute the major foundation of our 
physiological freedom... Superficially, it might be said that the function 
of the kidneys is to make urine; but in a more considered view one can 
say that the kidneys make the stuff of philosophy itself.” 
Homer W. Smith 
From Fish to Philosopher (1953) 
 
 
Plain language summary 
People with kidney disease are at greater risk of dying from infection than people without 
kidney disease. This study investigated the relationship between kidney disease and 
infections among older people with diabetes. I used anonymised healthcare records for 
219,145 patients, combined from primary care, admissions to hospital, and death 
certificate records.  
Older people with diabetes had frequent chest and urinary tract infections. Chest and 
bloodstream infections were more common among people with kidney disease. The 
relationship between kidney disease and frequency of infection was stronger for 
bloodstream infection than for chest infection. Protein in the urine marked an increased 
risk of infection separately from the other standard marker of kidney disease, the 
estimated filtering rate of the kidneys. 
In general, vaccines provide less protection for patients with kidney disease. A single ‘flu or 
pneumococcal vaccine did not seem to offer effective protection against the burden of 
chest infections for older people with diabetes, whether or not they had kidney disease. 
After being diagnosed with pneumonia or bloodstream infection, patients with severe 
kidney disease had a higher risk of dying than patients without kidney disease, but this did 
not seem to be true for patients with mild or moderate kidney disease. 
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Abstract 
This thesis describes the epidemiology of community-acquired infections among older 
people with diabetes without a history of renal replacement therapy, according to markers 
of chronic kidney disease (CKD): proteinuria and reduced estimated glomerular filtration 
rate (eGFR). The thesis uses linked electronic health records from primary and secondary 
care, and mortality records. 
Among a cohort of 219,145 patients with diabetes aged ≥65 years there was a high burden 
of community-acquired infection: lower respiratory tract infections (LRTIs) having the 
highest crude rate (152.7/1,000 years) followed by urinary tract infections (male 51.4, 
female 147.9/1,000 years). All-cause 28-day mortality was 32.1% for pneumonia (as a 
subset of LRTI) (3,115/9,697) and 31.7% for sepsis (780/2,461). Reduced eGFR was 
associated with a strong and graded increased risk of community-acquired LRTI, pneumonia 
and sepsis incidence, after adjustment for co-morbidities, smoking status and 
characteristics of diabetes mellitus. The effect sizes were larger for sepsis than pneumonia, 
and for pneumonia than LRTI. Proteinuria was a marker of increased risk of infection 
incidence independently of eGFR, for LRTI (rate ratio 1.07: 95%CI 1.05–1.09), pneumonia 
(1.26:1.19–1.33), and sepsis (1.33:1.20–1.47), after adjustment for co-morbidities, smoking 
status and characteristics of diabetes. 
Advanced CKD (eGFR<30ml/min/1.73m2) was associated with 28-day mortality following 
community-acquired pneumonia (risk ratio=1.27:95%CI 1.10–1.47) and sepsis 
(RR=1.42:1.10–1.84) compared to eGFR≥60 ml/min/1.73m2), adjusted for age, sex, socio-
economic status, smoking status and co-morbidities. Lesser reductions in eGFR and 
proteinuria were not associated with mortality.  
The protective effects of pneumococcal vaccine against community-acquired pneumonia 
appeared to wane swiftly. There was scant evidence for any impact of influenza vaccination 
against the total burden of community-acquired LRTI. 
This study allows patients, clinicians and public health planners to quantify infection risks 
among older people with diabetes according to CKD status. Further research could explore 
mechanisms and prevention strategies, including enhanced vaccination schedules.  
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SUS Secondary Uses Service 
TIA Transient Ischaemic Attack 
UK United Kingdom 
US United States of America 
UTI Urinary tract infection 
QOF Quality and Outcomes Framework 
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BACKGROUND SECTION  
This thesis uses routinely-collected electronic health records to investigate the 
epidemiology of acute, community-acquired infections according to markers of chronic 
kidney disease (CKD) prior to end-stage renal disease, among older people with diabetes 
mellitus.  
This Background section introduces the study question and sets out the thesis aims and 
objectives. Chapter 1 outlines the general background of acute, community-acquired 
infections as a cause of morbidity among older people, and the epidemiology of chronic 
kidney disease (CKD). The rationale for studying infections among older people with 
diabetes according to CKD status is presented and the aims and objectives of the thesis are 
described. 
Chapter 2 presents a systematic review of the association between CKD and community-
acquired infection incidence. 
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Chapter 1. General background  
1.1 Community-acquired infection in older age 
Community-acquired infections are common among older adults, causing a high burden of 
morbidity.[1-5] They are an important cause of mortality at older ages: pneumonia is the 
second commonest cause of death in people aged ≥75 years in England.[6]  
The UK population is ageing. The proportion of the UK population aged ≥65 years is 
predicted to rise from 17% in 2010 to 23% in 2035. The fastest increase has been among 
the ‘oldest old’. The number of people aged ≥85 years doubled from 0.7 million in 1985 to 
1.4 million in 2010, and is predicted to reach 3.5 million (5% of the UK population) by 
2035.[7]  
Hospitalisations for infection are rising even faster than the population is ageing: age-
standardised hospital admission rates for community-acquired pneumonia and urinary 
tract infections (UTIs) more than doubled between 2001/2001 and 2010/2011 in 
England.[8] The cost of hospitalisations was estimated at £235 million for pneumonia and 
£316 million for UTI in 2010/2011[8]. The increase in pneumonia hospitalisations has been 
most marked among older adults.[9] The driving factors behind this rise in admissions for 
community-acquired infections are not currently well understood but it does not appear to 
be purely due to lower thresholds for hospital  admission, as the rising incidence of 
community-acquired LRTI remains when diagnoses in primary and secondary care are 
combined.[5] Suggested explanations include population ageing among the ‘oldest old’, 
together with higher prevalence of co-morbidities such as diabetes mellitus.[8, 9] 
1.2 Chronic kidney disease 
1.2.1 Definition of chronic kidney disease 
Chronic kidney disease (CKD) is an impairment of kidney function or structure which 
persists for at least 3 months.[10] Kidney function is described by the glomerular filtration 
rate (GFR), the rate at which the glomerular capillaries in the kidney filter waste products 
such as creatinine. GFR is usually estimated from serum creatinine measurements adjusted 
for age, sex and ethnicity.[11, 12] Other evidence of kidney damage may include 
haematuria, structural abnormalities, or persistent protein in the urine (proteinuria). 
22
[23] 
 
Classification of CKD has since 2002 been based upon a 5-level staging of function (using 
two GFR estimations at least 3 months apart), and evidence of proteinuria.[13] 
Classification of CKD has evolved over the study period, and this is discussed in detail in 
5.1.1. The classification to which this thesis will refer most regularly is that recommended 
by the National Institute for Health and Care Excellence (NICE) in 2008, which was the 
dominant classification in UK clinical practice by the end of the study period (Table 1.1).[11]  
CKD may progress to kidney failure, which is usually treated with renal replacement 
therapy: either kidney transplant or dialysis, in which waste products are filtered and 
removed from the blood (haemodialysis) or via the peritoneal cavity (peritoneal dialysis). In 
2009, 2% of patients with CKD in England were receiving renal replacement therapy: of this 
group, approximately half were renal transplant recipients, with the majority of the rest 
treated with haemodialysis, and 8% with peritoneal dialysis.[14] Patients receiving renal 
replacement therapy are also referred to as having end-stage renal disease (ESRD).[13] In 
this thesis, the term end-stage renal disease will be used to identify patients receiving renal 
replacement therapy, and chronic kidney disease (CKD) will refer to patients with CKD not 
receiving renal replacement therapy, unless otherwise specified. 
Table 1.1: NICE 2008 classification of chronic kidney disease (CKD)  
CKD stage GFR1 Evidence of kidney damage also required2 
1 ≥ 90 Yes 
2 60-89 Yes 
3A 45-59  
3B 30-44  
4 15-29  
5 < 15  
Based on the National Institute for Health and Care Excellence 2008 guidelines[11] 
1. Glomerular filtration rate (ml/min/1.73m2) 
2. Persistent proteinuria, albuminuria or haematuria, or structural abnormalities 
1.2.2 Chronic kidney disease as a public health problem 
As CKD is usually asymptomatic until quite severe, it is often unrecognized, and estimates 
of prevalence vary. Estimates of the prevalence of CKD stages 3-5 among adults in England 
range from 4.3% to 8.5%.[15-18] This rises steeply with age: the 2009/2010 Health Survey 
for England identified stage 3–5 CKD among 29% of men and 35% of women aged ≥75 
years.[16] Other risk factors for CKD include female sex, hypertension, diabetes mellitus, 
smoking and overweight at a younger age, many of which are modifiable.[12, 19] Among an 
ageing population with a rising prevalence of diabetes mellitus and hypertension, the 
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prevalence of CKD may be increasing but this is difficult to distinguish from increasing 
diagnosis and recording.[20, 21]  
CKD is associated with a high burden of morbidity, mortality and health service use.[21, 22] 
The cost of CKD to the English NHS was recently estimated at £1.45 billion (1.3% of the 
total budget).[14] Even at early stages, CKD is associated with reduced quality of life, more 
frequent hospital admission and higher mortality compared to normal kidney function.[21, 
23]  
Older people with CKD are more likely to die of other causes than to develop end-stage 
renal disease.[22] Much of the burden of CKD is due to its association with non-renal 
adverse outcomes, such as cerebrovascular disease (causing stroke and cognitive 
impairment) and cardiovascular disease, which accounts for 58% of deaths among patients 
with CKD.[22-24]  
1.2.3 CKD and infections 
Infection is an important cause of morbidity and mortality among patients with ESRD. 
Patients with ESRD have higher rates of mortality caused by sepsis and pulmonary 
infections, and higher rates of infection-related hospitalisation, than the general 
population.[25-27] Among patients with ESRD in the US, the second commonest recorded 
cause of death after cardiac arrest is septicaemia.[28] 
The association between ESRD and infection is partly driven by renal replacement therapy, 
which carries specific risks for infection. For example, patients who have received a kidney 
transplant require life-long immunosuppressive medication, while dialysis necessitates 
vascular or peritoneal access which disrupts the cutaneous barrier to infection.[27] 
However, the side effects of treatment do not fully account for the burden of infection in 
ESRD: the HEMO study found that only 23% of infection-related hospitalisations among 
haemodialysis patients in the US were related to vascular access.[29]  It is possible that the 
association between CKD and infection is also present at earlier stages of CKD, prior to 
ESRD. 
Patient characteristics which pre-dispose to infection are associated with all stages of CKD, 
including older age, high prevalence of co-morbidities and exposure to infectious agents 
from frequent healthcare attendance.[27]  
Patients with ESRD and earlier stages of CKD are known to have a reduced response to 
some vaccinations. This is not only relevant as a risk factor for vaccine-preventable 
24
[25] 
 
infections, but also suggests that CKD may itself cause underlying impairment of the 
adaptive immune system which could increase incidence of infections in general even at 
early stages of CKD.[30, 31] A causal relationship between CKD itself and infection 
incidence or prognosis is plausible. There are multiple potential mechanisms for CKD to 
alter cell-mediated and humoral immune system function (such as malnutrition, 
hypoalbuminaemia, anaemia, complement loss, disrupted calcium regulation and vitamin D 
insufficiency, chronic renal inflammation, and immunosuppressive therapy for renal 
disease) which are not limited to patients receiving renal replacement therapy.[27, 32] 
Even at early stages, CKD is associated with a higher mortality rate than among the general 
population, part of which is attributed to infection, and with more frequent infection-
related admission to hospital.[33-35] Several expert narrative reviews have agreed that an 
association between CKD prior to ESRD and infection is plausible or even likely, but that the 
clinical epidemiology of such an association is insufficiently characterized to establish this 
at present.[27, 36-39] 
1.3 Diabetes mellitus 
Diabetes mellitus is a common endocrine disorder in which there is an insufficiency of, or 
resistance to, the hormone insulin, which regulates blood glucose levels. The estimated 
number of adults in England with diabetes mellitus was 3.1 million in 2010 and is predicted 
to rise to 4.6 million by 2030. Diabetes is more common among men, people with South 
Asian or Black ethnicity, and older adults. The estimated prevalence of diabetes among 
adults in England aged >75 years is 16.5% (95% CI 12.3–22.0%).[40]  
Diabetes is associated with considerable morbidity and mortality: at 50 years old, a 
diagnosis of diabetes reduces life expectancy by 6 years.[41] Diabetes causes 
macrovascular complications such as cardiovascular disease and stroke, and microvascular 
complications such as retinopathy and nephropathy (diabetic kidney disease). Diabetes 
accounts for approximately 10% of UK health spending, and this is forecast to rise to 17% 
by 2035/2036. The cost of treating diabetic complications is £7.7 billion, and predicted to 
increase to £13.5 billion by 2035/6.[42]  
1.3.1 Diabetes and CKD 
Diabetic nephropathy is a major cause of CKD: diabetes is the commonest cause of CKD 
among patients requiring renal replacement therapy.[43] Patients with diabetes may also 
experience other causes of renal disease. In total estimates of the prevalence of stage 3–5 
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CKD among adults with diabetes in the UK range from 18% to 31%.[44-46] Death from renal 
disease is three times more common among patients with diabetes than patients 
without.[41]  
1.3.2 Diabetes and infection 
Diabetes has long been believed to increase susceptibility to infection (and certain rare 
infections occur almost exclusively among patients with diabetes),[47] but the 
epidemiology of infection among patients with diabetes was until recently surprisingly 
under-determined.[47, 48] 
Diabetes is a risk factor for hospitalisation and mortality from infection.[41, 49, 50] This 
appears to be partly driven by an increased risk of hospitalisation and of death following 
infection onset.[50] However, an association between diabetes and infection diagnosed in 
primary care has also been observed among the general adult population, suggesting 
diabetes is likely to be a risk factor for infection incidence as well as severity.[50-52]  
The association between diabetes and infection may be modified by age. A large 
population-based case-control study in Denmark found that the relative risk of 
hospitalisation with pneumonia for patients with diabetes compared to people without 
diabetes was considerably stronger among patients aged <40 years (adjusted RR 3.21: 
95%CI 2.51–4.12) than those aged 65–79 (adjusted RR 1.22: 1.15–1.29) or ≥80 years 
(adjusted RR 1.11: 1.05–1.18).[49] Studies of risk factors for community-acquired infection 
among older adults have not been powered for precise estimates of infection incidence or 
risk ratios among the subgroup with diabetes.[53-57] Among older people with diabetes, 
data on the burden of infection from a community or primary care perspective, or risk 
factors for community-acquired infection, are scarce. 
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1.4 Thesis rationale, aims and objectives 
1.4.1 Thesis rationale  
Community-acquired infections are responsible for a large burden of morbidity and 
mortality among older people. This is a growing public health problem: not only is the UK 
population ageing, but hospitalisation rates for pneumonia and urinary tract infections are 
rising even after standardisation for age. One factor potentially driving the increasing 
incidence of infection-related hospitalisation could be the rising prevalence of co-
morbidities such as diabetes and CKD. 
CKD is common among older people, and in an ageing population the prevalence is 
expected to increase. Infection is an important cause of morbidity and mortality among 
patients with end-stage renal disease, and this is at least partly due to the 
immunosuppressive effects of renal replacement therapy. The majority of patients with 
CKD do not have, nor progress to, ESRD. Patients with earlier staged of CKD also have 
higher rates of infection-related hospitalisation and mortality than the general population. 
However, the precise relationship between CKD and infection is unclear.  
Older people with diabetes are an important population in which to understand the 
epidemiology of CKD and infection. Diabetes is a risk factor for infection-related 
hospitalisation and mortality. The population of older people with diabetes is large and 
growing, with a high prevalence of CKD. Any role of CKD in increasing infection risk among 
the diabetic population would be of clinical and public health significance.  
There are also epidemiological advantages to studying this population. Older age and 
diabetes are important a priori confounders of any association between CKD and infection: 
restricting the study population to older people with diabetes reduces confounding. 
Patients with diabetes are also regularly monitored for CKD, which should ensure 
reasonable ascertainment of CKD status from routinely-collected electronic health records. 
An observational study of the epidemiology of infections according to CKD status is not 
well-suited to establishing the precise mechanisms which underlie any causal relationship 
between CKD and infection – but studying a focused question may still lead to a better 
understanding of a causal relationship and potential underlying mechanisms for further 
research. Studying patients prior to ESRD excludes any association resulting purely from the 
immunosuppressive effects of renal replacement therapy. Studying community-acquired 
infections allows identification of any inherent association of CKD with infection separately 
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from increased infection resulting from frequent hospital attendance. Thorough 
adjustment for co-morbidities may also clarify whether any association exists 
independently of co-morbidities. 
Quantifying the risk of infection among older people with diabetes, overall and according 
to CKD status, would itself be valuable information for older people with diabetes and their 
clinicians, and also for planning health-care provision for this growing population, and 
health economics analyses of the impact of CKD.  
Identifying whether and to what extent early stages of CKD are associated with increased 
risk of infection incidence, or greater severity of infections, could help ensure efforts at 
preventing excess infection-related mortality are targeted appropriately. Given the 
generally reduced response to vaccination among patients with ESRD, it is particularly 
important to identify whether vaccines are effective at preventing common infections 
among patients with earlier stages of CKD.  
1.4.2 Aims and objectives 
Among a cohort of people aged ≥65 years with diabetes mellitus, and using large, linked 
electronic health records, this thesis aims to describe: 
 the incidence of, hospitalisation with and mortality from of acute community-
acquired infections that are common (urinary tract and lower respiratory tract 
infections) or severe (pneumonia and sepsis); and 
 the association between incidence of community-acquired infection and chronic 
kidney disease (excluding patients with a history of renal replacement therapy); 
and 
 pneumococcal and influenza vaccine effectiveness according to stage of chronic 
kidney disease (excluding patients with a history of renal replacement therapy); 
and 
 the association between short-term mortality following community-acquired 
infection and chronic kidney disease (excluding patients with a history of renal 
replacement therapy). 
The objectives are detailed in Table 1.2. 
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1.4.3 Organisation of the thesis 
The thesis comprises 11 chapters, which are grouped into Background, Methods, Results 
and Discussion sections. Chapter 1 introduced the study question, aims and objectives. 
Each thesis objective was addressed with a separate study, and Table 1.2 which sets out 
the objectives, may be used to navigate the thesis. A systematic review of the association 
between kidney disease and acute, community-acquired infections (objective 1) is 
presented in Chapter 2 to complete the Background section.  
The Methods section (Chapters 3–6) presents the general materials and methods used in 
common across the thesis objectives. Chapter 3 describes the data sources used in the 
study, and identification of the study population. Chapter 4 describes the methods used to 
identify episodes of infection and calculate infection rates. Chapter 5 describes the 
identification of chronic kidney disease. Chapter 6 describes the definition of covariates.  
The Results section (Chapters 7–10) contains research articles which present the study 
design and analysis, results and discussion specific to the particular study objective. 
Chapter 7 describes the incidence of community-acquired LRTI (including pneumonia), 
pneumonia (as a subset of LRTI), UTI and sepsis among older people with diabetes mellitus 
(objective 2). Chapter 8 presents estimates of the association between markers of CKD and 
incidence of LRTI (including pneumonia), pneumonia (as a subset of LRTI) and sepsis among 
older people with diabetes (objective 3). Chapter 9 explores the effectiveness of 
pneumococcal vaccine to prevent community-acquired pneumonia, and influenza vaccine 
against community-acquired LRTI, and whether this varies according to CKD status 
(objective 4). Chapter 10 describes the association of markers of CKD with all-cause short-
term mortality following infection (objective 5). 
Finally, the Discussion summarises the main results of each study, considers the 
overarching strengths and weaknesses of the thesis as a whole, and suggests implications 
of the findings for clinical practice and future research (Chapter 11). 
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Chapter 2. Systematic review of the association between 
chronic kidney disease and infection incidence 
2.1 Introduction to Paper 1 
This paper was published in BMJ Open and presents a systematic literature review of the 
association between chronic kidney disease and four acute, community-acquired 
infections: lower respiratory tract infection, urinary tract infection, central nervous system 
infection, and sepsis.  
Fourteen studies were identified, all consistent with a positive association between CKD 
and infection risk. Considerable heterogeneity precluded meta-analysis, and most studies 
gave cause for concern about study quality. A few large, high-quality studies found a 
graded association between CKD and risk of hospitalisation with infection. Other than 
these, there was a scarcity of high-quality studies on this research topic, and in particular a 
lack of data on the relationship between proteinuria and infection incidence independently 
of glomerular filtration rate. There were few data available on the association of CKD with 
infection incidence using less severe outcome measures than hospitalisation, and thus it 
was not possible to identify an effect on susceptibility to infection separately from an effect 
on the severity of infection. 
The study search terms and the detailed inclusion criteria and study quality assessment 
referred to in the article as supplementary material are available in this thesis as Appendix 
A.  
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ABSTRACT
Objective: A systematic review of the association of
predialysis chronic kidney disease (CKD) with the
incidence of acute, community-acquired infections.
Design: We searched the MEDLINE, EMBASE and
Cochrane databases (inception to 16 January 2014) for
studies analysing the association of predialysis kidney
disease with the incidence of acute, community-
acquired urinary tract infection (UTI), lower respiratory
tract or central nervous system infections or sepsis.
Studies were required to include at least 30
participants with and without kidney disease.
Setting and participants: Community-based
populations of adults in high-income countries.
Outcome measures: Acute, community-acquired
UTI, lower respiratory tract or central nervous system
infections or sepsis.
Results: We identified 14 eligible studies. Estimates
from two studies lacked 95% CIs and SEs. The
remaining 12 studies yielded 17 independent effect
estimates. Only three studies included infections
managed in the community. Quality assessment
revealed that probable misclassification of kidney
disease status and poor adjustment for confounding
were common. There was evidence from a few large
high-quality studies of a graded association between
predialysis CKD stage and hospitalisation for infection.
One study found an interaction with age, with a
declining effect of CKD on infection risk as age
increased. There was evidence of between-studies
heterogeneity (I2=96.5%, p<0.001) which persisted in
subgroup analysis, and thus meta-analysis was not
performed.
Conclusions: Predialysis kidney disease appears to be
associated with increased risk of severe infection.
Whether predialysis kidney disease increases the
susceptibility to infections and whether age modifies
this association remains unclear.
INTRODUCTION
Chronic kidney disease (CKD) is common,
and its prevalence is increasing.1 Infection is
a major cause of mortality in end-stage renal
disease (ESRD) and hospitalisation at all
stages of CKD. The second commonest cause
of death among patients with ESRD in the
USA is septicaemia, and patients with ESRD
are at increased risk of death from infection
compared to the general population.2–4
Patients with ESRD and predialysis CKD in
the USA are at higher risk of hospitalisation
for infection than the general population.2 5 6
Predialysis CKD has been found to increase
mortality among patients hospitalised with
infections.7
Increased mortality and hospitalisation
from infection could be driven by increased
severity of infection, that is, once an infection
is present, the course of the associated illness
is more severe, or increased incidence, that is,
CKD may make people more susceptible to
develop an infection. Patients with CKD
display impaired host immunity: reduced vac-
cination responsiveness is observed at all
stages of CKD.8
Among patients with ESRD, aspects of dialy-
sis, such as vascular and peritoneal access for
dialysis, may be a risk factor for infection inci-
dence and severity. However, this does not tell
the whole story, and only 23% of infection-
related hospitalisations among patients
undergoing haemodialysis in the USA were
identiﬁed as related to vascular access in the
Strengths and limitations of this study
▪ This study used a sensitive search strategy, with
a broad definition of kidney disease, for a thor-
ough and inclusive search.
▪ Study quality was assessed using a tool adapted
to observational studies, providing a transparent
assessment of the risk of a range of biases for
each study.
▪ Between-study heterogeneity and the low quality
of many of the studies limit the interpretation of
results of the studies currently available.
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HEMO study.9 Risk factors for infection identiﬁed among
patients with ESRD which are not related to renal
replacement therapy, and could apply at all stages of pre-
dialysis CKD, include: the causes and treatment of kidney
disease; comorbidities; reduced vaccine effectiveness;
and high levels of exposure to healthcare facilities.10
If there is an increased risk of infection incidence at
early stages of CKD, this would affect a large and growing
number of patients. Awareness and quantiﬁcation of this
risk could have beneﬁts for patient management, more
effective vaccination strategies and healthcare planning.
Narrative reviews have concluded that it is likely that
CKD in itself increases infection incidence, but reported
a lack of evidence.10–12 We are not aware of any relevant
systematic literature reviews of the effect of CKD on
infection incidence.
This review sought to assess systematically whether pre-
dialysis CKD is a risk factor for the incidence of acute,
community-acquired urinary tract infection (UTI), lower
respiratory tract infection (LRTI), central nervous
system (CNS) infection or sepsis, among community-
based adults in high-income countries.
METHODS
Data sources and searches
One reviewer (HIM) searched the MEDLINE and
EMBASE databases, and the Cochrane library, from
inception to 16 January 2014. The search strategies com-
bined text words and MeSH terms for three concepts:
acute community-acquired infection (sepsis, UTI, LRTI
or CNS infection), kidney disease and relative risk. We
used search terms to identify studies among adult
humans in high-income countries (according to the
World Bank classiﬁcation),13 and limited the search to
articles in English, French or German. The full strategies
are available in online supplementary tables S1–S3.
We searched the reference lists of all included studies
and any pertinent review articles to identify further eli-
gible studies.
Study selection
One reviewer (HIM) screened titles and abstracts,
reviewed the full text of identiﬁed studies and made
initial decisions on eligibility according to prespeciﬁed
inclusion criteria (see online supplementary table S4).
Any borderline cases were discussed between HIM, DN
and SLT. A second reviewer (DN) checked a sample of
100 abstracts, selected randomly after de-duplication of
records, and a κ statistic was calculated to describe
agreement in the selection of studies.
Eligible studies analysed the effect of predialysis kidney
disease on the relative risk of at least one of the four spe-
ciﬁed acute, community-acquired infections among
community-based adults in high-income countries. We
excluded study populations managed in secondary care
(unless for kidney disease), routinely treated with immu-
nosuppressants, or exclusively of pregnant women, as
these groups have a raised risk of infection, and the rela-
tionship of CKD to infection risk may be different among
these groups compared to that in the general adult popu-
lation in primary care. Ascertainment of CKD, as a silent
disease, and, to a certain extent, ascertainment of acute
community-acquired infections are dependent on high
levels of monitoring and good access to healthcare, so we
restricted our search to high-income countries. Chronic
infections such as tuberculosis were not included, as the
relationship between CKD and chronic infection is very
likely to differ from that between CKD and acute infec-
tions, which was our focus in this review.
To maximise the sensitivity of our search strategy, we
accepted a wide range of deﬁnitions of kidney disease,
including: medical diagnosis of kidney disease, reduced
estimated glomerular ﬁltration rate or creatinine clear-
ance, elevated creatinine, proteinuria, microalbuminuria
or macroalbuminuria and renal structural abnormalities.
We also accepted deﬁnitions which included some
patients with ESRD among the patients with CKD, but
excluded deﬁnitions which were exclusively patients
receiving renal replacement therapy.
Outcomes of interest were relative risk estimates of acute
community-acquired LRTIs, UTIs, CNS infections or sepsis.
We accepted outcomes describing incidence of severe
infections (such as hospitalisation with pneumonia).
We restricted our search to published studies which
were sufﬁciently large to include at least 30 participants
with and without kidney disease, to allow reasonable pre-
cision of the study estimate. Detailed eligibility criteria
are listed in online supplementary table S4.
Data extraction and quality assessment
Data were extracted from relevant studies using a prespe-
ciﬁed collection form. Study characteristics extracted
included study design, data source, any participant
exclusion criteria, number of participants, age, gender,
baseline renal function, deﬁnition of renal impairment
and deﬁnition of the outcome infection. An estimate of
relative risk (rate ratio, risk ratio or OR) with any mea-
sures taken to address confounding was extracted from
each eligible independent analysis in each study. Studies
with no CIs and for which the SE was not calculable
from the data presented were included in the review but
not considered for meta-analysis.
When multiple estimates were available from a study
but were not independent, a single estimate was identi-
ﬁed for potential meta-analysis by selecting the estimate
best adjusted for confounding, using the most recent
data, comparing the level of CKD most common in the
general population with no CKD.
Study quality was assessed using a prespeciﬁed tool
adapted from Higgins et al14 for observational studies.
Studies were assigned a high, low or uncertain risk of each
of the following: selection bias, non-differential measure-
ment error for exposure and outcome, information bias in
exposure and outcome, confounding and reverse caus-
ation. The minimum requirement for a low risk of bias
2 McDonald HI, Thomas SL, Nitsch D. BMJ Open 2014;4:e004100. doi:10.1136/bmjopen-2013-004100
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from confounding was appropriate management of con-
founding by age, sex and diabetes. The speciﬁc criteria
used are detailed in online supplementary table S5.
Data synthesis and analysis
The relationship between CKD and UTIs was considered
likely to differ from that of CKD to other infections, due
to potential reverse causality. For example, repeat UTIs
may cause kidney disease, or structural kidney disease
may be identiﬁed through investigation of repeat UTIs.
Therefore, in all quantitative analysis, UTIs were ana-
lysed separately from other infections.
Estimates were examined for heterogeneity using
Cochran’s Q statistic and the I2 statistic as described by
Higgins et al.15 If I2 was less than 50% and Cochran’s Q
statistic p≥0.1, ﬁxed-effects meta-analysis was considered
for each of the two categories (UTI and other infections).
Funnel plots were constructed to look for publication
bias. All analysis was conducted using STATAV.12.0.
RESULTS
The database searches identiﬁed 10 380 citations, of
which 1204 were duplicates (ﬁgure 1). Both reviewers
had 100% agreement on which studies to extract for full-
text analysis from screening a random sample of 100
abstracts (Cohen’s Κ=1).
We identiﬁed 14 eligible studies, with varying study
characteristics (table 1). Four studies were case–control
studies,16–19 and 10 were cohort studies.20–29 Seven
studies investigated a range of risk factors for infec-
tion,16–19 21 28 29 two studies reported the effect of CKD
on infection as a confounder of the effect of interest24 25
and ﬁve studies investigated the effect of CKD on infec-
tion risk as their primary research question.5 20 22 26 27
Seven studies were based among the general popula-
tion.5 16 19 21 23 28 29 Other study populations included:
attendants at a specialist renal clinic,22 patients with
diabetes mellitus,25 patients admitted to hospital for
an acute cardiovascular event or an arterial revascularisa-
tion procedure,24 and the Navajo Nation—a population
which experiences 3–5 times higher rates of invasive
pneumococcal disease than the general US population.17
The population of the cohort studies in Calgary,
Canada comprised adults with a serum creatinine test
result available in their medical records.26 27 There is
some overlap in the study populations of these two cohort
studies: residents aged over 65 years with a serum creatin-
ine measurement between 1 July 2001 and 31 December
2001 and also between 1 July 2003 and 30 June 2004
would have been included in both studies for the period
from the second creatinine measurement until 31
December 2004.26 27
Figure 1 Flow chart of study
selection. *Common examples of
ineligible studies returned by the
database searches included:
studies in which renal failure and
infection were both outcomes,
studies in which renal failure and
infection were both exclusion
criteria, studies of acute renal
failure resulting from sepsis or
antibiotic use, studies of chronic
infections (e.g. hepatitis C, BK
viraemia, tuberculosis) following
organ transplantation, descriptive
studies of UTIs, descriptive
studies of CKD, studies of
predictors of prognosis among
patients with infections, and
review articles without any
original data.
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Deﬁnitions of kidney disease included medical diagno-
ses of chronic renal disease, elevated creatinine levels,
impaired creatinine clearance and structural abnormalities
of the kidney. Five studies excluded patients with ESRD,
and one speciﬁed the number included, but for the
remaining eight studies it was unclear how many of the
included patients received renal replacement therapy
(table 1).
Three studies recorded infections diagnosed in
primary care or outpatients,16 19 29 two recorded infec-
tions identiﬁed from a positive culture result,17 26 one
included infections diagnosed in the emergency depart-
ment,18 seven required hospital admission for infec-
tion5 21 23–25 27 28 and for one study the deﬁnition and
severity of infection was unclear.22
For two studies, the results extracted had no CI or SE
and these could not be calculated from the reported
data. From the remaining 12 studies, 17 independent
effect estimates with SEs were available for meta-analysis,
among which UTI was the outcome in three estimates.
For all infections, there was strong evidence of consider-
able heterogeneity (Cochran’s Q statistic p<0.001,
I2=96.5%). This persisted when estimates for UTIs were
excluded (p<0.001, I2=97.2%), when considering LRTIs
alone (p<0.001, I2=98.2%), when limited to cohort studies
(p<0.001, I2=97.3%), and when stratiﬁed by exclusion of
patients with ESRD (ESRD excluded, p<0.001, I2=88.9%:
ESRD not excluded p<0.001, I2=97.2%). Owing to this het-
erogeneity, meta-analysis was not performed.
All results are displayed in the Forest plot (ﬁgure 2).
Despite the quantitative heterogeneity, the results were
qualitatively similar: all estimates were compatible with a
positive association between kidney disease and infec-
tion. The four studies which compared different stages
of CKD found a graded association of increased risk of
infection with more severe CKD. All four of these
studies excluded patients with ESRD.22 23 26 27 One
study found that the effect of CKD on infection risk was
modiﬁed by age, with a declining effect of CKD on
infection risk as age increased.27 This effect was consist-
ent with the lower effect of CKD on UTI incidence
found among 86–90 year-olds (0.90, 95% CI 0.50 to
1.77) compared with an adult study population with a
mean age of 66 years (1.50, 95% CI 1.10 to 1.90).25 29
The funnel plot was sparsely populated, with widely
scattered effect estimates, and provides no clear evi-
dence for or against publication bias (see online supple-
mentary ﬁgure S1).
Study quality was variable. Relying on routine medical
diagnosis introduced a potential source of misclassiﬁca-
tion of kidney disease status for seven studies.5 16–19 21 24
There was variable adjustment for confounding, from
unadjusted crude estimates to estimates adjusted for a
range of comorbidities, demographic and socio-
economic factors. Six studies did not meet this review’s
minimal requirements.19 21 22 25 28 29 The summarised
results are displayed in table 2, and the full quality
assessment is in online supplementary table S5.
DISCUSSION
Our comprehensive search strategy identiﬁed 14 studies
describing an association between kidney disease and
acute community-acquired infection. Although between-
study heterogeneity precluded meta-analysis, all studies
were consistent with a positive direction of association.
Four studies which reported estimates on more than one
category of kidney disease found a graded association in
which risk of infection increased with greater severity of
CKD. These four studies excluded patients with ESRD,
and three were at low risk of bias in all categories of
quality assessment.22 23 26 27
To the best of our knowledge, this is the ﬁrst review to
address this research question systematically. We used a
sensitive search strategy, with a broad deﬁnition of
kidney disease, for a thorough and inclusive search. The
results are consistent with the conclusion of previous
narrative reviews: that an association between CKD and
infection incidence is likely, but that there is a paucity of
evidence.10–12
Heterogeneity between the studies precluded a
meta-analysis of results. Variable study designs and biases
may have contributed to the heterogeneity: for example,
the four case–control studies calculated ORs, which may
differ from equivalent rate ratios for common infec-
tions.16–19 Failure to control the confounding effects of
age, sex and diabetes would be likely to result in overesti-
mation of the effect of CKD on infection. Non-
differential misclassiﬁcation of kidney disease status in
studies which relied on routine medical diagnosis would
be expected to underestimate the effect of CKD on
infection risk. In general, the risk of ascertainment bias
from increased monitoring for infection among patients
with CKD is probably low, although one study assessed
risk factors for hospitalisation with inﬂuenza during an
inﬂuenza pandemic, in which context patients with
inﬂuenza-like symptoms may have been more likely to
be tested for inﬂuenza A(H1N1) if they also had CKD.21
The heterogeneity may reﬂect true differences in
effect size between the studies.
First, the studies considered a range of outcomes.
CKD may have a different effect on the incidence of dif-
ferent infections. For all but three studies, detection of
infection required either hospital attendance for the
infection or a positive blood culture. CKD may affect
severity of infection, as an alternative, or in addition to
any effect on infection incidence. CKD may also increase
the probability of hospital admission for management of
a moderately severe infection. Either would result in a
larger effect of CKD on the risk of severe infectious out-
comes (such as hospitalisation for sepsis) than on less
severe infections (such as community-diagnosed LRTI),
and could result in the graded association we observed,
with increasing hospitalisation for patients with more
severe stages of CKD.
Second, the studies included a variety of deﬁnitions of
kidney disease. For example, proteinuria (and renal loss
of complement) may represent a separate mechanism
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for risk of infection than uraemia. For the nine studies
which did not exclude patients with ESRD, it is unclear
to what extent the results reﬂect the effect of treatments
associated with dialysis, such as vascular or peritoneal
access for dialysis, on infection incidence.
Third, the association of CKD with infection may be
modiﬁed by age. James et al observed a weaker associ-
ation of CKD with hospitalisation for pneumonia as age
increased. They suggested that such an observation
could be explained by a lower baseline rate of hospital-
isation for pneumonia among younger adults, the
natural decline in renal function by age, and inaccuracy
in the estimation of renal function using the
Modiﬁcation of Diet in Renal Disease (MDRD) study
equation in older populations.27 As their study popula-
tion included only adults who had had a creatinine test
result, reasons for testing creatinine could also be rele-
vant confounders. As age increases, more comorbidities
accrue which require creatinine tests to guide therapy.
Hence, younger people who receive a creatinine test
may be at an unusually high risk for infections and CKD
due to the reasons associated with getting a creatinine
test. A real age-dependency of the CKD-infection associ-
ation would be consistent with the lower effect of CKD
on UTI incidence found among 86–90-year-olds (0.90,
95% CI 0.50 to 1.77) compared with an adult study
population with a mean age of 66 years (1.50, 95% CI
1.10 to 1.90). However, it may be that the study among
the older adults measured a less severe outcome, and
CKD may be associated with other factors that eventually
lead to hospitalisation for UTI.25 29
CKD was not a component of the primary study ques-
tion for nine of the 14 studies; thus, there is a risk that
this association may have been reported and published
only when CKD was found to be a risk factor for infec-
tion or an important confounder of another relation-
ship. This would result in selective reporting bias, with a
subsequent overestimation of the association of CKD
with infection risk. This bias would be expected to affect
smaller studies to a greater extent, and a funnel plot
might show an asymmetry of relative risk estimates about
the central pooled estimate among smaller studies. The
sparsely populated funnel plot (see online supplemen-
tary ﬁgure S1) provides no clear evidence for or against
selective reporting bias, but some evidence of selective
reporting bias comes from within the individual studies.
For example, the crude HR for the association of cre-
atinine clearance with UTI incidence is reported in
Figure 2 Forest plot of all estimates of the association of chronic kidney disease with infection (n=17) from all 14 studies
identified. The estimates from Higgins 1985 and USRDS 2010 did not include SEs. Dalrymple 2012: presented estimates
compare eGFR 45–59 with eGFR ≥90 mL/min/1.73m2; James 2009: presented estimates compare eGFR 45–59 with eGFR 60–
104 mL/min/1.73m2; James 2008: presented estimates compare eGFR 45–59 with eGFR≥60 mL/min/1.73m2. eGFR, estimated
glomerular filtration rate; ESRD, end-stage renal disease; USRDS, US Renal Data System; UTI, urinary tract infection.
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Caljouw et al29 (0.9, 95% CI 0.5 to 1.7), but as creatinine
clearance was not found to be signiﬁcant in the multi-
variable model, the adjusted association is not reported.
The overlap in the study populations of the two large
cohort studies based in Calgary, Canada could result in
more similar estimates than if the study populations
were independent.26 27 Outcomes in the two studies are
likely to be correlated with each other: hospitalisation
with pneumonia could cause a positive blood culture,
which would result in one infection being included as
an outcome in both studies. This is unlikely to have a
large effect, particularly in the qualitative assessment of
the combined evidence, as the potential overlap of
person-time is limited.
Although we excluded study populations routinely
treated with specialist medication (unless for kidney
disease), some study populations may have been at
higher risk of infection than the general population,
and this may have affected the relationship of CKD to
infection. For example, the cohort of patients admitted
for an acute cardiovascular event or an arterial revascu-
larisation procedure will have had a higher prevalence
of comorbidities (such as diabetes) than the general
population and excluded patients with severe comorbid-
ities who did not survive an acute cardiovascular event,
or who were not ﬁt enough to undergo the procedure.24
Each of the selected study populations limits the gener-
alisability of the individual study result, but the qualita-
tively similar ﬁndings across the variety of study
populations, and their qualitative consistency with the
studies based among the general population,5 16 19 21 23 28 29
support a positive association between CKD and infec-
tion risk in a variety of study populations.
A few large, high-quality studies which excluded
patients with ESRD have found a graded association
between predialysis CKD and risk of hospitalisation with
infection. All studies identiﬁed in this review were com-
patible with a positive association of CKD with increased
infection risk. There are little data available on the asso-
ciation of CKD with infection incidence using less severe
outcome measures than hospitalisation, and it is not pos-
sible in most studies to distinguish an effect on suscepti-
bility to infection from an effect on the severity of
infection.
The potential age-dependency of the relationship
between CKD and infection is intriguing and needs
further research. Also, there is currently no evidence on
the relationship between proteinuria and infection inci-
dence independent of the glomerular ﬁltration rate.
Future studies should identify infections in the commu-
nity in addition to hospitalisations for infection, charac-
terise the association of proteinuria adjusted for the
glomerular ﬁltration rate, explore the age-dependency
of the association and assess vaccine efﬁcacy among
older people with CKD.
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Table 2 Summary of risk of bias within studies (quality assessment tool adapted from Higgins et al14)
Selection bias:
control selection
Selection
bias:
participation
Selection bias:
loss to
follow-up
Non-differential
misclassification:
exposure
Information
bias: exposure
Non-differential
misclassification:
outcome
Information
bias: outcome Confounding
Reverse
causation
Case–control studies
Vinogradova et al16 NA
Watt et al17 NA
Loeb et al18 NA
Schnoor et al19 NA
Cohort studies
Higgins22 NA NA
Hackam et al24 NA NA
Dalrymple et al23 NA NA
Karunajeewa et al25 NA NA
James et al26 NA NA
James et al27 NA NA
Wang et al28 NA NA
Caljouw et al29 NA NA
Campbell et al21 NA NA
USRDS 201020 NA NA
Key to table 2.
Low risk of bias
Uncertain risk of bias
High risk of bias
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METHODS SECTION 
In this section, Chapter 3 describes the data sources used in the study and identification of 
the study population, Chapter 4 presents the methods used to identify episodes of 
infection and calculate infection rates, Chapter 5 describes the identification of CKD, and 
Chapter 6 provides detailed definition of all other variables used in analyses.  
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Chapter 3. Data sources and study population 
3.1 Use of electronic health records for epidemiological 
research 
Primary care in the United Kingdom (UK) is comprehensively computerised.[58] Clinicians 
record consultations and diagnoses directly into electronic clinical management systems, 
and prescribe electronically. Laboratory test results are increasingly reported electronically. 
The UK National Health Service (NHS) is free at the point of care for all UK residents, and 
provides near-universal coverage: 99% of the population are registered with a General 
Practitioner in primary care, and patients register with each practice for an average of 12 
years.[59, 60] Once these electronic patient records have been collected, anonymised and 
aggregated into large administrative databases, they permit large observational studies 
with a dataset rich in detail, with long follow-up based among the general population.[61] 
As with any secondary data analysis, care must be taken in interpretation.[62] It is 
important to assess data quality, including completeness and accuracy.[63] Appropriate 
data handling and interpretation require an understanding of the context within which the 
data were generated.[64] Secular trends in electronic health records may reflect changing 
epidemiology, patient health service use, clinical practice or recording patterns. In 
particular, the Quality and Outcomes Framework (QOF), introduced 1 April 2004, financially 
incentivised electronic recording of certain outcomes in primary care to demonstrate the 
achievement of ‘pay for performance’ indicators.[65] 
Data linkage offers the opportunity to combine the advantages of different datasets: for 
example, to capture co-morbidities recorded in primary care, while identifying time in 
hospital from secondary care records.[63] This study used a large database of anonymised 
electronic health records from primary care in the UK, with linkages to secondary care, 
mortality and socio-economic status datasets. 
3.2 Primary care data from the Clinical Practice Research 
Datalink 
Primary care data were obtained from the Clinical Practice Research Datalink (CPRD). CPRD 
contains data continuously recorded from 1987 under its previous incarnations, Value 
Added Medical Products Ltd (VAMP) and the General Practice Research Database 
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(GPRD).[66, 67] Data were extracted in May 2011, when CPRD contained data for 
12,808,177 patients at 627 practices across the UK.[68, 69]  
The CPRD population has been found to be representative of the general UK population in 
terms of sex and age structure, with some under-representation of single-GP practices, and 
of practices in inner London.[67]  
3.2.1 CPRD data collection 
All participating practices use VISION Practice Management software. Events in primary 
care are recorded directly by the healthcare practitioner. Information recorded includes 
patient demographics and registration dates, consultation dates and diagnoses, lifestyle 
information (e.g. smoking status), clinical details (e.g. blood pressure), test results, 
prescriptions, and interactions with secondary care (e.g. referrals, discharge 
summaries).[69] Diagnoses are encoded contemporaneously by the healthcare practitioner 
using the Read coding system, the national standard.[70] General practices submit 
anonymised records for all registered patients to the central database.  
3.2.2 CPRD data quality 
CPRD checks data quality indicators by general practice and for individual patient 
records.[66, 67, 69] Specific requirements for data quality from each primary care practice 
have altered over time, but are based on markers of continuity of recording and a recorded 
mortality rate within predicted parameters. Each practice is considered ‘up-to-standard’ for 
the latest continuous period of time during which the practice records have met the quality 
and continuity standards.[66, 67, 69] Quality requirements for individual patient records 
include a valid gender, year of birth, reason supplied for any transfer out from the practice, 
and permanent registration. Only patients with acceptable records are included in the 
database made available to researchers. The commonest reason for rejecting a patient’s 
record is temporary registration.[69] In May 2011, when the data for this thesis were 
extracted, all CPRD practices were ‘up-to-standard’ and 11,287,981 (88.1%) of the patients 
had acceptable records.[68]  
One well-recognised quality issue is the over-estimation of incidence rates in the initial 
period following a patient’s registration with the practice. Disease symptoms may lead 
some patients to register with a new practice, biasing observed incidence rates upwards for 
the time shortly after registration. In addition, pre-existing co-morbidities or past major 
medical events are often entered without distinction from new diagnoses, during the early 
patient visits in which previous medical history is established. Lewis et al. found that this 
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increased incidence rate following new patient registration returned to baseline within 6 
months for most acute conditions (including pneumonia), and within a year for most 
chronic conditions (including diabetes mellitus).[71]  
A 2010 systematic review of validation studies in CPRD found 357 validations for 183 
diagnoses. Most studies estimated the positive predictive value of a CPRD diagnosis (the 
proportion of cases recorded in CPRD which represented true cases) by requesting 
confirmation from the patient’s GP. Estimates of positive predictive value of a diagnosis in 
CPRD were generally good: the median proportion of cases confirmed by validation was 
89% (range 24-100%). Fewer studies calculated sensitivity (the proportion of true cases 
identified as such in CPRD) or specificity (the proportion of patients without a disease 
correctly identified in CPRD as non-cases), but those that did found high validity for the 
diagnoses studied.[72] Disease rates in CPRD have been compared against other UK 
sources for 99 different diagnoses, including diabetes, pneumonia, chickenpox and asthma, 
providing some indirect support to claims of both good validity of recorded diagnoses and 
representativeness of the CPRD population to the UK.[72]  
3.2.3 CPRD data structure 
Data are recorded as a combination of free-text and coded data. For reasons of patient 
confidentiality, information entered as free text is not routinely available.[66] These may 
include comments on encoded material, or longer communications such as letters to or 
from secondary care. The essentials of longer free-text communications, such as conditions 
diagnosed in secondary care, may also be entered as encoded records.[69] 
Data are available in a set of files, sorted by type of information (Table 3.1). Prescriptions 
are recorded in the therapy file. These are encoded using the Multilex product coding 
system, and also contain the BNF chapter for the prescription. CPRD provide a dictionary of 
medication product codes (“the CPRD Product Browser”), which may be searched by drug 
name and BNF code. Immunisations are recorded in the immunisation file using product 
codes and a CPRD variable labelled “immstype” which also records the vaccine type. A wide 
range of information including medical diagnoses, clinical symptoms and signs, and some 
lifestyle factors and test results are encoded using the Read code system. Read codes may 
be recorded in clinical, referral, immunisation and test files. CPRD provide a dictionary of all 
Read codes (“the CPRD Medical Browser”) which occur in the database.  
Structured data are recorded using CPRD ‘entity types’. These are used to record test 
results and clinical data entered using templates (such as blood pressure recordings).The 
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entity type variable encodes the record type, e.g. ‘Blood pressure recording’. Each entity 
type has up to seven data fields attached which contain the test results or template 
contents. CPRD provide a key for each entity type of what it records, how the data are 
structured, and look-up tables to translate each data field. Entity types with all data fields 
are recorded in additional clinical details files and test files. Entity codes may also be 
recorded in clinical files, but without accompanying data fields.  
Thus: diagnostic records are available as Read codes in clinical, referral, immunisation and 
test files; prescription records are available as product codes in therapy files; and test 
results are available as entity codes in test and additional clinical details files and may also 
be entered using Read codes in clinical, referral, immunisation and test files.  
Table 3.1: Data files in the Clinical Practice Research Datalink (CPRD) 
File Selected contents 
Patient Patient demographics (gender, year of birth, death date) and 
registration dates 
Practice Practice details (region, date of last data collection, date since which 
practice has met data quality standards) 
Staff Practice staff details (gender and role) 
Consultation Details of the type of consultation (e.g. home visit) 
Clinical Medical history details 
Additional 
Clinical 
Details 
Information recorded using templates, e.g. blood pressure recordings 
Referral Patient referrals to external centres (specialty, urgency, type e.g. day 
case) 
Immunisation Immunisation records 
Test Test results 
Therapy Prescriptions issued in primary care (Multilex product code, BNF code, 
quantity) 
BNF, British National Formulary 
3.2.4 Principles of data management in CPRD 
To identify each diagnosis in CPRD, a Read codelist was compiled using a combination of 
text-based and hierarchical searching. The CPRD Medical Browser was first searched using 
text terms, to identify an initial codelist. Relevant Read code headings were identified from 
this codelist, and used to search the CPRD Medical Browser hierarchically, and the two 
codelists were then combined.  
To identify prescriptions, a medication code lists was compiled using the CPRD Product 
Browser using search terms identified from the British National Formulary (BNF).[73]  
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To identify test results or other structured data records, the relevant entity codes were 
identified from CPRD meta-data.  
Records were then extracted from the relevant data files, and merged with a patient list to 
identify events of interest among the study population. Records were cleaned and any 
required algorithms applied, to identify the event of interest. The detailed methods used to 
define particular diagnoses are described in Chapter 4 for infections, Chapter 5 for CKD, 
and Chapter 6 for other variables. 
3.3 Data linkages with CPRD  
CPRD patient records are linked to other routine datasets for English general practices, 
subject to practice-level consent.[68] This thesis used linkages to inpatient secondary care 
records from Hospital Episode Statistics (HES), mortality data from death registrations and 
socio-economic data from the national census, the latter both held by the Office for 
National Statistics (ONS).  
All linkages were performed by a third party (the Health and Social Care Information 
Centre), so that patient anonymity to the database users was maintained.[74] Linkage 
between CPRD and HES was based on the patient’s NHS number, gender, and partial date 
of birth. Linkage between CPRD and mortality data was based on the patient’s NHS 
number, supplemented with date of birth and postcode. Socio-economic status estimates 
were linked to CPRD records by the postcode of patient residence. 
3.4 Secondary care data from Hospital Episode Statistics 
Hospital Episode Statistics (HES) is a database of all attendances at NHS hospitals in 
England. This study used anonymised HES inpatient admissions data, which have been 
collected from 1989 onwards.[75] The seventh version of the CPRD-linked HES inpatient 
admissions dataset was used. 
3.4.1 HES data collection 
Hospital care providers submit coded records of all hospital inpatient admissions to the 
Secondary Uses Service (SUS). Data are encoded retrospectively, typically by administrative 
coders, using inpatient records and hospital discharge summary. Since the phased 
introduction of Payment by Results in the mid-1990s, payment for hospital care providers 
has been based on activity levels calculated from these reported data, which has thus 
50
[51] 
 
provided a strong financial incentive for full recording of patient diagnoses and treatments, 
and admission and discharge dates, since before the start of our study period.[76] Data are 
extracted monthly and annually from SUS and cleaned to form Hospital Episode 
Statistics.[77]  
3.4.2 HES data quality 
Inpatient data collection includes a system of checks designed to assure data quality. Tools 
to check the validity of reported data are made available to hospital care providers, to 
encourage good quality data coding at source. SUS data submissions are audited for 
completeness and invalid data formats, with results fed back to hospital care providers. 
HES data extracted from SUS are also cleaned and checked for internal validity.[77] 
The effectiveness of these data quality checks is unclear. The Audit Commission audits the 
payment claims against the cost of care provided annually. Errors in clinical coding vary 
from 0–20% by hospital care provider when considered in terms of whether an appropriate 
payment was claimed.[78] The accuracy of clinical coding considered in terms of whether 
the diagnoses recorded provide an accurate assessment of the health status of each 
patient from a clinical perspective is less clear. The Commission noted that co-morbidities 
were inconsistently recorded, and that coding was more accurate when there was clinical 
overview of the diagnoses recorded.[78]  
3.4.3 HES data structure 
HES data are structured in episodes, which together form spells. Any period of time a 
patient spends continuously in hospital is referred to as a spell, which spans the time from 
hospital admission to discharge. When the clinical team responsible for a patient’s care 
changes, a new episode is recorded within that spell (Figure 3.1). A set of up to 20 
diagnoses are recorded for each episode, of which the first (primary) diagnosis for the first 
episode encodes the main reason for admission.[75] The coding system is based on the 10th 
revision of the International Classification of Diseases (ICD-10).[79] 
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Figure 3.1: Hospital Episode Statistics (HES) data structure 
The HES dataset is provided as a set of text files. The files used in this thesis are 
summarised in Table 3.2.  
Table 3.2: Selected data files in Hospital Episode Statistics (HES) 
File Selected contents 
Patient file Patient identifier, ethnicity 
Episode file: one 
record per episode 
Spell number (constant for all episodes which together form a 
single spell in hospital for a patient) 
Episode key (identifier for each episode of care) 
Admission date (Date of admission for the spell) 
Discharge date (Date of discharge for the spell) 
E-order (field which identifies the order of episodes within a spell) 
Episode diagnosis 
file 
Episode key (identifier for each episode of care) 
ICD-10 codes for the episode 
D-order (field which identifies the order of diagnoses within an 
episode) 
 
3.4.4 Principles of data management in CPRD-HES linked data 
ICD-10 codes for a diagnosis of interest were selected using a hierarchical approach from 
the ICD-10 classification.[75] These were extracted from the ‘episode diagnosis’ files, and 
merged with the ‘episode’ files using the episode key to locate the diagnosis within a 
hospital spell. The primary reason for admission was identified as the diagnosis recorded as 
the primary diagnosis (d-order value of 1 in the episode diagnosis file) for the first episode 
of an admission (e-order of 1 in the episode file). 
3.5 Mortality data from the Office for National Statistics 
This study used anonymised Office for National Statistics (ONS) mortality data derived from 
death registration records. Updated mortality data were obtained during this study. The 
Episode 1 Episode 2 Episode 3
Spell
Patient attends hospital and is admiitted e.g.to assessment unit
Referred to the care of consultant A e.g. surgery
Transferred to the care of consultant B e.g. elderly care
Discharged
Reason for admission: primary diagnosis of episode 1
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original version of ONS mortality data was used to identify exit from the study cohort for 
objectives 2–4, and to describe mortality following infection in the analysis of burden of 
infection among patients ≥65 with diabetes (objective 2). The updated version was used for 
the analysis of the association of CKD with post-infection mortality (objective 5). 
3.5.1 ONS data collection 
Date and cause of death for all deaths in England and Wales are collated from civil 
registration records. Information on cause of death is recorded on a death certificate by a 
doctor in approximately 80% of cases, and these are coded automatically by a software 
programme. Causes of death are recorded in free-text by a coroner (following post-mortem 
and/or inquest) in approximately 20% of cases, and these are coded manually.[80]  
3.5.2 ONS data quality 
Mortality data derived from death registration records in the UK are high quality, with good 
completeness, systematic coding rules applied consistently to clinically-led diagnosis 
selection, and low use of ill-defined codes.[81]  
3.5.3 ONS data structure 
Text files contained the date of death and up to 15 causes of death. The updated dataset 
also included meta-data describing the quality of the linkage to CPRD.  
Causes of death were coded using the Ninth Revision of the International Classification of 
Disease (ICD-9) until 2001, and the Tenth Revision (ICD-10) subsequently. This not only 
altered the format and number of codes available, but also the rule governing the selection 
of the underlying cause of death (Rule 3). This rule states that if the condition which would 
otherwise be selected as the underlying cause of death “is obviously a direct consequence 
of another reported condition... select this primary condition”. In particular, this has 
reduced the number of deaths with underlying cause of death assigned to pneumonia. The 
conditions considered underlying causes if they are co-reported differ according to the 
precise code used to record pneumonia, but may include any conditions that impair the 
immune system, wasting diseases (such as cancer), diseases causing paralysis (such as 
stroke), and chronic lung disease.[80] 
A bridging study used both ICD-9 and ICD-10 coding to assign underlying cause of death to 
deaths which occurred in 1999, and compared the results. For nearly half of all deaths with 
pneumonia assigned as the underlying cause of death using the ICD-9 coding system, the 
underlying cause of death was reassigned using the ICD-10 coding system. Most of the 
affected deaths were reassigned to Chapter IX (Diseases of the circulatory system, which 
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includes stroke and ischaemic heart disease), and a substantial proportion were reassigned 
to dementia, Parkinson’s disease, and neoplasms.[82] Hence, recording of infection and 
particularly pneumonia as a specific cause of death is vulnerable to artefactual change, and 
full capture of infection-related mortality necessitates use of both underlying and 
contributory cause of death ICD codes. 
3.6 ONS socio-economic status data 
The study used linked ONS socio-economic status data for individual patients, based on 
residence. 
Socio-economic status was described using the index of multiple deprivation (IMD), a 
composite area-level marker of deprivation.[83] Deprivation is identified in seven 
dimensions: housing, income, employment, education and training, health and disability, 
living environment, and crime. These are combined to form a single estimate of multiple 
deprivation, which is calculated at the level of lower super output area, a geographical unit 
with a population of approximately 1,000–3,000. The lower super output areas are then 
ranked, and divided into quintiles. ONS IMD estimates from 2007 were used.  
3.7 Software 
Data management and analysis were conducted in Stata unless otherwise specified: version 
12.0 for objective 2, and version 13.0 for objectives 3–5.  
3.8 Ethics 
This study formed part of a project led by Dr Sara Thomas on the burden, determinants and 
outcomes of severe infections in older people in the UK, which received ethics approval 
from the LSHTM ethics committee (LSHTM ethics reference 6116) and GPRD/CPRD data use 
approval by the CPRD ethics committee (ISAC reference 11_033). 
An amendment which provided further detail of the definition of chronic kidney disease as 
part of aim 4 of the original protocol, was submitted to and approved by the CPRD ethics 
committee (ISAC reference 11_033A). This amendment made no changes to the original 
protocol. 
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3.9 Identifying the study cohort 
The primary study population comprised patients registered in CPRD aged ≥65 years with 
diabetes mellitus (study population A, 3.9.1). The rationale for studying older people with 
diabetes mellitus is discussed in 1.4.1.  
For analyses of the association of CKD with infection incidence or vaccine effectiveness 
among patients with CKD (objectives 3 and 4), patients were required to have a valid serum 
creatinine result, and patients with a history of renal replacement therapy were excluded 
(study population B, 3.9.2).  
To study the association between CKD and short-term post-infectious mortality (objective 
5), the study population was additionally restricted to patients with available linkage to 
ONS mortality data, and the cohort was identified anew using the updated linked ONS 
mortality data (study population C, 3.9.3). 
3.9.1 Study cohort A: patients aged ≥65 years with diabetes mellitus 
The primary study population comprised all 219,145 patients registered in CPRD during the 
study period (1 April 1997 – 31 March 2011) aged ≥65 years with diabetes mellitus.  
To ensure data quality, patients were only eligible if both patient and practice data met 
CPRD quality standards (3.2.2). To allow good assessment of co-morbidities at baseline, and 
prevent over-estimation of infection incidence (3.2.2), patients were required to be 
registered with the practice for at least a year before study entry.[71]  
Patients entered study cohort A at the last date of: diabetes diagnosis date, 65th birthday, 
one year anniversary of current registration at the practice, date practice data reached 
quality control requirements ‘up-to-standard’, or 1 April 1997. Patients exited study cohort 
A at the first date of: date of death, leaving the practice, last date of data collection from 
the practice, or 31 March 2011.  
Diabetes mellitus was identified from diagnoses recorded in primary care. Two Read 
codelists were used, both compiled by Dr Sara Thomas, listed in Appendix B. The first 
codelist contained Read codes which were considered to encode a definite diagnosis of 
diabetes. Any one of these ‘definite’ codes identified a patient with diabetes mellitus. The 
second codelist contained Read codes which suggested a possible diagnosis of diabetes. 
These codes identified a patient with diabetes only if the patient had also received a 
prescription for an antidiabetes medication. I compiled product code lists for antidiabetes 
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medications, which are discussed in 6.6.3 and listed in Appendix B. The ‘diabetes diagnosis 
date’ was the earliest date of any qualifying diagnosis code or prescription.  
To maintain patient anonymity, CPRD provides year but not day or month or birth. To 
calculate age from year of birth, all patients were assigned a nominal birthday of 1 July. 
Date of death was identified from ONS mortality records if the patient had a death 
recorded in linked ONS data, and from CPRD date of death records if not.  
Identification of the cohort is described in Figure 3.2. In total, 13.8% (35,186/254,388) of all 
patients were excluded: 13,335 patients had only ‘possible’ codes for diabetes, with no 
relevant medications to confirm diabetes; and 21,850 patients met a criterion for exit 
before becoming eligible for entry, and thus contributed no time to the study. Among the 
219,203 eligible patients, the median time eligible was 3.9 years (range 29 days to 14.0 
years).  
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Figure 3.2: Defining study cohort A: patients aged ≥65 years with diabetes mellitus 
Initial list:
254,388 patients
At least one 
‘definite’ code:
240,649 (94.6%)
ELIGIBLE
None:
13,335 
(5.2%)
EXCLUDED
At least one 
prescription:
404 (0.16%)
ELIGIBLE
Any 
diabetes 
code
‘Definite’ 
diabetes 
code
Relevant  
medication
Time eligible
None (exit before 
entry to study):
21,908 
(9.1%)
EXCLUDED
INCLUDED
219,145 
(86.1% of initial list)
CPRD
patients
Yes
Yes Yes
Yes
No
No
No
 
CPRD, Clinical Practice Research Datalink  
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3.9.2 Study cohort B: patients with a serum creatinine test and no history of 
renal replacement therapy 
Study cohort B comprised the subset of study population A who had a valid serum 
creatinine result recorded, after patients with a history of renal replacement therapy had 
been excluded.  
Excluding patients with a history of renal replacement therapy 
Renal replacement therapy was identified in CPRD by a Read code for renal transplant or 
dialysis. The Read code list is described in 5.3 and listed in Appendix D.  
For objective 2, patients with a history of renal replacement therapy in CPRD prior to the 
study were excluded, and patients with a first incidence of renal replacement therapy in 
CPRD during the study were censored from this date. 
Subsequently, identification of renal replacement therapy was improved by additionally 
excluding patients with an ICD-10 code for renal transplant or dialysis in HES (listed in 
Appendix D). A sensitivity analysis was conducted for objective 2 in which this was also 
applied to study cohort B: an additional 62 patients were excluded, and the study exit date 
was altered for 440 patients. Results of this are presented in 8.4. 
Identifying patients with a valid serum creatinine result 
A valid serum creatinine result was required to define the patient’s CKD status.  
Clinical reasons for testing serum creatinine include acute illness, particularly infection, and 
patient characteristics which may be related to infection. There is therefore a risk of 
ascertainment bias in estimates of the association between CKD and infection from greater 
creatinine recording among patients with higher incidence of, or potential mortality from, 
infection. This risk may be mitigated by routine monitoring and complete recording. Several 
of the entry criteria to the study cohort (such as a diagnosis of diabetes mellitus, age ≥65 
years, or practice recording reaching required CPRD data standards) may be associated 
with completeness of serum creatinine monitoring or recording. We examined 
completeness of serum creatinine recording in the year prior to entry to study cohort A 
compared to the first year after entry to study cohort A among patients without a history 
of renal replacement therapy. Serum creatinine recording was more complete after entry 
to study cohort A (5.4.2).  
Classifying patients’ CKD using serum creatinine results prior to fulfilling the eligibility 
criteria for study population A would therefore have increased the risk of ascertainment 
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bias in estimation of the association between CKD and infection incidence. It was therefore 
decided that patients would only enter study cohort B from the date of the first valid serum 
creatinine test after fulfilling other eligibility criteria. Serum creatinine results were 
identified and cleaned as described fully in 5.4.1. 
Cohort B entry and exit dates 
Patients entered study cohort B on the date of the first valid creatinine result recorded 
after the last time-point of: diabetes diagnosis date, 65th birthday, one year anniversary of 
current registration at the practice, date practice data reached quality control 
requirements ‘up-to-standard’, or 1 April 1997.  
Patients exited study cohort B at the first date of: date of death, leaving the practice, last 
date of data collection from the practice, renal replacement therapy (dialysis or renal 
transplant) or 31 March 2011. 
3.9.3 Study population C: patients with ONS mortality data linkage 
Analysis of the association of CKD with short-term post-infection mortality (objective 5) 
was restricted to patients with an available linkage to ONS mortality data, to optimize 
timely ascertainment of mortality. An updated linkage to ONS mortality data was available, 
and so the study cohort were defined anew using the date of death recorded in the 
updated ONS dataset.  
The updated mortality dataset recorded deaths registered from 1 January 1998 to 10 
January 2012, and so the study period was restricted to start on 1 January 1998. Dates of 
death in CPRD were not used to identify patient death for the cohort exit date. As death 
would not be identified after the date on which the datasets linkage was established, the 
date on which record linkage was checked (linkage date) was additionally used to define 
cohort exit. 
Study cohort C was otherwise defined using the same criteria as cohort B. 
Cohort C study entry and exit dates 
Patients entered study cohort C on the date of the first valid creatinine result recorded 
after the last time-point of: diabetes diagnosis date, 65th birthday, one year anniversary of 
current registration at the practice, date practice data reached quality control ‘up-to-
standard’, or 1 January 1998. Patients exited study cohort C at the first date of: date of 
death (recorded in the updated ONS dataset), leaving the practice, last date of data 
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collection from the practice, renal replacement therapy (dialysis or renal transplant in CPRD 
or HES), ONS data linkage date, or 31 March 2011.  
3.9.4 Relationship between study cohorts 
Study cohort A comprised all patients in CPRD with diabetes mellitus aged ≥65 years. Study 
cohort B represented the subset of cohort A who had valid serum creatinine result and no 
history of renal replacement therapy. These restrictions were introduced to permit analysis 
of infection incidence and vaccine effectiveness according to CKD status, excluding patients 
with end-stage renal disease (Objectives 3 and 4).  
Study cohort C would have been the subset of cohort B who had ONS mortality data linkage 
available. However, an updated mortality dataset linkage was available. Defining the cohort 
anew with this dataset offered the opportunity to study a larger cohort for this objective. 
As date of death was defined using an updated mortality dataset for study cohort C, which 
could alter the date of study exit to be earlier or later, study cohort C was not a direct 
subset of study cohort A.  
The relationship between study cohorts A, B and C is illustrated in Figure 3.3. Any 
additional study exclusion criteria (such as exclusion of patients with missing data) are 
described in the chapter presenting the relevant data analysis.  
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Figure 3.3: Overview of eligibility criteria for study cohorts A, B and C 
 
CPRD, Clinical Practice Research Datalink; RRT, renal replacement therapy; HES, Hospital Episode Statistics; 
ONS, Office for National Statistics  
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Chapter 4. Definition of infections 
Four acute, community-acquired infections were studied: urinary tract infection (UTI), 
lower respiratory tract infection (LRTI), pneumonia (as a subset of LRTI) and sepsis.  
The strategy for defining episodes of infection was based on previous work by Elizabeth 
Millett and Sara Thomas in defining LRTIs and pneumonia.[5] The general principles were 
that: infections were identified from clinical diagnoses in primary or secondary care; 
diagnoses recorded within 28 days of one another were treated as a continuation of the 
same infection; hospital-acquired infections were excluded; time in hospital was excluded 
from time at risk of that infection; and combined CPRD and HES data were used whenever 
HES-linked data were available for a patient. 
I used the data management files created by Elizabeth Millett and Dr Sara Thomas to define 
episodes of LRTI (including pneumonia), and adapted these to define episodes of other 
infections (Elizabeth Millett, PhD thesis, LSHTM, unpublished). Both Elizabeth Millett and 
Dr Sara Thomas provided extensive practical advice and support towards applying their 
methods to this study’s dataset, and adapting them for UTIs and sepsis. Elizabeth Millett’s 
methods for defining LRTI and pneumonia are described in 4.1, followed by adaptations for 
this thesis to sepsis and UTI.  
4.1 Lower respiratory tract infections (LRTIs), including 
pneumonia 
4.1.1 LRTI diagnosis codes  
The Read code list used to identify clinical diagnoses of LRTI in CPRD, and the ICD-10 code 
list used to identify clinical diagnoses of LRTI in HES, were developed by three clinical 
epidemiologists (Dr Sara Thomas, Dr Jennifer Quint, a respiratory physician, and Prof. Liam 
Smeeth, GP). The codes are listed in Appendix C. Exacerbations of chronic obstructive 
pulmonary disease (COPD) were not included unless they specified an infectious aetiology. 
Codes identified as pneumonia codes defined both an LRTI and a pneumonia. Codes such as 
acute bronchitis and influenza identified LRTI but not pneumonia. The Read code list 
included one diagnosis for a post-operative infection, H262.00 ‘Postoperative pneumonia’ 
which was used to identify hospital-acquired infections (4.1.4).  
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4.1.2 CPRD data extraction 
CPRD records which included a Read code for LRTI were extracted from clinical, test and 
referral files. There were no instances of the listed Read codes in the immunisation files.  
4.1.3 Definition of LRTI episodes in CPRD  
An LRTI diagnosis code defined the incident date for an LRTI if there were no LRTI diagnoses 
recorded within the previous 28 days. A diagnosis recorded within 28 days of a previous 
LRTI diagnosis continued the same episode of LRTI. The duration of each episode of LRTI 
was from the incident date until 28 days after the last diagnosis of LRTI within the episode 
(Figure 4.1: A). 
4.1.4 Identification of hospital-acquired LRTI episodes using unlinked CPRD 
data 
If the episode of LRTI included the diagnostic code H262.00 ‘Postoperative pneumonia’, the 
entire episode was considered an episode of hospital-acquired pneumonia.  
If the incident date of an episode was within 14 days after a CPRD record of hospitalisation 
(including inpatient admissions, hospice stays, day cases and non-urgent admissions), the 
episode was judged to be hospital-acquired (Figure 4.1: B). Records which defined 
inpatient admission were: Read codes for inpatient admission or hospice stay in a clinical, 
test or referral file; consultation type field recorded as 23 ‘Hospital admission’ or 47 
‘Hospital Inpat Rept’ in a patient’s consultation file; or inpatient field recorded as 1 
‘Inpatient’ in a referral file. Records which defined day case or non-urgent admissions were: 
Read codes for day cases or non-urgent admissions in a clinical, test or referral file; 
consultation type field recorded as 25 ‘Day Case Report’ in a consultation file; or inpatient 
field recorded as 2 ‘Day Case’ in a referral file. Emergency department attendances were 
not used to identify hospitalisations. 
Hospital-acquired LRTIs were not included as outcomes, and the duration of a hospital-
acquired LRTI was removed from time at risk of a community-acquired LRTI.  
Episodes of LRTI which did not contain a code for post-operative infection, and did not 
occur within 14 days of a CPRD record of hospitalisation were considered community-
acquired for patients without CPRD-HES linkage available. 
4.1.5 HES data extraction and cleaning 
All hospital episodes for the study population were extracted from the HES ‘episode’ file. 
Episodes which included an LRTI were identified by extracting records which included an 
63
[64] 
 
LRTI ICD-10 code from the HES ‘episode diagnosis’ file. LRTI diagnoses were merged into 
the ‘episode’ files by matching records on patient identifier, spell number and the episode 
key.  
The data were collapsed to form one record for each hospital spell, with an indicator for 
whether an LRTI occurred as the primary diagnosis for the first episode of the spell, or at 
any point during the spell. The first episode was identified using the e-order field of the 
‘episode’ file, and the primary diagnosis of the episode was identified using the d-order 
field, of the ‘episode diagnosis’ file (3.3.3).  
Hospital spells with a missing admission or discharge date, and hospital spells with a 
discharge date earlier than the admission date, were discarded. When a patient had two 
spells with the same admission date, at least one had a discharge date on the same day for 
all cases, and so these are likely to represent same day readmissions. Hospital spells for a 
single patient which overlapped in time or were nested one within another were also 
identified. For patients with multiple spells on one date, nested spells, or overlapping 
spells, these spells were combined to form one record of continuous hospitalisation from 
the earliest admission date to the latest discharge date. The spell with the earliest 
admission date (and lowest spell number for same day admissions) was used to determine 
whether LRTI was the primary reason for admission at the start of the combined period of 
continuous hospitalisation. All spells were used to identify whether there was any LRTI 
diagnosis at any point during the combined period of continuous hospitalisation. 
4.1.6 Definition of LRTI episodes in CPRD-HES linked data 
Combined CPRD and HES data were used to define LRTIs for all patients with HES-linkage 
available.  
When a patient is admitted to hospital for a community-acquired infection, LRTI should be 
recorded as the main reason for hospital admission. Hospital spells with LRTI recorded as 
the primary diagnosis for the first episode of the spell are referred to in this thesis as 
“hospitalisations for LRTI”, and defined an incident community-acquired LRTI, with duration 
from hospital admission until 28 days after hospital discharge (Figure 4.1: C).  
Patients may also be admitted to hospital with a community-acquired infection which is not 
their main reason for admission (for example, if a myocardial infarction occurs secondary to 
a community-acquired LRTI). The LRTI which is recorded cannot be distinguished in the HES 
records from a hospital-acquired LRTI. Hospital spells with an LRTI diagnosis which was not 
recorded as the primary diagnosis for the first episode are referred to in this thesis as 
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“hospitalisations including an LRTI”. In the absence of other evidence, these were assumed 
to represent hospital-acquired LRTIs, with duration from hospital admission to 28 days 
after hospital discharge (Figure 4.1: D).  
Either HES or CPRD diagnoses could continue an ongoing LRTI, without changing its status 
as community- or hospital-acquired. If a hospital admission for or including an LRTI 
occurred during a community- or hospital-acquired LRTI identified from CPRD diagnosis, 
the LRTI was continued until 28 days after hospital discharge (Figure 4.1: F and G). A CPRD 
diagnosis of LRTI recorded during the 28 days after discharge from a hospital spell for or 
including an LRTI continued the LRTI until 28 days after the last diagnosis (Figure 4.1: H and 
I). 
Hospital records with no LRTI were also used to define LRTIs as hospital-acquired. Any 
incident LRTI occurring within 14 days after any hospital discharge recorded in HES was 
defined as hospital-acquired (Figure 4.1: E and J). A diagnosis of LRTI in CPRD which was 
during a hospital spell recorded in the linked HES data was also considered a hospital-
acquired LRTI, with duration until 28 days after hospital discharge (Figure 4.1: K).  
An exception was made when a CPRD diagnosis of LRTI was recorded on the same day as a 
HES admission for a spell which did not have any record of LRTI in the spell. It was 
considered possible for these patients that the patient had been diagnosed as having 
possible pneumonia in primary care, and referred to hospital for investigation and 
admission. However, as LRTI was absent from all records of that hospital spell it appeared 
likely that investigation in secondary care had provided an alternative diagnosis. In this 
case, the increased investigation possible in secondary care (for example, the easy 
availability of chest X-rays) were considered to cast doubt upon the primary care diagnosis. 
Thus, if a CPRD diagnosis of LRTI occurred on the same day as a hospital admission for a 
spell with no record of LRTI in the spell, this was not used to define an LRTI. 
Any one episode of LRTI could combine multiple records of LRTI in CPRD and HES in any 
order; the same principles were applied (Figure 4.1: L). 
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4.1.7 Pneumonia as a subset of LRTI  
Pneumonia was identified as a subset of LRTI. Codes which defined pneumonia diagnoses 
are listed in Appendix C. The first pneumonia diagnosis within an LRTI defined the 
pneumonia incident date. The duration of the pneumonia episode was from the 
pneumonia incident date to the end of the LRTI within which it occurred. 
A major difference between community-acquired and hospital-acquired pneumonia is that 
each is associated with a different profile of pathogens.[84] If a pneumonia episode 
developed from a hospital-acquired LRTI, the causative pathogen was likely to be hospital-
acquired. If a patient was admitted to hospital with a community-acquired LRTI, any 
subsequent progression to pneumonia might be caused by hospital-acquired pathogens. To 
ensure we classified as community-acquired only those episodes of pneumonia which were 
likely to be caused by pathogens acquired in the community, pneumonia was defined as 
community-acquired only if it was within a community-acquired LRTI and there was no 
hospitalisation between the LRTI incident date and the pneumonia incident date (Figure 
4.2).  
Figure 4.2: Defining community-acquired and hospital-acquired pneumonia episodes 
 
LRTI, Lower Respiratory Tract Infection; CPRD, Clinical Practice Research Datalink; HES, Hospital Episode 
Statistics 
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4.2 Sepsis 
Clinical diagnoses were used to identify community-acquired and hospital-acquired 
episodes of sepsis, applying the same strategy as described above for defining episodes of 
LRTI. 
4.2.1 Identification of diagnostic codes for sepsis 
The outcome of interest was clinically diagnosed acute, community-acquired sepsis. Sepsis 
is defined as a systemic inflammatory response in the presence of infection.[85] 
Bacteraemia, or disseminated infections which commonly arise through haematogenous 
spread, may occur in the absence of a systemic inflammatory response, and so these codes 
were not considered sufficient evidence to identify sepsis, and were not included in the 
diagnosis code lists. Likewise, positive blood culture tests may occur without a systemic 
inflammatory response, and were not considered sufficient evidence of a clinically relevant 
episode of sepsis. Systemic infections which are commonly subacute, or chronic, or with a 
long latent period, such as disseminated blastomycosis or systemic cryptococcosis, were 
not considered acute, and were not included. 
I identified diagnostic Read codes for sepsis using the search strategy in Table 4.1, which 
started with a text-based search and then also used the identified codes to search 
hierarchically. I combined this list with a Read code list compiled separately by Dr Sara 
Thomas and discussed this with Dr Sara Thomas and Dr Dorothea Nitsch to compile a final 
set of Read codes, listed in Appendix C. Codes specifying that sepsis was post-operative or 
a result of a blood transfusion were identified, but none were recorded for the study 
population, and so these were not used to identify hospital-acquired episodes of sepsis. 
Table 4.1: Search strategy for sepsis Read codes 
Search 
details 
CPRD Medical browser version 1.3.2 
Database build ‘ever’ 
Search date 10 April 2012 
Stage 1 Text-based search 
Read terms *sepsis*, *septic*, *blood*infect*, *blood*poison*, *endocard*, 
*pyaem*, pyem*, *viraem*, *virem*, *fungaem*, *fungem*, 
*system*mycos*, *system*inf*, *SIR*, *bacteraem*, *bacterem* or 
*culture* 
Stage 2 Identifying relevant Read code hierarchies 
 Sorted results of text-based search by Read code to identify relevant 
Read code headings. 
Stage 3 Hierarchical search 
Read codes 14O*, A*, G51*, G54*, H5*, J65*, J66*, J67*, L04*, L09*, L29*, L40*, 
L43*, Q40*, Qyu*, R05*, R10*, SL4*, SP2*, SP3* 
CPRD, Clinical Practice Research Datalink 
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ICD-10 codes were searched hierarchically to identify diagnostic codes for sepsis. Two 
codes were identified which were not sufficient to identify a sepsis episode, but could have 
been consistent with a diagnosis of sepsis. These were: B349 ‘Viral infection’, unspecified 
and A499 ‘Bacterial infection’, unspecified. These would have been used to confirm a 
diagnosis of sepsis if they occurred during a hospital spell with a CPRD diagnosis on the day 
of admission, but there were no instances of this combination. The ICD-10 code list for 
sepsis diagnoses is listed in Appendix C. 
4.3 Urinary tract infections 
Acute urinary tract infections (UTIs) were identified from clinical diagnoses using the same 
strategy as used to define LRTIs, modified to incorporate diagnostic codes for suspected 
UTI, and with a difference in how a primary care diagnosis on the same day as hospital 
admission was classified.  
4.3.1 Identification of diagnostic codes for UTIs 
The outcomes of interest were acute, community-acquired infections of the bladder and 
upper urinary tract. Urethritis and male accessory gland infections such as prostatitis have 
different clinical presentations from bladder and upper urinary tract infections, with 
different risk profiles.[86] We considered these to be separate clinical entities from bladder 
and upper urinary tract infections. As less severe conditions, they may also be more 
vulnerable to ascertainment bias from health-seeking behaviour, diagnosis and recording 
bias. We thus did not include urethritis and male accessory gland infections as UTIs. While 
UTIs may cause positive urine cultures, these may also occur in the context of 
asymptomatic bacteruria. To ensure we only identified clinically-relevant infections, we 
used clinical diagnoses to identify UTIs, and did not use urine bacterial culture test results. 
Diagnostic codes for UTI were identified by Dr Sara Thomas and code lists were finalised in 
discussion with Dr Dorothea Nitsch and myself. The Read and ICD-10 codes selected to 
define UTIs are listed in Appendix C. Codes for ‘recurrent UTI’ were assumed to be 
recorded in the context of a current infection. Codes which specified that a UTI had 
occurred in pregnancy were assumed to be historical in this age group and were not used.   
If Read code K190200 ‘Post operative urinary infection’ occurred during a UTI episode, the 
entire episode was classified as hospital-acquired.  
Codes for pyelonephritis were vulnerable to cross-use to describe chronic kidney disease. 
For example, acute renal infections are recorded in HES records using the ICD-10 codes N10 
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‘Acute tubulo-interstitial nephritis’ or N12 ‘Tubulo-interstitial nephritis, not specified as 
acute or chronic’, both with an additional code B95-99 to identify the infectious agent. If an 
infectious agent is not recorded, code N12 could represent a chronic tubulo-interstitial 
nephritis (a cause of CKD), or an episode of pyelonephritis where the infectious agent was 
not identified or not recorded. To avoid misclassifying patients with CKD as having episodes 
of pyelonephritis, a cautious approach was taken in selecting codes to identify 
pyelonephritis. Codes which were ambiguous or required another code to identify an 
infectious aetiology were not used to identify pyelonephritis. 
4.3.2 Resolving conflict between primary care diagnosis and hospital records 
For patients admitted to hospital on the same day as a diagnosis of UTI in primary care, the 
hospital records did not always include a diagnosis of UTI for the admission. 
Urinary tract infection is usually a clinical diagnosis in primary care, and the diagnostic gold 
standard is urine microscopy and culture, which is available in primary care.[87] Primary 
care diagnoses were therefore treated with some confidence. It was thought plausible that 
recording of UTIs in hospital discharge records could be incomplete for patients admitted 
to hospital who had a community-acquired UTI at the time. 
If a UTI was recorded in CPRD on the same day as a hospital admission, this was defined as 
a community-acquired UTI even if the hospital spell did not include an ICD-10 code for UTI. 
Otherwise, CPRD and HES records were combined to identify community-acquired and 
hospital-acquired UTI using the same principles as those used to define LRTI. 
4.3.3 Codes for suspected UTI 
In clinical practice, a patient with symptoms of UTI may be recorded as having a suspected 
UTI: pending the results of urine microbiology, for example. We included Read code IJ4..00 
‘Suspected UTI’ in the UTI code list used to define episodes of UTI. ‘Suspected UTI’ codes 
were treated in the same way as other UTI diagnostic codes for defining the start, end or 
duration of any group of UTI codes within 28 days of one another to form a UTI episode 
(Figure 4.3: A). However, a group of diagnoses which comprised only codes for suspected 
UTI without any other code for UTI did not define an episode of UTI (Figure 4.3:B). Other 
than this requirement, suspected UTI codes were treated identically to other UTI diagnostic 
codes in defining UTIs in combined CPRD-HES records (Figure 4.3: C).  
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Figure 4.3: Use of Read code IJ4..00 'Suspected UTI' in defining episodes of UTI 
time
28 days
S U S U
S S
SS
no 
UTI 
episode
UTI
UTI
A
B
C
Key
UTI Community-acquired UTI
U
UTI Read code
U
HES hospital admission 
(UTI as primary code)
U
S
Suspected UTI Read code
UTI, Urinary Tract Infection; HES, Hospital Episode Statistics 
4.4 Identifying infectious aetiology 
Data sources identifying infectious aetiology were available within both primary and 
secondary care datasets. Aetiology may be recorded in diagnostic codes for infection, 
either as Read codes in primary care records (e.g. H21..00 Lobar (pneumococcal) 
pneumonia) or as ICD-10 codes in secondary care records (either directly in the diagnostic 
ICD-10 code, such as J13 Pneumonia due to Streptococcus pneumonia, or by attachment of 
a separate code recording the causative pathogen).[76] Microbiological test results sent 
from primary care were available in CPRD, although tests conducted in secondary care 
were not available in HES.  
Infectious aetiology is incompletely identified and recorded for community-acquired 
infections: fewer than half of patients with community-acquired pneumonia have a 
pathogen identified.[84, 88] In part this is due to the low diagnostic yield of many 
microbiological tests, especially among patients who have commenced antibiotic 
treatment.[89] However, it is also due to selective investigation, particularly in primary 
care. Guidelines on the management of community-acquired UTI and LRTI in primary care 
71
[72] 
 
recommend that microbiological tests should be sent only for selected patients.[88, 90, 91] 
Impaired renal function is an indication for microbiological investigation for UTI and if 
associated with poorer prognosis of infection would also influence microbiological 
investigation more generally.[90] Thus, information on infectious aetiology was incomplete 
among the study population, and was likely to be differential by CKD status. Restricting any 
analysis to infections with identified aetiology would have included only a selected subset 
of patients, and would have been likely to introduce selection bias into estimates of the 
association of CKD with infection incidence or mortality. Description of infectious aetiology 
was therefore not attempted for this thesis. 
4.5 Time at risk of community-acquired infection 
Time at risk of community-acquired infection was identified separately for each type of 
infection. Patients were considered at risk of a community-acquired infection unless they 
were experiencing an ongoing episode of infection, or were a current hospital inpatient, or 
were within 14 days of discharge from hospital. Community-acquired or hospital-acquired 
infections were removed from person-time at risk for each patient. When HES-linkage was 
available, time in hospital was also removed from time at risk for each patient. 
4.6 Calculating infection incidence 
Infection rates were calculated using Poisson regression models. Poisson regression was 
selected in preference to Cox regression because it allowed me to look at how infection 
rates changed over several dimensions of time (for example age and calendar year). Fitting 
Poisson regression models is also computationally less intensive than fitting Cox regression 
models, which is relevant with this large dataset. Lexis expansions were used to allow 
adjustment for age and calendar year. The Poisson regression model assumes that baseline 
hazard is constant within a period of time which does not cross boundaries of age category 
or calendar year.  
A random effects model was used to adjust for clustering of multiple infections among 
individual patients. Random effects models specify explicitly the between-cluster variation, 
and include it in the model. This adjusts both the parameter estimate and standard errors 
for clustering, with less weight given to infections which are part of a cluster of infections 
occurring to one patient. This approach also allows likelihood ratio tests to be used. 
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Chapter 5. Defining chronic kidney disease in electronic health 
records 
This chapter describes the identification of chronic kidney disease (CKD) from electronic 
health records among older people with diabetes. CKD was classified using two separate 
markers of kidney disease: estimated glomerular filtration rate, and a history of 
proteinuria. The general principles were that: CKD status was identified from primary care 
records; eGFR was calculated from serum creatinine test results using the CKD-EPI 
equation, and classified according to clinical categories; patients without a serum 
creatinine test result were excluded from studies of the association of CKD with infection-
related outcomes; proteinuria was identified from test results and Read code records; a 
history of proteinuria was a binary non-reversible exposure in which the first valid 
proteinuria record changed the patient’s status from negative to positive for the rest of the 
patient’s follow-up; a cautious approach was taken to identifying positive proteinuria status 
(for example, a ‘trace’ of proteinuria was not counted as positive); proteinuria records 
coincident with a urinary tract infection were removed; and the absence of a positive 
proteinuria record was assumed to indicate a negative status. 
This definition of CKD was developed in the light of how CKD is classified, monitored and 
recorded in electronic health records, and following an exploration of data quality in CPRD. 
This chapter first describes the classification, identification and monitoring of CKD in clinical 
practice, and discusses the likely impact of changes in clinical practice over the study period 
(1997–2011) on CKD recording. The chapter then discusses what was already known about 
the validity of CKD recording in CPRD. The data cleaning and categorisation used to define 
CKD in this thesis are presented in detail, and alternative approaches which were explored 
are briefly reviewed. 
5.1 Chronic kidney disease 
Chronic kidney disease (CKD) is an impairment of kidney structure or function that persists 
for at least three months. CKD is almost always asymptomatic until advanced, and 
diagnosis depends on screening or incidental findings of impaired kidney structure or 
function. Although the kidney has many functions, the rate at which the glomerular 
capillaries in the kidney filter waste products, known as the glomerular filtration rate (GFR), 
is considered the best overall indicator of kidney function. Impaired kidney structure may 
be evidenced by a broad range of signs, including structural abnormalities observed on 
imaging, histological abnormalities, and protein in the urine (proteinuria).[10]  
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5.1.1 Classification of CKD 
Classification of CKD in the UK has evolved over the last decade. Changes in CKD 
classification have been driven by accumulating evidence from large epidemiological 
studies of the prognostic importance of both proteinuria and even moderate reductions of 
estimated GFR (eGFR), particularly in combination.[10] Albuminuria and reduced eGFR are 
associated with increased cardiovascular events, and all-cause and cardiovascular 
mortality, even at early stages of CKD.[23, 92-94]  
The first widely adopted classification of CKD was developed by the US National Kidney 
Foundation as part of the Kidney Disease Outcomes Quality Initiative (K/DOQI) in 2002 
(Table 5.1).[13] This described five stages of CKD. Stages 3-5 were identified based on two 
GFR estimations at least three months apart. Stages 1-2 additionally required other 
evidence of kidney damage, such as proteinuria. This classification was recommended for 
use in the UK by the Department of Health in 2005, and will have been used clinically in the 
UK for the majority of the study period.[95]  
In 2008, the UK National Institute for Health and Care Excellence (NICE) recommended the 
division of stage 3 into 3a (eGFR 45–59 ml/min/1.73m2) and 3b (eGFR 30–44 
ml/min/1.73m2), and acknowledgement of persistent proteinuria within each stage.[11] 
Table 5.1:  K/DOQI 2002 classification of chronic kidney disease  
CKD 
stage GFR1 
Evidence of kidney 
damage required2 Description 
1 ≥ 90 Yes Kidney damage with normal/↑eGFR 
2 60-89 Yes Kidney damage with mild ↓eGFR 
3 30-59  Moderate ↓eGFR 
4 15-29  Severe ↓eGFR 
5 < 15 or dialysis  Kidney failure 
From the Kidney Disease Outcomes Quality Initiative (K/DOQI) 2002 classification of CKD [13] 
1. Glomerular filtration rate (ml/min/1.73m2) on at least two occasions three months apart 
2. Persistent proteinuria, albuminuria or haematuria, or structural abnormalities 
In 2012, the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group in the 
US recommended that CKD be classified by GFR status, albuminuria status, and the cause of 
CKD.[10] In this classification, GFR is categorised as previously, including the distinction 
between 3a and 3b. The ratio of albumin to creatinine in the urine (ACR) is categorised as 
normal/ mildly elevated (<3 mg/mmol), moderately elevated, or severely elevated (>30 
mg/mmol). These categories are combined to describe the severity of CKD: for example, a 
patient with eGFR 50ml/min/1.73m2 on at least two occasions three months apart, and 
persistent albuminuria of 20 mg/mmol has CKD status G3a A2 (Table 5.2). This 
74
[75] 
 
classification is based on evidence of the prognosis associated with the combination of GFR 
and albuminuria status, and represents recommended practice in the UK at the time of 
writing but was published after the end of the thesis study period.[96]  
Table 5.2: KDIGO 2012 classification of CKD prognosis by GFR and albuminuria status 
 Persistent ACR categories 
Description and range 
A1 A2 A3 
<3 mg/mmol 3–30 mg/mmol >30 mg/mmol 
Normal to 
mildly 
increased1 
Moderately 
increased 
Severely 
increased 
G
FR
 c
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ge
 G1 >90 Normal 
Low risk2 Moderately 
increased risk 
High risk 
G2 60–89  Mildly decreased1 
Low risk2 Moderately 
increased risk 
High risk 
G3a 45–59  
Mildly to moderately 
decreased 
Moderately 
increased risk 
High risk Very high risk 
G3b 30–44  
Moderately to severely 
decreased 
High risk Very high risk Very high risk 
G4 15–29  Severely decreased Very high risk Very high risk Very high risk 
G5 <15 Kidney failure Very high risk Very high risk Very high risk 
KDIGO, Kidney Disease: Improving Global Outcomes; CKD, chronic kidney disease; GFR, glomerular 
filtration rate; ACR, albumin:creatinine ratio  
1. Relative to young adult level 
2. No chronic kidney disease if no other markers of kidney disease 
5.1.2 Estimating glomerular filtration rate 
GFR cannot be measured directly. It can be measured indirectly by measuring the rate at 
which an exogenous marker of filtration, such as inulin or iothalamate, is cleared from 
plasma into urine. This is expensive, requires close monitoring over an interval of time, may 
involve exposure to radiation, and is not used in routine clinical practice.[97]  
GFR is more conveniently estimated using endogenous markers of filtration, such as serum 
creatinine, which is simple and inexpensive to measure. Creatinine is a waste product of 
muscle metabolism which is eliminated renally, with free glomerular filtration and only a 
small component of tubular excretion. The level of creatinine in the serum reflects the 
equilibrium between the rate at which it is produced and the rate at which it is filtered. 
Creatinine production is influenced by a range of factors including age, sex, ethnicity, 
muscle mass and dietary protein. Among patients with low creatinine production, reduced 
GFR may therefore co-exist with a ‘normal’ level of serum creatinine.[97] 
Equations such as the Cockcroft-Gault equation, which address this problem by adjusting 
the serum creatinine result for age, sex and weight to estimate GFR, have existed since the 
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1970s.[97] However, at the start of the study period, the commonest approach to 
identifying impaired renal function in primary care was to classify an unadjusted serum 
creatinine level as normal (<120 µmol/l), raised (120-150 µmol/l) or requiring nephrology 
referral (>150 µmol/l).[44] Thus patients with impaired eGFR but low creatinine production 
were not identified. As age is a strong predictor of creatinine production, this particularly 
affected older people. In a Canadian study, 47.3% (316/668) of primary care patients aged 
≥70 years  with a ‘normal’ serum creatinine (≤130 μmol/l) had a reduced eGFR ≤50 ml/min 
using the Cockcroft-Gault equation.[98] 
The Modification of Diet in Renal Disease (MDRD) Study equation was published in 
1999,[99] and widely adopted following its recommendation in Royal College of General 
Practitioner (RCGP) 2005 guidelines,[100] and automatic reporting of calculated eGFR by 
UK laboratories from April 2006.[20, 101] The MDRD equation tends to underestimate 
eGFR at higher levels of GFR, and a new estimating equation, the CKD Epidemiology 
Collaboration (CKD-EPI) creatinine equation was published in 2009.[102] The CKD-EPI 
equation has been validated among diverse populations, including older people, and 
provides a more accurate estimation of GFR, which is more closely correlated with 
prognosis than estimates using the MDRD equation.[97]  
A more accurate estimation of GFR is also possible by combining creatinine with another 
endogenous marker, cystatin, using the 2012 CKD-EPI creatinine-cystatin C equation.[97] 
However, serum cystatin is infrequently measured in clinical practice, and so this is not 
available in routinely collected historic electronic health records.  
Laboratory estimation of serum creatinine has seen improvements since 1997. Laboratory 
variation in estimation of serum creatinine was addressed with the phased introduction of 
laboratory-specific standardisation from 2006.[103] Creatinine assays are now calibrated to 
a reference assay using isotope-dilution mass spectrometry. The CX3 assay method used 
for the majority of the study period tended to a slight positive bias in creatinine estimation: 
serum creatinine results are 5% lower after IDMS-standardisation.[97, 104]  
5.1.3 Measurement of proteinuria  
A variety of tests exist to identify proteinuria. These range from urine reagent strips 
(‘dipsticks’) which provide results at the bedside within minutes, to more accurate 
laboratory measurement of protein: creatinine ratio or albumin: creatinine ratio.  
Proteinuria, although most commonly caused by kidney damage, may result from other 
aetiologies (for example, multiple myeloma causes overproduction of immunoglobulin light 
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chains, which circulate in the plasma and are excreted by the kidneys into the urine). 
Albumin is a plasma protein normally found at low levels in the urine, but which at 
increased quantities is pathognomonic of kidney disease.[10] The urinary albumin: 
creatinine ratio (ACR) is more sensitive to low levels of proteinuria than the protein: 
creatinine ratio (PCR).[10] It is albuminuria which has been studied and found to have a 
graded association with all-cause and cardiovascular mortality.[92] For these reasons, 
urinary ACR was recommended by NICE in 2008 as the test of choice for screening for 
diabetic nephropathy and is considered best practice for CKD screening in general.[10, 11]   
Bedside urine reagent strips are used in clinical practice for a variety of reasons, such as 
investigating suspected UTIs. Although ACR has been the recognised test of choice for CKD 
screening among patients with diabetes since at least 2008, the less precise and less 
renally-specific test of ‘dipstick’ for total proteinuria will also occur in primary care records, 
both for CKD screening during the early years of the study, and for other clinical purposes. 
5.1.4 The effect of changes in primary care on CKD diagnosis 
Over the study period 1997–2011, CKD diagnosis in primary care has changed considerably. 
Changes in CKD testing and classification have been driven by a growing evidence base for 
the prognostic significance of CKD, which may itself have influenced clinical practice. In 
particular, uncertainty as to whether early stages of CKD held any prognostic implications 
for older people may have reduced enthusiasm for formally diagnosing CKD among older 
people at the start of the study period.[105] Any hesitance is likely to have reduced as 
evidence has accumulated that reduced eGFR and proteinuria among older people identify 
individuals at higher risk of hospitalisation, and reduced eGFR is associated with a higher 
risk of all-cause and cardiovascular mortality, although the significance of eGFR 45–60 
ml/min/1.73m2 remains less clear among this age group than among younger adults.[105-
108] The clinical value of monitoring for proteinuria has also been enhanced by finding that 
treatment of proteinuria with angiotensin converting enzyme inhitors can slow progression 
of CKD.[109] 
Adoption of changes in CKD testing and classification has been reinforced by other external 
factors and events (Figure 5.1). A number of guidelines for the identification and 
monitoring of CKD in primary care were published during 2005-8.[11, 95, 100] The Quality 
and Outcomes Framework (QOF) has incentivised GPs to monitor serum creatinine or 
creatinine clearance of diabetic patients annually since 2004, and to keep a register of 
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patients with CKD using a defined set of Read codes since 2006, which are likely to have 
increased monitoring and standardised recording of CKD, respectively.[65]  
The effect of these changes is difficult to quantify precisely, as increased CKD diagnosis 
could reflect a combination of increased ascertainment and increasing CKD prevalence. 
Many of the changes clustered around the years 2005-6 (Figure 5.1). Hobbs et al. identified 
a 47.5% increase in referrals to renal clinics in Kent in 2006–2008 compared with 2004–
2006, and this steep and sudden increase is likely to be substantially explained by changes 
in clinical practice rather than a step change in CKD prevalence.[20] The increasingly 
routine use of eGFR rather than absolute serum creatinine level over the study period will 
have directly resulted in increased recognition and earlier diagnosis of CKD in primary care, 
particularly among older people.[110, 111] This change is likely to have been substantial: 
among 5,072 patients in primary care with diabetes, serum creatinine of >120 µmol/l 
identified only 33% of the 1,588 patients diagnosed with CKD stages 3-5 when eGFR was 
estimated using the MDRD equation.[46] Other changes are likely to have contributed 
incrementally to earlier recognition of CKD. For example, automated laboratory reporting 
of eGFR in Australasia was temporally associated with a 4% decrease in late referral for 
renal replacement therapy.[112]   
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Figure 5.1: Timeline of changes to identification of CKD in primary care during the study period 1997-2011 
 
MDRD, Modification of Diet in Renal Disease; K/DOQI, Kidney Disease Outcomes Quality 
Initiative; QOF, Quality and Outcomes Framework; RCGP, Royal College of General 
Practitioners; NICE, National Institute for Health and Care Excellence; CKD-EPI, Chronic 
Kidney Disease Epidemiology Collaboration 
Thus CKD identification in primary care has changed enormously during the study period, 
and records of CKD diagnosis in CPRD will reflect this. If CKD were ascertained in our study 
exclusively from clinical diagnoses, there would be a risk of ascertainment bias. Rates of 
infection have increased over time in older individuals, and if ascertainment of CKD also 
increased over time due to changes in primary care practice, this could result in severe 
over-estimation of an association between CKD and infection rates.[5]  
Throughout the many changes in clinical practice over the study period which have affected 
ascertainment and recording of CKD, serum creatinine testing has remained the constant 
underlying test for CKD in primary care. 
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5.1.5 Classifying renal disease by cause 
Clinical guidelines recommend that clinicians consider the cause of disease when classifying 
CKD.[10] Investigation and diagnosis of the cause of CKD generally occurs in secondary care 
outpatient clinics, but would be communicated to primary care via letter, which may be 
recorded in free-text (and hence unavailable in the CPRD dataset) or encoded (and 
available).  
Not all patients with CKD will routinely have underlying renal pathology investigated, and 
this may particularly be true among older patients with multiple co-morbidities. Renal 
impairment among young patients with no co-morbidities is more likely to have an 
underlying cause which would benefit from investigation and specialist management than 
among older patients with diabetes.[100]  
A wide range of pathologies may cause CKD, and within each condition there may be a 
range of severity of CKD. Assessing the prognostic significance of the underlying cause of 
renal disease for a patient with CKD is informed at an individual patient level by knowledge 
of the presentation and progression of the renal pathology, and the patient’s medical 
history, and relies on clinical judgment rather than a systematic classification of aetiologies. 
For these reasons, the cause of disease is likely to be unavailable for most older patients 
with diabetes in CPRD, and population-level classification of CKD by aetiology is less 
practicable than classification by eGFR and proteinuria status. 
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5.2 CKD recording in electronic health records 
Most patients with CKD are identified, monitored and managed entirely in primary 
care.[100] CPRD is therefore the most relevant database for identifying CKD status in this 
thesis. 
Electronic health records are secondary data, which were not generated for the purpose of 
this research.[62] The primary purpose for which these data were recorded is clinical care 
of the patient. Data generation is driven by clinical practice: for example, screening for CKD 
is a response to patient risk factors. Secondary reasons for data recording include local 
audit and quality improvement, external pressures such as financial incentives, and 
awareness that the practice participates in research by submitting records to the CPRD. 
Aspects of data recording, information technology, and database curation may also 
influence how CKD is recorded in CRPD, separately from clinical changes. The valid 
identification of CKD in CPRD is thus dependent on a wide range of factors. 
5.2.1 Data recording affects completeness and validity of CKD records 
Data recording in primary care, and curation of the research database may affect the 
quality and availability to researchers of different data types encoding CKD status. How 
clinical data are recorded in CPRD in general was described in 3.2.  
The variety of tests for proteinuria will be reflected in less uniform recording of proteinuria 
test results than serum creatinine tests. Proteinuria tests may be recorded in a variety of 
formats in the database, and may frequently be unrecorded, especially if proteinuria is 
absent. In particular, bedside urine reagent strip tests may be recorded in free-text rather 
than coded, particularly if negative. In a validation study of primary care records, among 
432 patients with a recorded diagnosis of CKD stage 3–5, proteinuria testing was only 
recorded using a Read code or structured test result record if positive. The Read code 4672 
‘Urine protein test negative’ was not used at all, among 93 records of proteinuria testing 
recorded in structured data. Manual test searches identified tests for proteinuria recorded 
in free text without a Read code. Nearly half of these were negative (69/142).[113] To 
maintain anonymisation of the database, free-text is not available in CPRD without the 
considerable expense of checking by a third party for any identifying information, and thus 
a high proportion of negative proteinuria test results may be absent in the dataset available 
for this thesis.  
In contrast, the shift of laboratory test result reporting in primary care from fax or letter to 
automated electronic reporting directly into patient records, which was almost universal by 
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2007,[101] is likely to have enhanced consistency of recording, reduced data entry error, 
and reduced the risk of under-recording of ‘normal’ results for serum creatinine test 
results.  
5.2.2 What do we know about completeness of CKD recording among older 
people with diabetes mellitus? 
Older people with diabetes are a highly-monitored population for CKD. Diabetic 
nephropathy has been well-recognised as a potential complication of diabetes mellitus for 
some time, and standard care for patients with diabetes should have included regular 
monitoring for CKD throughout the study period. Guidelines published during the study 
have consistently recommended annual screening for, and at least annual monitoring of, 
impaired renal function and proteinuria in primary care.[11, 95, 100] Among 5,072 patients 
with diabetes registered at 17 English practices in 2003–4, 92% had a serum creatinine 
measurement recorded in the previous 2 years.[46] There was sufficient information to 
estimate GFR for 4,139 (81.6%) using the simplified MDRD equation. Completeness of 
creatinine recording is likely to have improved since, as this study pre-dated QOF 
incentivisation of creatinine monitoring. Albuminuria was poorly recorded: only 36% of 
patients with diabetes had any record of albuminuria having been measured.[46]  
5.2.3 What do we know about the validity of CKD recorded in CPRD? 
The validity of classification of a variable is generally considered from two perspectives: 
sensitivity and specificity; or positive and negative predictive values.[62] These describe the 
relationship of the classification to the true underlying state (Table 5.3). 
Table 5.3: Describing validity: classification of binary variables compared to the true underlying state 
 Recorded CKD status  
Positive Negative Total 
Gold standard 
(true CKD status) 
True positive a b a + b 
True negative c d c+d 
 Total a + c b + d a + b + c + d 
 
Specificity is the probability of correctly classifying as unexposed a person who is truly 
unexposed. This can be represented as d/(c+d). Sensitivity is the probability of correctly 
classifying as exposed a person who is truly exposed. This can be represented as a/(a+b).  
The positive predictive value is the probability that a person who is classified as exposed is 
truly exposed, which can be represented as a/(a+c). The negative predictive value is the 
probability that a person classified as unexposed is truly unexposed, which can be 
represented as d/(b+d). 
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The positive predictive value of diagnoses recorded in CPRD are generally good.[72] 
However, as CKD is ‘silent’, or asymptomatic, until quite advanced, under-ascertainment is 
a particularly high risk for CKD compared to many diseases. This would reduce sensitivity of 
CKD diagnosis recording.  
Most studies of the validity of CKD coding in administrative database coding and existing 
datasets have investigated inpatient hospital claims databases in the US. These datasets 
differ considerably from CPRD, in that coding uses ICD classifications, the purpose of coding 
is for cost claims not case management, and the study population is usually inpatient.[114, 
115] 
Van Staa et al. conducted an external validation of a range of recorded diagnoses in CPRD 
against a reference standard of diagnoses on hospital discharge summaries for 500 
patients. For diabetic nephropathy there was 96.1% agreement: this high agreement may 
be misleading, as for 413 patients with concordant results the diagnosis was absent in both 
sources, which may simply reflect incomplete recording in both CPRD and hospital 
discharge summaries.[116]  
Two studies have assessed the performance of CKD Read codes in primary care records 
against eGFR calculated from serum creatinine. In a general practice of approximately 
11,000 patients, a quarter of patients had a creatinine recorded, of whom 492 had CKD 
stage 3-5 according to the calculated eGFR. CKD Read code searches identified 36/492 
(7.3% sensitivity compared to eGFR). Full-text manual searching of patient records only 
identified a further 4 cases: 452/492 (92%) were undiagnosed cases.[113] A list of 45 CKD 
Read codes were validated against eGFR for all subjects with at least one creatinine 
measurement between 2002–8 in The Health Improvement Network, a large electronic 
primary care dataset. Read codes had 48.8% sensitivity and 98.2% specificity to identify 
CKD stages 3–5 compared to recorded eGFR, with a positive predictive value of 88.9% (95% 
CI 88.7–89.1) and negative predictive value of 86.5%.[117]  
GFR estimated from routinely monitored serum creatinine test is not a true reference 
standard, and may itself lack validity. For example, CKD may be over-estimated when using 
a single serum creatinine result.[118] It would therefore be a simplification to see these 
results purely as demonstrating the sensitivity lost downstream of creatinine testing by the 
requirement for clinical interpretation, diagnosis and Read code recording. These internal 
validations may also not be generalisable to patients without a recorded serum creatinine 
test. 
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However, the results do suggest that CKD Read codes are considerably less sensitive for 
identifying CKD in primary care than eGFR calculated from serum creatinine results. This 
inference is supported by the NEOERICA study, which studied the prevalence of CKD using 
primary care records for the population of Kent, Manchester and Surrey. The prevalence of 
stage 3–5 CKD identified using serum creatinine results (8.5%) was among the highest UK 
estimates to date, suggesting that this method of establishing CKD status is not unduly 
limited by missing creatinine results, while only 1.6% of the cohort had a diagnosis of renal 
disease in their primary care records.[17] 
If CKD were ascertained in our study from diagnosed CKD only, there would be a greater 
risk of under-ascertainment of CKD than if serum creatinine results are used to estimate 
GFR. Non-differential under-ascertainment of CKD could result in under-estimation of the 
associations between CKD and infections, as the observed associations would be diluted 
versions of the true underlying associations. If diagnosis were influenced by clinical factors 
which were risk factors for infection as well as risk factors for CKD – such as smoking – use 
of CKD diagnosis to identify CKD in CPRD could cause ascertainment bias, in which the 
association between CKD and infection would be over-estimated. 
5.3 Identification of patients with CKD in CPRD 
As discussed in 5.1.1, current best clinical practice is to classify CKD according to eGFR, 
albuminuria and cause.[10] There is good evidence that eGFR and albuminuria are both 
independently associated with CKD prognosis.[92] Classifying CKD status according to eGFR 
and proteinuria independently and according to the categories in current classification 
schemes would allow comparison of the relationships between CKD and infection with 
those between CKD and cardiovascular disease, and would facilitate translation of results 
into clinical practice. 
This study identified patients with CKD in CPRD by first excluding patients with a history of 
renal replacement (5.3.1), estimating glomerular filtration rates from serum creatinine 
tests (5.4) and, separately, identifying patients with a history of proteinuria (5.5). 
5.3.1 Exclusion of patients with a history of renal replacement therapy  
A history of renal replacement therapy was used to exclude patients from study 
populations B and C (3.9.2 and 3.9.3). 
I identified Read codes for renal replacement therapy using the search strategy in Table 
5.10 (5.5.2). These were sorted into codes specifying renal transplant, dialysis, and 
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acquired arteriovenous fistula (Table 5.4). For most dialysis codes it was not specified 
whether dialysis was historical or ongoing, nor whether the dialysis was short-term (for 
AKI) or longer-term for CKD. Therefore, no distinctions were made between short-term and 
long-term dialysis, nor between historical and ongoing dialysis.  
Codes recording the creation of an arterio-venous fistula were not used to exclude patients 
from the study population, as patients may be prepared for haemodialysis in advance of 
renal failure, and so this would have risked introducing selection bias to analyses of the 
association between CKD and infection. For example, if patients with fewer co-morbidities 
or receiving more active preventive care received arterio-venous fistulae at an earlier stage 
of CKD, this could create a selection bias in which patients remaining in the study at CKD 
stages 4-5 had higher risk of infection than those excluded, resulting in a spurious 
association between CKD stages 4-5 and infection risk. 
Table 5.4: Summary of Read codes identifying renal replacement therapy in CPRD 
Subgroup Number of 
codes 
Number of 
events in 
CPRD 
Commonest code in CPRD 
Renal transplant  24 11,718 7B00.00 Transplantation of kidney 
Dialysis (any) 34 13,114 7L1A200 Haemodialysis NEC 
Acquired arteriovenous 
fistula 
16 3,008 7A60100 Creation of arteriovenous 
fistula NEC 
Total 74 29,840  
CPRD, Clinical Practice Research Datalink 
Patients with a history of renal replacement therapy were identified from CPRD using the 
Read codes listed in Appendix D.  
Patients with a history of renal replacement therapy recorded in Hospital Episode Statistics 
were identified using a list of ICD-10 codes developed by Dr Sara Thomas (Appendix D).  
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5.4 Estimating glomerular filtration rate from serum 
creatinine tests in CPRD 
CKD status was described among the 218,688 patients aged ≥65 years with diabetes 
mellitus and no history of renal replacement therapy in CPRD. 
GFR status was assigned by calculating eGFR from serum creatinine tests (using the CKD-EPI 
equation and adjusting results to the current assay standardisation), and categorised 
according to eGFR thresholds used in current clinical CKD classification.[10] 
5.4.1 Data extraction and cleaning of serum creatinine test results 
Test results in CRPD are curated as “entity codes” (3.2.3). Entity code 165 records serum 
creatinine test results. This contains seven data fields: operator (e.g. >), value (e.g. 78), unit 
of measure (e.g. µmol/l), qualifier (e.g. [8] High), normal range from, normal range to (e.g. 
120), normal range basis (e.g. [3] Age and sex based). An entity code record may also have 
an attached Read code. 
All records with entity code 165 were extracted from the test files. Entity codes may also be 
recorded in clinical files but these files do not include the data fields containing the test 
result value, and so were not extracted. Entity codes may be stored in additional clinical 
files with all relevant data fields, but there were none in this location for entity code 165.  
Duplicate records were dropped, and the 2,632,313 non-duplicate records with entity code 
165 among 207,616 patients were cleaned as Figure 5.2.  
Of the 76 records excluded for an inconsistent Read code, 66 had Read code 44HG.00 
‘Serum creatine kinase level’. Other Read codes judged inconsistent were 4679 ‘Urine 
dipstick for protein’, 46W..00 ‘Urine microalbumin’, C04..13 ‘Hypothyroidism’ and G581.00 
‘Left ventricular failure’.  
Acceptable serum creatinine values (20–3000 μmol/l) were selected by consulting the 
improbable values excluded by the National Diabetes Audit[119] and discussion with Dr 
Dorothea Nitsch, nephrologist. Non-duplicate records on the same day were kept in this 
dataset at this point. 
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Figure 5.2: Data cleaning of serum creatinine tests (entity code 165) 
Creatinine value missing n=14,266
Creatinine value zero n=3,660
2,632,313 non-duplicate 
records among 207,616 
patients
Record labelled with a Read code 
inconsistent with serum creatinine 
test n=76 
Improbable values:
Creatinine value <20 n=1,542
Creatinine value >3000 n=119
Record duplicate other than Read 
code n=173
1,761,603 valid records 
during the study period 
among 193,658 patients
1,781,439 non-duplicate 
records during the study 
period among 193,976 
patients
Date: 
Missing n=24
Prior to study entry n=845,777 
After study exit n=5,073
 
Additional data cleaning could have been provided by checking whether the Read code was 
consistent with the serum creatinine value, for example, looking for patients with a high 
serum creatinine value and a Read code for low serum creatinine. The potential for this was 
limited, as 96.8% (1,705,552/1,761,603) of the included serum creatinine tests were 
labelled with Read code 44J3.00 ‘Serum creatinine’. In addition, classification of an absolute 
serum creatinine level as normal is consistent with impaired GFR, which could make 
interpretation of Read codes for normal renal function unreliable. This data cleaning option 
was therefore not used. 
The potential for using the unit of measure to identify records in alternative units (such as 
mg/dl) or units raising suspicion of a GFR estimate recorded as a serum creatinine result 
was explored by tabulating creatinine values by the unit recorded (Table 5.5). Again, this 
appeared to have limited potential for data cleaning: 93.6% of valid tests had the expected 
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unit for serum creatinine in the UK (umol/L), and median test result values did not differ 
markedly across units of measure. 
Table 5.5: Serum creatinine test values by unit of measure among valid tests (n=1,762,411) 
Number of valid tests  Unit of measure Median value (interquartile range) 
n % 
1,649,647 93.6 umol/L 96 (81 – 119) 
79,598 4.5 missing 97 (83 – 118) 
23,768 1.3 mmol/L 98 (83 – 118) 
8,564 0.5 mol/L 93 (76 – 118) 
299 0.02 /uL 92 (74 – 124) 
289 0.02 microU/L 112 (94 – 149) 
61 0.003 Mmol 90 (75 – 113) 
57 0.003 Umol 99 (88 – 115) 
<20  mL/min, 1, mg/mmol, mmol/mmol (creat) 
<10  ng, nmol/L, h, mmol/mol, mg/dL, u/L, umol/min, %, mg/L, pmol/L, L, 
mg/mmol (creat), iu/L, m,ug.L, umol/g (creat), umol/mmol 
1  1(tot), 1/mL, mL, mmol/d, ng/mL, rad, u, ug, um, umol/mL/h, 
umol/mol 
Total exceeds 1,761,603 (the number of valid serum creatinine tests), as records which are duplicates for serum creatinine 
value and date but with different units of measure are included in this table.  
5.4.2 The decision not to use serum creatinine tests prior to study entry 
Several study entry criteria (such as diagnosis of diabetes mellitus) may be associated with 
subsequent increased serum creatinine screening and monitoring. Valid serum creatinine 
test results prior to study entry were also identified and cleaned identically to the process 
in Figure 5.2, other than selection by study entry date, to see if serum creatinine results 
were less complete in the year prior to study entry. Completeness of serum creatinine 
recording was compared between the year prior to study entry and the first year in the 
study, stratified according to whether study entry was pre- or post-QOF (1 April 2004), as 
this was expected to alter screening for CKD. Completeness was 12.6% higher after study 
entry among patients who entered the study pre-QOF (Table 5.6). Including historical 
serum creatinine tests prior to study entry therefore carried a risk of introducing 
ascertainment bias (as discussed in 3.9.2), hence it was decided to use serum creatinine 
results only after study entry. 
Table 5.6: Are serum creatinine results less complete in the year prior to study entry? 
Year of creatinine record Number of creatinine 
results 
Number of patients with a 
creatinine result (%) 
Study entry before 1 April 2004 (111,591 patients) 
Year prior to study entry 69,873 44,623 (40.0%) 
First eligible year 105,575 58,701 (52.6%) 
Study entry on or after 1 April 2004 (107,097 patients) 
Year prior to study entry 185,868 92,769 (86.6%) 
First eligible year 195,919 90,716 (84.7%) 
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5.4.3 Estimating GFR from serum creatinine tests  
Serum creatinine values were multiplied by 0.95 for assay adjustment to IDMS-
standardised serum creatinine,[104] and divided by 88.4 to convert units from μmol/l to 
mg/dl. GFR was estimated using the CKD-EPI equation:[102]  
GFR = 141 × min(Scr/κ, 1)α × max(Scr/κ, 1)-1.209 × 0.993Age × 1.018 [if female] _ 
1.159 [if Black ethnicity] 
where:  Scr is serum creatinine (mg/dL) 
κ is 0.7 for females and 0.9 for males,  
α is -0.329 for females and -0.411 for males,  
min indicates the minimum of (Scr/κ) or 1, and  
max indicates the maximum of (Scr/κ) or 1. 
For example, eGFR for a 65-year old woman with black ethnicity and serum creatinine 
0.8mg/dL: 
 GFR= 141 x 1 x (0.8/0.7)-1.209 x (0.993)65 x 1.018 x 1.159 = 90 ml/min/1.73 m2 
Methods for identifying patients with Black ethnicity are described in 6.1.2. 
Individual serum creatinine records were classified corresponding to clinical categories 
used during the study period (eGFR <15, 15-29, 30-44, 45-59, or ≥60 ml/min/1.73m2).[10] 
To allow analysis to compare with epidemiological studies, a longer classification was also 
used, which classified eGFR results over 60 as 60-74, 75-89, 90-104, and ≥105 
ml/min/1.73m2).[92] There were 1,501 pairs of records which produced different estimates 
of eGFR on the same day according to the longer classification. As omitting these results 
was likely to have a minimal effect on data completeness, and an intuitive way to identify 
the estimate most likely to be correct was to consult the previous result for that patient, it 
was decided to omit records on the same day where the estimated GFR categories clashed.  
5.4.4 Completeness of serum creatinine test results 
Serum creatinine tests provided good completeness with regular updating during the study 
period. Among the 218,688 patients in the study population, 88.5% (193,646) had 
1,760,094 valid serum creatinine tests during the study period. Figure 5.3 shows the 
percentage of patients who had a valid serum creatinine test available in each financial 
year for which they were eligible for inclusion throughout the full year. Completeness of 
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test result availability improved steadily from 32.8% in 1997-8 to 89.0% in 2004-5, and 
remained steady at over 90% for each subsequent year.  
Serum creatinine was frequently monitored. Among the 193,646 patients with at least one 
result, the median number of serum creatinine results per patient during the study period 
was 15 (range 1-272, IQR 8-21). For 89% of records, the next test result was within a year. 
The time from each GFR estimate to the next test result or study exit was a median of 137 
days (IQR 56-242).  
Figure 5.3: Completeness of serum creatinine recording among patients eligible for each full financial year 
(among the 193,646 patients with at least one creatinine result during follow up) 
 
5.4.5 Identifying chronicity of impaired eGFR 
The clinical classification of CKD requires that impaired renal function persist for at least 3 
months for CKD diagnosis. In epidemiological studies of the effect of CKD on mortality, the 
definition of CKD is often based on a single measurement of serum creatinine at 
baseline.[24] However, serum creatinine fluctuates, and identifying CKD based on a single 
estimate of GFR will tend to over-estimate CKD prevalence.[118] A single impaired GFR may 
also be caused by acute kidney injury, AKI. AKI describes a rapid reduction in renal function, 
identified by a sudden decline in eGFR.[120] Both impaired eGFR and albuminuria, as well 
as being markers of CKD, are strongly and independently associated with an increased risk 
of AKI.[121] The commonest trigger of AKI among hospital inpatients is sepsis.[120] 
Misclassifying AKI as CKD could therefore result in over-estimation of the association 
between CKD and infection.  
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Two tests at least three months apart could be used at baseline to identify CKD, and this 
would be more robust to misclassification from creatinine fluctuation or AKI. However, 
creatinine monitoring may be more frequent among patients at higher risk of infection. In 
particular, acute or severe infections will prompt monitoring of eGFR, and if patients with 
more frequently monitored creatinine are more likely to be identified as having CKD (for 
example, as they are more likely to be eligible for a definition requiring two test results 
rather than one) this could also introduce ascertainment bias which would result in over-
estimation of the association of CKD with infection incidence. 
Thus, if using serum creatinine test results to assign CKD status based on eGFR, a balance 
must be found between minimising misclassification of a single reduced eGFR as CKD by 
requiring two results, and minimising ascertainment bias that would result from differential 
testing by using a single eGFR result. How best to do this may depend on the length of 
follow-up time. Over a short period of follow-up, a ‘best-of-two’ method could be used. 
CKD status could be ascertained at baseline using the highest eGFR result of the latest two 
serum creatinine tests recorded at baseline that were at least three months apart. This 
would approximate the clinical requirement that eGFR be impaired at a certain level for at 
least three months before that stage of CKD be diagnosed. In the absence of two suitable 
results, the single most recent creatinine result could be accepted, to reduce ascertainment 
bias. 
Measuring CKD at baseline without updating status over time might not be suitable for a 
study with a long follow-up time, over which patients’ CKD may progress. If patients with 
more rapid progression of CKD also experience higher rates of infection, the association of 
CKD with infection could be severely under-estimated by identifying CKD only at baseline. 
Risk factors for progression of CKD are not fully understood but poor glycaemic control may 
be a common risk factor for CKD progression and increased risk of infection incidence.[122]  
If two results are required to define time-updated CKD status in epidemiological studies, 
the time between the first and second result must be handled with care to avoid immortal 
time bias.[123] If this time is considered ‘exposed’ to CKD (or removed from analysis), 
infections following the first test are attributed to the exposed group (or excluded) for 
patients who have a second test but to the unexposed group for patients who have a single 
test. If infections are associated with increased creatinine testing this would bias estimates 
the association between CKD and infection upwards. The approach of choice is to classify 
this time as unexposed (Figure 5.4).  Events attributed to the unexposed group may reflect 
91
[92] 
 
the effect of early CKD, overestimating the infection rate among the unexposed: this results 
in a conservative estimate of the effect of CKD on infection incidence.  
Figure 5.4: The risk of immortal time bias if two creatinine test results are required to define CKD status 
Unexposed person time
Unexposed person time
Exposed person time
Creatinine test
eGFR <60
Creatinine test
eGFR <60
Repeat creatinine test
eGFR <60
No repeat creatinine test
CKD status remains unexposed
Removing this time (or classifying as exposed) 
would bias  estimates of association between 
CKD and infection upwards if repeat test is 
associated with infection
 
 
The ‘last-carried-forward’ method used by James et al. may be more suitable for studies 
with a sufficiently long follow-up time for CKD progression to be an issue.[124, 125] In this 
approach, CKD stage is defined at any given time using the GFR estimate produced by the 
single most recent creatinine result (Figure 5.5). This method allows updating of the 
patient’s status as CKD progresses. Although creatinine fluctuation and AKI will result in 
over-estimation of CKD stage, the patient’s status will be updated at the next test result, 
minimising misclassified person-time. If AKI is evident among serum creatinine results 
being monitored in primary care, frequent testing would be expected until GFR has 
stabilised, and so misclassified person-time from AKI should be minimal.  
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Figure 5.5: The last-carried-forward method for establishing GFR status 
 
eGFR, estimated glomerular filtration rate 
Another option could be to use Read codes to try to identify CKD rather than temporarily 
reduced GFR. However, encoding of CKD may not be sufficiently complete to permit this, 
and the negative predictive value of Read codes for CKD is unclear. In a validation of Read 
codes in CPRD, 10% of potential cases of acute renal failure were found to have CKD on 
manual review of the patient records, despite all patients with identified CKD Read codes 
having been removed from the sample.[126]  
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5.5 Identification of proteinuria status in CPRD 
Proteinuria tests are less consistently and completely recorded than serum creatinine tests, 
and are particularly likely to be missing from the database if negative. Test records and 
Read codes for proteinuria were combined to identify a proteinuria variable. This was a 
binary non-reversible exposure recording a history of proteinuria. The first valid positive 
proteinuria record changed the patient’s status from negative to positive, which it then 
remained until study exit. The absence of a positive proteinuria record was assumed to 
indicate negative status. As this approach allows a single result to define ongoing 
proteinuria status, caution was indicated in interpreting test results as positive. A ‘trace’ of 
proteinuria was not counted as positive, and the results were extensively cleaned to ensure 
internal consistency. This approach involved tolerating likely under-ascertainment of 
proteinuria, but should result in conservative estimates for the association between 
proteinuria and infection. 
The possibilities of quantifying proteinuria, and of identifying albuminuria separately from 
total proteinuria, to allow classification consistent with current clinical practice, were also 
explored. 
5.5.1 Proteinuria entity code data extraction  
Three entity codes recorded proteinuria test results (Table 5.7). Albumin: creatinine ratio 
test results were not available as a separate entity code in the May 2011 CPRD database I 
used to select my study population. All test records with entity code 287, 431 or 435 were 
extracted from the test files. None were recorded in the additional clinical files. Entity 
codes were cleaned as described in Figure 5.6. 
Table 5.7: Entity codes available in CPRD for identifying proteinuria status 
Entity code Data format 
287 Urinalysis-Protein test  4 data fields: qualifier (e.g. [8] High), normal 
range from (e.g. 3), normal range to (e.g. 10), 
normal range basis (e.g. [3] Age and sex based). 
May also have Read code label. 
431 Urine dipstick for protein test  
435 Urine microalbumin test 
 
Removal of records coincident with urinary tract infection 
Persistent albuminuria is a sign of renal damage used to classify CKD: transient proteinuria 
has a variety of causes including fever and urinary tract infection (UTI).[127] Misclassifying 
transient proteinuria resulting from fever as persistent proteinuria indicating CKD could 
result in ascertainment bias which could overestimate the association between CKD and 
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infection. Ideally, the definition of proteinuria for identifying CKD would avoid this, for 
example by using only Read codes which clearly indicated persistent proteinuria, or by 
requiring repeated positive proteinuria tests. This was likely to be impractical without 
severely reducing ascertainment of persistent proteinuria. As a compromise, proteinuria 
records coincident with a urinary tract infection (UTI) were removed. 
Records with a Read code for UTI on the same day were identified using Read codes listed 
in Appendix C. This list was an expanded version of the list of Read codes used to identify 
diagnoses of UTI for the purposes of defining episodes of infection (4.3.1). Infectious 
urethritis was included, as urethritis may cause transient proteinuria. Of the 9,028 
proteinuria records on the same day as a UTI, 3,264 (36.2%) recorded a positive proteinuria 
result.  
Figure 5.6: Data cleaning of proteinuria tests (entity codes 287, 431 and 435) 
Urinary tract infection diagnosis on 
same day n=9,028
1,517,09 proteinuria test 
records among 176,957 
patients
Record uninformative 
n=492,830
Record internally inconsistent 
n=27,392
Record negative or trace result 
n=800,202
107,689 valid positive test 
results during the study 
period among 46,589 
patients
1,437,141 non-duplicate 
proteinuria test records 
during the study period 
among 176,893 patients
Date missing n=40
Date after study exit n=1,619
Duplicates dropped n=92,357
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Removal of uninformative records 
A test result could not be obtained from 492,830 records where both the test value 
(recorded in the qualifier field) and the Read code were missing or uninformative (e.g. Read 
term 467..00 ‘Urine protein test’ with test value [0] missing).  
Checking for internal consistency of records 
Internal consistency was assessed by comparing the test value with the attached Read code 
as shown in Table 5.8. Records were judged internally inconsistent if: (1) the test value was 
[20] ‘Not examined’; (2) the Read code was inconsistent with the label for a proteinuria 
result (of the 5,874 records judged to have an inconsistent Read code, 98.9% had Read 
code 4691 ‘Urine protein test not done’); or (3) one of the test value and Read code 
recorded a positive result while the other recorded a negative result. The distribution of 
these internally inconsistent tests is described in Table 5.9. Trace results were considered 
consistent with either positive or negative interpretation, depending on clinical context, 
and so records containing a trace result and either a positive or negative value were not 
considered internally inconsistent. The internally inconsistent test records which contained 
both a positive and a negative result formed 0.2% (2537/1,437,141) of the non-duplicate 
proteinuria test records, and probably represent data entry error. 
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5.5.2 Identifying a Read code list for proteinuria  
I extracted 2,174 Read codes identifying CKD status using the strategy in Table 5.10, which 
starts by identifying text-based search terms, and uses these to identify relevant chapters 
for a hierarchical search. I then identified the subset describing proteinuria or proteinuric 
disease manually. 
Table 5.10: Search strategy for Read codes identifying chronic kidney disease 
Search 
details 
CPRD Medical browser version 1.3.2 
Database build ‘ever’ 
Search date 17 January 2012 
Stage 1 Text-based search 
Read 
terms 
*rena* OR *nephr* OR *kidn* OR *glomerul* OR *creatinin* OR *GF* 
Stage 2 Identifying relevant Read code hierarchies 
 Sorted results of text-based search by Read code to identify relevant Read 
code headings. 
Stage 3 Hierarchical search 
Read 
codes 
ZV* TB11* TB00* TA22*TA02*SP15*SP14*SP08*SK0* SB24*S76*R14* 
R13* R08*Q48* Q20* Pyu* PD*P76* L393*L162*L121* 
Kyu*K1*K0*G76*G72*G71*G70*G23*G22*D31*D21* Cyu*C35*C31* 
C10*B9* B8*B7*B5*B4*9O*9N*9h* 9b*8L*8H*8A*7P1* 7P0*7N5* 7L* 
7B1* 7B0* 7A6*6A* 68*66* 585*57*557*53B* 4Q*4I*46*45*262*1Z,, 
1J*, 1A5*, 14V*, 14* 
 As the aim was to identify proteinuria separately from eGFR status, codes which did not 
unambiguously record proteinuria were not included. Although diabetic nephropathy 
causes albuminuria, a record of diabetic nephropathy in primary care for an older patient 
with diabetes mellitus might also be used less formally to identify CKD in the presence of 
diabetes. Codes for diabetic nephropathy which did not specify proteinuria were therefore 
not included. For example, neither C109012 ‘Type 2 diabetes mellitus with renal 
complications’ nor C10FC00 ‘Type 2 diabetes mellitus with nephropathy’ were included, 
whereas C10FL00 ‘Type 2 diabetes mellitus with persistent proteinuria’ was included. Codes 
which identified proteinuria in pregnancy (such as pre-eclampsia) were not included, as 
they would not imply ongoing persistent proteinuria among a population aged ≥65 years. 
This codelist was also compared with a Read code list for proteinuria compiled separately 
by Dr Catriona Shaw (Clinical Research Fellow, UK Renal Registry) and Dr Anoop Shah 
(Clinical Research Association, University College London) with Dr Dorothea Nitsch. The 
comparison identified 13 additional codes which were added to this codelist.  
The final proteinuria Read code list comprised four subgroups (Table 5.11) and is listed in 
full in Appendix D. Codes which could represent a single positive test result or transient 
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proteinuria were identified within this codelist. Several of these codes (such as R110.00 
‘[D]Proteinuria’ and R110z00 ‘[D]Proteinuria’) were codes incentivised for use to record 
persistent proteinuria among patients with diabetes by QOF.[65] As these codes were 
ambiguous, a cautious approach was taken and these were treated as potentially recording 
transient proteinuria, although they were in practice likely to indicate persistent 
proteinuria (these codes are flagged in Appendix D). 
Table 5.11: Read codes identifying proteinuria 
Subgroup Sample Read codes Number 
of codes  
May be 
transient 
Proteinuria test 
result or status  
R110.00 [D]Proteinuria 
8 Yes 
4675 Urine protein test = ++ 
Albuminuria test 
result or status  
R110300 [D]Microalbuminuria 
3 Yes 
46W0.00 Urine microalbumin positive 
Proteinuria status 
that does not 
appear to reflect a 
single test result 
C10FL00 Type 2 diabetes mellitus with persistent 
proteinuria 
33 No 1Z1B.00 Chronic kidney disease stage 3 with 
proteinuria 
K190X00 Persistent proteinuria, unspecified 
Proteinuric 
diseases 
K011.00 Nephrotic syndrome with membranous 
glomerulonephritis 68 No 
K020.00 Chronic proliferative glomerulonephritis 
5.5.3 Data extraction and cleaning of Read codes for proteinuria 
All Read codes for proteinuria were extracted from test, clinical and referral files. There 
were 84,627 Read codes for proteinuria extracted for 41,281 patients. The 26,349 records 
which had already been cleaned as they were proteinuria test records were dropped. The 
61 records with a missing date and 215 with a date after study exit were dropped. Records 
were de-duplicated, and 56,828 records for 31,845 patients remained. 
A small number of Read codes (6.6%, 3,762/56,828) were attached to an entity code record 
which was not an entity code for a proteinuria analysis. The entity codes to which Read 
codes were attached were all considered consistent with a proteinuria result being 
indicated by the Read code (Table 5.12). These entity code test values were not used to 
identify proteinuria status, but the Read code for proteinuria remained in the analysis. 
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Table 5.12: Entity codes for tests other than proteinuria analysis to which proteinuria Read codes were 
attached 
Entity code N % 
286 ‘Urinalysis – Glucose’ 1,739 46.2 
240 ‘Urine test’ 1,356 36.0 
288 ‘Other laboratory tests’ 576 15.3 
340 ‘ Urine biochemistry’ 59 1.6 
430 ‘Urine dipstick for glucose’ 32 0.9 
Total 3,762  
 
There were 48,443 records with Read codes which could identify transient proteinuria. 
They were kept in the analysis unless there was a UTI recorded on the same day, using the 
same Read codes for UTI as were used to clean the proteinuria test results in 5.5.1. Once 
the 429 proteinuria records which were recorded on the same day as a UTI diagnosis were 
removed, this left 56,399 valid, non-duplicate records among 31,684 patients. 
5.5.4 Records defining onset of a history of proteinuria 
Using the combined proteinuria test results and Read codes, there were 165,247 records of 
proteinuria before study exit among 62,367 (28.5%) of the 218,688 eligible patients. For 
48% of these patients, this status relied upon a single record of proteinuria before or during 
the study (29,822/62,367). Table 5.13 shows the record types defining onset of a history of 
proteinuria. For 90% of patients with a history of proteinuria identified before study exit, 
this was defined by a proteinuria or albuminuria test result or status which could have been 
transient (56,324/62,367).  
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Table 5.13: Description of records defining onset of proteinuria (n=62,367) 
 
Read term or test type n (%) 
Total 
n (%) 
Proteinuria 
test result or 
status 
 
‘Urinalysis-Protein test’  (entity code 287)* 22,773 (36.5) 
34,113 
(54.7) 
[D] Proteinuria 3,326 (5.3) 
‘Urine dipstick for protein test’ (entity code 431)* 3,157 (5.1) 
Proteinuria 2,480 (4.0) 
Urine protein test = + 1,613 (2.6) 
Urine protein test = ++ 491 (0.8) 
Urine protein test = +++ 194 (0.3) 
Urine protein test = ++++ 48 (0.1) 
[D]Proteinuria NOS 31 (0.1) 
Albuminuria 
test result or 
status 
 
‘Urine microalbumin test’ (entity code 435)* 13,191 (21.2)) 
22,211 
(35.6) 
[D] Microalbuminuria  6,823 (10.9) 
[D] Albuminuria 1,858 (3.0) 
Urine microalbumin positive 339 (0.5) 
Proteinuria 
status that 
does not 
appear to 
reflect a 
single test 
result 
Type 2 diabetes mellitus with persistent proteinuria 1,355 (2.2) 
2,277  
(3.7) 
Type 2 diabetes mellitus with persistent proteinuria 452 (0.7) 
Chronic kidney disease stage 3 with proteinuria 138 (0.2) 
Persistent proteinuria, unspecified 77 (0.1) 
Chronic kidney disease stage 3A with proteinuria 60 (0.1) 
Chronic kidney disease stage 3B with proteinuria 45 (0.1) 
Type 1 diabetes mellitus with persistent proteinuria 33 (0.1) 
Chronic kidney disease stage 2 with proteinuria 30 (0.1) 
Chronic kidney disease stage 4 with proteinuria 27 (<0.1) 
Type 1 diabetes mellitus with persistent proteinuria 24 (<0.1) 
Benign postural proteinuria 11 (<0.1) 
Other records with <10 cases each 25 (<0.1) 
Proteinuric 
diseases 
Nephrotic syndrome 131 (0.2) 
473  
(0.8) 
Acute glomerulonephritis 60 (0.1) 
Unspecified glomerulonephritis NOS 50 (0.1) 
Nephrotic syndrome in diabetes mellitus 45 (0.1) 
Acute interstitial nephritis 39 (0.1) 
Berger's IgA or IgG nephropathy 20 (<0.1) 
Glomerulosclerosis 16 (<0.1) 
Other records with <10 cases each 112 (0.2) 
Multiple 
records 
  3,293 
(5.3) 
Total   62,367 
* with a positive result indicated within the entity type record 
5.5.5 Exploration of quantification of proteinuria, and identification of 
albuminuria in test results  
Positive proteinuria test results were explored to see whether albuminuria could be 
distinguished from total proteinuria, and whether albuminuria could be quantified. Read 
codes specifying that the analysis was albuminuria were almost exclusively limited to 
records with entity code 435 ‘Urine microalbumin’. These Read codes therefore added little 
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information, although they do provide evidence of internal consistency for these records. 
Records with entity code 435 formed 38.0% of the proteinuria test records, and all but two 
had a Read code specifying albuminuria measurement, and so it is reasonable to assume 
that at least 38% of proteinuria tests recorded albuminuria rather than total proteinuria 
(Table 5.14). 
It was not possible to quantify albuminuria in these data. The only quantification available 
for any of these entity types was in terms of +/++/+++/++++, a system which is used for 
total protein urine reagent strips. This result was also occasionally recorded in Read codes, 
e.g. 4674 ‘Urine protein test = +’. This information was only available for 63.7% of positive 
proteinuria tests, and so precise quantification was not attempted.  
Table 5.14: Description of positive proteinuria test results  
 Result 
quantified 
 
Conflict in 
quantification* 
Total 
 
 
 n (row %) n (row %)  
Entity code 287 ‘Urinalysis-Protein test’    
Microalbuminuria positive 0 0 3 
Urinary albumin measurement 2 (16.7) 0 12 
Albumin not specified 53,764 (94.3) 216 (0.4) 57,005 
Entity code 431 ‘Urine dipstick for protein’   
Urinary albumin measurement 4 (100) 0 4 
Albumin not specified 9,647 (99.1) 0 9,736 
Entity code 435 ‘Urine microalbumin’    
Albumin:creatinine ratio measurement 40 (97.6) 0 41 
Microalbuminuria positive 726 (8.9) 0 8,156 
Microalbuminuria measurement 4,397 (13.4) 0 32,730 
Albumin not specified 2 (100) 0 2 
Total 68,582 (63.7) 216 (0.2) 107,689 
* conflict between proteinuria quantity recorded in test value and quantity specified in Read code 
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5.6 Summary of definition of CKD in CPRD  
Two markers of CKD, estimated glomerular filtration rate (eGFR) and proteinuria, were 
identified separately, to allow analyses to treat these as potential independent markers of 
infection risk. 
5.6.1 Defining eGFR in CPRD 
Serum creatinine tests offered a relatively complete and frequently updated source of GFR 
estimates for a high proportion of the study population. They offered good granularity of 
GFR categorisation, both distinguishing stage 3a and 3b, and permitting categorisation of 
GFR at levels above 60 ml/min/1.73m2. As the most consistently recorded data available for 
assessing GFR status, they were the data source least vulnerable to ascertainment bias 
arising from changes in the clinical context of CKD recording over the study period. The 
completeness of recording among this study population minimised the risk of under-
ascertainment and ascertainment bias from CKD identification according to patient 
characteristics (such as smoking status), changes in clinical practice and data recording 
patterns.  
For these reasons, eGFR was calculated from serum creatinine test results using the CKD-
EPI equation, including adjustment for ethnicity, and classified according to NICE 2008 
guidelines.[11, 102] 
The choice of the last-carried-forward method or the best-of-two method for each cohort 
study was based upon the length of individual patient follow-up, to allow the tension 
between misclassification of CKD with the risk of ascertainment bias to be balanced 
according to whether CKD progression was likely during the follow-up period.  
5.6.2 Defining a history of proteinuria in CPRD 
Proteinuria was less consistently recorded. The quality of data recording did not permit 
adequate ascertainment of a negative status: thus a pragmatic approach was taken, in 
which it was assumed that absence of a positive test result implied a negative proteinuria 
status. As a single positive result defined a positive status for the rest of the study, caution 
was taken in accepting potential positive records. A conservative approach to identifying 
positive results was taken which comprised excluding proteinuria records on the same day 
as a UTI, not counting trace results as positive, extensive data cleaning to check internal 
consistency of records, and not including diagnostic codes for diabetic nephropathy in the 
codelist for proteinuria identification. 
103
[104] 
 
A binary variable of ‘history of proteinuria’ was defined in which absence of a positive 
record was assumed to indicate no history of proteinuria.  Data quality did not permit 
confident identification of albuminuria, or quantification of proteinuria.  
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5.7 Potential alternative approaches to identifying CKD 
CPRD contains several other sources of data which could inform CKD status.  
5.7.1 Unspecified tests in CPRD 
Entity codes may be recorded together with a Read code: thus, a serum creatinine result 
could be inferred from the unspecified test of entity code 288 ‘Other laboratory tests’ if this 
were labelled with a Read code identifying a serum creatinine test or test result, such as 
44J3300 ‘Serum creatinine raised’. Non-specific entity code test results could be 
interpreted as proteinuria tests if labelled with a relevant Read code, such as 46TC. 
‘Protein:Creatinine Ratio’. This inference depends on a Read code having been used 
accurately and for the purpose of identifying the accompanying test result. Potential for 
data entry error may be high among these records, as entry of a test result under ‘Other 
laboratory test’ suggests an abnormal data entry context. Processing a GFR estimate as a 
crude serum creatinine level, for example, would result in considerable misclassification of 
CKD status. For these reasons, entity code 288 ‘Other laboratory tests’ was not used to 
identify GFR status nor proteinuria.  
5.7.2 Creatinine clearance test results in CPRD 
Entity code 166 ‘Creatinine clearance’ records creatinine clearance test results, with the 
same seven data fields as entity code 165 ‘Serum creatinine’ (5.4.1). All records with entity 
code 166 were extracted from the test files: there were none in the additional clinical files.  
Duplicate records were dropped, and the 12,093 non-duplicate records with entity code 
166 among 5,750 patients were cleaned as Figure 5.7. Read codes judged inconsistent with 
creatinine clearance were G20..00 ‘Essential hypertension’ (n=1), 46TC.00 ‘Urine 
albumin:creatinine ratio’ (n=2), and 44J7.00 ‘Albumin/creatinine ratio’ (n=2). Non-duplicate 
records on the same day were kept in this dataset at this point. 
Creatinine clearance tests added little to completeness of data. There were only 4,244 valid 
creatinine clearance tests among 2,456 patients during the study period. For 895 creatinine 
clearance tests, there was a serum creatinine test recorded on the same day. They also 
restricted categorisation of eGFR: 375 records recorded only that creatinine clearance was 
>60 ml/min. They were not found to be a useful addition to serum creatinine test results, 
and were therefore not used.  
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Figure 5.7: Data cleaning of creatinine clearance tests (entity codes 166) 
Value missing n=3,157
Value zero n=60
12,093 non-duplicate 
records among 5,750 
patients
Record labelled with a Read code 
inconsistent with creatinine 
clearance n=5 
Improbable values:
Negative values n=2
Value >1000 n=2
Operator > with value neither 60 
nor 90 n=1
Record duplicate other than Read 
code n=1
4,244 valid records during 
the study period among 
2,456 patients
7,472 non-duplicate records 
during the study period 
among 3,532 patients
Date: 
Missing n=15
Prior to study entry n=4,581 
After study exit n=25
 
5.7.3 Read codes recording GFR status 
From the search strategy described in Table 5.10, I identified Read codes which could be 
used to identify staged CKD. These comprised: CKD stages 1–2; CKD stages 3–5; and end-
stage renal failure (assumed to indicate CKD stage 5). These codes are listed in Appendix D 
and summarised in Table 5.15.  
Table 5.15: Summary of Read codes identifying staged CKD status 
Subgroup Number 
of codes 
Codes 
indicating 
proteinuria 
Commonest example in CPRD 
CKD stage 1-2 9 4 1Z11.00 Chronic kidney disease stage 2 
CKD stage 3-5 25 10 1Z12.00 Chronic kidney disease stage 3 
End-stage renal failure 3 0 K050.00 End stage renal failure 
Total 37 14  
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These Read codes were extracted from clinical and referral files (there were none present 
in test files). Six records with missing dates were dropped, records were de-duplicated and 
restricted to those between study entry and study exit.  
Staged Read codes added only slightly to completeness: there were 75,731 staged CKD 
Read codes among 48,012 patients during the study period, of which 18,680 (24.7%) were 
on the same day as a serum creatinine result. They permitted a less fine categorisation of 
GFR than serum creatinine results. Among 58,795 read codes for CKD stage 3 during the 
study period, 55,990 (95.2%) did not specify between stage 3a or 3b, which has been found 
to be an important distinction in terms of prognosis among older people.[107, 108] They 
were not found a useful addition to serum creatinine tests among this population, and 
were not used. 
This approach is supported by a recently published study of CKD prevalence in the total 
population of CPRD, which identified CKD from either two eGFR measurements <90 
ml/min/1.73m2, or a Read code for CKD, or both. Only 0.5% of the patients with CKD were 
identified from a Read code alone. [18] 
5.7.4 Renal disease aetiology 
The cause of renal disease may not be fully investigated among this population, and 
classification of CKD by cause of disease involves clinical interpretation of an individual 
patient’s health, rather than application of a systematic classification of aetiologies (5.1.5). 
As infection itself and the presence of risk factors for infection may influence clinical 
investigation of the cause of CKD, classification of CKD according to aetiology risks 
introducing ascertainment bias to the association between CKD and infection. However, 
validity of diagnostic codes may differ among the older people with diabetes from the 
general population, and the potential use of diagnostic codes to supplement CKD 
classification by eGFR and proteinuria was explored in this population.[114] 
From the codes extracted using the search strategy in Table 5.10, I identified Read codes 
for renal pathology likely to cause CKD. These were disparate and difficult to classify 
according to CKD status. In particular, many aetiologies could have varying relationships 
with eGFR, proteinuria and prognosis, according to presentation and severity. Within each 
subgroup, the most commonly occurring codes were usually those that would be ‘high-
level’ codes in a hierarchical coding system. These codes provide the least detailed 
information and are thus least useful when seeking granularity of data. These Read codes 
could be used as exclusion characteristics, to obtain a patient population unlikely to have 
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CKD, but are less useful for classifying CKD status for an individual patient, as many codes 
would have poor specificity for CKD. 
5.7.5 Could we have used secondary care records to identify CKD? 
The majority of CKD is identified, managed and monitored in primary care.[100] Patients 
may be referred to secondary care for specialist investigation and management of 
underlying renal disease, management of complications such as uncontrolled hypertension, 
or initiation of renal replacement therapy. Patients referred to nephrologists from primary 
care, for example for management of advanced CKD, or investigation of underlying renal 
disease, are mostly treated in outpatient clinics: only about 5% of patients under the care 
of a nephrologist at any one time are inpatients.[43] Outpatient records which provided 
details of renal disease among these patients could be a useful supplement to primary care 
records, but were not available to this study.  
Linked hospital admission records were available, and co-morbidities are recorded in these. 
However, there is a high risk of ascertainment bias if CKD status is established from 
inpatient admission records. Infection is a major cause of hospital admission among older 
people.[9] Infection is the leading trigger of AKI among hospital inpatients, and admission 
with infection would therefore prompt monitoring of renal function.[120, 128] Pre-existing 
CKD is also a recognised risk factor for development of AKI during infection.[121] CKD may 
therefore be more likely to be recorded for patients admitted with infection, and so using 
hospital acute admission records to supplement identification of CKD status would risk 
increasing CKD ascertainment differentially among patients with a history of hospital 
admission for infection. This could introduce ascertainment bias, with over-estimation of 
the association between CKD and infection. For this reason, secondary care records were 
not used as a data source for CKD status in this thesis. 
Even if this were not the case, HES admission records would still not be ideal for 
ascertaining CKD status. The HES inpatient database does not include secondary care test 
results. CKD diagnoses may be under-recorded in hospital admission records: the sensitivity 
of a diagnostic code of kidney disease in a Canadian administrative database of hospital 
admissions was 38% compared to eGFR from serum creatinine results.[129] Co-morbidities 
in hospital admission records are encoded using the 10th revision of the International 
Classification of Diseases (ICD-10).[75] This coding system is not ideal for establishing CKD 
status, as kidney disease is classified according to aetiology rather than function, which 
would not permit ascertainment of staged CKD status.[79] 
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Primary care of patients with CKD continues after referral to secondary care, and the GP 
retains responsibility for co-ordination of the patient’s overall care. It is therefore to be 
hoped that CKD identified in secondary care would be recorded in primary care records. 
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Chapter 6. Describing the cohort  
The cohort was described in terms of demographics, health behaviours, co-morbidities, and 
characteristics of diabetes. Not all characteristics were relevant to every analysis: the 
rationale for how covariates were included in each analysis is presented in Chapters 7-11.  
6.1 Demographics 
6.1.1 Age, gender and region 
Year of birth, gender and region of residence were obtained from patient files in CPRD. 
These records were complete for all patients. To calculate age from year of birth, patients 
were assigned a nominal birthday of 1 July. Unless otherwise specified, age was categorised 
in five-year bands up to age ≥85 years. 
6.1.2 Ethnicity 
Ethnicity is recorded in CPRD and HES. A study by Mathur et al. of usability of CPRD and 
HES ethnicity records found that the consistency of ethnic category was high: within each 
dataset, for patients with multiple ethnicity records within either dataset; and between 
datasets, for patients with an ethnicity recorded in both datasets. In CPRD, ethnicity 
recording increased considerably after recording was financially incentivised by the Quality 
and Outcomes Framework (QOF) in 2006. Patients in CPRD with a recorded ethnicity in 
2011 had a very similar ethnic breakdown to that recorded for the UK population in the 
2011 census.[130]  
The single ethnicity provided in the HES patient file was used as a descriptive variable for 
objective 2. This variable is based on all ethnicity recordings in HES inpatient records for 
each patient with HES linkage. Where multiple ethnicities were recorded for one patient, 
the most frequently recorded code was provided. Where there was a tie, the more specific 
ethnicity code was provided. 
A more complete identification of Black ethnicity was required for calculation of estimated 
glomerular filtration rate (eGFR) to identify CKD status for objectives 3–5. For this purpose, 
CPRD and HES records were combined. A Read code list developed by Rohini Mathur was 
used to extract ethnicity records from clinical and referral files in CPRD (there were none in 
other files). Patients with a single usable ethnicity record in CPRD were assigned this 
ethnicity. Patients with multiple ethnicity records in CPRD were assigned the most 
frequently recorded code for the patient: in the event of a tie, the most recently recorded 
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of the frequently recorded codes for the patient was used. For patients with HES linkage 
and no usable record of ethnicity in CPRD, the ethnicity variable in the HES patient file was 
assigned. Where Mixed Black ethnicity was recorded, the patient was assigned Black 
ethnicity for the purposes of adjusting for Black ethnicity in calculation of eGFR. 
6.1.3 Socio-economic status 
Socio-economic status was described using the index of multiple deprivation.[83] For all 
patients, practice-level socio-economic status was available. This was the index of multiple 
deprivation quintile for the postcode of the patient’s primary care practice. For patients 
with data linkage, patient-level socio-economic status was available. This was the index of 
multiple deprivation quintile for the postcode of the patient’s home address. The type of 
socio-economic status used was specified in each analysis. 
6.2 Nursing or residential home  
A history of residence in a nursing or residential home was identified using a combination 
of CPRD records, including a Read code list compiled by Elizabeth Millett. Many of the 
commonly used Read codes were not sufficiently granular to distinguish between nursing 
or residential homes (e.g. 13F6.00 ‘Nursing/other home’ and 13F7.00 ‘Residential 
institution’). Warden-controlled and sheltered home residency were not included. A patient 
was classified as having a history of nursing or residential home residence if there was any 
eligible positive record without evidence of internal inconsistency (Table 6.1). 
Table 6.1: Records defining nursing or residential home status 
Record type Positive record Evidence of internal inconsistency 
(records with these characteristics 
were discarded)  
Consultation type 
field in the 
consultation file. 
Values 30, ‘nursing home 
visit’, or 31, ‘residential 
home visit’. 
 
Read code in clinical 
or referral files 
(none in 
immunisation or 
test files). 
Read code for nursing or 
residential home status, 
e.g. 9N1G.00 ‘Seen in 
nursing home’. 
Eligible Read code was labelling an 
entity type 132 record which also 
recorded that residence was 
warden-supported or sheltered 
accommodation, or that the patient  
lived alone. 
Entity type 132 
‘Residence’ in 
additional clinical 
details file. 
Any entity type 132 record 
with residence field values 
1 ‘nursing home’ or 2 
‘residential home’.  
Record labelled with a Read code for 
warden-controlled or sheltered 
accommodation, or with a Read 
code recording that the patient lived 
alone. 
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6.3 Smoking 
Smoking status was identified as a descriptive variable for objective 2 using an algorithm 
and data management file developed by Dr Ian Douglas. Entity type code 4 ‘Smoking’ in 
CPRD records smoking status as ‘Non’, ‘Current’, or ‘Ex’. The latest smoking record prior to 
the relevant index date for each study objective was used to identify ex- or current 
smokers. Patients with their most recent smoking status recorded as non-smoker were only 
identified as non-smokers if all previous records were consistent with this: if they had a 
prior record of current or ex-smoking but their most recent status at the index date was 
non-smoker, they were classified as an ex-smoker. If there was no smoking record prior to 
the index date, the first smoking record after the index date was used. To be identified as a 
non-smoker from the first record after the index date, all later values must also have been 
consistent with never smoking: otherwise, the patient was classified as an ex-smoker.  
For all other objectives, a fuller ascertainment of smoking status was developed which 
combined entity type 4 ‘Smoking’ records, Read codes for smoking status (using a list 
compiled by Dr Sara Thomas and Elizabeth Millett), prescriptions for smoking cessation 
therapy (using a medication code list compiled by Dr Sara Thomas) from CPRD, and ICD-10 
codes Z716 ‘Tobacco abuse counselling’ and Z720 ‘Tobacco use’ from HES. Smoking 
cessation at baseline was identified at the timepoint of the latest relevant record prior to 
study entry or (if there were no relevant records prior to study entry) the first record after 
study entry. 
As the success of smoking cessation attempts is generally low, success of smoking cessation 
was not presumed, and a prescription for smoking cessation therapy was taken as evidence 
of current smoking.[131] Similarly, both ICD-10 codes were taken as evidence of current 
smoking. Read codes were categorised as: current smoker (e.g. 1374 ‘Moderate smoker - 
10-19 cigs/d’), non-smoker (e.g. 1371.11 ‘Non-smoker’), ex-smoker (e.g. 1379 ‘Ex-moderate 
smoker (10-19/day)’), or ever-smoker (where it was unclear whether the patient was a 
current or ex-smoker, e.g. H310100 ‘Smokers' cough’).  
A recorded non-smoker status may be consistent with never having smoked, or with being 
an ex-smoker. If a patient had a record with ex-smoker status on the same day as a record 
with non-smoker status (e.g. an entity type 4 record with value ‘non-smoker’ labelled with 
a Read code 137K.00 ‘Stopped smoking’), the patient was assumed to be an ex-smoker, and 
was assigned ex-smoker status. A record of current or ex-smoker status re-categorised any 
subsequent non-smoker record to ex-smoker status for that patient. 
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For 0.1% of smoking status records (2,183/ 2,068,167) the patient was recorded as both a 
current smoker and a non-smoker on the same day. These records could not be assigned a 
smoking status, and were discarded. 
For 3.3% of smoking status records (68,016/ 2,068,167) it was unclear whether the patient 
was a current or ex-smoker, either because the only record was an ‘ever-smoker’ Read 
code, or because there was a records of both current and ex-smoker status on the same 
day. This was too small a group to be viable as a separate category in analyses. It was 
considered better to classify these patients as either current or ex-smokers, to avoid any 
risk of another record classifying them as non-smokers. These patients were classified as 
current smokers. In the context of inability to quantify cigarette pack-years, the effect of 
potentially misclassifying a small number of ex-smokers as current smokers was thought 
likely to be minor. 
6.4 Body mass index 
Body mass index (BMI) was calculated from entity type codes for height and weight, using 
an algorithm and data management file developed by Dr Krishnan Bhaskaran. Records of 
height were cleaned, including conversion of values >100 from centimetres to metres, and 
applying cut-offs at range extremes of <1.37m or >2.3m (4’ and 7’6’’). Records of weight 
were cleaned, which included discarding records at range extremes of <25.4kg or >222 kg 
(4 and 35 stone). BMI was calculated using the weight recorded closest to the index date. 
6.5 Co-morbidities  
Co-morbidities were identified using diagnoses in primary care using Read code lists 
developed by Dr Sara Thomas and Elizabeth Millett. Co-morbidities identified, for different 
purposes according to individual objectives, included: hypertension, congestive heart 
failure, ischaemic heart disease (including myocardial infarction, angina pectoris, and other 
ischaemic heart disease), peripheral vascular disease, cerebrovascular disease (including 
stroke, transient ischaemic attack, and cerebrovascular dementia), other dementia, chronic 
lung disease (including chronic obstructive pulmonary disease and other chronic lung 
conditions, but not asthma), cancer (including haematological and metastatic cancers), 
chronic liver disease (not including hepatorenal disease), connective tissue disorders 
(including rheumatoid arthritis and systemic lupus erythematosus), human 
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immunodeficiency virus infection, hyposplenia (including asplenia, coeliac disease and 
sickle cell disease), and history of cochlear implant. 
Read codes were extracted from clinical, referral and test files. All co-morbidities were 
modelled as binary variables. A patient was defined as having a history of the co-morbidity 
from the first instance of a Read code for the relevant co-morbidity, until study exit. 
Absence of a Read code was assumed to indicate a negative status, as the absence of a co-
morbidity would not be recorded in a patient’s health care records. The diagnosis of 
hypertension was supplemented with entity code type 15 ‘Hypertension register’ for the 
analysis of the association of CKD with post-infection mortality (objective 5). 
6.6 Medications 
6.6.1 Steroid use 
Oral steroid prescriptions were extracted from the CPRD therapy files, using a medication 
code list compiled by Dr Sara Thomas, to identify steroid prescriptions within the three 
months before study entry for objective 5, the association of CKD with short-term mortality 
following infection.  
6.6.2 Influenza and pneumococcal vaccinations 
A history of pneumococcal vaccination or influenza vaccination was identified by extracting 
pneumococcal and influenza vaccine prescriptions from therapy files in CPRD (using a 
medication code list compiled by Elizabeth Millett) and Read codes for pneumococcal or 
influenza vaccination status from clinical, test, referral and immunisation files in CPRD. 
Pneumococcal and influenza vaccination status were determined separately. Any relevant 
prescription or Read code defined a positive vaccinated status for the relevant vaccine: the 
absence of a record was assumed to indicate a negative vaccination status. This 
classification of influenza and pneumococcal vaccine status was used as a descriptive 
variable for objective 2. 
A more detailed definition of influenza and pneumococcal vaccination status was 
developed for the estimation of vaccine effectiveness according to CKD status (objective 4) 
and this is described in Chapter 9. 
6.6.3 Anti-diabetes medications 
The CPRD Product browser was searched using text terms and a hierarchical search using 
the strategy in Table 6.2.   
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Table 6.2: Search strategy for anti-diabetes medications 
Search 
details 
CPRD Product browser version 1.3.2 
Database build ‘ever’ 
Search date 2 February 2012 
Stage 1 BNF search to identify text-terms and BNF headings 
BNF BNF version 62 online 
Stage 2 Text search of product names and drug substance names  
Text terms *insulin* and *insu*, *hypurin*, *bovine*, *porcine*, *actrapid*, 
*humulin*, *aspart*, *novo*, *glulisine*, *apidra*, *lispro*, *huma*, 
*detemir*, *levemir*, *glargine*, *lantus*, *lente*, *isophane*, 
*basal*, *protamine*, *biphasic* 
*sulfonyl* , sulphonyl*, *gliben*, *gliclaz*,*zicron*,  *diamicro*, *vitil*, 
*glime*, *amaryl*, *glipiz*, *minod*, *tolbu* 
*biguan*, *metfor*, *metsol*, *glucoph*, *bolamy*, *metabe* 
*acarbo*, *glucob*, *exena*, *byet*, *liragl*, *victoz*, *nategl*, 
*starl*, *piogl*, *actos* (and did not upload lactose-related codes), 
*competac*, *repagl*, *prandi*, *saxagl*, *ongl*, *sitagl*, *janu*, 
*vildagl*, *galv*, *eucrea* 
Stage 3 Hierarchical search 
BNF headings 06010101*, 06010102*, 06010103*, 06010201*, 06010202*, 
06010203* 
BNF, British National Formulary  
The product codes identified for insulin therapy are listed in Appendix B. A prescription of 
insulin itself was required, rather than products which may be prescribed as adjuncts to 
insulin treatment. Thus glucagon prescriptions, lancets, blood sugar monitoring devices and 
delivery devices (unless pre-filled with insulin) were not considered sufficient evidence on 
their own of insulin use, and were not included.  
The product codes identified for oral anti-diabetes medications are listed in Appendix B. 
Medications no longer licensed at the time of the search, such as first generation 
sulphonylureas and rosiglitazone, were included, to capture historical prescriptions. 
Metformin was included, as it is a commonly prescribed first-line oral anti-diabetes 
medication. Metformin also has other indications, including treatment of polycystic ovarian 
syndrome and metabolic syndrome. All patients included in the study cohort were required 
to have a code for diabetes mellitus, and so prescription of metformin for indications other 
than diabetes is likely to be rare among this cohort. Guar gum, a dietary fibre which can be 
prescribed as an anti-diabetes medication was not included, as this is not its main 
indication, and it is not commonly used for this purpose. Acarbose, which may be 
prescribed for either type 1 or type 2 diabetes mellitus, was not included as (unlike other 
oral anti-diabetes medications) it is not an indicator of type 2 diabetes mellitus. If would be 
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unusual to be prescribed this as a solitary anti-diabetes medication, and so its exclusion 
was unlikely to have affected the ascertainment of anti-diabetes medications for many 
patients.  
6.7 HbA1C 
Glycated haemoglobin, or HbA1C, reflects mean blood glucose levels over the preceding 
three months. It should be monitored at least every six months among patients with 
diabetes, and more frequently if blood glucose control is not stable.[132]  
HbA1C test results in CPRD may be reported in two forms, each with a different reference 
range. HbA1C assays in the UK were predominantly aligned to the Diabetes Control and 
Complications Trial (DCCT) assay and reported as a percentage during the study period. 
From 1 June 2009, HbA1C assays were International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) standardised and reported in mmol/mol, although for a period 
of dual reporting, the equivalent percentage was also provided, labelled “DCCT-
aligned”.[132] 
I aimed to identify the latest HbA1C test result at baseline (study entry). As regular 
monitoring of HbA1C is an important component of care for patients with diabetes, I 
included a ‘none recorded’ category. Rather than being a missing data category, this was an 
indicator for diabetes which may have been poorly monitored.  
6.7.1 Data extraction and cleaning 
HbA1C could be  recorded in CPRD using a template, available in the database as entity 
type 275 ‘HbA1c - diabetic control’, as a Read code containing the HbA1C result, or as a 
more general test result (such as entity type 288 ‘Other laboratory tests’ with a Read code 
label indicating that this was an HbA1C result. 
Read codes were identified from the CPRD Medical Browser searching for Read terms 
(*HbA*; *Hb*; *diab*control*; *glyc*haem*; *glyc*Hb*; *A1*) and Read codes (42c*; 
42V*; 42W*; 44T*; 66A*; C108*; C109*; C10E*;C10F*). This identified six codes which 
provided a value for an HbA1C test, and 11 terms which were labels for an HbA1C test but 
without the result (Table 6.3). 
From clinical, test and referral files I extracted all records with an entity code of 275, or any 
of the eligible Read codes in Table 6.3. There were no eligible records in the additional 
clinical files. 
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Table 6.3: Read codes for HbA1C tests and results 
 Read code Read term 
Read code containing 
HbA1C test result 
42c0.00 HbA1 < 7% - good control 
42c1.00 HbA1 7 - 10% - borderline control 
42c2.00 HbA1 > 10% - bad control 
42W1.00 Hb. A1C < 7% - good control 
42W2.00 Hb. A1C 7-10% - borderline 
42W3.00 Hb. A1C > 10% - bad control 
Read code indicating HbA1C 
test 
42c..00 HbA1 - diabetic control 
42c3.00 HbA1 level (DCCT aligned) 
42W..00 Hb. A1C - diabetic control 
42W..11 Glycosylated Hb 
42W..12 Glycated haemoglobin 
42W4.00 HbA1c level (DCCT aligned) 
42W5.00 Haemoglobin A1c level - IFCC standardised 
42WZ.00 Hb. A1C - diabetic control NOS 
44TB.00 Haemoglobin A1c level 
44TC.00 Haemoglobin A1 level 
44TL.00 Total glycosylated haemoglobin level 
HbA1C, glycated haemoglobin 
Records with no result available (Read code indicating a test performed but no entity type 
attached to contain the results) were discarded (n=16,762). Two records with entity type 
363 ‘Lipoprotein electrophoresis’ were discarded, because these were unlikely to encode 
HbA1C results, and because this entity type had no numerical data field attached for an 
appropriate result. Records with a missing data (n=70) or a date after study exit (n=5,983) 
were discarded. This left 2,850,694 records, 97.7% of which were entity code 275 ‘HbA1c – 
diabetic control’ with an attached Read code for an HbA1C test (Table 6.4). 
Table 6.4: Origin of records of HbA1C tests  
  Entity code 
Total   213 Blood 
glucose 
274 
Fasting 
glucose 
275 HbA1c 
– diabetic 
control 
288 Other 
laboratory 
tests 
none 
R
e
ad
 c
o
d
e
 Read code 
including result 
0 0 44,369          40 11,487 55,896 
Read code for 
HbA1C test 
8,047 1 2,784,487       2,191           –  2,794,726 
None – – 72 – – 72 
Total 8,047           1 2,828,928 2,231      11,487 2,850,694 
HbA1C, glycated haemoglobin 
6.7.2 Categorising HbA1C results 
HbA1C results were categorised as good (<7% or <53mmol/mol), borderline (7–10%, or 53–
86 mmol/mol), poor (>10% or >86 mmol/mol), or none recorded (no result prior to study 
entry).  
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For numerical results recorded as an entity code, there was potentially some ambiguity as 
to whether these should be treated as DCCT-aligned (%) or IFCC-standardised (mmol/mol). 
Each entity code had seven data fields attached. The second data field contained a 
numerical value, which provided the test result. Other data fields of interest were the first, 
which contained an ‘operator’ (e.g. <, >, =), the third, which contained a ‘unit’ (e.g. %), and 
the fifth and sixth, which contained the lower and upper limits of the normal range. These 
data fields were used to identify DCCT-aligned from IFCC-standardised results, for 
appropriate categorisation. 
Indicators of DCCT-alignment were: Read codes 42c3.00 ‘HbA1 level (DCCT aligned)’ or 
42W4.00 ‘HbA1c level (DCCT aligned)’, value 1–6, value 7 with operator recorded as <, unit 
recorded as %, or normal range recorded as 4–6. Indicators of IFCC-standardisation were: 
Read code 42W5.00 ‘Haemoglobin A1c level - IFCC standardised’, unit recorded as 
mmol/mol, or normal range recorded as 20–42. 
HbA1C records were categorised as shown in Figure 6.1. This assumed that results prior to 
2009 were DCCT-aligned unless otherwise specified. This left 10,692 (0.4%) of the entity 
records with a potentially usable result as unclassified. These records either had an 
indicator of both IFCC and DCCT with value ≥7, or no indicator of IFCC nor DCCT in or after 
2009 with value ≥7.  
Where multiple records occurred on the same date, I prioritised: (1) results from Read 
codes (as these had less potential for misclassification); (2) entity test results with an 
uncontradicted DCCT or IFCC indicator; and (3) other entity test results. After prioritisation, 
5528 pairs and 3 triplets of clashing results on the same day remained, and these were 
discarded. 
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Figure 6.1: Categorisation of HbA1C records 
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6.8 Alternative approaches considered 
6.8.1 Why were secondary care records not used to identify co-morbidities? 
The impossibility of distinguishing a patient who truly does not have a co-morbidity from a 
patient with missing co-morbidity data in routinely-collected health records means that co-
morbidity status is particularly vulnerable to ascertainment bias. Diagnoses were not 
supplemented with HES diagnoses, as this might have resulted in greater ascertainment of 
co-morbidities among patients with more hospital attendances. Patients with CKD have 
higher rates of hospital attendance than patients without CKD, and infection is a common 
cause of hospital admission among older people.[9, 107] Differential ascertainment of co-
morbidities among patients with CKD or among patients with frequent infection was 
relevant to each analysis in this thesis. For example, differential ascertainment of co-
morbidity status would be likely to bias estimates of the association between CKD and 
infection after adjustment for co-morbidities (objective 3). The direction of bias could differ 
for each co-morbidity, and would be difficult to predict, as it would depend on the 
relationship of the co-morbidity with CKD prevalence, all-cause hospital admission rates, 
infection-related hospitalisation rates, and whether the co-morbidity coding in secondary 
care was differential according to the reason for hospitalisation.  
6.8.2 Why were medications not used to identify co-morbidities? 
Medication status may vary systematically depending on CKD status. A large number of 
commonly prescribed medications are contraindicated by impaired renal function.[73] In 
addition, medications used to treat CKD may overlap with those prescribed for other co-
morbidities. For example, an angiotensin converting enzyme inhibitor (ACE inhibitor) 
should be prescribed to patients with diabetes and proteinuria: but is also commonly 
prescribed as an anti-hypertensive medication.[96] Adjusting estimates of the association 
between CKD and infection for medications rather than diagnosis could result in bias, the 
direction of which would be difficult to predict as it would depend upon the relationship 
between the medication and CKD, the medication and the other co-morbidities for which it 
is prescribed, and the relationship of these other co-morbidities with infection. As a general 
approach, therefore, we did not use medications as proxies for co-morbidities, and 
preferred to use clinical diagnoses to identify co-morbidities.  
6.8.3 Could hypertension have been identified from blood pressure recordings? 
As hypertension is ‘silent’, or asymptomatic, until quite advanced, and so may be under-
diagnosed, I investigated using blood pressure recordings to identify hypertension in 
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addition to diagnoses. I identified patients as hypertensive from the first date of: a 
diagnostic code for hypertension (as described above); inclusion on the hypertension 
register (entity type code 15); or the third recording of raised blood pressure if all 3 records 
were within a year of each other (not including records on the same day). Recordings of 
raised blood pressure could be either a Read code recording raised blood pressure, or an 
entity type code 1 (‘Blood pressure’) record with systolic blood pressure recorded as  ≥130 
mm Hg (only acceptable if ≤350 mm) or diastolic blood pressure >80 mmHg (only 
acceptable if  ≤200). Entity type 1 records were only included if they were also labelled with 
an appropriate Read code indicating a blood pressure measurement. The thresholds for 
raised blood pressure were obtained from NICE guidelines for medication of hypertension 
for patients with diabetes.[133]  
Applying this definition to study cohort A obtained a prevalence of hypertension of 76.0% 
(166,626/219,145) at baseline and 89.3% (195,621/219,145) by study exit. This was not 
useful for discriminating between patients. It was therefore decided to use clinical 
diagnosis to define hypertension, without blood pressure recordings. The process of 
diagnosis and recording suggests that clinically relevant hypertension has been identified, 
which may be more discriminatory in terms of risk. It is likely to capture patients with 
hypertension controlled by medication, and risks missing patients with undiagnosed (and 
uncontrolled) hypertension. 
6.8.4 Could we have distinguished type 1 from type 2 diabetes mellitus? 
Both infection risk and CKD prevalence may vary by the type of diabetes mellitus. Ideally, 
patients with type 1 and type 2 diabetes mellitus would be distinguished to allow 
consideration of this. However, diagnostic coding of type of diabetes is known to be 
problematic, with most patients not having the type of diabetes recorded in electronic 
health records, and considerable misclassification of those who do.[134] Completeness and 
validity can be improved by assigning diabetes type according to an algorithm developed by 
de Lusignan et al. which includes prescriptions, age at diagnosis and BMI at diagnosis.[135] 
Unfortunately, when patients register with a primary care practice, prevalent and incident 
diagnoses of diabetes cannot reliably be distinguished.[71] Hence, as many patients will 
have changed primary care practice between first diagnosis of diabetes and eligibility for 
our study population at age 65 years, the date of first diagnosis cannot be identified using 
these data for this study population. Neither duration of diabetes, nor age and BMI at 
diagnosis are therefore identifiable. We described the patients’ prescription histories of 
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insulin and oral anti-diabetes medications, but were unable otherwise to identify type 1 
from type 2 diabetes mellitus.  
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RESULTS SECTION 
Chapter 7 describes the burden of acute community-acquired infection among older 
people with diabetes (objective 2). Chapter 8 presents an investigation into the association 
between CKD and incidence of community-acquired LRTI (including pneumonia as a subset) 
and sepsis (objective 3). Chapter 9 presents a study of the extent to which community-
acquired LRTI may be preventable with pneumococcal and influenza vaccination among 
older people with diabetes, according to CKD status (objective 4). Chapter 10 describes a 
study of the association between CKD and short-term mortality following community-
acquired pneumonia and sepsis (objective 5). 
Results are presented in journal article format, each with a brief introduction, methods, 
results, and discussion of the individual study. Any additional results or further discussion 
relevant to the individual study is presented in the relevant chapter following the journal 
article. 
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Chapter 7. The burden of community-acquired infection among 
older people with diabetes mellitus 
This chapter presents and discusses the results of a study to investigate the burden of 
acute, community-acquired infections among older people with diabetes mellitus 
(objective 2). The results are presented and discussed in Paper 2. The Read code lists used 
to identify patients with diabetes mellitus (referred to in the article as additional 
supporting information) are available in Appendix B. The chapter concludes with a 
supplementary exploration of the impact of incomplete data linkages. 
7.1 Introduction to Paper 2  
This study used a retrospective cohort design to assess the infection incidence rates among 
patients aged ≥65 years with diabetes mellitus in CPRD (study cohort A, 3.9.1). This was a 
descriptive study. Key characteristics of the study population (including demographics, 
smoking status and common co-morbidities) were described at baseline, using definitions 
described in Chapter 6. 
The primary outcomes were incidence rates of community-acquired lower respiratory tract 
infection (LRTI), pneumonia (as a subset of LRTI), urinary tract infection (UTI), and sepsis. 
These infections were expected to be responsible for a high burden of morbidity or 
mortality among the study population. LRTI and UTI are common infections, responsible for 
a high burden of morbidity among the general population, and particularly among older 
people.[5, 136] Pneumonia and sepsis are severe infections, and the commonest infectious 
causes of death among patients receiving dialysis.[28] Methods used to identify 
community-acquired infection incidence were detailed in Chapter 4. Infection incidence 
rates were summarised by age, sex, region and year. 
Secondary outcomes were all-cause hospital admission within 28 days of infection onset 
and all-cause mortality within 28 and 90 days of infection onset. Infections may cause 
hospital admissions and death directly or indirectly through complications, such as 
myocardial infarction or stroke.[137] All-cause hospitalisation and mortality were therefore 
described within a time-period following infection, rather than including only 
hospitalisations and deaths attributed to infection. The time period was defined with 
respect to infection onset date, even for infections with longer duration, to avoid biasing 
estimates of hospitalisation and mortality upwards for patient groups prone to longer 
infection episodes.  
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Abstract
Aim To describe the incidence of acute community-acquired infections (lower respiratory tract infections, urinary tract
infections and sepsis) among the UK population aged ≥65 years with diabetes mellitus, and all-cause 28-day hospital
admission rates and mortality.
Methods We used electronic primary care records from the Clinical Practice Research Datalink, linked to death
certificates and Hospital Episode Statistics admission data, to conduct a retrospective cohort study from 1997 to 2011.
Results Among the 218 805 older people with diabetes there was a high burden of community-acquired infection,
lower respiratory tract infections having the highest incidence (crude rate: 152.7/1000 person-years) followed by urinary
tract infections (crude rates 51.4 and 147.9/1000 person-years for men and women, respectively). The incidence of all
infections increased over time, which appeared to be driven by the population’s changing age structure. Most patients
diagnosed with pneumonia and sepsis were hospitalized on the same day (77.8 and 75.1%, respectively). For lower
respiratory tract infections and urinary tract infections, a large proportion of 28-day hospitalizations were after the day
of diagnosis (39.1 and 44.3%, respectively), and a notable proportion of patients (7.1 and 5.1%, respectively) were
admitted for a cardiovascular condition. In the 4 weeks after onset, all-cause mortality was 32.1% for pneumonia
(3115/9697), 31.7% for sepsis (780/2461), 4.1% for lower respiratory tract infections (5685/139 301) and 1.6% for
urinary tract infections (1472/91 574).
Conclusions The present large cohort study provides up-to-date detailed infection incidence estimates among older
people with diabetes in the community, with variation by age, sex and region and over time. This should be of use for
patient communication of risk and future healthcare planning.
Diabet. Med. 31, 606–614 (2014)
Introduction
Community-acquired infections are common among older
adults, with a high burden of morbidity and mortality [1–4].
Pneumonia is the second most common cause of death in
people aged ≥75 years in England [5]. Hospitalizations for
infection are rising: age-standardized hospital admission rates
for community-acquired pneumonia and urinary tract infec-
tions more than doubled between 2000/2001 and 2010/2011
inEngland [6]. The increase in pneumonia hospitalizations has
been most marked among older adults [7]. The cost of
hospitalizations was estimated at £235 m for pneumonia
and £316 m for urinary tract infection in 2010/2011 [6].
Diabetes is a risk factor for hospitalization with and mortality
from infection [8–13]. A higher prevalence of comorbidities
such as diabetes mellitus has been suggested as a driving factor
for the rising burdenof infection-related hospitalizations [6,7].
The number of adults in England with diabetes mellitus is
predicted to rise from 3.1 million in 2010 to 4.6 million by
2030 [14]. Data on the burden of infection among older
adults with diabetes from a community or primary care
perspective, and their relationship with hospitalization and
mortality, are scarce. A large cohort study in Canada
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described the incidence of a range of infections among people
with diabetes of all ages, but not by age group, and noted
that the association between diabetes and infection changed
with age [15]. Studies of risk factors for community-acquired
infection among older adults have not been designed for
precise estimates of infection incidence among the subgroup
with diabetes [16,17].
Understanding the burden of infections in the community
among older adults with diabetes, and the short-term risk of
hospitalization and mortality after infection, is essential to
communicating risk of infections to patients, for designing
effective preventive care strategies, and for future healthcare
service planning.
The aim of the present study was to describe the incidence
of acute community-acquired infections (urinary tract infec-
tions, lower respiratory tract infections, including pneumo-
nia as a subset, and sepsis) among the UK population aged ≥
65 years with diabetes mellitus, and the short-term hospi-
talization and mortality rates following these infections.
Materials and methods
Data sources
The Clinical Practice Research Datalink (CPRD, formerly
GPRD) is a large UK database of anonymized primary care
medical records [18]. We used the May 2011 dataset,
comprising 12.8 million patient records at 627 practices.
Diagnoses are entered directly by healthcare workers during
the patient consultation, in the form of Read codes. The
records also include patient demographics, prescriptions,
health behaviours, test results and interactions with secondary
care such as referrals. TheCPRDpopulation has been found to
be representative of the general UK population [19]. The
CPRDasserts a range of data quality checks, and the validity of
recorded diagnoses in the CPRD is generally high [19,20].
Another strength of the CPRD is the availability of data
linkage for the subset of patients (> 50% of the total patients
included in the CPRD) registered at practices in England
which participate in CPRD data linkage [18]. The present
study used linked data on dates and diagnoses for all hospital
inpatient admissions to NHS hospitals in England from
Hospital Episodes Statistics, and mortality and socio-eco-
nomic status from the Office for National Statistics [21,22].
Study population and follow-up
Patients in CPRD aged ≥65 years with a diagnostic code for
diabetes mellitus were eligible for inclusion in the study. Two
lists of Read codes were used, ‘defining’ codes (sufficient
evidence of diabetes) and ‘possible’ codes (requiring confir-
mation). All patients with a ‘defining’ code were included
(e.g. C10F.11 ‘Type II diabetes mellitus’). Patients with a
‘possible’ code (e.g. 9N1Q.00 ‘Seen in diabetic clinic’) were
only included if there was a history of prescription of insulin
or oral antidiabetes medication (Tables S1 and S2).
Patients entered the study at whichever was the latest of the
following timepoints: the diabetes diagnosis date, 65th birth-
day, 1 year afterpractice registrationdate, the date thepractice
reached CPRD quality control standards or 1 April 1997. The
1-yeardelay fromregistrationwas topreventoverestimationof
incidence from recording of historical events at new patient
registration and early consultations [23]. Patients exited the
study atwhicheverwas the earliest of the following timepoints:
date of death (recorded in CPRD or Office for National
Statistics data), patient transferring out from the practice; last
data collection from the practice, or 31 March 2011.
Definition of infections
We studied urinary tract infection, lower respiratory tract
infection, pneumonia and sepsis. Urinary tract infections and
lower respiratory tract infections are common and are
responsible for a high burden of morbidity and mortality
among the older population, while pneumonia and sepsis are
rare but serious events which we would expect to be
well-ascertained in primary care records. Urinary tract
infections, lower respiratory tract infections and sepsis were
defined and analysed separately, while pneumonia was a
subset of lower respiratory tract infections.
Each infection was defined by a clinical diagnosis recorded
in primary care or hospital discharge records. To avoid
overestimation from repeat attendances for the same infec-
tion, diagnostic codes recorded within 28 days of one
another were attributed to a single episode of infection, with
the index date defined by the first diagnostic code, and
duration until 28 days after the last diagnostic code. Three
clinical epidemiologists agreed each list of diagnostic codes
What’s new?
• The present large cohort study is the first to describe the
burden of acute infections, including infections man-
aged in primary care, among older people with diabetes
for use in healthcare planning and communication of
risk with patients.
• On average per year among 1000 patients there
were 152.7 lower respiratory tract infections (95% CI
151.3–154.1) and 99.6 urinary tract infections (95%
CI 98.4–100.8).
• All infection rates were found to be increasing over
time.
• Within 28 days of pneumonia, 81.4% of patients were
hospitalized and 32.1% had died.
• An appreciable proportion of 28-day hospitalizations
after lower respiratory or urinary tract infection were
for cardiovascular conditions.
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to be used to define each infection before data analysis. Code
lists are available on request.
Pneumonia codes were a subset of lower respiratory tract
infection codes. If any lower respiratory tract infection
included a pneumonia code, the pneumonia index date was
the date of the first diagnosis of pneumonia, and the
pneumonia episode ended on the end-date of the lower
respiratory tract infection episode within which it occurred.
For conservative estimates, Read code IJ4.00 ‘Suspected
urinary tract infection’ alone did not define an infection but
did continue an ongoing episode of urinary tract infection if
it occurred within 28 days of another urinary tract infection
diagnostic code. This was designed to avoid over-recording
of urinary tract infections from non-confirmed diagnoses or
from repeat attendances with ongoing infection.
An infection was designated as hospital-acquired: if the
index diagnosis occurred during or within 14 days of a
hospital admission (recorded in Hospital Episodes Statistics
records for patients with linked data, or recorded in the
CPRD for patients with unlinked data); if the index diagnosis
was recorded in a hospital discharge record, but was not the
primary reason for hospital admission; or if any of the
diagnoses in the episode recorded that the infection was
postoperative or otherwise hospital-acquired (e.g. K190299
‘Postoperative urinary infection’). Other infections were
classified as community-acquired. These were necessarily
either first recorded in primary care records, or represented
the primary reason for hospital admission. The results
presented are for community-acquired infections only: hos-
pital-acquired infections were not included as outcomes.
Patients were at risk of a community-acquired infection
while eligible for study inclusion except during an infection
episode (community- or hospital-acquired) or during a
Hospital Episodes Statistics hospitalization spell or the
14 days after hospital discharge. Time at risk was calculated
separately for each type of infection; a patient could be at
risk of a lower respiratory tract infection despite an ongoing
urinary tract infection, for example.
The methods described above were based on or adapted
from previous work by Millett et al. [24] defining lower
respiratory tract infections and pneumonia.
Covariates
Socio-economic status was described using the index of
multiple deprivation, a composite area-level marker of depri-
vation [22]. TheOffice forNational Statistics indexofmultiple
deprivation estimates from 2007 were linked to individual
patient records by the postcode of patient residence. Smoking
status and BMI were described using CPRD data at the start
of follow-up (baseline). Comorbidities, medications and
vaccination status were described using CPRD records at
baseline and at study exit. No influenza vaccinations recorded
> 3 years before study entry were included at either timepoint.
For baseline comorbidities, medications and pneumococcal
vaccination, any record of positive status in the patient’s
records from their registration at the practice up to or
including the study entry date was eligible. Comorbidities
were based on diagnostic Read codes and included cardio-
vascular disease (myocardial infarction, other ischaemic
heart disease, congestive heart failure, stroke and transient
ischaemic attacks), chronic lung disease (chronic obstructive
pulmonary disease and chronic interstitial lung diseases but
not asthma) and peripheral vascular disease. Code lists are
available on request.
Data analysis
All data were used to calculate incidence and mortality
estimates. Analyses were restricted to patients with Hospital
Episodes Statistics-linked data for description of hospitaliza-
tions. Incidence rates were calculated for each infection using
Poisson regression with lexis expansions for age and calendar
year, and a random-effects model to accommodate multiple
episodes. We conducted likelihood ratio tests for the asso-
ciation of sex with incidence of each infection type, and for
the sex-specific linear association of age group with incidence
of each infection type. Age standardization used the Office
for National Statistics mid-year population estimate for the
UK in 2004 [22]. Age-standardized regional rates were
presented only within England, as Hospital Episodes Statis-
tics-linked data are not available for Scotland, Wales and
Northern Ireland, and the inability to exclude time in
hospital for these regions meant their rates were not
comparable. For each infection, the proportion of infections
among patients with Hospital Episodes Statistics-linked data
who were admitted to hospital within 4 weeks of diagnosis,
and the subset of these admitted to hospital on the day of
admission, were calculated. The cause of admissions for
patients admitted within 4 weeks was described using the
primary diagnosis of the first episode of the first admission
after infection onset. For each infection, the 4-week
case-fatality rate using all-cause mortality was calculated,
using deaths recorded in Office for National Statistics-linked
mortality data or CPRD records.
Data analysis was conducted using Stata version 12.0,
except age standardization, for which Microsoft Excel 2007
was used.
Ethics approval
The study was approved by the Independent Scientific
Advisory Group of the CPRD (ISAC reference 11_033) and
the London School of Hygiene and Tropical Medicine Ethics
Committee (LSHTM reference 6116).
Results
The study population comprised 218 805 patients, with up to
7 years follow-up (Table 1). Hospital Episodes Statistics
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data linkage was available for 128 373 patients (58.7%). The
median (interquartile range) age of the cohort at baseline was
71 (65–77 years). Few patients (n = 8137; 3.9%) were
medicated with insulin alone (with no history of oral
antidiabetes medications), consistent with a preponderance
of Type 2 diabetes mellitus in this age group. At baseline,
over a third of the cohort had a history of cardiovascular
comorbidity and 74.8% had received an influenza vaccina-
tion within the previous 3 years. Before the end of follow-up,
76.7% of patients had received a pneumococcal vaccine:
28.7% of unvaccinated patients (14 579/50 855) exited the
study before 2003, when the pneumococcal vaccine was
phased in for people > 60 years old [25].
Incidence by age and sex
For all infections, incidence increased sharply with increasing
age (Table 2). For example, pneumonia incidence was 6–8
times higher among patients aged ≥85 years than patients
aged 65–69 years.
Women were more likely to experience urinary tract
infections than men in every age group, but this difference
Table 1 Characteristics of study population at baseline and before end of follow-up (N = 218 805)
At Baseline Before end of follow-up
Men Women Men Women
Median (interquartile range) time in study, years* 3.9 (1.7–6.1) 4.0 (1.7–7.1)
Median (interquartile range) age, years 70 (65–76) 72 (66–79)
Ethnicity, n (%)
Bangladeshi 85 (0.8) 60 (0.1)
Black African 125 (0.1) 127 (0.1)
Black Caribbean 477 (0.4) 519 (0.5)
Black Other 88 (0.1) 83 (0.1)
Chinese 86 (0.1) 85 (0.1)
Indian 836 (0.8) 725 (0.7)
Mixed 89 (0.1) 99 (0.1)
Other Asian 216 (0.2) 169 (0.2)
Pakistani 270 (0.2) 219 (0.2)
White 44 400 (40.1) 43 524 (0.3)
Other 446 (0.4) 433 (0.4)
Missing or unknown 63 617 (57.4) 62 027 (57.4)
Socio-economic status: index of multiple deprivation quintile, n (%)
1 (least deprived) 12 105 (10.9) 10 485 (9.7)
2 14 037 (12.7) 12 831 (11.9)
3 12 290 (11.1) 11 893 (11.0)
4 11 595 (10.5) 12 273 (11.4)
5 (most deprived) 8626 (7.8) 9494 (8.8)
Not available 52 082 (47.0) 51 094 (47.3)
BMI, n (%)
<18.5 kg/m2 619 (0.6) 1741 (1.6)
18.5–24.9 kg/m2 22 140 (20.0) 22 691 (21.2)
25–29.9 kg/m2 47 111 (42.5) 34 086 (31.5)
30–34.9 kg/m2 26 076 (23.5) 24 279 (22.5)
≥35 kg/m2 9628 (8.7) 16 505 (15.3)
Missing 5161 (4.7) 8768 (8.1)
Smoking status, n (%)
Non-smoker 28 844 (26.1) 54 759 (50.7)
Current 16 380 (14.8) 12 812 (11.9)
Previous 63 764 (57.6) 37 650 (34.8)
Missing 1747 (1.6) 2849 (2.6)
Comorbidities, n (%)
Cardiovascular disease 43 927 (39.7) 34 979 (32.4) 55 539 (50.2) 46 439 (43.0)
Chronic lung disease 9258 (8.4) 7112 (6.6) 14 524 (13.1) 10 939 (10.1)
Peripheral vascular disease 9963 (9.0) 5609 (5.2) 16 195 (14.6) 9488 (8.8)
Vaccinations, n (%)
Pneumococcal: ever 55 641 (50.2) 51 103 (47.3) 87 418 (78.9) 80 532 (74.5)
Influenza: < 3 years before study entry 83 479 (75.4) 80 288 (74.3) 100 296 (90.6) 95 688 (88.5)
Antidiabetes medications, n (%)
Insulin only 4260 (3.8) 4049 (3.7) 4242 (3.8) 3897 (3.6)
Oral medication only 41 268 (37.3) 37 806 (35.0) 59 249 (53.5) 55 255 (51.1)
Both insulin and oral medication 6529 (5.9) 6082 (5.6) 15 924 (14.4) 14 491 (13.4)
None recorded 58 678 (53.0) 60 133 (55.6) 31 320 (28.3) 34 427 (31.9)
Total 110 735 108 070
*Time in study includes person-time as a hospital inpatient or during an infection, which was excluded from time at risk of
community-acquired infection.
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reduced with increasing age. For lower respiratory tract
infections, the incidence was similar for men and women
within each age group. For pneumonia, the incidence was
higher among men than women for all age groups >
70 years.
Trends over time
The crude incidence of all infections increased over time
(Fig. 1A). For example, the crude incidence of lower
respiratory tract infections among men was 117.1/1000
person-years in 1997 (95% CI 110.9–123.4), and 154.6
/1000 person-years in 2010 (95% CI 150.5–158.8). Much
of this trend disappeared after standardization for age
(Fig. 1B).
Differences by region
For lower respiratory tract infections, the highest incidence
rates were in the North West (men 139.9/1000 person-
years [95% CI 140.2–167.6]; women 177.5/1000 person-
years [163.3–191.7]), Yorkshire and the Humber and the
West Midlands regions, while London experienced the
lowest incidence (men 116.8/1000 person-years [95% CI
112.1–121.6]; women 114.6/1000 person-years [110.3–
119.0] (Fig. 2). For urinary tract infection, the two regions
with the highest incidence were the West Midlands (men
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74.5/1000 person-years [95% CI 69.6–79.4]; women
176.9/1000 person-years [95% CI 169.7–184.1]) and the
North East for both sexes (Table S3). Incidence rates by
region are not presented for sepsis and pneumonia because
of small numbers of events. Regional variation in lower
respiratory tract infection incidence was similar for men
and women.
Hospitalizations
The proportion of infections that resulted in hospitalization
within the subsequent 4 weeks were highest for pneumonia
and sepsis and lowest for lower respiratory tract infections
as a whole (including pneumonia) and urinary tract
infections (Table 3); however, the number of hospitaliza-
tions after an urinary tract infections diagnosis exceeded the
number after pneumonia and sepsis combined, for both
same-day and 28-day hospitalizations. Most patients who
were hospitalized for pneumonia and sepsis were admitted
on the day of diagnosis. For lower respiratory tract
infections and urinary tract infections, a large proportion
of hospitalizations within 4 weeks were not on the day of
infection diagnosis (6588/16 835; 39.1%, and 5159/11 651;
44.3%, respectively), and a notable proportion (1198/16
835; 7.1%, and 596/11 651; 5.1%, respectively) were
admitted for a cardiovascular condition (International
Classification of Diseases codes 10, chapter I ‘Diseases of
the circulatory system’).
Mortality
The case-fatality rate after pneumonia (32.1%) was similar
to that after sepsis [31.7% (Table 3)]. Although the 28-day
case-fatality rate after urinary tract infection was lower
(1.6%), the absolute number of deaths in the 28-days after
diagnosis of urinary tract infections (n = 1472) was still high
compared with those after sepsis (n = 780) because of the
higher incidence rate of urinary tract infections. The
case-fatality rate was similar for men and women for each
infection.
Discussion
To our knowledge this is the first large cohort study to give
detailed estimates of community-acquired infection rates
among older people with diabetes mellitus, including infec-
tions managed in primary care. There is a high burden of
community-acquired infection among older people with
diabetes, lower respiratory tract infections having the highest
incidence, followed by urinary tract infections. The incidence
of all infections increased with age (particularly pneumonia)
and increased over the study period; our age-standardization
analyses suggest that this increasing trend was driven by the
changing age structure of the population. Regional variation
in age-standardized rates could be attributable to the prev-
alence of risk factors for infection such as socio-economic
status, smoking, overweight and obesity, or diabetes control.
Lower respiratory tract infection incidence rate
100 – 124   /1000 person-years 
125 – 149 
150 – 174 
175 – 200 
Women Men
FIGURE 2 Age-standardized lower respiratory tract infection rates by region among older people with diabetes (patients eligible for Hospital
Episode Statistics data linkage, N = 128 373). Boundary data provided through EDINA UKBORDERS with the support of the Economic and Social
Research Council (ESRC) and Jisc and is copyright of the Crown.
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For lower respiratory tract infections and urinary tract
infections, it is interesting that a high proportion of hospi-
talizations within 28 days were not on the day of diagnosis.
This could reflect high underlying hospitalization rates in this
cohort, or could be attributable to exacerbation of underly-
ing comorbidities by acute infections. The considerable
number of hospitalizations within 4 weeks of lower respira-
tory tract infections and urinary tract infections with a
cardiovascular cause of admission (International Classifica-
tion of Diseases codes 10 chapter I ‘Diseases of the
circulatory system’) are particularly intriguing, as both
infections have been found to exacerbate underlying cardio-
vascular comorbidity [26].
Estimates of infection incidence rates specifically among
patients with diabetes are scarce. A cohort study of patients
with diabetes of all ages reported higher rates of pneumonia
and sepsis than the present study, but included both
hospital-acquired and community-acquired infections
together [15].
A cohort study in the CPRD of the general population aged
≥65 years (from which we drew our population of patients
with diabetes), using the same methodology as the present
study, found an incidence of 122.9/1000 person-years for
lower respiratory tract infection and 8.0/1000 person-years
for pneumonia among the general population aged
≥65 person-years [24]. The crude incidence of lower respi-
ratory tract infection and pneumonia observed in the present
study is ~50% higher. This could be consistent with a direct
effect of diabetes mellitus on infection incidence, or a higher
prevalence of risk factors for infection among patients with
diabetes, such as cardiovascular comorbidity or obesity. The
rates of pneumonia and urinary tract infections observed in
the present study are similarly raised compared with other
cohort studies of the general population of older people in
the UK/Europe [16,27].
Our sepsis estimate is lower than the rate of commu-
nity-acquired bloodstream infections in a large cohort study
in Canada, which found a rate of 4.5/1000 person-years
(95% CI 3.7–5.6) among a selected subset of the general
population aged ≥65 years with normal kidney function [28];
however, the Canadian study measured laboratory-defined
bacteraemia, while our outcome of interest was clinically
diagnosed sepsis.
The regional variation of lower respiratory tract infection
incidence within England has a similar pattern to that
observed in the general population [29].
The main strengths of the present study are: the large,
nationally representative cohort of an older population with
diabetes followed up over a prolonged period; the use of
primary care medical records to ascertain medically diag-
nosed community-acquired infections more fully than previ-
ous hospital-based studies; detailed definitions of
community-acquired infections including distinguishing
repeated infection-related consultations within 28 days from
recurrent infections; use of CPRD hospitalization codes andTa
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linked hospital data to exclude infections within 14 days of
discharge from hospital and to remove hospitalization
periods from time at risk for a more accurate estimation of
time at risk than previous studies; and the range of infections
considered.
The study methods were designed to produce conserva-
tive estimates of incidence rates, as follows. We used strict
criteria to identify and exclude possible hospital-associated
infections; we did not count diagnoses as new episodes of
infection if the record fell within 28 days of a previous code
for the same infection; patients without Hospital Episodes
Statistics data linkage had infections excluded from inci-
dence rates using CPRD indicators of possible hospi-
tal-acquired provenance (such as postoperative infection
codes) without removal of hospitalized time from time at
risk.
Potential limitations include secular changes in manage-
ment and diagnosis, but in the present study we saw no
evidence of this. We could not remove hospitalizations from
person-time at risk for patients with no Hospital Episodes
Statistics data linkage, which will have led to a slight
underestimate of infection rates.
Conclusions
The present study quantifies the high risk of commu-
nity-acquired infection among older people with diabetes,
and the proportion of patients who are admitted to hospital
or die within 4 weeks of infection onset. This will facilitate
discussions about risk of infections among older patients
with diabetes. Knowledge of regional variations and the
steep increase in risk with age among older people may assist
with designing effective preventive care strategies. Health-
care planners should consider the high infection incidence in
primary care and the proportion and pattern of 28-day
hospital admission in planning future healthcare provision
for this large and growing section of the UK population and
of healthcare users.
Future research should clarify the risk factors for infection
incidence, hospitalization and mortality, in particular any
modifiable risk or protective factors, among this growing
population.
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7.3 Discussion of the likely impact of incomplete data linkages 
on infection incidence estimates 
This section presents a more detailed discussion of the likely impact of incomplete data 
linkage on infection incidence estimates. Additional results referred to in this discussion are 
presented in 7.3.3. 
7.3.1 What is the likely impact of incomplete CPRD-HES linkage availability? 
HES linkage was available for 128,373/218,805 patients (58.7%). Practices in Northern 
Ireland, Scotland and Wales, which were not eligible for HES-linkage, contributed 50,910 
patients to the study population (23.3%). HES-linkage availability varied by region within 
England: only 57.5% of patients in CPRD within the East Midlands region had HES-linkage 
available, compared to 89.3% of patients in CPRD in the South West. Other than regional 
differences, patient characteristics were similar for patients with and without HES-linkage 
(Table 7.1). 
Time in hospital was removed from time at risk of community-acquired infection for 
patients with HES linkage, but this was not possible for patients without HES linkage. Thus, 
for patients without HES linkage, infection incidence rates are an under-estimation. The 
extent of this under-estimation will have been greater for patient groups who spent more 
time in hospital, such as older patients. Thus, the relationship between infection incidence 
and age may be even steeper than we observed.  
The difference in HES-linkage by region could result in greater under-estimation of 
infection incidence for regions with lower availability of HES-linkage. Table 7.2 presents 
region-specific estimates of infection incidence with 95% confidence intervals, to allow 
better assessment of the relationship between infection incidence rates by region than 
possible from the journal figure. There is no clear relationship between availability of HES 
linkage and region-specific infection incidence. For example, the East Midlands region has 
the lowest availability of HES-linkage, but is ranked 5th of 10 regions in terms of LRTI 
infection incidence for men and women. In addition, the regional variation in LRTI 
incidence we observed among older people with diabetes mirrors regional variation in 
primary care consultations for LRTI among the general population using Royal College of 
General Practitioners data.[138] This suggests that bias from varying HES-linkage 
availability is not sufficiently large to grossly distort estimates of regional variation in 
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infection incidence: the overall pattern is likely to be real, but region-specific incidence 
rates should be interpreted with caution.  
The proportion of patients admitted to hospital in the 28 days following infection onset 
was described only among patients with HES linkage available. Any differences in hospital 
admission thresholds between patients with and without HES linkage available could limit 
generalisability for patients without HES linkage. There may be differences in clinical 
practice resulting in different hospital admission thresholds between England and Scotland, 
Wales, and Northern Ireland for example, due to different provision of care in the 
community. However, hospital admission thresholds are unlikely to differ for patients with 
and without HES linkage within England, so these results are likely to be generalisable 
across England, rather than only to patients with HES linkage. 
7.3.2 What is the likely impact of incomplete CPRD-ONS linkage? 
A date of death was available from linked ONS records for 38,430 patients, of whom 23,707 
(61.7%) had a death recorded on the same day in CPRD (Table 7.3). Dates of death 
recorded in both CPRD and ONS showed good agreement, suggesting that CPRD death 
dates are reasonably accurate. Among the 7,600 patients with different dates of death 
recorded in CPRD and ONS datasets, 1934 (25.4%) were one day apart, and 6779 (89.2%) 
were within 28 days of each other. As CPRD death dates were used for patients without a 
death recorded in ONS, incomplete CPRD-ONS linkage may have resulted in under-
estimation of post-infection mortality. However, this appears to be a limited concern, as a 
high proportion of patients with a death recorded in ONS also had a death recorded in 
CPRD. 
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7.3.3 Additional results comparing the population with and without available 
data linkage 
The additional results presented here are discussed in 7.3.1 and 7.3.2. 
Table 7.1: Baseline characteristics of patients with and without HES linkage 
 Percentage 
of patients 
with HES 
linkage 
Characteristics 
of patients with 
HES linkage 
Characteristics of 
patients without 
HES linkage 
 median (IQR) median (IQR) 
Age (years) N/A 71 (65–77) 71 (65–77) 
Time in study (years) N/A 4.0 (1.8–7.3) 3.8 (1.8– 6.8)  
 row % n (column %) n (column %) 
Gender Female 58.6 63,295 (49.3) 44,775 (49.5) 
Socio-
economic 
status 1 
1 (least deprived) 50.5 19,236 (15.0) 18,853 (20.9) 
2 65.6 25,716 (20.0) 13,482 (14.9) 
3 58.8 26,664 (20.8) 18,670 (20.7) 
4 58.8 29,391 (22.9) 20,632 (22.8) 
5 (most deprived) 59.3 27,366 (21.3) 18,795 (20.8) 
Region North East 73.0 2,800 (2.2) 1,037 (1.2) 
North West 83.5 22,712 (17.7) 4,479 (5.0) 
Yorkshire & The 
Humber 
68.6 6,793 (5.3) 3,111 (3.4) 
East Midlands 57.7 5,168 (4.0) 3,785 (4.2) 
West Midlands 80.5 15,403 (12.0) 3,740 (4.1) 
East of England 79.3 15,455 (12.0) 4,042 (4.5) 
South West 89.3 17,075 (13.3) 2,046 (2.3) 
South Central 66.9 13,566 (10.6) 6,713 (7.4) 
London 71.4 15,694 (12.2) 6,284 (7.0) 
South East Coast 76.2 13,707 (10.7) 4,285 (4.7) 
Northern Ireland – – 7,601 (8.4) 
Scotland – – 19,248 (21.3) 
Wales – – 24,061(26.6) 
Body mass 
index (BMI) 
<18.5  57.4 1,354 (1.1) 1,006 (1.1) 
18.5–24.9 59.3 26,565 (20.7) 18,266 (20.2) 
25–29.9  58.9 47,822 (37.3) 33,375 (36.9) 
30–34.9  58.1 29,245 (22.8) 21,110 (23.3) 
35+ 58.5 15,298 (11.9) 10,835 (12.0)  
Missing 58.1 8,089 (6.3) 5,840 (6.5) 
Smoking 
status  
Non-smoker 58.0 48,470 (37.8) 35,133 (38.9) 
Current 57.0 16,644 (13.0) 12,548 (13.9) 
Ex-smoker 59.8 60,635 (47.2) 40,779 (45.1) 
Unknown 57.1 2,624 (2.0) 1,972 (2.2) 
Co-
morbidities  
Cardiovascular disease 57.3 45,185 (35.2) 33,721 (37.3) 
Chronic lung disease 57.1 9,351 (7.3) 7,019 (7.8) 
Peripheral vascular 
disease 
56.4 8,787 (6.8) 6,785 (7.5) 
Total patients 58.7 128,373 90,432 
HES, Hospital Episode Statistics 
1. practice-level index of multiple deprivation quintile 
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Table 7.2: Age-standardised infection incidence rates by region (n=218,805) 
Region 
 
n 
LRTI 
/1,000 years (95% CI) 
UTI 
/1,000 years (95% CI) 
Female Male Female Male 
North East 3,837 
177.5 
(163.3-191.7) 
153.9 
(140.2-167.6) 
182.4 
(166.1–198.8) 
66.9 
(57.0–76.7) 
North West 27,191 
199.5 
(193.6-205.4) 
185.1 
(179.1-191.1) 
151.9 
(146.6–157.2) 
61.0 
(57.6–64.5) 
Yorkshire & 
the Humber 
9,904 
190.8 
(180.9-200.7) 
183.6 
(173.6-193.6) 
131.7 
(123.5–139.9) 
53.5 
(48.3–58.7) 
East 
Midlands 
8,953 
152.7 
(144.4-161.0) 
153.8 
(144.6-163.0) 
143.2 
(143.4–152.0) 
55.8 
(50.2–61.4) 
West 
Midlands 
19,143 
190.4 
(183.6-197.3) 
194.5 
(187.1-201.8) 
176.9 
(169.7–184.1) 
74.5 
(69.6–79.4) 
East of 
England 
19,497 
143.0 
(137.5-148.5) 
149.9 
(144.0-155.7) 
143.7 
(137.7–149.8) 
59.8 
(55.9–63.7) 
South West 19,121 
133.7 
(128.3-139.0) 
136.6 
(131.2-142.0) 
149.8 
(143.5–156.2) 
56.9 
(53.2–60.7) 
South 
Central 
20,279 
134.1 
(129.0-139.2) 
138.0 
(132.6-143.3) 
161.2 
(154.7–167.8) 
62.2 
(58.3–66.2) 
London 21,978 
114.6 
(110.3-119.0) 
116.8 
(112. 1-121.6) 
131.2 
(125.9–136.6) 
56.8 
(53.0–60.6) 
South East 
Coast 
17,992 
122.6 
(117.5-127.7) 
129.3 
(123.9-134.7) 
134.3 
(128.3–140.3) 
51.9 
(48.2–55.6) 
LRTI, lower respiratory tract infection: UTI, urinary tract infection: 95% CI, 95% confidence interval 
 
 
 
Table 7.3: Deaths recorded in CPRD and ONS for patients aged ≥65 with diabetes mellitus (n=218,805) 
Source of date of death record Number (%) 
CPRD only 31,613 (45.1) 
ONS only 7,123 (10.2) 
CPRD and ONS coincident dates 23,707 (33.8) 
CPRD and ONS discrepant dates 7,600 (10.9) 
Total 70,043 
CPRD, Clinical Practice Research Datalink; ONS, Office for National Statistics  
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Chapter 8. The association of chronic kidney disease with 
incidence of acute, community-acquired infection 
This chapter presents a study of the association of markers of chronic kidney disease (CKD) 
with incidence of acute, community-acquired infections (objective 3). The results are 
presented and discussed in the journal article, and additional discussion follows in 8.3 and 
8.4. The full results of all sensitivity analyses referred to are available in Appendix E. 
8.1 Introduction to Paper 3 
This paper presents a retrospective cohort study to identify incidence rate ratios of 
infection according to markers of CKD using primary care records from the Clinical Practice 
Research Datalink linked to Hospital Episode Statistics admissions data. The study 
population comprised 191,672 patients aged ≥65 years with diabetes mellitus and a valid 
serum creatinine result during follow-up, with no history of renal replacement therapy 
(study population B), identified as described in 3.9.2.   
The outcomes were acute, community-acquired lower respiratory tract infection (LRTI), 
pneumonia (as a subset of LRTI) and sepsis. Methods used to identify community-acquired 
infection incidence were detailed in Chapter 4.  
The exposure of interest was CKD, identified by a history of proteinuria or reduced 
estimated glomerular filtration rate (eGFR) as described in Chapter 5.  
Incidence rate ratios were adjusted for a priori potential confounders of the association 
between markers of CKD and infection as described in the article. Detailed definitions of 
these confounders are described in Chapter 6. The interpretation of adjusted analyses are 
discussed in the article, and further detailed discussion follows in 8.3.4. 
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Original Investigation
CKD and the Risk of Acute, Community-Acquired Infections
Among Older People With Diabetes Mellitus: A Retrospective
Cohort Study Using Electronic Health Records
Helen I. McDonald, MSc,1 Sara L. Thomas, PhD,2 Elizabeth R.C. Millett, MSc,2 and
Dorothea Nitsch, MD1
Background: Hospital admissions for community-acquired infection are increasing rapidly in the United
Kingdom, particularly among older individuals, possibly reflecting an increasing prevalence of comorbid
conditions such as chronic kidney disease (CKD). This study describes associations between CKD
(excluding patients treated by dialysis or transplantation) and community-acquired infection incidence
among older people with diabetes mellitus.
Study Design: Retrospective cohort study using primary care records from the Clinical Practice Research
Datalink linked to Hospital Episode Statistics admissions data.
Setting & Participants: 191,709 patients 65 years or older with diabetes mellitus and no history of renal
replacement therapy, United Kingdom, 1997 to 2011.
Predictor: Estimated glomerular filtration rate (eGFR) and history of proteinuria.
Outcomes: Incidence of community-acquired lower respiratory tract infections (LRTIs, with pneumonia as a
subset) and sepsis, diagnosed in primary or secondary care, excluding hospital admissions from time at risk.
Measurements: Poisson regression was used to calculate incidence rate ratios (IRRs) adjusted for age,
sex, smoking status, comorbid conditions, and characteristics of diabetes. Estimates for associations of eGFR
with infection were adjusted for proteinuria, and vice versa.
Results: Strong graded associations between lower eGFRs and infection were observed. Compared with
patients with eGFRs$ 60 mL/min/1.73 m2, fully adjusted IRRs for pneumonia among those with eGFRs, 15,
15 to 29, 30 to 44, and 45 to 59 mL/min/1.73 m2 were 3.04 (95% CI, 2.42-3.83), 1.73 (95% CI, 1.57-1.92), 1.19
(95%CI, 1.11-1.28), and 0.95 (95%CI, 0.89-1.01), respectively. Associations between lower eGFRs and sepsis
were stronger, with fully adjusted IRRs up to 5.56 (95% CI, 3.90-7.94). Those associations with LRTI were
weaker but still clinically relevant at up to 1.47 (95% CI, 1.34-1.62). In fully adjusted models, a history of pro-
teinuria remained an independent marker of increased infection risk for LRTI, pneumonia, and sepsis (IRRs of
1.07 [95% CI, 1.05-1.09], 1.26 [95% CI, 1.19-1.33], and 1.33 [95% CI, 1.20-1.47]).
Limitations: Patients without creatinine results were excluded.
Conclusions: Strategies to prevent infection among people with CKD are needed.
Am J Kidney Dis. -(-):---. ª 2015 The Authors. Published by Elsevier Inc. on behalf of the National Kidney
Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
INDEX WORDS: Community-acquired infections; lower respiratory tract infections (LRTIs); pneumonia;
sepsis; non–dialysis-dependent chronic kidney disease (CKD); decreased renal function; estimated
glomerular filtration rate (eGFR); proteinuria; diabetes mellitus; aged; elderly; electronic health records.
Hospitalization rates for infections in the UnitedKingdom are increasing rapidly, particularly
among older individuals: age-standardized hospital
admission rates for community-acquired pneumonia
more than doubled between 2000 and 2010.1,2 The
driving factors behind this increase are unclear, but a
higher prevalence of comorbid conditions in the aging
population has been suggested.1,2
One comorbid condition associated with hospitali-
zation for infection is chronic kidney disease (CKD).
Patients receiving renal replacement therapy may be at
increased infection risk due to their treatment. This
study focuses on patients with CKD not treated by
dialysis or transplantation, which will be referred to as
CKD. A graded association between increasing
severity of CKD and higher risk of hospitalization
with pneumonia and sepsis has been reported, even at
early stages of CKD.3-5 These studies identiﬁed CKD
by reduced estimated glomerular ﬁltration rate (eGFR).
Proteinuria also has been found to indicate an
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increased risk of infection-related hospitalization
among patients with diabetes.6,7 CKD is a risk factor
for poor prognosis from infection, so this could be
driven by a higher chance of hospital admission for
patients with community-acquired infection if they
have CKD.8 It is unclear whether CKD is a risk factor
for higher incidence of infection in the community.
One large case-control study identiﬁed CKD as a risk
factor for incidence of community-acquired pneu-
monia in primary care, but relied on routine diagnosis
of CKD in the general population and did not exclude
patients receiving renal replacement therapy.9
There is a high prevalenceofCKDamongpeoplewith
diabetes, particularly older people.10-12 Patients with
diabetes are monitored regularly in primary care for
CKD, and this has been ﬁnancially incentivized in the
United Kingdom since 2004.13,14 Thus, studying people
with diabetes minimizes the potential for ascertainment
bias in estimating the association between CKD and
infection from routinely collected electronic health re-
cords. The subset of the UK population with diabetes
mellitus and aged 65 years or older is large and growing
and experiences a high burden of infection.15,16 This
population also is at higher risk of infectious complica-
tions such as acute kidney injury.17 If CKD is a risk
factor for infection incidence among older people with
diabetes, this could be important to health service plan-
ning, as well as to patients and their clinicians.
We aimed to describe, among older people with
diabetes, the associations between CKD (excluding
patients with a history of renal replacement therapy)
and community-acquired lower respiratory tract
infection (LRTI), pneumonia (as a subset of LRTI),
and sepsis. We used linked health records to identify
infections managed in primary or secondary care.
METHODS
Data Sources
We used the May 2011 data set of the Clinical Practice Research
Datalink (CPRD), a database of anonymized primary care medical
records comprising 12.8 million patient records at 627 practices in
the United Kingdom.18 Data include patient demographics, health
behaviors, test results, diagnoses, and prescriptions. The CPRD
population is representative of the general UK population and the
validity of recorded diagnoses generally is high.19,20 Linked data
are available for patients registered at consenting English prac-
tices. For linked patients, this study used linked data for all hos-
pital inpatient admissions to National Health Service hospitals in
England from Hospital Episodes Statistics (HES) and socioeco-
nomic status from the Ofﬁce for National Statistics.21,22
Study Population and Follow-up
All patients in CPRD at any point between April 1997 and
March 2011 with diabetes mellitus, aged 65 years or older, with at
least one valid serum creatinine result during the study period, and
with no history of renal replacement therapy were eligible. The
deﬁnition of diabetes was based on diagnostic Read codes.
“Deﬁnite” codes, for example, C10F.00 Type 2 diabetes mellitus,
were sufﬁcient evidence of diabetes. “Possible” codes, for
example, 90LA.11 Diabetes monitored, required an antidiabetes
medication prescription for conﬁrmation. Full code lists were
published previously.15 Patients met eligibility criteria at the latest
date of diabetes diagnosis, 65th birthday, 1 year after practice
registration, practice fulﬁlling CPRD quality control standards, or
April 1, 1997. Their study entry date was their ﬁrst valid serum
creatinine result after the eligibility criteria were met. Patients left
the study at the earliest date of death, leaving the practice, last data
collection from the practice, renal replacement therapy (dialysis or
kidney transplantation), or March 31, 2011.
Deﬁnition of CKD
We estimated glomerular ﬁltration rate from primary care serum
creatinine test results, multiplied by 0.95 to correct for lack of
isotope-dilution mass spectrometry standardization, using the
CKD-EPI (CKD Epidemiology Collaboration) creatinine equa-
tion.23-25 We included adjustment for black ethnicity.26 To reduce
misclassiﬁcation of eGFR from variability in serum creatinine
results or acute illness, we used a last-carried-forward method,
with eGFR initially deﬁned using the creatinine result that marked
entry to the study and updated at each subsequent creatinine result
so that eGFR was always deﬁned by the single most recent
creatinine result, as previously performed by James et al.3,27 For
our main analyses, we used eGFR categories corresponding to
those used in diagnosis (,15, 15-29, 30-44, 45-59, and $60 mL/
min/1.73 m2).25 During the study period, many UK laboratories
did not report the speciﬁc value of eGFR results if they
were $60 mL/min/1.73 m2 and so we did not distinguish eGFR
categories . 60 mL/min/1.73 m2 in the main analysis. We
repeated the ﬁnal model including additional separate categories
for eGFR of 60 to 74, 75 to 89, and $90 mL/min/1.73 m2, with
patients with eGFRs of 75 to 89 mL/min/1.73 m2 as a reference
group.
Either a positive urine protein test result or a diagnosis of
proteinuric kidney disease in CRPD deﬁned onset of a history of
proteinuria. We excluded urine protein test results that occurred on
the same day as a diagnostic Read code for urinary tract infection.
Figure 1. Flowchart of study eligibility and participation.
*Baseline characteristics described in Table 1.
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We did not count trace results as positive and checked records for
internal consistency.
Deﬁnition of Infections
We studied 3 acute community-acquired infections: LRTI
(which included diagnoses such as inﬂuenza and acute bronchitis),
pneumonia (as a subset of LRTI), and sepsis. Either diagnostic
Read codes in CPRD or any International Classiﬁcation of Dis-
eases, Tenth Revision code that formed the primary diagnostic
code on hospital admission in HES could deﬁne an infection. To
avoid overestimation from repeat attendances for the same infec-
tion, diagnostic codes recorded within 28 days of one another were
attributed to a single episode of infection, with index date deﬁned
by the ﬁrst diagnostic code and duration until 28 days after the last
diagnostic code. If any LRTI included a pneumonia code, the
pneumonia episode was considered to start from the ﬁrst instance
of the pneumonia code and end on the end date of the LRTI within
which it occurred. Any infection with onset date during an HES
hospitalization spell, within 14 days after hospital discharge, or
that included a code for postoperative infection was identiﬁed as a
hospital-acquired infection and excluded. These methods were
described in detail previously.15,28
Time at Risk
Patients were not at risk of a community-acquired infection
during an infection (community or hospital acquired), during an
HES hospitalization spell, or within 14 days following hospital
discharge, and these periods were removed from time at risk. Time
Table 1. Baseline Characteristics of Potentially Eligible Study Population by Baseline eGFR
No Scr (n 5 24,738)a eGFR $ 60 (n 5 124,521)b eGFR , 60 (n 5 68,952)b
Female sex 12,662 (51.2) 54,246 (43.6) 40,907 (59.3)
Age category
65-69 y 7,356 (29.7) 63,364 (50.9) 15,849 (23.0)
70-74 y 4,852 (19.6) 28,549 (22.9) 13,668 (19.8)
75-79 y 4,570 (18.5) 18,689 (15.0) 15,610 (22.6)
80-84 y 3,843 (15.5) 9,297 (7.5) 12,816 (18.6)
$85 y 4,117 (16.6) 4,622 (3.7) 11,009 (16.0)
SESc by practice
1: least deprived 3,839 (15.5) 21,818 (17.5) 12,341 (17.9)
2 4,269 (17.3) 22,312 (17.9) 12,515 (18.2)
3 5,101 (20.6) 26,136 (21.0) 13,962 (20.3)
4 6,037 (24.4) 28,355 (22.8) 15,500 (22.5)
5: most deprived 5,492 (22.2) 25,900 (20.8) 14,634 (21.2)
Smoking status
Current smoker 3,976 (16.1) 21,398 (17.2) 9,127 (13.2)
Ex-smoker 7,034 (28.4) 51,901 (41.7) 25,991 (37.7)
Nonsmoker 10,968 (44.3) 50,551 (40.6) 32,741 (47.5)
Missing 2,760 (11.2) 671 (0.5) 1,093 (1.6)
Comorbid conditions
Ischemic heart disease 6,381 (25.8) 30,743 (24.7) 23,308 (33.8)
Congestive heart failure 3,108 (12.6) 6,221 (5.0) 10,122 (14.7)
Hypertension 12,229 (49.4) 73,263 (58.8) 45,915 (66.6)
Cerebrovascular disease 4,169 (16.9) 13,157 (10.6) 11,500 (16.7)
Other dementia 1,350 (5.5) 1,651 (1.3) 1,889 (2.7)
Chronic lung disease 2,344 (9.5) 9,266 (7.4) 5,847 (8.5)
Antidiabetes medications
Insulin only 1,407 (5.7) 3,936 (3.2) 3,346 (4.9)
Oral medication only 9,811 (39.7) 54,635 (43.9) 27,169 (39.4)
Both insulin and oral 1,473 (5.6) 8,078 (6.5) 5,764 (8.4)
None recorded 12,047 (48.7) 57,872 (46.5) 32,673 (47.4)
Hemoglobin A1c
d
Good 7,256 (29.3) 58,177 (46.7) 31,026 (45.0)
Borderline 5,185 (21.0) 46,122 (37.0) 24,157 (35.0)
Poor 1,431 (5.8) 7,433 (6.0) 4,142 (6.0)
None recorded 10,866 (43.9) 12,789 (10.3) 9,627 (14.0)
Note: N 5 218,211. Values are given as number (percentage). Baseline is date of study entry for study participants (n 5 191,709)
and date of eligibility for study entry for patients not included in the study due to having no available Scr result or no available smoking
status. eGFRs expressed in mL/min/1.73 m2.
Abbreviations: eGFR, estimated glomerular filtration rate; Scr, serum creatinine; SES, socioeconomic status.
aThese patients had no Scr result available and hence were not included in study.
bThese patients had an Scr result available and were included in study unless smoking status was missing.
cIndex of multiple deprivation.
dGood, ,53 mmol/mol (,7%); borderline, 53-86 mmol/mol (7%-10%); poor, .86 mmol/mol (.10%).
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at risk was calculated separately for each type of infection; a pa-
tient could be at risk of sepsis despite an ongoing LRTI, for
example.
Deﬁnition of Covariates
Age was deﬁned in 5-year age bands up to a ﬁnal category of 85
years or older. Socioeconomic status was assigned at practice level
using 2007 Ofﬁce for National Statistics estimates of the Index of
Multiple Deprivation, a composite area-level marker of depriva-
tion.22 Smoking status was identiﬁed as current, ex-smoker, or
nonsmoker from both HES and CPRD data. Smoking cessation
products were considered to indicate current smoking because
cessation success rates are low.29 The most recent smoking status
record by the study entry date deﬁned smoking status at baseline
when available; if not recorded, the ﬁrst subsequent record deﬁned
smoking status at baseline. Comorbid conditions (ischemic heart
disease, congestive cardiac failure, hypertension, cerebrovascular
disease, other dementia, and chronic lung disease) were deﬁned
using diagnostic CPRD Read codes. The ﬁrst diagnostic record at
any point in the patient’s records deﬁned onset of the condition.
Baseline hemoglobin A1c level was deﬁned by the most recent
hemoglobin A1c test result in CPRD prior to (or on) the study entry
date. Baseline diabetic medication history was deﬁned using
CPRD prescription records.
Data Analysis
Incidence rates were calculated for each infection using Poisson
regression with lexis expansions for age and a random-effects
model to adjust for multiple infection episodes. Analysis was
conducted separately for each type of infection (LRTI, pneumonia,
and sepsis) using 3 main regression models.
Negative proteinuria test results tend to be under-recorded in
primary care records.30 For comorbid conditions and proteinuria
status, absence of a positive record was treated as absence of
disease, and for hemoglobin A1c, absence of a recorded result was
included as a category of hemoglobin A1c status. We excluded
patients with no smoking status available.
Our ﬁrst model adjusted for age, sex, socioeconomic status at
practice level, and date prior to or post April 1, 2004, when
Quality Outcomes Framework guidelines introduced ﬁnancial in-
centives for recording CKD status among people with diabetes in
primary care that are suggested to have improved ascertainment of
CKD in primary care.31 Our second model additionally adjusted
for confounding by smoking status and comorbid conditions. This
second model was run both with all variables assessed at baseline
and separately with new onset of comorbid condition time updated
during the study (but not smoking status because changes in
smoking status are particularly vulnerable to reverse causation).
Our ﬁnal model additionally adjusted for hemoglobin A1c level
and diabetic medication history at baseline. All nonbinary cova-
riates were modeled as categorical variables.
Sensitivity analyses repeated the ﬁnal model with the following
adjustments: limiting follow-up to post April 1, 2004; restricting
the data set to patients with HES linkage available; and using only
the ﬁrst infection as an outcome.
All estimates for the associations of eGFR with infection were
adjusted for proteinuria, and vice versa, so that the effect estimates
for eGFR and proteinuria are independent.
We looked for evidence of interaction between eGFR and
proteinuria and between eGFR and age (65-74 and $75 years) in
the ﬁnal models for LRTI and pneumonia using likelihood ratio
tests to assess nested models with and without interaction terms.
We did not look for interaction in the sepsis regression model due
to the smaller number of events.
Stata, version 13.1 (StataCorp LP), was used for data analyses.
All code lists are available on request.
Ethics Approval
The study was approved by the Independent Scientiﬁc Advisory
Committee of the CPRD (ISAC reference 11_033A) and the
London School of Hygiene & Tropical Medicine Ethics Com-
mittee (LSHTM reference 6116).
RESULTS
Of 218,211 patients potentially eligible for inclu-
sion, 191,709 (87.9%) had a valid serum creatinine
result and complete data available (Fig 1). Study
participants were followed up for a median of 4.6
(interquartile range [IQR], 2.3-7.6) years. Median age
at study entry was 71 (IQR, 66-78) years. For 113,106
study participants (59.0%), HES linkage was avail-
able. The population with no available serum creati-
nine result had a high prevalence of missing data for
both smoking status (2,760 of 24,738 [11.2%]) and
hemoglobin A1c results (10,866 of 24,739 [43.9%]),
suggesting that this population may not attend pri-
mary care services frequently. The population with no
available creatinine result had a comorbid condition
proﬁle similar to patients with CKD stages 3 to 5 in
terms of prevalence of congestive heart failure and
cerebrovascular disease (Table 1).
We found good completeness of serum creatinine
result recording: only 11% of potentially eligible pa-
tients lacked a valid serum creatinine result (Fig 1). The
median time for which each creatinine result was car-
ried forward was 137 (IQR, 56-242) days. At study
entry, 67,859 (35.4%) participants had CKD stages 3 to
5, deﬁned as eGFR, 60 mL/min/1.73 m2, and 25,433
(13.3%) had a history of proteinuria (Table 2).25
We observed 115,080 LRTIs among 56,076 pa-
tients, 7,870 episodes of pneumonia among 7,095
patients, and 1,980 episodes of sepsis among 1,902
patients. Crude incidence rates were as follows:
LRTI, 155.8 (95% conﬁdence interval [CI], 154.3-
157.4)/1,000 person-years; pneumonia, 10.3 (95% CI,
Table 2. Prevalence of Markers of CKD at Baseline for Study
Participants
eGFR Proteinuria Absent History of Proteinuria Total
,15 307 234 (43.3) 541
15-29 3,373 1,205 (26.3) 4,578
30-44 14,857 3,417 (18.7) 18,274
45-59 38,672 5,794 (13.0) 44,466
60-74 52,168 6,726 (11.4) 58,894
75-89 41,446 5,379 (11.5) 46,825
$90 15,453 2,678 (14.8) 18,131
Total 166,276 25,433 (13.3) 191,709
Note: n 5 191,709. Markers of CKD are eGFR and history of
proteinuria. Values are given as number or number (row per-
centage). eGFR categories expressed in mL/min/1.73 m2.
Abbreviations: CKD, chronic kidney disease; eGFR, esti-
mated glomerular filtration rate.
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10.1-10.6)/1,000 person-years; and sepsis, 2.5 (95%
CI, 2.4-2.6)/1,000 person-years (Table 3).
Both eGFR and proteinuria were independent risk
markers for incidence of LRTI, pneumonia, and sepsis
(P , 0.001 for each analysis). A high incidence of
infection was observed among patients with CKD. For
example, crude LRTI rates were 228.0 (95% CI,
219.8-236.2)/1,000 person-years among patients with
eGFRs of 15 to 29 mL/min/1.73 m2 compared to 143.0
(95% CI, 141.3-144.7)/1,000 person-years among pa-
tients with eGFRs $ 60 mL/min/1.73 m2. The associ-
ation between eGFR and infection incidence was
graded, with increased infection incidence even at
early stages of CKD. Strong and graded associations
between reduced eGFR and infection remained after
adjustment for age, sex, smoking status, comorbid
conditions, and characteristics of diabetes. Compared
to eGFR $ 60 mL/min/1.73 m2, fully adjusted inci-
dence rate ratios (IRRs) for pneumonia were 3.04 (95%
CI, 2.42-3.83), 1.73 (95% CI, 1.57-1.92), 1.19 (95%
CI, 1.11-1.28), and 0.95 (95% CI, 0.89-1.01) for
eGFRs , 15, 15 to 29, 30 to 44, and 45 to 59 mL/min/
1.73 m2, respectively. The associations between
reduced eGFR and sepsis were stronger, with fully
adjusted IRRs up to 5.56 (95% CI, 3.90-7.94), while
those with LRTI were less strong but still clinically
relevant, with fully adjusted IRRs up to 1.47 (95% CI,
1.34-1.62; Table 3). Fully adjusted rates and rate ratios
using patients with eGFRs of 75 to 89 mL/min/1.73 m2
as a reference group suggested a J-shaped relationship
between eGFR and LRTI and pneumonia incidence
(Fig 2; Table S1 [available as online supplementary
material]).
Proteinuria was an independent risk marker for
infection incidence after adjustment for eGFR
(Table 4). In minimally adjusted analyses, patients
with a history of proteinuria had a higher incidence of
LRTI, pneumonia, and sepsis (IRRs of 1.13 [95% CI,
1.10-1.15], 1.37 [95% CI, 1.30-1.45], and 1.44 [95%
CI, 1.30-1.59], respectively) compared with patients
Table 3. Infection Rates With Corresponding Rate Ratios by eGFR
Infection
No. of
Events
Time at
Risk
(person-y)
Crude Rate/1,000
Person-y (95% CI)
Minimally
Adjusteda,b
Adjusted for
Comorbid
Conditions
at Baselineb,c
Adjusted for
Time-Updated
Comorbid
Conditionsb,d
Adjusted for
Characteristics
of Diabetesb,e
LRTI 115,080 808,194 155.8 (154.3-157.4)
eGFR, 15 607 2,532 295.3 (265.8-324.8) 1.78 (1.61-1.96) 1.67 (1.51-1.85) 1.52 (1.38-1.68) 1.47 (1.34-1.62)
eGFR 15-29 5,153 25,016 228.0 (219.8-236.2) 1.38 (1.33-1.43) 1.28 (1.23-1.33) 1.20 (1.15-1.24) 1.17 (1.13-1.22)
eGFR 30-44 16,557 96,214 188.7 (184.8-192.6) 1.19 (1.16-1.22) 1.13 (1.10-1.15) 1.09 (1.07-1.12) 1.08 (1.05-1.10)
eGFR 45-59 29,783 204,866 159.9 (157.4-162.4) 1.06 (1.05-1.08) 1.04 (1.03-1.06) 1.03 (1.02-1.05) 1.03 (1.01-1.04)
eGFR$ 60 62,980 479,565 143.0 (141.3-144.7) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pneumoniaf 7,870 816,517 10.3 (10.1-10.6)
eGFR, 15 99 2,570 52.8 (40.7-65.0) 4.26 (3.37-5.38) 3.69 (2.92-4.65) 3.25 (2.58-4.10) 3.04 (2.42-3.83)
eGFR 15-29 650 25,362 30.6 (27.8-33.3) 2.29 (2.07-2.53) 2.01 (1.82-2.23) 1.82 (1.65-2.01) 1.73 (1.57-1.92)
eGFR 30-44 1,523 97,360 17.4 (16.4-18.4) 1.42 (1.33-1.53) 1.31 (1.22-1.40) 1.23 (1.15-1.32) 1.19 (1.11-1.28)
eGFR 45-59 1,980 207,025 10.2 (9.7-10.7) 1.01 (0.95-1.07) 0.98 (0.93-1.04) 0.96 (0.91-1.02) 0.95 (0.89-1.01)
eGFR$ 60 3,618 484,200 7.8 (7.6-8.1) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Sepsis 1,980 816,826 2.5 (2.4-2.6)
eGFR, 15 41 2,572 17.8 (11.8-23.9) 7.40 (5.19-10.55) 6.93 (4.86-9.90) 6.19 (4.34-8.82) 5.56 (3.90-7.94)
eGFR 15-29 186 25,382 8.1 (6.8-9.3) 3.29 (2.75-3.94) 3.01 (2.52-3.61) 2.69 (2.25-3.23) 2.50 (2.08-3.00)
eGFR 30-44 387 97,416 4.2 (3.7-4.6) 1.80 (1.58-2.06) 1.70 (1.49-1.95) 1.60 (1.39-1.83) 1.51 (1.32-1.73)
eGFR 45-59 499 207,103 2.5 (2.2-2.7) 1.19 (1.06-1.34) 1.17 (1.04-1.32) 1.14 (1.02-1.29) 1.11 (0.99-1.25)
eGFR$ 60 867 484,352 1.8 (1.7-2.0) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Note: Unless otherwise indicated, values are given as rate ratio (95% CI). eGFR categories expressed in mL/min/1.73 m2.
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; LRTI, lower respiratory tract infection.
aAdjusted for proteinuria (updated), age (updated), sex, socioeconomic status by practice, and financial year prior to or post 2004.
bP , 0.001 for all rate ratios. Likelihood ratio test for inclusion of eGFR as a categorical variable in the model.
cAdjusted for proteinuria (updated), age (updated), sex, socioeconomic status by practice, financial year prior to or post 2004,
ischemic heart disease, congestive cardiac failure, hypertension, cerebrovascular disease, other dementia, chronic lung disease, and
smoking at baseline.
dAdjusted for proteinuria (updated), age (updated), sex, socioeconomic status by practice, financial year prior to or post 2004,
ischemic heart disease (updated), congestive cardiac failure (updated), hypertension (updated), cerebrovascular disease (updated),
other dementia (updated), chronic lung disease (updated), and smoking (baseline).
eAdjusted for proteinuria (updated), age (updated), sex, socioeconomic status by practice, financial year prior to or post 2004,
ischemic heart disease (updated), congestive cardiac failure (updated), hypertension (updated), cerebrovascular disease (updated),
other dementia (updated), chronic lung disease (updated), smoking (baseline), hemoglobin A1c level (baseline), and antidiabetes
medication history (baseline).
fSubset of LRTI.
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without a history of proteinuria. These associations
were diminished but persisted after adjustment for
time-updated comorbid conditions and characteristics
of diabetes for LRTI, pneumonia, and sepsis (IRRs of
1.07 [95% CI, 1.05-1.09], 1.26 [95% CI, 1.19-1.33],
and 1.33 [95% CI, 1.20-1.47], respectively). The effect
of proteinuria did not vary by eGFR category (Fig 2).
No clinically important interaction between age
and eGFR was observed for LRTI or pneumonia.
Sensitivity analyses limiting follow-up to post April
2004, restricting the data set to patients with HES
linkage available, or using only the ﬁrst infection
as an outcome found similar results to the main
analysis.
DISCUSSION
In our study population of older patients with dia-
betes, there was a high burden of community-acquired
LRTI, pneumonia, and sepsis among those with CKD
(manifested as reduced eGFR and/or history of pro-
teinuria). Reduced eGFR and history of proteinuria
represented independent risk markers for incidence of
LRTI, pneumonia, and sepsis. Associations between
eGFR and infection incidence were graded, with
increased infection incidence at more severe stages of
CKD. These associations persisted after adjustment
for comorbid conditions, smoking status, and char-
acteristics of diabetes mellitus. The association be-
tween eGFR and infection was not modiﬁed by age.
Effect sizes were larger for sepsis than for pneumonia,
and for pneumonia than for LRTI.
The strengths of the study include the following:
ﬁrst, consideration of both eGFR and proteinuria in
mutually adjusted analyses; second, frequent moni-
toring of serum creatinine and proteinuria, allowing
good ascertainment of CKD status; third, the detailed
methods used to deﬁne infections, including exclu-
sion of time in hospital from time at risk and treating
recurrent consultations for infection within 28 days as
a single episode; and fourth, inclusion of infections
managed in primary care, not just those resulting in
hospitalization or death.
The study is limited by the nature of routinely
collected data; we may have underascertained pro-
teinuria or comorbid conditions. The high prevalence
of proteinuria and comorbid conditions observed in
the study population suggests that neither is an
extensive problem. Proteinuria monitoring has been
ﬁnancially incentivized in primary care for this pop-
ulation since 2004.32 A small percentage of the po-
tential study population had no available creatinine
results and therefore were not included. These people
did not appear to seek regular care, which may have
led to us underestimating the association between
CKD and infection. We do not have formal validation
study data for our outcomes, but the advantage of
linked data is capturing a more complete ascertain-
ment of infections than in the stand-alone data sets
used previously.
The complex relationships between CKD, infec-
tion, and cardiovascular disease limit interpretation
of the direction of any causal association between
CKD and infection. The same comorbid conditions,
such as cardiovascular events, may both cause and be
caused by CKD. Adjustment for baseline comorbid
conditions risks underestimation of the association
Figure 2. Fully adjusted infection rates/1,000 person-years
(with 95% confidence intervals) against category of estimated
glomerular filtration rate, by proteinuria status. Solid line, pa-
tients with a history of proteinuria; dashed line, patients with
no history of proteinuria. Rates adjusted for age (updated),
sex, socioeconomic status by practice, financial year prior to or
post 2004, ischemic heart disease (updated), congestive cardiac
failure (updated), hypertension (updated), cerebrovascular dis-
ease (updated), other dementia (updated), chronic lung disease
(updated), smoking (baseline), hemoglobin A1c level (baseline),
and antidiabetes medication history (baseline). *LRTI y-axis
scale is 10-fold greater than the pneumonia and sepsis scales.
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between CKD and infection by residual confounding
from new-onset comorbid conditions that may reﬂect
baseline risk factors for these comorbid conditions,
such as poorly treated hypertension prior to CKD.
Adjustment for time-updated comorbid conditions is
vulnerable to overadjusting for events that mediate
any effect of CKD on infection. We present both
models. The true association between CKD and
infection is likely to lie between the 2 results. We
avoided time-updating hemoglobin A1c levels and
smoking status because these are vulnerable to reverse
causality from infection (eg, pneumonia may motivate
smoking cessation). We also addressed the risk of
reverse causality by conducting a sensitivity analysis
in which we limited follow-up to the ﬁrst infection,
which found results similar to the main analysis. We
did not adjust for vaccination status because inter-
relationships between CKD status, receipt of vacci-
nation, and infection are likely to be complex and
looking formally for vaccine effectiveness was
beyond the scope of this report.
Our results may not be generalizable to the gen-
eral population without diabetes because there may
be a particular relationship between CKD and
infection among older people with diabetes. How-
ever, older people with diabetes are a large and
growing population with a high burden of CKD and
infection, and so our ﬁndings in this population are
important.
The associations we observed of preexisting eGFR
with sepsis and pneumonia were similar to those
observed between eGFR with bloodstream infections
and pneumonia diagnoses in hospital records among
the general population 65 years and older (although
different outcome deﬁnitions mean the absolute rates
are not comparable).3,5 A large case-control study in
the United Kingdom identiﬁed CKD as a risk factor
for primary care diagnosis of pneumonia (adjusted
odds ratio, 1.72; 95% CI, 1.3-2.07), but the unclear
deﬁnition of CKD may have included patients with an
increased risk of infection from renal replacement
therapy and did not permit stage-speciﬁc rate ratios.9
James et al3 and Dalrymple et al33 observed a J-
shaped association between eGFR and infection
risk, which was not present using cystatin C–based
eGFR. Our results suggested that patients with
eGFRs $ 90 mL/min/1.73 m2 had a slightly increased
risk of LRTI or pneumonia compared with those with
eGFRs of 75 to 89 mL/min/1.73 m2, but we did not
observe a J shape for the association of eGFR with
sepsis. James et al found that the association of eGFR
with hospitalization for pneumonia was weaker
among older age groups.3 We did not observe an
interaction between eGFR and age in the present
Table 4. Infection Rates With Corresponding Rate Ratios by Proteinuria Status
Infection
No. of
Events
Time at
Risk
(person-y)
Crude Rate/1,000
Person-y (95% CI)
Minimally
Adjusteda,b
Adjusted for
Comorbid
Conditions
at Baselineb,c
Adjusted for
Time-Updated
Comorbid
Conditionsb,d
Adjusted for
Characteristics
of Diabetesb,e
LRTI 115,080 808,194 155.8 (154.3-157.4)
Proteinuria 31,823 202,658 178.7 (175.7-181.8) 1.13 (1.10-1.15) 1.15 (1.13-1.17) 1.09 (1.07-1.11) 1.07 (1.05-1.09)
No proteinuria 83,257 605,536 148.9 (147.3-150.5) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Pneumoniaf 7,870 816,517 10.3 (10.1-10.6)
Proteinuria 2,646 204,908 14.4 (13.8-15.1) 1.37 (1.30-1.45) 1.40 (1.33-1.48) 1.31 (1.24-1.39) 1.26 (1.19-1.33)
No proteinuria 5,224 611,609 9.0 (8.8-9.3) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Sepsis 1,980 816,826 2.5 (2.4-2.6)
Proteinuria 712 205,002 3.6 (3.3-3.9) 1.44 (1.30-1.59) 1.46 (1.32-1.61) 1.41 (1.27-1.56) 1.33 (1.20-1.47)
No proteinuria 1,268 611,824 2.1 (2.0-2.2) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Note: Unless otherwise indicated, values are given as rate ratio (95% CI).
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; LRTI, lower respiratory tract infection.
aAdjusted for eGFR (updated), age (updated), sex, socioeconomic status by practice, and financial year prior to or post 2004.
bP , 0.001 for all rate ratios. Likelihood ratio test for inclusion of eGFR as a binary variable in the model.
cAdjusted for eGFR (updated), age (updated), sex, socioeconomic status by practice, financial year prior to or post 2004, ischemic
heart disease, congestive cardiac failure, hypertension, cerebrovascular disease, other dementia, chronic lung disease, and smoking
at baseline.
dAdjusted for eGFR (updated), age (updated), sex, socioeconomic status by practice, financial year prior to or post 2004, ischemic
heart disease (updated), congestive cardiac failure (updated), hypertension (updated), cerebrovascular disease (updated), other
dementia (updated), chronic lung disease (updated), and smoking (baseline).
eAdjusted for eGFR (updated), age (updated), sex, socioeconomic status by practice, financial year prior to or post 2004, ischemic
heart disease (updated), congestive cardiac failure (updated), hypertension (updated), cerebrovascular disease (updated), other
dementia (updated), chronic lung disease (updated), smoking (baseline), hemoglobin A1c level (baseline), and antidiabetes medication
history (baseline).
fSubset of LRTI.
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study, which may be due partly to our study popu-
lation being limited to older people. In a previous
study identifying albuminuria as a risk factor for
infection-related hospitalization among patients with
diabetes, eGFR was not an independent risk marker
for infection, and infections managed in primary
care were not included.6 To our knowledge, our
ﬁnding that proteinuria is a risk marker for incidence
of LRTI, pneumonia, and sepsis, independently of
eGFR, and including infections managed in primary
care, is novel.
This study found that the associations of reduced
eGFR and history of proteinuria with infection
appeared to be due in part to underlying accrued
cardiovascular and cerebrovascular comorbid condi-
tions, but a strong graded association remained after
adjustment for these. It has been suggested that CKD
as a risk marker for infection may be a surrogate for
chronicity of diabetes or poor glycemic control.6
Adjustments for cardiovascular and cerebrovascular
comorbid conditions will reﬂect chronicity and
severity of diabetes to a certain extent, but further
adjustment for severity and control of diabetes had
little effect on the associations between CKD and
infection, suggesting that the associations between
CKD and infections are not explained fully by these
factors. Stronger independent associations with CKD
were observed for pneumonia than LRTI, and stron-
ger still for sepsis, consistent with a view of CKD as a
risk factor for poorer prognosis and greater incidence
of infection. For clinicians managing older people
with diabetes, our ﬁndings may help identify patients
at increased risk of infection and inform discussions
about infection risk and vaccination.30 For policy
makers, the association of CKD with a high burden of
morbidity from infection is important for health ser-
vice planning because the populations with diabetes
and CKD are predicted to grow.34
Several unanswered questions remain. More
research is needed to identify the biological mecha-
nisms underlying the associations of proteinuria and
eGFR with infection and to improve infection pre-
vention strategies. For example, better understanding
of vaccine effectiveness among people with CKD
could inform whether pneumococcal and inﬂuenza
vaccination recommendations should include people
with proteinuria.35
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Table S1: Sensitivity analysis of the association between estimated glomerular 
filtration rate (eGFR) and infection incidence, using patients with eGFR 75-90 
ml/min/1.73m2 as the reference group 
 eGFR 
ml/min/1.73m2 
Number of 
infections 
Rate ratio 
(95% confidence interval) a 
P b 
Lower respiratory tract infection (LRTI) 
 <15 607 1.48 (1.34–1.64) 
<0.001 
 15-29 5,153 1.18 (1.13–1.23) 
 30-44 16,557 1.08 (1.05–1.11) 
 45-59 29,783 1.03 (1.01–1.06) 
 60-74 31,538 1.00 (0.98–1.02) 
 75-90 24,110 1 (reference) 
 ≥90 7,063 1.09 (1.06–1.13) 
 Total 114,811   
Pneumonia (subset of LRTI) 
 <15 99 2.97 (2.35–3.76) 
<0.001 
 15-29 650 1.69 (1.51–1.88) 
 30-44 1,523 1.16 (1.07–1.27) 
 45-59 1,980 0.93 (0.86–1.00) 
 60-74 1,815 0.92 (0.85–0.99) 
 75-90 1,397 1 (reference) 
 ≥90 387 1.40 (1.24–1.58) 
 Total 7,851   
Sepsis 
 <15 41 5.72 (3.96–8.26) 
<0.001 
 15-29 186 2.57 (2.09–3.15) 
 30-44 387 1.55 (1.32–1.83) 
 45-59 499 1.15 (0.99–1.33) 
 60-74 449 1.03 (0.88–1.18) 
 75-90 324 1 (reference) 
 ≥90 87 1.11 (0.87–1.42) 
 Total 1,973   
eGFR, estimated glomerular filtration rate 
a. Adjusted for proteinuria (updated), age (updated), sex, socio-economic status by practice, 
financial year prior to or post 2004, ischaemic heart disease (updated), congestive cardiac failure 
(updated), hypertension (updated), cerebrovascular disease (updated), other dementia (updated), 
chronic lung disease (updated) and smoking (baseline). 
b. Likelihood ratio test for inclusion of eGFR as a categorical variable in the model 
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8.3 Further discussion of adjusted estimates of CKD and 
infection incidence  
The study presented several models for the association between markers of CKD and 
infection incidence, with increasingly full adjustment for patient characteristics. The 
“minimally adjusted model” was adjusted for time-updated age (within 5-year age bands 
up to age ≥85 years), sex, practice-level socio-economic status, financial year prior to or 
post 2004, and eGFR or proteinuria. The association between CKD and infection incidence 
was also modelled with additional adjustment for patient co-morbidities and smoking 
status at baseline (the “baseline co-morbidities model”); with adjustment for time-updated 
co-morbidities and smoking status at baseline (the “time-updated model”); and with 
further adjustment for characteristics of diabetes at baseline (the “characteristics of 
diabetes model”). The results of each analysis are presented in Table 3 of Paper 3 (8.2). 
This section offers an expanded discussion of the advantages and disadvantages of each 
model in describing the association between CKD and infection incidence, taking LRTI as an 
illustrative example, in the context of the conceptual model used to design the study. 
8.3.1 How were effect estimates altered by adjustment for co-morbidities? 
The minimally adjusted model provided effect estimates for the association of CKD with 
infection incidence which was not explained by age, sex, socio-economic status, or changes 
in recording practice pre and post-QOF. Estimates of the association between CKD and 
infection from the minimally adjusted model may be explained by other confounding 
patient characteristics. 
Figure 8.1 shows a simplified conceptual diagram illustrating key relationships between 
selected patient characteristics at baseline, new-onset CKD, and a first subsequent LRTI. 
Age, sex and socio-economic status are associated with each component of the diagram, 
and these relationships are not individually shown. Baseline patient characteristics were 
considered a priori confounders if they were risk factors for community-acquired LRTI, and 
also associated with CKD, but not on any causal pathway between CKD and LRTI. Baseline 
patient characteristics identified as a priori confounders of the association between 
markers of chronic kidney disease and first incidence of community-acquired LRTI among 
older people with diabetes included: age, sex, socio-economic status, smoking status, 
ischaemic heart disease, hypertension, cerebrovascular disease, and chronic lung disease. 
The omission of other patient characteristics from this model is discussed in 8.3.6. Several 
of these characteristics were expected a priori to have a strong confounding effect: for 
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example, smoking is an important risk factor CKD and for LRTI (directly and via co-
morbidities including COPD and cardio- and cerebrovascular disease). 
Overweight is represented on the diagram as an upstream cause of CKD and infection; 
however, the relationship between overweight and CKD varies over the lifecourse and is 
straightforward. Historical weight records were not uniformly available, and so mediators 
of the causal relationship of overweight with CKD and infection were adjusted for instead 
of overweight itself.  
Figure 8.1 Key relationships between selected baseline patient characteristics, new-onset chronic kidney 
disease (CKD) and lower respiratory tract infection (LRTI) 
Chronic kidney 
disease (CKD)
Lower 
respiratory tract 
infection (LRTI)
Hypertension
Smoking
Overweight
Hyperlipidaemia
COPD
Ischaemic 
heart 
disease
Cerebrovascular 
disease
Stroke/ TIA
MI
Older age
Sex
Diabetes severity, 
control, duration 
and type
Socio-economic status
 
MI, myocardial infarction; TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease 
Adjustment for these a priori confounders appeared to have a surprisingly small impact. 
Estimates for the association between eGFR and infection incidence were slightly lower in 
the baseline comorbidities model than the minimally adjustment model, but the 
confidence intervals for most estimates overlapped between the two models, and the size 
of each difference was too small to be of particular clinical relevance. Estimates of the 
association between CKD and infection incidence in the time-updated model were slightly 
lower again, but still similar in magnitude (8.2: Table 1, Paper 3).  
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8.3.2 Why were effect estimates so little altered by adjustment for co-
morbidities? 
There are three main explanations for the similarity between the results of different 
models. First, the association of CKD with infection incidence may in fact be relatively 
independent of confounding by these patient characteristics. This appears unlikely, given 
that a number of co-morbidities were identified which were expected to have a strong 
confounding effect on the association between CKD and infection incidence.  
Second, misclassification of patient characteristics could have resulted in under-adjustment 
for confounding in the adjusted models. Classification of co-morbidities was vulnerable to 
under-ascertainment, as a negative could not be definitely established. Routinely-collected 
health records will positively identify the presence of a co-morbidity, but not its absence. 
Thus the absence of a co-morbidity was assumed for all patients without a relevant 
diagnostic code. In general, diagnostic codes recorded in CPRD have been found to have a 
high positive predictive value, in that a high proportion of patients with a diagnostic code 
have been confirmed as having the relevant co-morbidity. However, the proportion of 
patients with a co-morbidity who have a relevant diagnostic code (sensitivity) is less well 
established.[72] As most of the co-morbidities were a priori positive confounders of the 
association, under-ascertainment of co-morbidities could have resulted in over-estimation 
of the association between CKD and infection incidence in all adjusted models.  
This risk was mitigated by studying a highly monitored population, by using detailed 
codelists, modelling each a priori confounder individually to allow adjustment for 
confounding by individual characteristics to be undiluted by any patient characteristics 
incorrectly identified as potential confounders, and taking a tailored approach to 
categorising co-morbidities where there were specific concerns. For example, congestive 
cardiac failure has been found to have a particularly strong association with LRTI and so 
was included as an independent variable separately from ischaemic heart disease.[56] 
Dementia was also separated into two independent variables: cerebrovascular dementia 
was included with stroke and TIA as evidence of cerebrovascular disease, which shares risk 
factors with CKD including a history of smoking, hypertension and age. Although only 
dementia of cerebrovascular aetiology is likely to confound the association between CKD 
and LRTI, the aetiology of dementia will not necessarily be identified, and may be less likely 
to be investigated or coded among patients with other severe co-morbidities or older age. 
To capture cerebrovascular dementia recorded using more general codes I also adjusted for 
‘other dementia’, a category which included all dementia which did not have a 
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cerebrovascular aetiology specified (for example Eu02z00 ‘[X] Unspecified dementia’). This 
category will inevitably include patients with dementia of other aetiologies, and so to 
minimise misclassification of cerebrovascular dementia, ‘other dementia’ was retained as 
an independent variable. 
A reassuringly high prevalence of co-morbidities was ascertained (8.2: Table 1, Paper 3). 
The effect estimates for the association of CKD and infection were large, and only slightly 
reduced by adjustment for the high prevalence of co-morbidities which was identified, 
suggesting that the confounding effect of these co-morbidities was not large, and a low 
level of under-ascertainment could perhaps be tolerated without invalidating the adjusted 
effect estimates. The possibility of residual confounding from under-ascertained co-
morbidities resulting in over-estimation of the association between CKD and infection 
incidence cannot be excluded, but is unlikely to be a large enough issue to fully explain the 
similarity of observed effect estimates across adjusted models. 
Third, the similarity may result from partial control for confounding already achieved in the 
minimally adjusted model. Partial control of two important a priori confounders, age and 
diabetes mellitus, had been achieved by restricting the study population to older people 
with diabetes. In addition, adjustment for age and socio-economic status may have 
partially adjusted for confounding by co-morbidities and smoking status. This may explain 
the small size of adjustment to effect estimates which was observed with additional 
adjustment for baseline or time-updated co-morbidities. 
8.3.3 What are the advantages and disadvantages of adjustment for time-
updated comorbidities? 
The baseline co-morbidities model estimates the association between CKD and infection 
incidence which is not explained by differences in patient characteristics at baseline. 
However, the baseline co-morbidities model is vulnerable to residual confounding from co-
morbidities diagnosed during follow-up for two reasons. First, CKD status was updated 
during follow-up, and co-morbidities which developed or were diagnosed during follow-up 
may have influenced subsequent development or progression of CKD, and confounded the 
association between subsequent CKD status and later infection incidence. Second, several 
of the co-morbidities identified as confounders (including MI, stroke and COPD) may occur 
after a long time lag from the patient’s initial exposure to their underlying risk factors (such 
as smoking or hypertension). Cardio- and cerebrovascular events, and diagnoses of COPD 
which occur after the onset or progression of CKD may therefore still indicate confounding 
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by risk factors (such as smoking or hypertension) which existed prior to CKD onset or 
progression.  
This is illustrated in Figure 8.2, a simplified conceptual diagram illustrating key relationships 
of new-onset time-updated CKD and a first subsequent LRTI, with cardio- and 
cerebrovascular events occurring throughout follow-up. MI t0 represents a myocardial 
infarction occurring prior to the onset of CKD (time t0). This confounds the association 
between CKD and the first infection via several pathways of common risk factors, for 
example (CKD t1←smoking→IHD→MI t0→Infection).  
MI t1 represents a myocardial infarction which occurs after CKD onset but prior to a first 
infection. Despite occurring after CKD onset,  MI t1 also confounds the association between 
new-onset CKD and infection due to the lag time between patient exposure to risk factors 
for IHD (such as smoking and hypertension) and occurrence of MI, via several pathways 
(e.g. CKD t1←smoking→IHD→MI t1→infection). MI t1 would additionally confound the 
association between any later progression of CKD status and subsequent infection via the 
same pathways as MI t0. Adjustment for time-updated co-morbidities is designed to 
remove confounding by co-morbidities which occur during follow-up. 
Figure 8.2: Key relationships between selected baseline patient characteristics, new-onset chronic kidney 
disease (CKD), cardio- and cerebrovascular events during follow-up, and first subsequent lower respiratory 
tract infection  
 
MI, myocardial infarction; TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease 
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However, adjusting for time-updated co-morbidities may represent over-adjustment of the 
association between CKD and infection. For example, both reduced eGFR and proteinuria 
are associated with MI and stroke, which can cause secondary LRTI: thus cerebro- and 
cardiovascular events may lie on the causal pathway between CKD status and LRTI.[137] 
This is represented in Figure 8.2: MI t1 may mediate the association between CKD t1 and 
infection (CKD t1→ MI t1→ infection).  
Adjusting the association between CKD and infection for co-morbidities at baseline risks 
residual confounding of the association between CKD and infection from co-morbidities 
which occur or are diagnosed during follow-up. The time-updated model addresses the 
vulnerability of the baseline co-morbidities model to this residual confounding but removes 
the component of the association between CKD and infection which is mediated via these 
co-morbidities, which may result in over-adjustment. As the specified a priori confounders 
are predominantly risk factors for both CKD and infection, residual confounding would be 
expected to result in over-estimation of the association between CKD and infection, while 
over-adjustment would be expected to result in under-estimation of the association. 
Consistent with this expectation, the results of the time-updated model were slightly lower 
than those of the baseline co-morbidities model. While the best estimate is likely to lie 
between the two approaches, the two models produced very similar estimates for each 
infection and so interpretation of the association between CKD and infection appears 
robust to this difference in approach to adjustment for confounding. 
8.3.4 What are the advantages and disadvantages of including repeat 
infections? 
Some patients experienced multiple infections during follow-up, and repeat infections were 
included in the main analysis. The study included 115,080 LRTIs among 56,076 patients, 
7,870 episodes of pneumonia among 7,095 patients, and 1,980 episodes of sepsis among 
1,902 patients: thus 51.3% of LRTIs, 9.8% of pneumonia episodes, and 3.9% of sepsis 
episodes occurred as repeat episodes of the relevant infection for the patient.  
As repeat infections represent a cluster of multiple outcomes occurring to an individual 
patient, including repeat infections requires appropriate analysis to avoid over-precise 
estimation of the association between CKD and infection. We addressed this by using a 
Poisson regression with a random effects model, as discussed in 4.6. This results in less 
weight being given to infections which are part of a cluster of repeated infections occurring 
to one patient, which avoids over-precision of estimates. 
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Including repeat outcomes in a model with time-updated variables risks introducing reverse 
causation to the estimate of the association of CKD and infection incidence. If a first 
infection is a risk marker for repeat infection and itself hastens the onset or progression of 
CKD (for example by causing acute kidney injury, AKI, which increases the subsequent risk 
of CKD progression),[139] then an association will be observed between CKD incidence and 
infections which is driven by a causal relationship from infection to CKD.  
There is also a risk of introducing reverse causation by adjusting for other time-updated 
patient characteristics when including multiple infections. Smoking status is particularly 
vulnerable to reverse causation. For example, an episode of pneumonia may motivate a 
patient towards successful smoking cessation, which may reduce the risk of subsequent 
pneumonia and also reduce CKD progression. The confounding effects of a history of 
smoking are multi-dimensional, including the cumulative volume of smoking (measured in 
cigarette pack-years, which combine frequency and duration of smoking), and recentness 
of cessation, as well as immediate status as a current or former smoker. As only a crude 
measure of smoking status was consistently and routinely available within the data, 
classifying recent smokers who had been prompted to stop smoking by infection as ex-
smokers (who generally have a lower risk of infection than current smokers) risked the 
category of ex-smokers among patients who had experienced a previous infection 
comprising a population at higher risk from recent smoking than other ex-smokers in the 
study. Adjustment for ex-smoking status applied equally to all patients would represent a 
greater under-adjustment among patients with a history of previous LRTI. The direction of 
effect from this would be unpredictable. The risks of this reverse causation were reduced 
by the decision not to time-update smoking status. 
Inclusion of multiple infections with adjustment for time-updated co-morbidities which 
may be caused by either or both CKD and infection risks introducing collider bias. Collider 
bias is bias introduced by adjusting for a variable which is a common outcome of both the 
exposure of interest and the outcome of interest. An example is illustrated in Figure 8.3, a 
simplified conceptual diagram illustrating key relationships of time-updated CKD and 
subsequent LRTIs, with MI and stroke/TIA occurring during follow-up. MI t2 represents a 
myocardial infarction which occurs after both the onset of CKD t1 and a first subsequent 
infection. MI t2 confounds the associations between CKD t1 and the first infection and 
between CKD t2 and the second infection, and may partially mediate the association 
between CKD t1 and the second infection. In addition, since MI t2 may be a result of CKD 
and infection, the effects of CKD and infection ‘collide’ along the way to producing MI t2 
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(CKD t2← CKD t1→ MI t2←Infection 1→Infection 2). Adjusting the association between CKD 
t2 and Infection 2 for MI t2 could introduce a collider bias which would bias the estimate of 
the association between CKD t2 and Infection 2 downwards.  
Figure 8.3: Key relationships between selected baseline patient characteristics, time-updated chronic kidney 
disease (CKD), cardio- and cerebrovascular events during follow-up, and lower respiratory tract infections 
over time 
 
MI, myocardial infarction; TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease 
For simplicity, the ongoing effects of most baseline covariates on CKD t2 and Infection 2 are shown via an 
association between CKD t1 and CKD t2, and an association between Infection 1 and Infection 2. 
There are compelling advantages to including repeat infections within the main analysis. As 
LRTI is common, patients who entered the older age groups without a history of LRTI during 
follow-up would be a selected population, consisting either of patients at low risk of LRTI 
(for example patients with good overall health status), or patients who had entered the 
study at an older age (for example patients who had moved areas and newly registered 
with a GP at an older age, which may reflect better or worse health status than patients 
who are less geographically mobile). If patients had been followed up only to first 
occurrence of each infection, there would be a risk of introducing survivor bias among 
older age groups, particularly for LRTI, the direction of effect of which would be 
unpredictable. Including repeat infections also increased the power of the study to 
estimate the association between CKD and infection incidence precisely.  
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For these reasons, the main analysis included repeat infections, but a sensitivity analysis 
was conducted in which patients were followed-up only to the first infection (Appendix E). 
The effect estimates for the association between CKD and infection were unchanged, 
suggesting that the effects of reverse causation and collider bias on the main analysis were 
minimal.  
8.3.5 Which model provides the best overall estimate of the association 
between CKD and infection? 
Each model has a different profile of advantages and disadvantages for understanding the 
association between CKD and infection incidence. The minimally adjusted model provides 
an estimate of the size of the association (independent of demographics and changes in 
recording practice pre and post-QOF) which may be useful for health planners and 
economic analyses of the burden of excess morbidity among patients with CKD. 
From a clinical perspective, it is perhaps more important to understand whether CKD is a 
useful risk marker of infection risk independently of other co-morbidities. The baseline co-
morbidities and time-updated models estimate this association. While the baseline co-
morbidities model may somewhat overestimate the association between CKD and infection 
due to residual confounding, and the time-updated model is vulnerable to over-adjustment 
for factors which mediate the relationship between CKD and infection incidence, both 
models produced similar results, and so either is a reasonable indicator of the use of eGFR 
and proteinuria as risk markers of infection incidence independently of other co-
morbidities. 
This is an observational study and thus had limited ability to explore causation of any 
observed association. However, one aspect of causation was explored: the role of severity 
of diabetes mellitus. It has been suggested that any use of CKD as a risk marker for 
infection among patients with diabetes mellitus is due to its status as a marker of diabetes 
severity. The characteristics of diabetes model adjusted for available characteristics of 
diabetes (HbA1C and history of antidiabetes medications), in addition to adjustment for 
cardiovascular disease which may also be a marker of macro-vascular complications of 
diabetes. Peripheral vascular disease and diabetic retinopathy were not adjusted for in this 
model. As these represent microvascular complications of diabetes, and this reflects the 
same aspect of diabetes severity as diabetic nephropathy, these were expected to have 
considerable collinearity with the association of CKD with infection among people with 
diabetes, and were not expected to have any separate causative association with the 
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infections studied. The association between CKD and infection incidence was slightly 
diminished after adjustment for characteristics of diabetes, but remained similar in 
magnitude, suggesting that the association between CKD and infection incidence is not 
merely explained by difference in severity of diabetes at baseline.  
8.3.6 To what extent were all models vulnerable to residual confounding from 
omission of patient characteristics? 
All models are vulnerable to confounding from patient characteristics not measured or 
adjusted for, if these confound the association between CKD and infection incidence.  
Some baseline patient characteristics relevant to infection risk were omitted in the 
interests of parsimony as they were not believed to be relevant confounders. For example, 
ethnicity was considered a distal determinant of infection incidence. Ethnicity may be 
associated with infection incidence via prevalence of smoking, diabetes mellitus and 
cardiovascular disease. The study population was restricted to patients with diabetes, and 
the models adjusted for factors downstream of ethnicity (including smoking, cardiovascular 
disease and a range of co-morbidities). Ethnicity was not expected to be independently 
associated with infection incidence other than via the co-morbidities which had been 
adjusted for, and so was not included separately in the model. Black ethnicity may also 
affect estimation of eGFR from serum creatinine, but eGFR estimates were adjusted for 
Black ethnicity to reduce misclassification of eGFR (5.4.3). Body mass index and 
hyperlipidaemia were also considered distal determinants of infection, as the main 
confounding effects of these would be mediated via downstream characteristics (such as 
hypertension and cardiovascular disease) which were included in the model (Figure 8.3.1). 
Risk factors for infection were also not adjusted for if their primary relationship between 
CKD and infection was on any causal pathway between CKD and infection incidence. 
Adjusting for variables on any causal pathway between CKD and infection would have 
resulted in over-adjustment and under-estimation of the association between CKD and 
infection incidence. For example, if anaemia and Vitamin D status are associated with both 
CKD and infection incidence this is likely to be as mediators of any causal relationship 
between CKD and infection incidence, and these patient characteristics were therefore not 
considered a priori confounders. The omission of functional status (which in practice is 
difficult to define using data available in CPRD) was also considered acceptable, as 
functional status is not a direct cause of CKD (except as a distal determinant) and is likely to 
have an important mediating role in any causal association between CKD and infection.  
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The approach throughout the thesis of adjusting for confounding by identifying diagnoses 
of co-morbidities rather than prescriptions of medication is discussed in 6.8.2, and the 
rationale for identifying co-morbidities from primary care records but not secondary care 
records is discussed in 6.8.1. 
8.4 Additional sensitivity analysis of the association between 
CKD and infection incidence 
An exclusion criterion for patients in study population B, who were the study population for 
Paper 3, was a history of renal replacement therapy in CPRD. This was revised for the 
subsequent studies comprising this thesis by additionally excluding patients with a history 
of renal replacement therapy identified in HES.  
An additional sensitivity analysis was conducted post-publication exploring the impact of 
this change in Paper 3. The final model for the association of CKD with infection incidence 
adjusted for time-updated co-morbidities and the characteristics of diabetes was repeated 
for each infection, additionally excluding patients with a history of RRT in HES. This 
excluded an additional 62 patients, and 440 patients exited the study at an earlier date. The 
effect estimates of the association between CKD and infection incidence were unchanged 
(Appendix E). 
8.5 How plausible is the observed prevalence of CKD? 
The implications of any misclassification of CKD for estimating the association between CKD 
and infection incidence were discussed in Paper 3. This additional discussion considers the 
extent to which CKD may have been misclassified. First, the observed baseline prevalence 
of CKD is presented. The vulnerabilities of the study definition of CKD status to 
misclassification are briefly recapped, and the prevalence estimate is compared to the 
existing literature. 
8.5.1 Observed prevalence of CKD 
Table 8.1 presents the baseline prevalence of CKD for study population B, which comprised 
218,688 patients with diabetes ≥65 years with no history of renal replacement therapy 
(including patients with missing data for smoking status, who were excluded from analysis 
in Paper 3). The identification of study population B was described in 3.9.2.  
Overall, 39.4% of the population had CKD of any stage as identified by either eGFR <60 
ml/min/1.73m2 or a history of proteinuria (86,192/218,688). The baseline prevalence of 
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CKD stages 3–5 (eGFR<60 ml/min/1.73m2) was 31.6% (69,050/218,688). The prevalence of 
a history of proteinuria was 12.7%, and showed a graded increase with reduced eGFR: 
15.5% of patients with CKD stages 3–5 had a history of proteinuria (10,714/69,050). 
Table 8.1 Prevalence of markers of chronic kidney disease (eGFR and a history of proteinuria) at study entry  
eGFR 
No history of 
proteinuria 
History of 
proteinuria Total 
ml/min/1.73m2 n  n (row %) n (column %) 
<15 360 244 (40.4) 604 (0.3) 
15-29 3,568 1,219 (25.5) 4,787 (2.2) 
30-44 15,248 3,433 (18.4) 18,681 (8.5) 
45-59 39,160 5,818 (12.9) 44,978 (20.6) 
60-74 52,559 6,735 (11.4) 59,294 (27.1) 
75-89 41,710 5,396 (11.5) 47,106 (21.5) 
≥90 15,511 2,685 (14.8) 18,196 (8.3) 
None recorded 22,716 2,326 (9.3) 25,042 (11.5) 
Total  190,832 27,856 (12.7) 218,688 
eGFR, estimated glomerular filtration rate based on the single serum creatinine result at study entry 
8.5.2 Comparison of the observed CKD prevalence to the literature 
The overall 39.4% prevalence of any CKD (eGFR <60 ml/min/m2 or proteinuria) observed in 
the present study among people aged ≥65 years with diabetes appears to be broadly 
consistent with large US studies which have pro-actively tested for CKD. The National 
Health and Nutrition Examination Survey (NHANES) and the Kidney Early Evaluation 
Program (KEEP) both found approximately 44% prevalence of any CKD (identified as eGFR 
<60 ml/min/m2 or albuminuria) among people aged ≥65 years in the US.[140] The NHANES 
study identified a 39% prevalence of any CKD (using the same definition) among people 
with diagnosed diabetes: although this estimate is not limited to older people, 44% of this 
population were aged ≥60 years.[22]  
The 31.6% prevalence of stage 3-5 CKD observed in this study is at the upper end of 
international prevalence estimates of eGFR <60 ml/min/m2 among people ≥65 years, which 
range from 4.7% to 35.8%,.[141, 142] In England, the 2009/2010 Health Survey for England 
pro-actively identified stage 3–5 CKD among 29% of men and 35% of women in the general 
population aged ≥75 years.[16] The present estimate is higher, as would be expected, as 
diabetes is as additional risk factor for CKD. 
The 31.6% stage 3-5 CKD prevalence observed is also higher than estimates of CKD 
prevalence among people with the general population with diabetes in the UK. The 
National Diabetes Audit 2012/3 reported a prevalence of 20.1% (203,983/1,014,698) of 
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CKD stages 3–5 among patients with type 2 diabetes in England and Wales.[143] Studies of 
adults with diabetes in the UK using routinely-collected electronic health records have 
reported CKD stage 3-5 prevalence ranging from 18-31%.[18, 46, 144, 145] Although the 
population with diabetes is older than the general adult population, age is a strong risk 
factor for CKD and so the present study would still expect to observe a higher CKD 
prevalence than these. A study in Salford reported that the prevalence of CKD stages 3–5 
rose from 27.5% among all patients with diabetes to 49% among those aged ≥70 years 
old.[144] 
The 12.7% baseline proteinuria prevalence may be lower than expected for this study 
population. The Health Survey for England 2009 tested a randomly selected sample of the 
adult general population for albuminuria, and found a prevalence of 10% among men and 
8% among women, rising to 26% of men and 18% of women aged ≥75 years.[16] In several 
studies using electronic health records, low recording of proteinuria in routine records has 
hindered assessment of proteinuria prevalence.[46, 144] However, in a study of patients 
with diabetes in East London a proteinuria test result was recorded for 75% of all patients. 
The prevalence of proteinuria was 8.6% among all patients tested, and 18.6% among all 
patients with eGFR <60 ml/min/1.73m2.[145] Our study found comparable results but 
might be expected to be higher as the East London study was not limited to older people. 
In a 2014 study of the general population in CPRD, the prevalence of proteinuria was 7.7%, 
12.2%, 20.1% and 38.0% among patients with CKD stages 3a, 3b, 4 and 5, respectively, and 
did not change over the study period, which spanned the introduction of QOF.[18] Our 
study found higher prevalences (as might be expected given that diabetic nephropathy will 
be more common in the study population of older people with diabetes), but both studies 
are equally vulnerable to under-ascertainment. 
8.5.3 How likely is misclassification of CKD status according to reduced eGFR? 
GFR was estimated from serum creatinine test results using the CKD-EPI equation, adjusted 
for Black ethnicity as described in 5.4.3.[102] This offers a precise and granular estimate of 
eGFR status at the time of testing. There is still a risk of misclassification, however, as 
serum creatinine testing was driven by the clinical status of the patient rather than the 
needs of the study. The implications of this are discussed in depth in 5.4.4. Briefly, the 
timing and frequency of creatinine testing may reflect a patient’s overall health status and 
could even be directly related to incidence of infections. Serum creatinine levels fluctuate, 
and may in particular be raised during a period of acute illness (for example due to AKI), 
without existence of CKD. Basing classification on a single creatinine result tends to 
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overestimate CKD prevalence.[118] Attempts to reduce this risk by requiring multiple 
results over time to confirm chronicity of reduced eGFR risk under-estimation of CKD 
among patients lacking repeat tests, which could result in ascertainment bias affecting 
estimates of the association between CKD and infection incidence.  
The main defence against this risk is complete and frequent routine testing of eGFR. Older 
people with diabetes were expected to be a highly-monitored population, and the study 
found that serum creatinine tests offered a relatively complete and frequently updated 
source of GFR estimates for this population: 88.5% of study population B had a creatinine 
test during follow-up, and 89% of creatinine tests were followed by another within the next 
year. This summary figure masks a marked change in serum creatinine test completeness 
before and after the introduction of QOF (5.4.4).  
In Paper 3, GFR status at any given time was estimated from the single most recent serum 
creatinine test (the last-carried-forward method). This is vulnerable to over-estimation of 
CKD due to creatinine fluctuation and misclassification of AKI. Mimicking this approach, in 
Table 8.1 baseline GFR was estimated from the first creatinine result after meeting 
eligibility criteria for entry to the study population to allow comparison of this estimate to 
existing literature. 
8.5.4 How likely is misclassification of CKD status according to identification of 
persistent proteinuria? 
Proteinuria status was defined from a proteinuria test results and diagnostic Read codes for 
proteinuria or proteinuric disease, as described in 5.5. Methodological issues in identifying 
proteinuria status from routinely-collected primary care records are discussed in detail in 
5.2 and 5.5. To summarise, there were three main issues. First, test results are 
incompletely recorded in the coded dataset available to researchers, and negative test 
results are known to be particularly incomplete. Second, a patient with persistent 
proteinuria may have subsequent negative proteinuria tests (for example due to treatment 
with ACE inhibitors), but the history of persistent proteinuria may still be a relevant marker 
of increased clinical risk.  Third, many records of proteinuria (such as test results) could 
represent either transient or persistent proteinuria.  
To mitigate the risk of ascertainment bias from uncoded negative test results, it was 
assumed that absence of a positive test result implied a negative proteinuria status. This 
may have resulted in under-estimation of proteinuria prevalence due to misclassification of 
patients with proteinuria but no recorded test result.  
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To address the second issue, a single positive result defined a history of proteinuria for the 
rest of the patient’s time in the study. Any misclassification of transient proteinuria as 
persistent proteinuria therefore had the potential to cause appreciable over-estimation of 
proteinuria status over the study period. To address this, proteinuria test results (and any 
Read codes which did not explicitly define persistent proteinuria) were excluded if 
recorded on the same day as a urinary tract infection, as this is a major cause of transient 
proteinuria. In addition, a cautious approach was taken to identifying positive results which 
included: not classifying trace results as positive, extensive data cleaning for internal 
consistency of records, and not including diagnostic codes for diabetic nephropathy in the 
codelist for proteinuria identification. If this approach was overly cautious, this may have 
resulted in under-ascertainment of proteinuria due to exclusion of positive records. 
Proteinuria prevalence was therefore vulnerable to both under- and over-estimation. Many 
of the patients with an identified history of proteinuria had this status defined by a single 
record, many of which were test results, which potentially identify only transient 
proteinuria (5.5.4). It is hard to interpret whether this is due to the cautious approach to 
including positive proteinuria records (which would suggest under-estimation of 
proteinuria prevalence) or misclassification of some patients with transient proteinuria as 
having persistent proteinuria (which would cause over-estimation of proteinuria 
prevalence) but both may be partly responsible. 
  
167
[168] 
 
Chapter 9. The effectiveness of pneumococcal and influenza 
vaccinations in preventing community-acquired LRTI and 
pneumonia 
This chapter presents a study of the extent to which the burden of community-acquired 
LRTI and pneumonia among older people with diabetes may be preventable with 
pneumococcal and influenza vaccination, and whether this varies according to CKD status 
(objective 4). The study-specific methods and results are presented in a draft article.  
An ethics application has been made to the Royal College of General Practitioners Research 
and Surveillance centre requesting the dates of the first week in which 10% of nose and 
throat specimens sent as part of the RCGP influenza surveillance scheme tested positive for 
influenza virus, for each year of the study period.[146] This data would allow the definition 
of ‘winter’ in the analysis of influenza vaccine effectiveness to be tailored to the influenza 
season for each year. If the application is accepted, these data will be used to refine the 
draft article before submission. If not, the article will be submitted for publication as it 
stands. These data will not be obtained within the timeframe of the thesis, and so the draft 
paper is included in this thesis. 
9.1 Introduction to Paper 4 
This draft paper presents a retrospective cohort study to identify the vaccine effectiveness 
of pneumococcal vaccine against all community-acquired pneumonia, and of influenza 
vaccine against community-acquired LRTI, and whether these vary according to markers of 
CKD. The study population comprised 191,672 patients aged ≥65 years with diabetes 
mellitus and a valid serum creatinine result during follow-up, with no history of renal 
replacement therapy (study population B), identified as described in 3.9.2.   
The outcomes were acute, community-acquired lower respiratory tract infection (LRTI), and 
pneumonia (as a subset of LRTI). Methods used to identify community-acquired infection 
incidence were detailed in Chapter 4. Pneumococcal and influenza vaccinations were 
identified as described in the draft paper. CKD was identified by a history of proteinuria or 
reduced estimated glomerular filtration rate (eGFR) as described in Chapter 5. Incidence 
rate ratios were adjusted for a priori potential confounders of the association between 
markers of vaccination and infection. Detailed definitions of these confounders are 
described in Chapter 6.  
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Title: How helpful are influenza and pneumococcal vaccines in the bid to prevent 
community-acquired LRTI among older people with diabetes and does this vary with 
chronic kidney disease? A cohort study using electronic health records 
Authors: Helen I McDonald,1 Sara L Thomas,2 Elizabeth RC Millett,2 Jennifer K Quint,1 
Dorothea Nitsch.1 
1. Department of Non-Communicable Disease Epidemiology, London School of 
Hygiene & Tropical Medicine, London, UK. 
2. Department of Infectious Disease Epidemiology, London School of Hygiene & 
Tropical Medicine, London, UK. 
9.2.1 Abstract 
Objective: We aimed to estimate the effectiveness of influenza and pneumococcal 
vaccination to reduce the burden of community-acquired lower respiratory tract infection 
(LRTI) among older people with diabetes, and whether this varied with chronic kidney 
disease.  
Research design and methods: We used linked UK electronic health records for a 
retrospective cohort study of 190,492 patients ≥65 years with diabetes mellitus and no 
history of renal replacement therapy, 1997–2011. We included community-acquired LRTIs 
managed in primary or secondary care. Infection incidence rate ratios were estimated using 
Poisson regression. Pneumococcal vaccine effectiveness (VE) was calculated as (1 - effect 
measure). To estimate influenza VE a ratio-of-ratios analysis (winter effectiveness/summer 
effectiveness) was used to address confounding by indication. Final estimates of VE were 
stratified according to estimated glomerular filtration rate and proteinuria status. 
Results: Neither influenza not pneumococcal vaccine uptake varied according to CKD status 
among older people with diabetes. Pneumococcal VE was 22% (95%CI 11–31) against 
community-acquired pneumonia for the first year after vaccination, but was negligible after 
five years. Using a ratio-of-ratios analysis, current influenza vaccination had 7% 
effectiveness for preventing community-acquired LRTI (95%CI 3–12). Pneumococcal vaccine 
effectiveness was lower among patients with a history of proteinuria than patients without 
proteinuria (p=0.04), but otherwise this study did not identify variation in pneumococcal or 
influenza VE according to markers of CKD. 
Conclusions: The public health benefits of influenza vaccine may be modest among this 
population. Pneumococcal vaccination protection against community-acquired pneumonia 
declines swiftly: annual vaccination schedules should be investigated.  
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9.2.2 Introduction 
Hospital admissions for pneumonia are rising rapidly in the UK, most steeply among older 
people.[9] Older people with diabetes have a particularly high burden of lower respiratory 
tract infection (LRTI) and pneumonia.[147] 
Directly or indirectly, Streptococcus pneumoniae (‘pneumococcus’) and seasonal influenza 
viruses are responsible for a large burden of community-acquired pneumonia. 
Pneumococcus is the commonest cause of community-acquired pneumonia among older 
people.[91] Up to a third of community-acquired pneumonia may be influenza-related, due 
to bacterial co-infection or secondary bacterial pneumonia.[148] Vaccination is available 
against both these pathogens, and recommended in the UK for everyone aged ≥65 
years.[149] However, the extent to which these vaccines protect against pneumonia among 
older people remains unclear for both vaccines.  
The effectiveness of pneumococcal vaccination against all-cause pneumonia among older 
people is unclear, and meta-analyses have been hampered by unexplained 
heterogeneity.[150-152] Waning immunity among vaccinated participants has been 
suggested as a possible cause, but few estimates are available of pneumococcal vaccine 
effectiveness (VE) according to time since vaccination.[153]  
Traditional observational studies of influenza VE among older people may have over-
estimated influenza VE due to uncontrolled confounding by indication, in which the 
patient’s functional status affects vaccine uptake.[154-156] Observational studies which 
have used strategies to control confounding by indication (such as a “ratio-of-ratios” 
analysis in which the excess influenza VE during winter compared to summer is calculated) 
have suggested a null or modest influenza VE against community-acquired pneumonia 
among older people.[154, 157-159] 
Older people with diabetes have a high prevalence of chronic kidney disease (CKD).[160] 
Even at early stages, patients with CKD have increased incidence of LRTI and 
pneumonia.[125, 160, 161] Patients with CKD have a generally reduced response to 
vaccines, and a faster decline in antibody levels following vaccination.[30] A ratio-of-ratios 
analysis of influenza VE found no evidence of any protection against influenza-like-illness, 
influenza/pneumonia hospitalisation, or mortality among patients receiving 
haemodialysis.[162] Influenza VE at earlier stages of CKD is unclear, and still less is known 
about pneumococcal VE among patients with CKD.[27, 30]  
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We aimed to describe the extent to which the burden of community-acquired LRTI and 
pneumonia among older people with diabetes may be preventable with pneumococcal and 
influenza vaccination, and whether this varied according to CKD status. We conducted a 
retrospective cohort study using linked primary and secondary care electronic health 
record to calculate the vaccine effectiveness of pneumococcal vaccine against all 
community-acquired pneumonia. Since influenza vaccine may potentially reduce incidence 
of both influenza infection and secondary pneumonia, we calculated the influenza VE to 
prevent all community-acquired LRTI (considered as a broad category of all ‘chest 
infections’, including influenza infections, and possible secondary infections such as 
bronchitis and pneumonia), using a ratio-of-ratios analysis to address confounding by 
indication.   
9.2.3 Research design and methods 
Data sources 
We analysed data from the Clinical Practice Research Datalink (CPRD), a database of 
anonymised primary care medical records. Data were extracted in May 2011, and 
contained records for 12.8 million patients at 627 practices across the UK.[68] Records 
include patient demographics, health behaviours, test results, diagnoses, and prescriptions. 
Diagnoses are recorded using Read codes, and have generally been found to have good 
positive predictive value in validations.[72] The CPRD population is similar to the general 
UK population in terms of age and sex.[66, 67] 
Linked data are available for patients in England, subject to practice-level consent. This 
study used linked data on all hospital inpatient admissions to NHS hospitals in England from 
Hospital Episodes Statistics (HES), and socio-economic status from the Office for National 
Statistics (ONS).[75, 163] 
Study population 
The study population comprised all patients in CPRD with diabetes mellitus, aged ≥65 
years, with no history of renal replacement therapy, who had at least one valid serum 
creatinine result recorded in primary care. Diabetes was identified by diagnostic Read 
codes. For less definitive Read codes, we required confirmation with an antidiabetes 
medication prescription, as described in detail previously.[147] 
Patients met eligibility criteria at the latest time-point of: diabetes diagnosis, 65th birthday, 
one year after practice registration, practice fulfilling CPRD quality control standards, or 1 
April 1997. Their study entry date was their first valid serum creatinine result after the 
173
[174] 
 
eligibility criteria were met. Patients left the study at the first time-point of: death, leaving 
the practice, last data collection from the practice, renal replacement therapy (dialysis or 
renal transplant), or 31 March 2011. Patients with a diagnosis of HIV or hyposplenia 
(including coeliac disease or sickle cell disease) at any point in their medical record were 
excluded from the study. 
Definition of infections 
Lower respiratory tract infection was defined as a broad category of all infections of the 
lower respiratory tract, including influenza infections, bronchitis and pneumonia.  
A clinical diagnosis of infection was identified by a diagnostic Read code in primary care 
records, or a diagnostic International Classification of Disease 10 (ICD-10) code as the 
primary cause of hospital admission in secondary care records. To avoid overestimation 
from repeat attendances for the same infection, diagnostic codes recorded within 28 days 
of one another were attributed to a single episode of infection. The first consultation for 
infection was treated as the date of infection onset, and the infection had duration until 28 
days after the latest of the last diagnostic code or hospital discharge. All infections with 
onset date during a HES hospitalisation spell, or within 14 days following hospital discharge, 
or which included a code for postoperative infection, were designated hospital-acquired, 
and excluded. These methods have also been described in detail previously.[5]  
Time at risk 
Patients were not at risk of incident community-acquired infection during ongoing infection 
(community- or hospital-acquired), during any hospitalisation, or within 14 days following 
hospital discharge. These time periods were removed from time at risk. As pneumonia was 
a subset of LRTI, a patient could be at risk of pneumonia during an ongoing LRTI. 
Assignment of vaccination status 
Vaccination status was identified from primary care records using Read codes, prescription 
data, and immunisation record forms.  
For pneumococcal vaccination, any of these records could define a first vaccination, and 
any subsequent prescription could identify a booster vaccination. Time-updated 
pneumococcal vaccination status was classified according to time since the latest 
pneumococcal vaccination (<1 year, 1 – 5 years, ≥5 years, never vaccinated).  
Time-updated influenza vaccination status was assigned within vaccination years (1 
September to 31 August). Within each vaccination year, influenza vaccination status was 
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current from the first vaccination record to the subsequent 31 August. Patients without a 
current vaccination who had received an influenza vaccination within any of the previous 
five vaccination years were classified as having ‘residual’ influenza vaccination status, and 
other patients were categorised as unvaccinated. 
Definition of CKD 
We studied two markers of CKD: estimated glomerular filtration rate (eGFR) and 
proteinuria. Estimated GFR was calculated from serum creatinine test results in primary 
care, using the CKD-EPI equation, including adjustment for Black ethnicity.[102] Estimated 
GFR status was time-updated using a last-carried-forward method, with eGFR status 
assigned according to the most recent creatinine result.[125] 
A history of proteinuria was established from a Read code for persistent proteinuria or 
proteinuric disease, or a positive test result which did not coincide with a urinary tract 
infection diagnosis. 
Definition of covariates 
Age was categorised in five-year bands up to a final category of ≥85 years. Socio-economic 
status was assigned at a practice level, using 2007 ONS estimates of the Index of Multiple 
Deprivation, a composite area-level marker of deprivation.[163] Smoking status was 
identified as current, ex-smoker or non-smoker from HES or CPRD records. Co-morbidities 
were identified from diagnostic Read codes in CPRD and were modelled as separate 
variables which were: ischaemic heart disease, congestive cardiac failure, hypertension, 
cerebrovascular disease, other dementia, chronic lung disease (which included chronic 
obstructive pulmonary disease and other non-reversible lung disease, but not asthma), 
chronic liver disease. Baseline HbA1C was defined by the most recent HbA1C test result in 
CPRD prior to (or on) the study entry date. Baseline medication history was identified from 
CPRD prescription records.  
Data analysis 
Analysis was conducted separately for pneumococcal vaccine effectiveness against 
pneumonia and for influenza vaccine effectiveness against LRTI.  
We excluded patients with missing smoking status. For co-morbidities and proteinuria 
status, absence of a positive record was treated as absence of disease. Absence of a 
recorded HbA1C test result was included as indicating a relevant category of control.  
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Incidence rates and rate ratios were calculated for each infection using Poisson regression 
with lexis expansions for age, and a random effects model to adjust for multiple infection 
episodes. We adjusted models for pre-specified a priori confounders of the association 
between vaccination status and respiratory infection, and/or the relationship between 
chronic kidney disease and respiratory infection. These were: age, sex, socio-economic 
status at practice level, residential or nursing home care, baseline smoking status, time-
updated co-morbidities, steroid use in the 3 months prior to study entry, HbA1C and 
diabetic medication history at baseline, and date prior to or post 1 April 2004 (when Quality 
Outcomes Framework guidelines introduced financial incentives for recording CKD status 
among people with diabetes in primary care which may have improved ascertainment of 
CKD in primary care).[20]  
For pneumococcal vaccine, vaccine effectiveness was calculated as (1 – effect estimate). To 
explore waning of immunity we described pneumococcal VE according to time since 
vaccination. 
To control for confounding by indication in influenza vaccination we estimated the ratio of 
influenza VE in summer to influenza VE in winter in a “ratio-of-ratios” analysis by including 
an interaction term between influenza vaccination status and season, and reporting the 
antilog of the beta coefficient for the interaction term.[162] Winter was defined as 1 
September to 31 March, to capture excess winter influenza-like-illness.[164] 
Final estimates of VE were stratified by time-updated eGFR and history of proteinuria, as 
markers of CKD. 
Stata version 13.1 was used for data analyses. All code lists are available on request. 
Sensitivity analyses 
Pneumococcal vaccination has been recommended for patients with CKD in the UK since 
1992, but in 2003 the recommendation was extended to everyone aged ≥65 years.[149] As 
a sensitivity analysis we estimated pneumococcal VE separately for the periods before and 
after 31 March 2003 (to avoid separating the 2002-3 winter season) to check for bias from 
secular changes in vaccine uptake.  
The match of influenza vaccine strain to circulating influenza varies each year, which affects 
vaccine effectiveness.[162] As a sensitivity analysis, we estimated influenza VE separately 
for each winter.  
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We conducted a sensitivity analysis of influenza VE excluding patients with chronic lung 
disease or congestive heart failure, as the relationship of influenza to LRTI aetiology for 
these patients may differ from that among the general population.  
Ethics 
The study was approved by the Independent Scientific Advisory Group of the CPRD (ISAC 
reference 11_033A) and the London School of Hygiene & Tropical Medicine Ethics 
Committee (LSHTM reference 6116). 
9.2.4 Results 
Of 193,470 eligible patients, 1,049 patients with a diagnosis of HIV or hyposplenia, 1,764 
patients with no smoking status available, and 165 patients who had a record of 
pneumococcal vaccine administration with a missing date, were excluded from both 
analyses (Figure 1). For both pneumococcal and influenza vaccinations, unvaccinated 
patients had a lower recorded prevalence of ischaemic heart disease and chronic lung 
disease than vaccinated patients. Unvaccinated patients may have had poorer diabetic 
control than vaccinated patients: a higher proportion had poor or unrecorded HbA1C 
status, and a lower proportion had a history of both oral antidiabetes medication and 
insulin prescription than vaccinated patients. Prevalence of chronic kidney disease was 
similar for vaccinated and unvaccinated patients, although unvaccinated patients had a 
slightly lower prevalence of a recorded history of proteinuria (Table 1). 
Pneumococcal vaccine  
190,492 patients contributed 811,498 person-years to the pneumococcal vaccine analysis, 
during which there were 7,805 pneumonia episodes among 7,036 people. At study entry, 
58.3% of patients (111,016/190,492) were vaccinated against pneumococcal disease (Table 
1). Baseline pneumococcal vaccination increased among patients who entered the study 
after 2003–4, and did not differ according to eGFR at baseline (Figure S1). 
Crude rates of pneumonia were lowest among patients within a year of pneumococcal 
vaccine. The adjusted effectiveness of pneumococcal vaccine for preventing pneumonia 
was 22% (95% CI 11–31) within the first year after vaccination, and fell with increasing time 
since vaccination. Pneumonia incidence among patients vaccinated more than 5 years 
previously was similar to that among patients with no record of vaccination (incidence rate 
ratio, IRR 1.03: 95% CI 0.95–1.11). There was the suggestion of a trend of decreased 
pneumococcal vaccine effectiveness among patients with reduced eGFR, but this was not 
statistically significant. There was evidence for a greater protective effect of pneumococcal 
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vaccine among patients without a history of proteinuria than with a history of proteinuria 
(Table 2). 
A sensitivity analysis of pneumococcal VE stratified by date before or after 1 April 2003 
suggested that the estimate was not affected by the change in vaccine recommendation in 
2003 (Table S1). 
Influenza vaccine 
For the influenza vaccine effectiveness analysis, 190,459 patients contributed 803,230 
person-years to time at risk, during which there were 114,313 cases of LRTI among 55,685 
patients. At study entry, 65.2% of patients (124,130/190,459) had received a current 
vaccination against influenza (Table 1). Baseline influenza vaccination status increased 
slightly over time, and did not differ by eGFR status (Figure S2). 
Vaccinated patients had a higher crude incidence of LRTI than unvaccinated patients, in 
winter and summer. After adjustment for age, sex, co-morbidities, pneumococcal 
vaccination, and characteristics of diabetes, the winter incidence rate of LRTI was higher 
among patients with a current influenza vaccine than unvaccinated patients (IRR 1.19: 
95%CI 1.15–1.23) and among patients with residual influenza vaccination than 
unvaccinated patients (IRR 1.23: 95%CI 1.18–1.28). Similar, or higher, adjusted incidence 
rate ratios were observed in summer. Using the ratio-of-ratios analysis, a 7% effectiveness 
of current influenza vaccine (95% CI 3–12) and a 12% effectiveness of residual influenza 
vaccination (95% CI 7–17) to prevent community-acquired LRTI were observed. There was 
no evidence to suggest a relationship between vaccine effectiveness and eGFR nor 
proteinuria (Table 3). 
Similar results were obtained in sensitivity analyses of influenza VE stratified by year (Table 
S2), and excluding patients with chronic lung disease and congestive heart failure (Table 
S3). 
9.2.5 Conclusions 
Pneumococcal vaccine had 22% (95%CI 11–31) effectiveness against community-acquired 
pneumonia within the first year after vaccination. Pneumonia incidence among patients 
vaccinated more than 5 years previously was similar to that among patients with no record 
of vaccination (incidence rate ratio, IRR 1.03: 95%CI 0.95–1.11). Community-acquired LRTI 
rates were higher among patients who received an influenza vaccination than among 
patients who did not, and this relationship remained after adjustment for age, sex, co-
morbidities and characteristics of diabetes, and was observed in both summer and winter. 
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Using a traditional analysis, a negative vaccine effectiveness of influenza vaccine to prevent 
community-acquired LRTI would have been observed. However, using a ratio-of-ratios 
analysis, a 7% effectiveness (95% CI 3–12) of current influenza vaccine against community-
acquired LRTI was observed. There was no evidence of a trend in influenza vaccine 
effectiveness according to CKD status, however there was evidence that the protective 
effect of pneumococcal vaccine was greater among patients without a history of 
proteinuria than patients with a history of proteinuria.  
Previous meta-analyses have found insufficient evidence for a protective effect of 
pneumococcal vaccine against all-cause pneumonia among the adult population due to 
heterogeneity.[150-152] A subgroup analysis of a large Spanish cohort study found that 
only recent pneumococcal vaccination (<5 years) protected against hospitalisation for all-
cause community-acquired pneumonia (hazard ratio 0.75; 95% CI 0.58–0.98) among the 
general population aged ≥60 years.[153] The authors suggested that the heterogeneity 
observed in meta-analyses might be explained by waning immunity among the vaccinated 
population. Our results support this view and suggest that pneumococcal vaccination 
appears to be effective against all-cause community-acquired pneumonia for a year 
following vaccination among people aged ≥65 years with diabetes, after which time we 
observed a decrease in pneumococcal vaccine effectiveness to a null effect after five years. 
Previous cohort studies among older people have provided evidence of a “healthy vaccinee 
effect”, in which higher vaccine uptake among healthier patients resulted in likely over-
estimation of influenza VE.[154-156, 165] Evidence suggesting a healthy vaccinee effect has 
also previously been found among older people with diabetes.[166-170] In contrast, we 
observed higher rates of LRTI among patients who had received an influenza vaccination 
than among unvaccinated patients: our vaccinated patients appear, on this outcome 
measure, to be less healthy than unvaccinated patients. This finding is intriguing. The major 
difference between our study and most previous studies of this question is that we have 
included community-acquired LRTIs diagnosed and managed in both primary and 
secondary care. One possible explanation of the difference is that vaccination may reflect 
health-seeking behaviour in primary care. When patients develop symptoms of LRTI, 
patients who attend primary care for diagnosis and treatment may also be patients who 
were more likely to take up the influenza vaccine. This ascertainment bias may be less 
relevant to studies with hospitalisation as an outcome - or could even be reversed, as 
vaccinated patients who attended primary care promptly with LRTI may be less likely to 
require hospital admission. An alternative explanation is that the healthy vaccinee effect 
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observed in studies of hospitalisation for LRTI/pneumonia may reflect residual confounding 
by ‘frailty’ in which frailer patients are less likely to take up vaccination and more likely to 
be admitted to hospital when they develop infection. This would be less relevant to 
diagnosis of LRTI in primary care, and so our outcome may be less vulnerable to residual 
confounding by indication. 
Our “ratio-of-ratios” estimate suggested 7% VE of current influenza vaccination against 
LRTI among older people with diabetes (95% CI 3–12). Previous studies using similar 
strategies among the general population of older people, have found no evidence of 
influenza VE against community-acquired pneumonia (VE 8%: 95% CI -10–23%), and 
evidence of a modest protection against influenza-related excess hospitalisation with 
pneumonia/influenza (VE 19%: 95% CI 4–31%).[158, 159] Our estimate is consistent with 
both these estimates, and the difference may be due to the higher precision available for 
the present study due to the large cohort size.  
Our results suggested that pneumococcal VE may be reduced among patients with a history 
of proteinuria. We did not find any evidence of altered influenza VE among patients with 
CKD, but this may be due to limited power for the stratified ratio-of-ratios analysis. To the 
best of our knowledge, neither pneumococcal VE against pneumonia nor influenza VE 
against LRTI using methods to control for confounding by indication have previously been 
studied among patients with CKD who are not receiving dialysis. Studies of patients 
receiving dialysis may give some indication as to whether alteration of VE with CKD status is 
likely. A large observational study of pneumococcal vaccine found no evidence of 
effectiveness against hospitalisation for pneumonia or respiratory infections among 
patients receiving dialysis.[171] A study of influenza vaccine which calculated a ratio-of-
ratios VE comparing influenza effectiveness in years with good match between the vaccine 
and circulating strain to effectiveness in a poorly-matched ‘placebo year’ found no 
evidence of protection against influenza/pneumonia hospitalisation among patients 
receiving haemodialysis (VE 2%: 95% CI −2– 5).[162] These studies suggest that the 
suggestion of reduced pneumococcal VE associated with CKD is plausible.  
This study has several strengths. We used large, linked datasets with a careful definition of 
infection episodes to identify community-acquired infections managed in primary or 
secondary care, and excluded hospital-acquired infections and hospitalisation from time at 
risk. This avoids differential hospital attendance patterns biasing estimates of VE according 
to markers of CKD.[107] We adjusted for a wide range of co-morbidities, and conducted a 
ratio-of-ratios analysis for influenza VE to address confounding by indication. We described 
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the effect of pneumococcal vaccine according to time since vaccination, including booster 
doses, to identify waning immunity following vaccination. Our study population of older 
people with diabetes is well-monitored for CKD,[46] and this permitted us to explore the 
relationship of influenza and pneumococcal VE with CKD among patients not receiving 
dialysis, which we believe is novel. 
As an observational study of vaccine effectiveness using routinely-collected health record 
data, the study has limitations. We may have under-ascertained vaccinations, proteinuria 
and co-morbidities: however, the selection of a highly monitored study population should 
minimise this risk, and the high prevalence of each we observed suggests that this was not 
a major source of misclassification. Despite adjustment for multiple co-morbidities, residual 
confounding by indication may remain in the pneumococcal VE analysis. Despite our use of 
large, linked datasets, we had limited power to estimate the relationship of VE according to 
CKD status, especially in a ratio-of-ratios influenza VE analysis.  
Our findings have implications for clinical practice, public health and future research. As 
LRTI and pneumonia are typically diagnosed clinically in general practice, without 
microbiological testing for the causative pathogen, we studied broad LRTI/pneumonia 
outcomes, in common with previous observational studies of influenza VEff. Our results 
should not be interpreted as demonstrating that influenza and pneumococcal vaccines are 
ineffective against their specific pathogens among this population. As such, the results 
should not discourage patients nor health professionals from influenza and pneumococcal 
vaccination.  
Our study question was the extent to which the burden of community-acquired LRTI may 
be preventable with vaccination and our results suggest that the growing burden of 
community-acquired LRTI and pneumonia among this population cannot be easily tackled 
by increasing uptake of existing routine vaccination programmes. This is relevant for public 
health – both in planning health service provision and designing effective strategies to 
prevent illness. It should also prompt a call for research into more effective immunisation 
strategies and vaccination schedules. Our findings suggest that protection against 
pneumonia may be improved by a more frequent, perhaps even annual, pneumococcal 
vaccination schedule among older people with diabetes. The low influenza VE we observed 
against community-acquired LRTI, when contrasted with the large burden of infection 
directly and indirectly attributed to influenza, suggests scope for improved influenza 
immunisation among this population, for example with adjuvants. The finding of reduced 
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pneumococcal VE among patients with proteinuria is novel, and further research is needed 
to confirm the relationship between CKD and influenza and pneumococcal VE. 
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Table 9.1 Baseline description of study population 
 Pneumococcal vaccine 
status at baseline 
n=190,492 
Influenza vaccine status at baseline 
n=190,459 
Never 
vaccinated 
n=79,476 
Vaccinated 
n=111,016 
Unvaccinated
1 
n=32,552 
Currently 
vaccinated 
n=124,130 
Residual 1–5 
years 
n=33,777 
Age in years, median (IQR) 71 (66–77) 72 (66–78) 71 (66–77) 72 (66–78) 71 (66–78) 
  n (%) n (%) n (%) n (%) n (%) 
Female gender 40,308 (50.7) 53,146 (47.9) 16,603 (51.0) 60,019 (48.4) 16,813 (49.8) 
Socio-economic status2      
 1 (least deprived) 13,701 (17.2) 19,912 (17.9) 5,618 (17.3) 22,181 (17.9) 5,809 (17.2) 
2 14,666 (18.5) 19,591 (17.7) 5,799 (17.8) 22,394 (18.0) 6,058 (17.9) 
3 16,156 (20.3) 23,329 (21.0) 6,567 (20.2) 25,957 (20.9) 6,956 (20.6) 
4 17,758 (22.3) 25,481 (23.0) 7,312 (22.5) 28,128 (22.7) 7,789 (23.1) 
5 (most deprived) 17,195 (21.6) 22,703 (20.5) 7,256 (22.3) 25,470 (20.5) 7,165 (21.2) 
Residential care 1,697 (2.1) 3,274 (3.0) 436 (1.3) 3,516 (2.8) 1,016 (3.0) 
Smoking status      
 Non-smoker 38,078 (47.9) 44,713 (40.3) 15,449 (47.5) 52,782 (42.5) 14,543 (43.1) 
Current smoker 13,901 (17.5) 16,439 (14.8) 6,252 (19.2) 18,327 (14.8) 5,756 (17.0) 
Ex-smoker 27,497 (34.6) 49,864 (44.9) 10,851 (33.3) 53,021 (42.7) 13,478 (39.9) 
Co-morbidities      
 Ischaemic heart disease 18,886 (23.8) 34,415 (31.0) 6,825 (21.0) 36,761 (29.6) 9,713 (28.8) 
Congestive cardiac 
failure 
5,935 (7.5) 10,018 (9.0) 2,175 (6.7) 10,721 (8.6) 3,065 (9.1) 
Hypertension 46,626 (58.7) 71,311 (64.2) 18,644 (57.3) 78,252 (63.0) 21,024 (62.2) 
Cerebrovascular disease 9,714 (12.2) 14,469 (13.0) 3,612 (11.1) 16,021 (12.9) 4,540 (13.4) 
Other dementia 1,437 (1.8) 1,956 (1.8) 322 (1.0) 2,326 (1.9) 729 (2.2) 
Chronic lung disease 4,016 (5.1) 10,881 (9.8) 1,515 (4.7) 10,530 (8.5) 2,851 (8.4) 
Chronic liver disease 402 (0.5) 734 (0.7) 168 (0.5) 729 (0.6) 240 (0.7) 
Steroid use in previous 3 
months 
2,870 (3.6) 5,560 (5.0) 1,039 (3.2) 5,841 (4.7) 1,544 (4.6) 
Latest HbA1C status      
 None recorded 11,202 (14.1) 10,620 (9.6) 4,872 (15.0) 13,317 (10.7) 3,627 (10.7) 
Good <7% 34,669 (43.6) 53,305 (48.0) 13,621 (41.8) 58,741 (47.3) 15,596 (46.2) 
Intermediate 7-10% 27,935 (35.2) 41,354 (37.3)  11,389 (35.0) 45,383 (36.6) 12,509 (37.0) 
Poor >10% 5,670 (7.1) 5,737 (5.2) 2,670 (8.2) 6,689 (5.4) 2,045 (6.1) 
Antidiabetes medication history     
 None 38,755 (48.8) 50,517 (45.5) 16,463 (50.6) 58,195 (46.9) 14,598 (43.2) 
Oral 33,623 (42.3) 46,949 (42.3) 13,613 (41.8) 51,914 (41.8) 15,031 (44.5) 
Insulin 2,889 (3.6) 4,136 (3.7) 1,024 (3.2) 4,687 (3.8) 1,314 (3.9) 
Oral and insulin 4,209 (5.3) 9,414 (8.5) 1,452 (4.5) 9,334 (7.5) 2,834 (8.4) 
Latest eGFR      
 <30 2,098 (2.6) 2,986 (2.7) 767 (2.4) 3,337 (2.7) 977 (2.9) 
30-44 7,558 (9.5) 10,607 (9.6) 2,932 (9.0) 11,964 (9.6) 3,254 (9.6) 
45-59 18,678 (23.5) 25,508 (23.0) 7,337 (22.5) 29,039 (23.4) 7,806 (23.1) 
≥60 51,142 (64.4) 71,915 (64.8) 21,516 (66.1) 79,790 (64.3) 21,740 (64.4) 
History of proteinuria      
 No 71,095 (89.5) 94,128 (84.8) 29,231 (89.8) 107,212 
(86.4) 
28,735 (85.1) 
Yes 8,381 (10.6) 16,888 (15.2) 3,321 (10.2) 16,918 (13.6) 5,042 (14.9) 
HbA1C, glycated haemoglobin; eGFR, estimated glomerular filtration rate ml/min/1.73m2 
1. Not vaccinated within the 5 previous years. 
2.  Index of multiple deprivation for primary care practice location
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Table 9.2 Pneumococcal vaccine effectiveness against pneumonia (n=190,492) 
 Pneumococcal vaccination status 
Never < 1 year 1–4 years ≥ 5 years 
Person-time (years) 189,776 51,397 275,841 294,484 
Infections (n) 1,661 326 2,255 3,563 
Crude pneumonia rate /1,000 
person-years (95% CI) 
9.0  
(8.6–9.5) 
6.6  
(5.9–7.3) 
8.7  
(8.3–9.1) 
13.6  
(13.1–14.1) 
Adjusted1 pneumonia rate ratio 
(95% CI) 
1 (reference) 0.78  
(0.69–0.89) 
0.92  
(0.85–0.99) 
1.03  
(0.95–1.11) 
Vaccine effectiveness 1 % (95% CI) 0 (reference) 22 (11–31) 8 (1–15) -3 (-11–5) 
Vaccine 
effectiveness1 % 
(95% CI)  
stratified by eGFR 
(ml/min/1.73m2) 
eGFR <30 0 (reference) 6 (-40–37) 4 (-22–25) 6 (-19–26) 
eGFR 30–44 0 (reference) 16 (-12–37) 1 (-18–17) -7 (-27–11) 
eGFR 45–59  0 (reference) 21 (-1–38) 9 (-6–21) -1 (-17–14) 
eGFR ≥60 0 (ref) 26 (11–39) 12 (2–22) -3 (-15–8) 
P (test for 
trend) 2 
— 0.25 0.49 0.07 
Vaccine 
effectiveness1 % 
(95% CI)  
stratified by 
proteinuria status 
No 
proteinuria 
0 (ref) 28 (16–38) 13 (5–20) 1 (-8–10) 
Proteinuria 0 (ref) 2  
(-25–23) 
-6  
(-23–9) 
-19  
(-38– -3)  
P 
(interaction) 3 
— 0.04 0.03 0.04 
1. Adjusted for: age, sex, socio-economic status at practice level, residential care, date post 1 April 2004, 
smoking status, time-updated co-morbidities (ischaemic heart disease, congestive cardiac failure, hypertension, 
cerebrovascular disease, other dementia, chronic lung disease, chronic liver disease), time-updated CKD status 
(eGFR, proteinuria), steroid use in the 3 months prior to study entry, influenza vaccination status, and HbA1C 
and diabetic medication history at baseline. 
2. Wald test for interaction term of pneumococcal vaccine with eGFR. 
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Figure 9.1 Flowchart of study inclusion 
 
Eligible
Patients  ≥65 years with:
• diabetes mellitus; and 
• a serum creatinine result 
available during time 
eligible for study inclusion; 
and
• no history of renal 
replacement therapy.
n=193,470
Excluded 
HIV or hyposplenia (including coeliac 
disease or sickle cell disease)
n=1,049
Missing smoking data
n=1,764
Pneumococcal vaccine record with 
missing date n=165
Included in pneumococcal 
vaccine analysis
n=190,492
No time at risk of LRTI 
n=33
Included in influenza vaccine 
analysis
n=190,459
 
HIV, human immunodeficiency virus infection; LRTI, lower respiratory tract infection 
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Chapter 10. The association of markers of chronic kidney 
disease with mortality following community-acquired 
pneumonia and sepsis 
This chapter presents a study of the association of chronic kidney disease (CKD) with short-
term mortality following community-acquired sepsis and pneumonia (objective 5). The 
results of two sensitivity analyses discussed in the article are presented in 10.3, followed by 
a brief additional discussion of the identification of CKD status in this study. 
10.1 Introduction to Paper 5 
This paper presents a retrospective cohort study to identify the risk of mortality following a 
first diagnosis of community-acquired pneumonia or sepsis according to markers of CKD 
among patients aged ≥65 years with diabetes mellitus, a valid serum creatinine result, and 
no history of renal replacement therapy. To ensure good ascertainment of mortality the 
study population was restricted to patients in CPRD who had data linkage available to an 
updated linked ONS mortality dataset. Identification of the study population was described 
in 3.9.3. 
The primary outcome was 28-day all-cause mortality following diagnosis of pneumonia or 
sepsis. The methods used to identify episodes of community-acquired pneumonia and 
sepsis were detailed in 4.1 and 4.2.  The exposure of interest was CKD, identified by a 
history of proteinuria or reduced estimated glomerular filtration rate (eGFR) as described in 
Chapter 5. As CKD status was not time-updated over the 28 day follow-up period, eGFR 
status was identified using the best-of-two method as described in 5.4.5. 
Mortality risk ratios were calculated to estimate the risk of mortality according to CKD 
status. The calculation of risk ratios rather than rate ratios reflects the selected study 
question: whether CKD was associated with a difference in the risk of death at any point 
within 28 days after infection, as opposed to whether CKD was associated with differences 
in timing of mortality within the 28 days following infection.  
Mortality risk ratios were adjusted for a priori potential confounders of the association 
between markers of CKD and post-infection mortality. Detailed definitions of these 
confounders are described in Chapter 6.  
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ABSTRACT
Background. We aimed to examine whether pre-existing
impaired estimated glomerular ﬁltration rate (eGFR) and pro-
teinuria were associated with mortality following community-
acquired pneumonia or sepsis among people aged ≥65 years
with diabetes mellitus, without end-stage renal disease.
Methods. Patients were followed up from onset of ﬁrst
community-acquired pneumonia or sepsis episode in a cohort
study using large, linked electronic health databases. Follow-
up was for up to 90 days, unlimited by hospital discharge.
We used generalized linear models with log link, normal dis-
tribution and robust standard errors to calculate risk ratios
(RRs) for all-cause 28- and 90-day mortality according to two
markers of chronic kidney disease: eGFR and proteinuria.
Results. All-cause mortality among the 4743 patients with
pneumonia was 29.6% after 28 days and 37.4% after 90 days.
Among the 1058 patients with sepsis, all-cause 28- and 90-day
mortality were 35.6 and 44.2%, respectively. eGFR <30 mL/
min/1.73 m2 was a risk marker of higher 28-day mortality for
pneumonia (RR 1.27: 95% CI 1.12–1.43) and sepsis (RR 1.32:
95% CI 1.07–1.64), adjusted for age, sex, socio-economic
status, smoking status and co-morbidities. Neither moderately
impaired eGFR nor proteinuria were associated with short-
term mortality following either infection.
Conclusions. People with pre-existing low eGFR but not on dia-
lysis are at higher risk of death following pneumonia and sepsis.
This association was not explained by existing co-morbidities.
These patients need to be carefully monitored to prevent modiﬁ-
able causes of death.
Keywords: chronic kidney disease, community-acquired
infections, electronic health records, infection/mortality,
proteinuria
INTRODUCTION
Chronic kidney disease (CKD) affects an estimated 1.8 million
people in England, 98% of whom do not require renal replace-
ment therapy [1]. CKD is deﬁned by reduced estimated glom-
erular ﬁltration rate (eGFR) or evidence of kidney damage such
as proteinuria and is commonest among older people [2, 3].
Most patients with CKD are managed in primary care [4].
Infection is an important cause of mortality among older
people [5, 6]. Both reduced eGFR and proteinuria are associated
with an increased rate of infection-related mortality, which
could be partly explained by increased incidence of infec-
tion [7–9]. It is less clear whether CKD is also associated with
poorer prognosis following infection. When clinicians assess
patients with community-acquired infection, developing com-
plications such as acute kidney injury (AKI) may not yet be ap-
parent, but they will know which patients have pre-existing CKD.
If pre-existing CKD is a risk marker for short-term mortality, this© The Author 2015. Published by Oxford University Press on behalf of ERA-
EDTA. This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and
reproduction in any medium, provided the original work is properly cited. For
commercial re-use, please contact journals.permissions@oup.com
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would be useful for risk stratiﬁcation and clinical management of
patients with infections, especially in primary care where clini-
cians may not have access to immediate laboratory tests. While
the implications of acute changes in eGFR during infection are
a focus of current research, few studies have investigated the
role of pre-existing CKD [10]. Low baseline eGFR has been
found to be associated with mortality following sepsis and com-
munity-acquired pneumonia, but rarely examined according to
clinically meaningful categories of eGFR [11–15]. To the best of
our knowledge, proteinuria has not been examined as a poten-
tial risk marker for mortality following infection [12, 15, 16].
Among older people, CKD frequently co-exists with other
co-morbidities [3]. An association of CKD with poor prognosis
of infections could thus be due to confounding from these
co-morbidities. For example, CKD is strongly associated with
cardiovascular disease, which may be complicated by infection,
resulting in post-infection mortality driven by the underlying
cardiovascular disease [17]. Such deaths would largely follow
hospitalization for cardiovascular events. CKD is associated with
healthcare-associated pneumonia, which carries a worse progno-
sis than community-acquired pneumonia [18, 19]. Focusing on
community-acquired infections should exclude infections arising
as short-term sequelae of cardiovascular events and improve
understanding of the relationship between pre-existing CKD
markers and infection prognosis.
Older people with diabetes mellitus form a large and growing
population in primary care who suffer a high incidence of com-
munity-acquired pneumonia and sepsis [20]. Forty per cent of
adults with diabetes have CKD, of whom three-quarters have
proteinuria, and CKD among these patients is associated with a
greater all-cause excess mortality than among patients without
diabetes [21]. If proteinuria is a risk marker for mortality among
older patients with diabetes who develop community-acquired
pneumonia or sepsis, this could inform clinical management
of a large primary care patient population with appreciable
mortality following infection [20].
This study aimed to examine whether baseline eGFR and
proteinuria were independent risk markers for short-term
mortality following community-acquired pneumonia or sepsis
among older people with diabetes mellitus, using large, linked
electronic health record databases.
MATERIALS AND METHODS
Data sources
The Clinical Practice Research Datalink (CPRD) is an anon-
ymized UK dataset, comprising primary care records (including
diagnoses, prescriptions and test results) for 12.8 million patients
in May 2011 when data were extracted. The CPRD population is
representative of the general UK population and validity of re-
corded diagnoses is generally high [22, 23]. Monitoring of eGFR
and proteinuria in primary care is standard practice for people
with diabetes and has been ﬁnancially incentivized by the Quality
Outcomes Framework since April 2004 [24].
Data linkage is available within England subject to practice-
level consent. Records of all patients in CPRD with available
linkage to Ofﬁce for National Statistics (ONS) mortality data
formed the study dataset [25]. We additionally used linked
Hospital Episodes Statistics admissions data, which were avail-
able for all patients [26].
Study population
The study population was a subset of a population described
in more detail previously [20]. It comprised people aged ≥65
years with diabetes mellitus who experienced a ﬁrst commu-
nity-acquired pneumonia or sepsis, with a valid serum creatin-
ine result and no history of renal replacement therapy.
A valid serum creatinine result was one recorded in primary
care after the latest time-point of diabetes diagnosis, 65th birth-
day, 1 year after patients’ practice registration, date the practice
reached CPRD quality control standards or 1 January 1998.
Study exit occurred at the ﬁrst time-point of death, patient
leaving the practice, last data collection from the practice, last
ONS data linkage date, renal replacement therapy (kidney trans-
plant or dialysis) or 31 March 2011. Patients with a history of
renal replacement therapy were excluded.
Deﬁnition of infections
Infection was identiﬁed by a diagnostic Read code in
primary care records, or a diagnostic International Classiﬁcation
of Disease 10 (ICD-10) code as the primary cause of hospital
admission in secondary care records. The ﬁrst consultation for
infection was treated as the date of infection onset. Any
community-acquired infection with onset at least 28 days after
the ﬁrst valid serum creatinine result, and before study exit,
was included in the study.
Hospital-acquired infections were identiﬁed and excluded
as described previously [20]. Brieﬂy, infections were desig-
nated as hospital-acquired if onset was during or within 14
days of discharge from a hospitalization. Hospital-acquired in-
fections continued until 28 days had passed without a diagnos-
tic code for the infection or 28 days after hospital discharge,
whichever was the later. After this, patients re-entered follow-
up for community-acquired infection.
Study outcomes
The outcomes were death from any cause recorded in ONS
mortality data within 28 days (primary outcome) or within 90
days (secondary outcome) of infection onset.
Deﬁnition of CKD
CKD was described in terms of eGFR and proteinuria,
using primary care records. We estimated eGFR from serum
creatinine test results using the CKD Epidemiology Collabor-
ation (CKD-EPI) equation including adjustment for ethnicity
[27]. We excluded serum creatinine results <28 days prior to
infection onset to avoid misclassiﬁcation of CKD status, as a
developing infection could disrupt serum creatinine levels.
Clinically, CKD diagnosis is based on two GFR estimates at
least 3 months apart [2]. Using a single GFR estimate can
result in over-ascertainment of CKD due to creatinine ﬂuctu-
ation [28]. If more than one serum creatinine result was re-
corded between the start of patient follow-up and 28 days prior
to infection onset, we used the higher eGFR from the latest two
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results that were at least 3 months apart, to obtain conservative
estimates of eGFR [28].
We aimed to categorize eGFR according to thresholds cor-
responding to those used in diagnosing CKD stage. Due to the
small number of outcomes in the category eGFR < 15 mL/
min/1.73 m2, we collapsed Stages 4 and 5 to categorize eGFR
as < 30, 30–44, 45–59 and ≥60 mL/min/1.73 m2 [2].
A history of proteinuria was deﬁned by either a positive
urine protein test result (excluding results on the same day as
a urinary tract infection diagnosis) or a diagnosis of proteinu-
ric renal disease. We did not count trace results as positive.
Other variables
Age was deﬁned in 5-year age-bands up to a ﬁnal category
of ≥85 years. Socio-economic status was assigned by quintile at
an individual level, using 2007 ONS estimates of the Index of
Multiple Deprivation, a composite area-level marker of depriv-
ation [25]. If this was not available, it was supplemented by
the socio-economic status for the patient’s primary care prac-
tice. Smoking status was deﬁned by the most recent record
before infection onset when available, otherwise by the ﬁrst
subsequent record. Non-cardiovascular co-morbidities (chronic
lung disease, dementia, cancer, connective tissue disorders,
hypertension and cerebrovascular disease) and cardiovascular
co-morbidities (congestive heart failure and ischaemic heart
disease) were deﬁned by diagnostic CPRD Read codes, and dia-
betic medication history by CPRD prescription records prior to
infection onset. HbA1C test results within 28 days before infec-
tion were excluded as these could reﬂect disturbed glycaemic
control during the early stages of infection.
Data analysis
Pneumonia and sepsis analyses were conducted separately.
A patient could be included in both the pneumonia and sepsis
analyses if they experienced both infections, but not for mul-
tiple episodes of either pneumonia or sepsis. We excluded
patients with no smoking status or HbA1C result available.
We described mortality using Kaplan–Meier survival curves
stratiﬁed by eGFR status. We calculated risk ratios (RRs) using a
generalized linear model with log link, normal distribution and
robust standard errors, according to a pre-speciﬁed analysis
plan [29]. Our ﬁrst model adjusted for age, sex, socio-economic
status and infection onset prior to 1 April 2004 (when Quality
Outcomes Framework guidelines ﬁnancially incentivizing re-
cording of CKD status among people with diabetes in primary
care were introduced) [24]. Our second model adjusted for con-
founding by smoking status, characteristics of diabetes (HbA1C
and diabetic medication history) and non-cardiovascular co-
morbidities. Our ﬁnal model additionally adjusted for con-
gestive heart failure and ischaemic heart disease, which could
confound or mediate an association between CKD and post-
infection mortality. We repeated the ﬁnal model with additional
adjustment for peripheral vascular disease as a sensitivity
analysis. We looked for effect modiﬁcation between eGFR and
proteinuria in the ﬁnal model.
We focused on whether pre-existing CKD was a risk marker
for short-term mortality following infection. Data on acute elec-
trolyte changes during infection were not routinely available,
and so potential causal mechanisms such as AKI could not be
explored [30].
Causes of death in ONS mortality data are recorded using
ICD-10 codes from 1 January 2001, and ICD-9 codes prior to this,
which are not easily comparable [31]. We therefore described
cause of death among patients who died after 1 January 2001.
Stata version 13.1 was used for data analysis. All code lists
are available on request.
Ethics
The study was approved by the Independent Scientiﬁc
Advisory Group of the CPRD (ISAC reference 11_033A) and
the London School of Hygiene & Tropical Medicine Ethics
Committee (LSHTM reference 6116).
RESULTS
We identiﬁed 4957 individuals with community-acquired
pneumonia and 1114 individuals with community-acquired
sepsis. Data were missing (for smoking status and/or HbA1C
results) for 212/4957 individuals with pneumonia (4.3%) and
56/1114 individuals with sepsis (5.0%). These patients were
excluded. Among patients with pneumonia, patients with
missing data were older (median age 83 years, IQR: 78–88)
compared with those included (median age 80 years, IQR: 74–
85), with a higher 28-day mortality (excluded 88/214, 41.1%:
included 1406/4743, 29.6%) but a similar distribution of
baseline eGFR. A similar pattern was seen for sepsis.
Estimated GFR was based on the higher of two results for
4029 patients with pneumonia (84.9%) and 919 patients with
sepsis (86.9%); for the remaining patients, only a single valid
serum creatinine result was available. CKD prevalence was
high: almost half of the patients had eGFR <60 mL/min/1.73
m2 and a third had proteinuria. Patients with eGFR <60 mL/
min/1.73 m2 were older, with a higher prevalence of ischaemic
heart disease and congestive heart failure than patients with
eGFR ≥60 mL/min/1.73 m2 (Table 1).
Patients with pneumonia experienced 29.6% 28-day all-
cause mortality (1406 deaths). Patients with sepsis experienced
35.6% 28-day all-cause mortality (377 deaths) (Table 2). Sur-
vival curves showed high mortality at infection onset, declining
over ∼30 days to a more stable rate for the next 60 days follow-
ing both pneumonia and sepsis (Figure 1). RRs for 28-day mor-
tality were higher among people with eGFR <30 mL/min/1.73 m2
compared with people with eGFR ≥60 mL/min/1.73 m2 for
pneumonia (RR = 1.27; 95% CI 1.10–1.47) and sepsis (RR = 1.42;
1.10–1.84), adjusted for age, sex, socio-economic status and
onset prior to April 2004. Adjustment for smoking status, co-
morbidities and characteristics of diabetes had minimal effect
on these RRs for pneumonia (fully adjusted RR = 1.27; 1.12–
1.43) or sepsis (fully adjusted RR = 1.32; 1.07–1.64). There was
no evidence of associations between intermediate levels of
eGFR and 28-day mortality for either infection, nor for an as-
sociation between proteinuria and 28-day mortality. The
pattern of associations of eGFR and proteinuria with 90-day
mortality was similar to those for 28-day mortality (Table 2).
Results were unchanged by additional adjustment for
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peripheral vascular disease. There was no good evidence of
effect modiﬁcation between eGFR and proteinuria, and in par-
ticular no evidence of any association of proteinuria with 28-
day mortality within any category of eGFR status (data not
shown).
The underlying causes of death following pneumonia and
sepsis were similar for patients with eGFR above and below 60
mL/min/1.73 m2. Causes of 28-day mortality following sepsis
were predominantly sources of infection (Table 3). Following
pneumonia onset, pneumonia was recorded as an underlying or
contributory cause of death for 83.9% (1191/1419) of deaths
within 28 days and 76.3% (1366/1790) of deaths within 90 days.
Among patients with eGFR <60 mL/min/1.73 m2, renal disease
was recorded as an underlying or contributory cause for 10.6%
(77/724) of those who died within 28 days of pneumonia onset
and 16.6% (152/913) of those who died within 90 days. Record-
ing of CKD as a cause of death increased with lower eGFR
(Table 4).
DISCUSSION
Among this population of older people with diabetes mellitus,
eGFR <30 mL/min/1.73 m2 was a risk marker of higher 28-
and 90-day mortality following community-acquired pneu-
monia and sepsis, compared with patients with eGFR ≥60
mL/min/1.73 m2. The relationship between eGFR and mortal-
ity did not change with adjustment for co-morbidities. Neither
moderately impaired eGFR nor proteinuria was associated
with higher short-term mortality following either infection.
The strengths of this study follow from the analysis of a
focused question using large, linked datasets for a highly mon-
itored primary care population with a cohort study design.
Our study identiﬁes that the association between eGFR and
post-infection mortality persists when patients with end-stage
renal disease (ESRD) are excluded (and is not explained by
renal replacement therapy), when considering ﬁxed-term
Table 1. Baseline characteristics of the study population
Pneumonia Sepsis
eGFR < 60 mL/min/1.73 m2 eGFR≥ 60 mL/min/1.73 m2 eGFR < 60 mL/min/1.73 m2 eGFR≥ 60 mL/min/1.73 m2
Age (years)
Median (IQR) 82 (77–87) 78 (72–83) 81 (75–86) 76 (71–82)
n (col %) n (col %) n (col %) n (col %)
Gender
Female 1231 (53.0) 1106 (42.0) 294 (55.7) 268 (45.7)
Onset prior to 1 April 2004 584 (25.1) 527 (20.0) 124 (23.5) 120 (20.5)
Socio-economic status (IMD quintile)a
1 (least deprived) 383 (16.5) 438 (16.6) 109 (20.6) 106 (18.1)
2 554 (23.8) 595 (22.6) 116 (22.0) 127 (21.7)
3 494 (21.3) 582 (22.1) 120 (22.7) 137 (23.4)
4 502 (21.6) 574 (21.8) 110 (20.8) 108 (18.4)
5 (most deprived) 391 (16.8) 444 (16.9) 73 (13.8) 108 (18.4)
Smoking status
Current 321 (13.8) 549 (20.9) 70 (13.3) 103 (17.6)
Ex-smoker 1185 (51.0) 1351 (51.3) 235 (44.5) 284 (48.5)
Non-smoker 776 (33.4) 698 (26.5) 207 (39.2) 193 (32.9)
Missing 42 (1.8) 35 (1.3) 16 (3.0) 6 (1.0)
Comorbidities
Chronic lung disease 503 (21.6) 686 (26.1) 59 (11.2) 95 (16.2)
Hypertension 1623 (69.8) 1662 (63.1) 372 (70.5) 381 (65.0)
Congestive heart failure 734 (31.6) 430 (16.3) 147 (27.8) 95 (16.2)
Ischaemic heart disease 966 (41.6) 887 (33.7) 223 (42.2) 207 (35.3)
Cerebrovascular disease 692 (29.8) 638 (24.2) 152 (28.8) 145 (24.7)
Other dementia 174 (7.5) 190 (7.2) 42 (8.0) 23 (3.9)
Cancer 382 (16.4) 474 (18.0) 99 (18.8) 120 (20.5)
Connective tissue disorders 228 (9.8) 215 (8.2) 36 (6.8) 52 (8.9)
HbA1C
Good <7% 1176 (50.6) 1401 (53.2) 251 (47.5) 308 (52.6)
Borderline 7–10% 966 (41.6) 1033 (39.2) 213 (40.3) 230 (39.3)
Poor >10% 108 (4.7) 131 (5.0) 41 (7.8) 34 (5.8)
None recorded 74 (3.2) 68 (2.6) 23 (4.4) 14 (2.4)
Prior antidiabetes medication
Insulin 122 (5.3) 126 (4.8) 34 (6.4) 23 (3.9)
Oral medications 1139 (49.0) 1426 (54.2) 247 (46.8) 312 (53.2)
Both 462 (19.9) 384 (14.6) 130 (24.6) 114 (19.5)
None 601 (25.9) 697 (26.5) 117 (22.2) 137 (23.4)
Total 2324 2633 528 586
eGFR, estimated glomerular ﬁltration rate.
aIndex of multiple deprivation (IMD) score for patient’s postcode where available, otherwise, practice-level IMD score.
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Table 3. Top ﬁve underlying causes of death by ICD-10 code for short-term mortality following pneumonia and sepsis (deaths after 2001)
a
eGFR
eGFR <60 mL/min/1.73 m2 eGFR ≥60 mL/min/1.73 m2
28-Day mortality following pneumonia,
n = 1419
J18 Pneumonia, organism unspeciﬁed, n = 256, 35.4%
J44 Other chronic obstructive pulmonary disease,
n = 63, 8.7%
I25 Chronic ischaemic heart disease, n = 47, 6.5%
I50 Heart failure, n = 43, 5.9%
I64 Stroke, not speciﬁed as haemorrhage or infarction,
n = 37, 5.1%
J18 Pneumonia, organism unspeciﬁed, n = 216, 31.1%
J44 Other chronic obstructive pulmonary disease,
n = 63, 9.1%
I64 Stroke, not speciﬁed as haemorrhage or infarction,
n = 35, 5.0%
C34 Malignant neoplasm of bronchus and lung, n = 34,
4.9%
I25 Chronic ischaemic heart disease, n = 29, 4.2%
Total = 724 Total = 695
29–90 Day mortality following
pneumonia, n = 371
J18 Pneumonia, organism unspeciﬁed, n = 38, 20.1%
I25 Chronic ischaemic heart disease, n = 24, 12.7%
J44 Other chronic obstructive pulmonary disease,
n = 13, 6.9%
C34 Malignant neoplasm of bronchus and lung, n = 12,
6.4%
I21 Acute myocardial infarction, n = 12, 6.4%
J18 Pneumonia, organism unspeciﬁed, n = 20, 11.0%
C34 Malignant neoplasm of bronchus and lung, n = 20,
11.0%
J44 Other chronic obstructive pulmonary disease,
n = 19, 10.4%
I25 Chronic ischaemic heart disease, n = 9, 5.0%
I64 Stroke, not speciﬁed as haemorrhage or infarction,
n = 9, 5.0%
Total = 189 Total = 182
28-Day mortality following sepsis, n = 387 N39 Other disorders of urinary systemb, n = 33, 15.9%
J18 Pneumonia, organism unspeciﬁed, n = 30, 14.4%
E14 Unspeciﬁed diabetes mellitus, n = 12, 5.8%
A41 Other sepsis, n = 11, 5.3%
L03 Cellulitis, n = 11, 5.3%
N39 Other disorders of urinary systemb, n = 20, 11.2%
A41 Other sepsis, n = 18, 10.1%
J18 Pneumonia, organism unspeciﬁed, n = 18, 10.1%
E14 Unspeciﬁed diabetes mellitus, n = 10, 5.6%
J44 Other chronic obstructive pulmonary disease,
n = 6, 3.4%
=K55 Vascular disorders of intestine, n = 6, 3.4%
=L03 Cellulitis, n = 6, 3.4%
Total = 208 Total = 179
aDeaths prior to 2001 were recorded using ICD-9 codes and have not been included.
bAll incidences of code N39 were N39.0 Urinary tract infection, site not speciﬁed.
F IGURE 1 : Survival curves of short-term mortality following infection onset by eGFR status for (A) pneumonia and (B) sepsis.
Table 4. Recording of renal disease as a cause of deatha following pneumonia among patients with reduced eGFR
eGFR (mL/min/1.73 m2) Deaths within 28 days of pneumonia onset Deaths within 90 days of pneumonia onset
Total N18 CKD, n (%) Renal disease,b n (%) Total N18 CKD, n (%) Renal disease,b n (%)
<15 8 6 (75.0) 7 (87.5) 8 6 (75.0) 7 (87.5)
15–29 109 19 (17.4) 41 (37.6) 139 26 (18.7) 53 (38.1)
30–44 275 14 (5.1) 2 (15.3) 347 20 (5.8) 56 (16.1)
35–59 332 8 (2.4) 27 (8.1) 419 10 (2.4) 36 (8.6)
Total 724 47 (6.5) 77 (10.6) 913 62 (6.8) 152 (16.6)
aDeaths prior to 2001 were recorded using ICD-9 codes and have not been included.
bAny ICD-10 code from Chapter XIV ‘Diseases of the genitourinary system’ except N10 ‘Acute tubule-interstitial nephritis’, which is used for pyelonephritis, N30 ‘Cystitis’, N34
‘Urethritis’ or N39.0 ‘Urinary tract infection, site not speciﬁed’.
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rather than in-hospital mortality (thus is not due to differences
in hospital stay) and when exclusively community-acquired
infections are considered (so does not result from increased
risk of healthcare-associated infections). The linked datasets
allowed us to identify infections both among patients present-
ing directly to hospital and those managed in the community,
maximized ascertainment of mortality and enabled descrip-
tion of the causes of death. The highly monitored population
allowed good ascertainment of CKD status. The cohort study
design has less potential for selection bias than an equivalent
case–control study.
A limitation is our assumption that the absence of a record
implies a negative status for proteinuria and co-morbidities.
Under-ascertainment of co-morbidities could result in re-
sidual confounding, with unpredictable effects, but the
high prevalence of co-morbidities observed suggests that as-
certainment was not markedly incomplete. We observed a
high prevalence of proteinuria, and this is a highly monitored
population (with ﬁnancial incentives for standardized record-
ing of proteinuria since 2004), but under-ascertainment of
proteinuria could result in underestimation of any association
between proteinuria and mortality [24]. Residual confounding
from undiagnosed cardiovascular disease should have been
minimized by adjustment for cardiovascular disease risk
factors including smoking, hypertension and characteristics of
diabetes.
Our ﬁndings for eGFR provide further detail to build on
previous ﬁndings that baseline eGFR <60 mL/min/1.73 m2 or
renal disease are risk factors for short-term mortality following
(hospital- or community-acquired) sepsis and for in-hospital
mortality following community-acquired pneumonia (includ-
ing patients receiving dialysis) [11–15]. A more comparable
Canadian study examined the associations between eGFR and
30-day mortality following community-acquired pneumonia
among the general population aged ≥65 years, excluding pa-
tients with ESRD [16]. Fully adjusted hazard ratios for 30-day
mortality were 1.22 (95% CI 1.01–1.49) for eGFR 45–59, 2.03
(1.64–2.50) for eGFR 30–44 and 4.94 (3.94–6.19) for eGFR <
30, compared with eGFR 60–104 mL/min/1.73 m2. These are
somewhat greater than the associations we observed. The dif-
ference may be explained by the different study populations.
Both studies required a baseline serum creatinine result for in-
clusion. Our study population of older people with diabetes
were routinely monitored for CKD (with ﬁnancial incentiviza-
tion in primary care) [32]. Creatinine testing of the Canadian
study population may have been encouraged by co-morbidities
or health-behaviours associated with CKD (such as smoking),
which increase post-infection mortality, resulting in over-
estimation of the association of eGFR and post-infection mor-
tality. Our study population is less vulnerable to differential
ascertainment of CKD. Alternatively, the association between
eGFR and post-infection mortality may be smaller among
patients with diabetes.
To the best of our knowledge, our examination of any asso-
ciation between proteinuria and mortality following commu-
nity-acquired pneumonia and sepsis is novel. A history of
proteinuria, although a marker for mortality in general, does
not appear to be a risk marker for short-term mortality
following community-acquired infection. This is unlikely to be
due to chance, as the study was large, with ﬁndings consistent
across both infections. We designed our study to produce con-
servative estimates and may have under-estimated the associ-
ation between proteinuria and post-infection mortality due to
under-ascertainment of proteinuria. Alternatively, any poten-
tial relationship between proteinuria and mortality may have
been mitigated by clinical care of patients with infection who
had pre-existing proteinuria, for example, through swift recog-
nition of AKI.
The survival curves demonstrate a steep initial mortality
following infection onset, and a high proportion of deaths
had the underlying cause assigned to infection. Since 2001 in
England, co-morbidities are assigned as the underlying cause
of death when pneumonia has occurred in the context of, for
example, malignancy or respiratory disease [25]. This suggests
that the associations we observed are driven by an association
between eGFR and infection prognosis, not merely high
underlying baseline mortality among patients with impaired
eGFR. This is supported by previous research which found
7.7-fold elevated mortality in the 30 days following commu-
nity-acquired pneumonia [19]. Estimates for associations
between eGFR and mortality were not substantially altered by
adjustment for co-morbidities, suggesting that any causal rela-
tionship between eGFR and mortality is not mediated through
co-morbidities.
Our ﬁndings apply to the large population of older patients
with community-acquired pneumonia or sepsis with diabetes
mellitus who do not have ESRD. Inclusion criteria are unlikely
to have limited generalizability appreciably. Practices which
consent to data linkage could be more research oriented, pro-
viding good primary care management of risk factors for
infection-related mortality (such as smoking cessation), but
this is unlikely to affect the relationship between CKD and
short-term mortality post-infection. Lack of pre-existing cre-
atinine test results is likely to reﬂect limited time potentially
eligible for the study rather than CKD status among this
highly monitored population. Missing data on smoking status
and HbA1C may be a marker of low patient engagement:
caution should be used in generalizing our results to patients
who are not actively managed in primary care.
We found that CKD is a useful clinical risk marker for
post-infectious mortality. Whether this relationship is causal is
less clear; but the association does not appear to be explained
by age, co-morbidities or hospital attendance. Potential me-
chanisms include immune system dysfunction, but also more
preventable complications such as AKI. Combinations of risk
factors may be important: for example, patients with post-
operative AKI have higher mortality if they also have pre-existing
CKD [30].
Our results have implications for patient management and
future research. Patients with baseline eGFR <30 mL/min/
1.73 m2 and community-acquired infection need careful mon-
itoring, particularly in the 28 days following infection. Future
research should investigate preventable mechanisms by which
low baseline eGFR could be related to post-infection mortality,
for example, ﬂuid management, AKI and drug dosage in pa-
tients with low renal clearance.
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10.3 Sensitivity analysis adjusting for peripheral vascular 
disease  
The relationship between peripheral vascular disease (PVD) and the association between 
CKD and post-infectious mortality is an interesting one. PVD is associated with excess 
mortality from cancer and cardiovascular disease.[172] PVD and diabetic nephropathy are 
both microvascular complications of diabetes, and PVD is strongly correlated with CKD 
among people with diabetes.[173] PVD could therefore be considered a confounder of the 
association of CKD with mortality. However, if PVD is a marker of underlying microvascular 
disease rather than a direct cause of mortality, the statistical association between PVD and 
mortality could in part be driven by a causal association between diabetic nephropathy and 
mortality. In this case, adjusting for peripheral vascular disease would risk obscuring the 
component of a causal association between CKD and mortality. In the main analysis I was 
therefore initially wary of adjusting for peripheral vascular disease, as this could result in 
over-adjustment.  
In response to a reviewer’s suggestion, I conducted a sensitivity analysis in which 
adjustment for PVD was included in the final model. Surprisingly, this did not change the 
estimates of the association between CKD and post-infectious mortality. The results are not 
presented, as every point estimate and 95% confidence limit was unchanged. This model 
enhances the robustness of the results, as it does not make assumptions about the 
causality of the association between PVD and mortality.  
10.4 No effect modification was observed between eGFR and 
proteinuria 
Little is understood about the potential causal mechanisms between CKD and post-
infectious mortality, nor how eGFR and proteinuria may relate to one another as risk 
markers. In addition to investigating whether eGFR and a history of proteinuria were 
independent risk factors for post-infection mortality, I therefore examined whether they 
combined multiplicatively or extra-multiplicatively.  
To look for effect modification I constructed the final models with an interaction term 
between eGFR and proteinuria. Table 10.1 presents the resulting estimates of the 
association of eGFR with mortality stratified by proteinuria status, and estimates of the 
association of proteinuria with mortality stratified by eGFR status. 
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There was no evidence that the effect of proteinuria was modified by eGFR status, and in 
particular no evidence of any association of proteinuria with 28-day mortality within any 
category of eGFR status. For both pneumonia and sepsis, the association of eGFR <30 
ml/min/1.73m2 with mortality may be slightly larger among patients without proteinuria 
than among patients with a history of proteinuria: however the confidence intervals of 
these two estimates were wide and overlapping. The effect was not seen in any other 
category of eGFR, suggesting that it may reflect the fact that the subgroups of patients with 
eGFR <30 ml/min/1.73m2 once stratified by proteinuria status were small. Wald tests for 
each interaction term did not provide any evidence against the null hypothesis that there 
was no interaction between eGFR and proteinuria. Overall, there was no good evidence of 
a clinically relevant effect modification.  
10.5 Why did this study focus on the first episode of 
community-acquired pneumonia and sepsis? 
Pneumonia and sepsis are severe infections, associated with a high short-term mortality 
among this study population, as described in Paper 2. They are therefore infections where 
any association of CKD with mortality would have particular relevance.  
There are epidemiological advantages to studying the first episode of infection during 
follow-up when mortality is the outcome of interest. If repeat infections were included in 
this study without an adjusted analysis, an assumption of the model would be that having 
survived a previous episode of infection does not affect the probability of surviving a 
further episode of infection. The frailty models used to adjust for clustering in the analysis 
of CKD with infection incidence (4.6) are not available to this study, as mortality is a unique 
event for each patient. One option would be to include previous infections as a variable in 
the model, with robust standard errors to adjust confidence intervals. This model would 
assume that the relationship between prior infection (and survival to encounter a second 
infection) with short-term mortality at a repeat infection was the same for all patients, 
which also seems unlikely. A simpler approach, without such assumptions, was to include 
only the first infection during follow-up. For a common infection, this might have the 
disadvantage of risking survivor bias among older age groups and in age-adjusted 
estimates, as patients who encountered a first infection at an older age might be unusually 
robust (as discussed in 8.3.4). However, as pneumonia and sepsis are uncommon infections 
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and repeat infection is rare, the risk of survivor bias when considering the first episode of 
these infections should be minimal. 
10.6 Identifying eGFR status using the ‘best-of-two’ approach 
The exposure of interest in this study was baseline CKD status at onset of infection, which is 
not a time-updated variable. It was therefore suitable for the ‘best-of-two’ method for 
identifying eGFR status. This method was discussed in 5.4.5, but briefly the approach is, 
from the diagnosis date of infection, to identify the latest two serum creatinine tests with 
at least a three month interval between them. The serum creatinine test which results in 
the highest GFR estimate of the pair is the ‘defining’ creatinine test, and is used to identify 
a ‘best-of-two’ estimate of eGFR status. 
The advantages of this method are that is approximates the clinical definition of CKD, 
prevents overestimation of CKD prevalence from fluctuation in creatinine levels, and 
minimises misclassification of acute kidney injury as CKD. The method risks under-
estimating CKD status, as if the patient’s CKD status has progressed between the two 
serum creatinine results this will not be reflected in the CKD status assigned.[118] If only 
patients with two results available were included, this would risk ascertainment bias, but 
this can be addressed by categorising eGFR based on a single result where only one serum 
creatinine test result is available. 
This ‘best-of-two’ method is selected from a range of methods for identifying CKD explored 
by de Lusignan et al. among the general population, who found that when using primary 
care records for the general population the best-of-two method assigned fewer patients to 
stage 3 CKD than the single latest GFR estimate, and adjusting for discrepant interim 
readings in the 3 month interval made little difference to CKD status estimates.[118]  
Among the general population, de Lusignan et al. found that GFR estimates were as likely 
to rise as fall over a two year period, but that eGFR tended to decline over five years.[118] 
This suggested that fluctuation rather than progression was the dominant phenomenon in 
serum creatinine changes over a two year timescale. If this was also the case among the 
present study population of older people with diabetes mellitus, it would suggest that the 
best-of-two method was more suitable than a single measurement to estimate baseline 
CKD status. 
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Among the 4,969 patients with pneumonia, eGFR was based on a single creatinine result 
for 813 (16.3%) and on the best-of-two for 4,173 patients (83.7%). The eGFR distribution 
obtained was similar whether defined using a single result or the best-of-two (Table 10.2). 
The serum creatinine test used to define eGFR status (whether a single result or the best of 
a pair) was within two years of infection diagnosis for 94.5% of patients with pneumonia 
(4714/4,969). Among the 4,173 patients with a pair of results, 4076 (97.7%) of the paired 
tests were within 2 years of one another. The first of the pair was the highest GFR estimate 
(used to define eGFR status) for 2,095 patients, and the second of the pair was the defining 
creatinine result for 1,947 patients (the values were the same for 131 patients). A 
histogram of the difference between pairs had a good approximation to a normal 
distribution (not shown).  
Table 10.2 Characteristics of eGFR classification using the best-of-two method 
 Pneumonia n=4,986 Sepsis n=1,119 
 Median (IQR) Mean [SD] Median (IQR) Mean [SD] 
eGFR (all patients) 61.6 (47.3–76.9) 61.4 [19.5] 61.5 (44.8–75.7) 60.4 [19.8] 
eGFR (patients with a 
single serum 
creatinine test) 
61.0 (44.8–75.8) 60.2 [20.8] 56.6 (41.6–73.4) 57.2 [20.9] 
Best-of-two eGFR 1 61.8 (47.8–77.2) 61.6 [19.2] 62.1 (46.3–76.3) 61.0 [19.6] 
Time between the 
pairs (days) 1 
211 (143–343) 262 [178] 215 (143–351) 264 [182] 
Absolute difference in 
serum creatinine 
from the first to the 
second of each pair 1 
+1 (-8 to +9) 1.9 (22.6) +1 (-8 to +11) 
+3.13 
[35.4] 
IQR, interquartile range boundaries; SD, standard deviation; eGFR, estimated glomerular filtration rate ml/min/1.73m2. 
1. Among patients who had two eligible serum creatinine tests, n=4,173 for pneumonia; n=948 for sepsis. 
Among the 1,119 patients with sepsis, eGFR was based on a single creatinine result for 171 
patients (15.3%), and on the best-of-two for 948 patients (84.7%). As with pneumonia, the 
eGFR distribution obtained was similar whether defined using a single result or the best-of-
two (Table 10.2). The serum creatinine test used to define eGFR status (whether a single 
result or the best of a pair) was within two years of infection diagnosis for 94.3% of patients 
with sepsis (1,055/1,119). Among the 948 patients who had a pair of results, 928 (97.9 %) 
of the paired tests were within 2 years of each other. The first of the pair was the highest 
GFR estimate (used to define eGFR status) for 487 patients, and the second of the pair was 
the defining creatinine result for 419 patients (the values were the same for 42 patients). A 
histogram of the difference between pairs had a good approximation to a normal 
distribution (not shown). 
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Thus, for both infections studied, most patients had eGFR based on the best-of-two serum 
creatinine tests, but patients with a single eGFR test result did not appear to differ in terms 
of assigned CKD status. Almost all tests used to define eGFR status were within 2 years of 
infection diagnosis, and this appeared to be a sufficiently short timescale that serum 
creatinine fluctuation dominated over progression, suggesting that the best-of-two was an 
appropriate method to this study. 
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Chapter 11. Overall discussion  
This thesis used routinely-collected electronic health records to investigate the 
epidemiology of acute, community-acquired infections according to markers of chronic 
kidney disease (CKD) prior to end-stage renal disease. Among patients aged ≥65 years with 
diabetes mellitus, the objectives (1.4.2) were to describe: the burden of acute community-
associated infections (objective 2); the associations between markers of CKD with incidence 
of, and short-term mortality following, selected community-acquired infections (objectives 
3 and 5, respectively); and the extent to which routine influenza and pneumococcal 
vaccination could prevent community-acquired LRTI and pneumonia according to CKD 
status (objective 4). 
This chapter reviews the main findings, briefly surveys the overall strengths and 
weaknesses of the thesis, and considers the implications of the results for clinical practice 
and research. 
11.1 Summary of main results 
11.1.1 Incidence of community-acquired infections among older people with 
diabetes  
What was known 
Hospital admission rates for community-acquired infections such as pneumonia are rising 
rapidly in the UK, particularly among older age groups. One suggested explanation is the 
increasing prevalence of co-morbidities such as diabetes. The estimated number of adults 
in England with diabetes mellitus was 3.1 million in 2010 and is predicted to have risen to 
4.6 million by 2030. Although diabetes mellitus is a risk factor for infection-related 
hospitalisation and mortality, the full burden of community-acquired infections among 
older people with diabetes mellitus had not been described.  
What this study adds 
There was a high burden of community-acquired infection among older people with 
diabetes, LRTI having the highest incidence (crude rate 152.7/1,000 years) followed by UTI 
(crude rates 51.4 and 147.9/1,000 years for males and females respectively). The incidence 
of all infections increased over the study period (1997–2011) which appeared to be driven 
by the changing age structure of the population. Although the proportion of patients 
hospitalised within four weeks of diagnosis was low for UTI compared to pneumonia or 
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sepsis, the absolute number of patients hospitalised within four weeks of diagnosis was 
higher for UTI than for pneumonia and sepsis combined. All-cause 28-day mortality was 
32.1% for pneumonia, 31.7% for sepsis, 4.1% for LRTI and 1.6% for UTI. 
11.1.2 Association of CKD with infection incidence  
What was known 
Chapter 2 presented a systematic review of the association between CKD prior to end-
stage renal disease with the incidence of acute, community-acquired UTI, LRTI, central 
nervous system infection or sepsis. The review identified 14 eligible studies, of which only 
three included infections managed in the community. Probable misclassification of kidney 
disease status and poor adjustment for confounding were common. There was evidence 
from a few large, high-quality studies of a graded association between reduced eGFR and 
increased hospitalisation for infection. There were little data available on the association of 
CKD with infection incidence using less severe outcome measures than hospitalisation, and 
it was not possible to distinguish an effect on susceptibility to infection from an effect on 
the severity of infection. There was no evidence on the relationship between proteinuria 
and infection incidence independent of eGFR. 
What this study adds 
This was the first large study to explore the association of both estimated glomerular 
filtration rate and a history of proteinuria with incidence of these community-acquired 
infections. The inclusion of infections managed in primary care, as well as those resulting in 
hospitalization, allowed estimation of the association of CKD with infection incidence that 
was not driven by hospital admission thresholds or infection severity. Among older people 
with diabetes mellitus and no history of renal replacement, reduced eGFR was associated 
with a strong and graded increased incidence of community-acquired LRTI, pneumonia (as 
a subset of LRTI) and sepsis. The association was steeper for more severe infections: the 
association between reduced eGFR and infection incidence was greater for sepsis than 
pneumonia, and for pneumonia than for LRTI more widely. Proteinuria was a risk marker of 
increased infection incidence independently of eGFR, for LRTI (rate ratio 1.07: 95% CI 1.05–
1.09), pneumonia (1.26: 1.19–1.33), and sepsis (1.33: 1.20–1.47), after adjustment for age, 
sex, co-morbidities, smoking status and characteristics of diabetes.  
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11.1.3 The use of pneumococcal and influenza vaccination against community-
acquired LRTI 
What was known 
Older people with diabetes have a high burden of morbidity and mortality from 
community-acquired LRTI and pneumonia. Streptococcus pneumoniae (‘pneumococcus’) 
and bacterial co-infections or secondary infections following seasonal influenza infection 
together account for a high proportion of cases of community-acquired pneumonia, 
especially among older people. Vaccines are available against both pneumococcus and 
influenza, but their effectiveness among this population is unclear.  Patients with CKD have 
a generally reduced response to vaccines; it was unknown whether influenza and 
pneumococcal vaccine effectiveness (VE) was reduced among patients with CKD, especially 
prior to end-stage renal disease. 
What this study adds 
The adjusted effectiveness of pneumococcal vaccine for preventing pneumonia was 22% 
(95% CI 11–31) within the first year after vaccination, but protection appeared to wane 
swiftly: pneumonia incidence among patients vaccinated more than 5 years previously was 
similar to that among patients with no record of vaccination (incidence rate ratio 1.03: 95% 
CI 0.95–1.11). There was some evidence for reduced pneumococcal vaccine effectiveness 
among patients with proteinuria, and possibly among patients with impaired eGFR.  
The incidence of LRTI was higher among patients with a current influenza vaccine than 
unvaccinated patients before and after adjustment for co-morbidities, in winter and 
summer. Using a traditional analysis, a negative influenza vaccine effectiveness against 
community-acquired LRTI would have been observed. Using the ratio-of-ratios analysis to 
address confounding by indication, a current influenza vaccination had 7% effectiveness 
(95% CI 3–12) and residual influenza vaccination 12% effectiveness (95% CI 7–17) to 
prevent community-acquired LRTI. There was no evidence to suggest that influenza vaccine 
effectiveness varied according to eGFR or proteinuria status. 
11.1.4 Association of CKD with short-term mortality following infection 
What was known 
Reduced eGFR and proteinuria are associated with an increased rate of infection-related 
mortality. This could be partly explained by increased incidence of community-acquired 
infection, but CKD may also be associated with poorer prognosis following infection. Low 
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baseline eGFR had been found to be associated with mortality following sepsis and 
community-acquired pneumonia, but rarely examined according to clinically meaningful 
categories of eGFR. To the best of our knowledge, proteinuria had not been examined as a 
potential risk marker for mortality following infection. 
What this study adds 
People with eGFR <30 ml/min/1.73m2 were at higher risk of death compared to people with 
eGFR≥60 ml/min/1.73m2 in the 28 days following diagnosis of pneumonia (adjusted risk 
ratio, RR 1.27: 95% CI 1.12–1.43) and sepsis (adjusted RR 1.32: 1.07–1.64), which was not 
explained by existing co-morbidities (adjusted for age, sex, socio-economic status, smoking 
and co-morbidities). Neither moderately impaired eGFR nor proteinuria were associated 
with short-term mortality following either infection. 
11.2 Strengths 
The strengths of the individual studies were discussed in Chapters 7 to 10. The overall 
strengths of this thesis follow from using large, linked datasets among a highly monitored 
population with study definitions, design and analysis tailored to a series of focused study 
questions designed to address identified gaps in the literature.  
11.2.1 The use of large, linked datasets 
The thesis used large, linked datasets of primary care and hospital admission records, with 
additional linkages to Office for National Statistics mortality data. Large cohorts permitted 
precise estimates of the main associations of interest with eGFR categorised into narrow 
categories to improve the clinical relevance of estimates and allow detection of graded 
associations.  
Data linkage allowed exploitation of the different strengths of a variety of datasets. Primary 
care datasets offered a rich source of patient characteristics and co-morbidities, including 
results of laboratory tests sent from primary care. Data linkage to secondary care allowed 
identification of infections both among patients presenting directly to hospital and those 
managed in the community, and the distinction of community-acquired from hospital-
acquired infections. Linkage to ONS mortality data maximized ascertainment of mortality 
and enabled description of the causes of death.  
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11.2.2 Selection of a highly monitored and clinically relevant study population 
All study populations were restricted to older people with diabetes. Among this population, 
a high proportion had regular serum creatinine tests recorded, and this reduces the risk of 
selection bias in studies in which serum creatinine tests were an inclusion criterion, of 
misclassification of eGFR status from infrequent monitoring, and of ascertainment bias in 
estimated associations of eGFR with outcomes of interest. Age and diabetes are important 
a priori confounders of any associations between CKD and infection incidence or mortality, 
and restriction of the study population helps control confounding by these characteristics 
(1.4.1).  
Older people with diabetes are a large population, who bear a high burden of morbidity 
and mortality from community-acquired infections, and have a high prevalence of CKD: the 
association of CKD with infection-related morbidity and mortality is thus particularly salient 
among this population, from clinical and public health perspectives. The population is 
ageing and the prevalence of diabetes is increasing, and the health service needs of this 
population are of growing relevance to health service planning and health promotion 
strategies. 
11.2.3 Tailored study definitions, design and analysis for a series of focused 
questions 
This thesis presents the first studies to describe mutually-adjusted associations of eGFR and 
proteinuria with incidence of these community-acquired infections, and with post-
infectious mortality. This allows interpretation of eGFR and proteinuria as independent 
markers of risk among older people with diabetes. 
Episodes of community-acquired infections were defined according to detailed methods 
developed by Elizabeth Millett for LRTI and pneumonia, and adapted in this thesis to sepsis 
and UTI, as described in Chapter 4. The methods were designed to minimise 
misclassification of infections, and the identification of community-acquired infections 
specifically allows the study of the association of CKD with infection incidence to be 
independent of more frequent hospital attendance among patients with CKD, and the 
association of CKD with post-infectious mortality to be independent of poorer prognosis of 
hospital-acquired infections.  
CKD was identified sensitively to the historical context of the data, among a highly 
monitored study population and data handling decisions were taken in the context of the 
thesis objectives, to minimise misclassification and ascertainment bias in the estimation of 
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the association of CKD with infection-related morbidity and mortality, as discussed in 
Chapter 5.  
Cohort study designs were used for all study objectives, and these have less potential for 
selection bias than an equivalent case-control study. Within this design, each study was 
analysed with respect to the main biases of concern to each specific study question, for 
example in the ratio-of-ratios analysis to address confounding by indication in influenza 
vaccine effectiveness estimates. The data permitted adjustment for a wide range of co-
morbidities. Confounders were identified using a conceptual framework and each 
confounder adjusted for individually, to adjust for confounding as accurately as possible 
while maintaining a parsimonious model. 
The systematic review presented in Chapter 2 identified that the roles of increased 
susceptibility to infection and poorer prognosis from infection in driving excess infection-
related mortality and hospitalization among patients with CKD could not be separately 
identified from existing studies of the association between eGFR and infection. This thesis 
addressed that gap, by conducting separate studies of the association of CKD with infection 
incidence (including infections managed in the community) and with short-term mortality 
following infection diagnosis. The thesis also presented novel analyses of the associations 
of proteinuria with infection-related morbidity and mortality independently of eGFR, which 
may advance the use of proteinuria as a marker of clinical risk. 
11.3 Limitations 
The potential for misclassification, information bias, selection bias and reverse causation 
specific to each study was discussed in Chapters 7 to 10. The overarching limitations of the 
thesis mostly arise from its reliance on historical data collected for clinical purposes. Data 
validity depended on full and accurate clinical investigation, diagnosis and coding.  
11.3.1 Misclassification and information bias 
All variables were subject to misclassification from clinical error or inaccurate coding. In 
general, the positive predictive value of diagnostic records in CPRD has been found to be 
high, but the negative predictive value is less clear.[72] Patient investigation, diagnosis and 
monitoring are driven by clinical criteria, which is inherently differential according to 
overall health status. As a wide range of factors inform CKD status and infection risk which 
are likely to be correlated with clinical management and coding (such as smoking status, 
age and co-morbidities), all analyses of the associations between CKD and infection-related 
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outcomes are vulnerable to information bias from misclassification, and poorly controlled 
confounding from misclassified confounders. Data recording also reflects clinical 
imperatives. In particular, negative results are often less clinically relevant to patient 
management than positive results, which distorts recording. The resulting missing data may 
cause misclassification, information bias, selection bias and uncontrolled confounding, 
depending on the context and how the data are handled. 
Misclassification resulting from missing data is particularly relevant to patient co-
morbidities and proteinuria status, as a negative status was inferred from absence of a 
positive record (5.2.4 and 6.5). Any misclassification of co-morbidities would impair control 
for confounding, biasing estimates of CKD with infection-related outcomes in either 
direction. Misclassification of proteinuria status that was non-differential by CKD status and 
infection-related outcomes is likely to have resulted in under-estimation of the association 
of proteinuria with infection-related outcomes. Information bias from differential 
misclassification of proteinuria status could bias estimates of the association of proteinuria 
with infection-related outcomes in either direction.  
It was not always possible to categorise variables finely. For example, smoking status was 
classified into crude categories based on current status, when ideally smoking pack year 
history would have allowed adjustment for cumulative exposure in addition to current 
status (6.3). This may have resulted in residual confounding by smoking status. The data did 
not permit confident identification of albuminuria, or quantification of proteinuria, both of 
which would have improved the detail in which the associations between proteinuria and 
infection-related outcomes could be described (5.5.5). 
Estimated GFR status was updated over time for two analyses (objectives 3 and 4). As the 
frequency and timing of serum creatinine testing reflects clinical imperatives, this risked 
misclassification over time which was likely to be differential with respect to infection 
incidence, potentially introducing ascertainment bias. This risk was mitigated by selecting a 
highly-monitored population. The high frequency of testing (5.4.4), and results of sensitivity 
analysis restricted to the period after the introduction of Quality Outcomes Framework 
incentivised annual testing for all (Paper 3), suggested that ascertainment bias was not a 
major problem among this population. 
11.3.2 External validity 
All studies included only a subset of older people with diabetes mellitus. The inclusion 
criteria for all studies required a diagnosis of diabetes mellitus; studies of the associations 
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of CKD with infection-related outcomes also required a valid serum creatinine test result 
and non-missing smoking status (objectives 3-5); and the study of post-infectious mortality 
additionally required an available HbA1C result (objective 5).  
Patients with undiagnosed diabetes mellitus do not receive care to manage their diabetes, 
thus patients excluded from the study by lack of diabetes diagnosis may be at greater risk 
of CKD and infection.[174] Serum creatinine testing, smoking cessation advice, and HbA1C 
monitoring are also key components of care for patients with diabetes, and while these 
data may be missing for a variety of reasons, excluded patients are likely to be a population 
with poorly managed diabetes compared to included patients. These results may not be 
valid to be generalised to all older people with diabetes mellitus. However, the results may 
be generalised to the population of older people with a diagnosis of diabetes mellitus who 
are actively managed in primary care, which  is a large and reasonably identifiable 
population. 
11.3.3 Confounding 
Adjustment for confounding is a strength of this thesis. Confounders were identified using a 
conceptual framework and a wide range of confounders were adjusted for individually, to 
adjust for confounding as accurately as possible while maintaining a parsimonious model. 
All adjusted estimates are of course still vulnerable to residual confounding from crude 
categorisation of confounders (11.3.1), or from omission of relevant confounders (8.3.6).  
11.3.4 Reverse causation 
Acute community-acquired infections may alter kidney function directly (for example by 
triggering acute kidney injury) or indirectly (for example by disrupting glycaemic control, or 
prompting smoking cessation). This results in a risk of reverse causation in estimates of the 
association of CKD and acute community-acquired infection incidence (objective 2), but the 
study was designed to mitigate this, and sensitivity analysis suggested this was not a major 
issue (8.3.4).  
11.3.5 Restricted lines of investigation 
The content and coding of the data reflected changing clinical practice, diagnostic 
categories and coding regulations during the study period, and this required consideration 
in the study designs. For example, the plan for identification and classification of CKD status 
was developed with careful reference to the clinical, historical and coding context of the 
study period (Chapter 5). In studying the association of CKD with post-infection mortality 
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(objective 5), all-cause 28-day mortality was selected as an outcome over deaths coded as 
caused by infection as this outcome was better supported by the data and coding rules, 
rather than due to its greater intrinsic interest (3.4.3). 
Some information was not consistently available to the study and this limited the feasible 
study questions. Infectious aetiology would have allowed the studies to identify the main 
causative pathogens driving the burden of infection-related mortality among older people 
with diabetes, to examine whether CKD status is associated with different infectious 
aetiologies than those among the general population, and to allow estimation of influenza 
and pneumococcal vaccine effectiveness against the specific outcomes of influenza and 
pneumococcal infections. However, the aetiology of community-acquired infections could 
not be uniformly and routinely identified from the available datasets (4.4). 
Data available in Hospital Episode Statistics were less rich than those in CPRD. For example, 
treatment and laboratory test results in secondary care were not available. This prevented 
an exploration of the role of events in secondary care (such as antibiotic prescription or 
acute changes in serum creatinine or electrolytes) as potential mechanisms for the 
association of CKD with prognosis among patients with acute community-acquired 
infections.  
11.4 Interpretation 
Among older people with diagnosed diabetes mellitus who are actively managed in primary 
care, both proteinuria and even mildly reduced eGFR are associated with increased 
incidence of acute community-acquired infections. The differences between this thesis and 
previous studies help clarify the possibly explanations for this. This study excluded patients 
with end-stage renal disease (identifying that the association is not due to renal 
replacement therapy), considered exclusively community-acquired infections (establishing 
that the association is not explained by increased risk of healthcare-associated infections), 
included infections managed in the community (identifying that CKD is truly associated with 
increased infection incidence, and the association is not solely a function of hospital 
admission thresholds or infection severity) and adjusted for a range of co-morbidities and 
characteristics of diabetes to limit the extent to which the association may be explained by 
confounding.  
An association between CKD and post-infection mortality was observed only among 
patients with severely reduced eGFR. This is not evidence that early stages of CKD are not 
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associated with poorer prognosis of infection. As the association between CKD and 
infection incidence was stronger for more severe infections (sepsis and pneumonia, 
compared to LRTI), it seems unlikely that there is no underlying relationship between CKD 
and infection severity. It is possible, for example, that an inherently poorer prognosis for 
patients with CKD may be unobserved if mitigated by good clinical care following diagnosis. 
A high burden of LRTI and pneumonia was observed among the population of older people 
with diabetes, and particularly patients with CKD. Among the general population, a large 
burden of LRTI and pneumonia is related to two pathogens against which immunisation is 
available. The results suggested that increased uptake of routine influenza and 
pneumococcal vaccine would have limited impact on the burden of community-acquired 
LRTI and pneumonia among older people with diabetes. This may be due to a high burden 
of non-vaccine preventable LRTI/pneumonia, but it may also be that vaccine effectiveness 
could be improved among older people with diabetes using current vaccine schedules.  
Are the associations of CKD with infection incidence and post-infectious mortality causal? 
The graded association of eGFR with infection incidence would be consistent with a causal 
explanation, although it could also be explained alternatively. There are plausible biological 
mechanisms for a causal relationship between CKD and infection incidence and CKD with 
post-infection mortality, but this thesis was not designed to investigate these (1.2.3). Even 
if CKD is not the cause of increased incidence of, and mortality from, acute community-
acquired infections, both eGFR and proteinuria are observable and quantifiable, and may 
serve as useful markers for identifying patients at risk of infection-related ill health.  
11.5 Implications for clinical practice 
This thesis may have some direct applications to clinical practice. For example, the 
quantification of incidence of selected acute community-acquired infections among older 
people with diabetes may allow primary care clinicians to offer more detailed information 
to patients than previously when discussing infection risk for patients with diabetes, and 
how CKD relates to this. This may, for example, inform and support vaccination uptake. The 
description of the association between baseline CKD status and short-term mortality may 
also inform risk-stratification of older patients with diabetes at diagnosis of acute, 
community-acquired infection.   
The UK population is ageing, and the prevalence of diabetes is increasing: understanding 
the health needs of older people with diabetes is of growing importance to health service 
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planning and public health. Quantifying the burden of community-acquired infection 
among older people with diabetes, and describing the role of CKD in this, should inform 
health service planning and help refine health economics analyses of the health and 
financial costs of CKD. 
11.6 Implications for research 
11.6.1 Investigating CKD using electronic health records  
This thesis worked within the limitations of historical routinely-collected data, by selecting 
a highly-monitored study population and by developing the study classification of CKD 
within the context of the available data and its clinical and historical context. It might be 
possible to improve usefulness of historical records for identifying and categorising 
proteinuria, for example, by developing tools to scan and automatically encode proteinuria 
results recorded in free text. There is potential to increase the scope of renal research using 
electronic health records by altering the capture and curation of CKD data in prospectively 
collected electronic health records. For example, data structure and curation which 
standardised the recording of proteinuria (using templates for data entry, and retaining 
detail in dataset curation) might allow quantification of proteinuria and albuminuria, 
improving the granularity of research into the relevance of proteinuria. 
11.6.2 Unanswered questions 
The ability to study potential mechanisms for any causal association of CKD with infection 
incidence and mortality in this thesis was limited, but future research investigating whether 
potential causal mechanisms are in fact observed would help to further answer the 
question of causality and identify the relevance of any modifiable mechanisms, such as 
acute kidney injury.  
Single pneumococcal and influenza vaccination appears to have limited scope to reduce the 
overall burden of community-acquired pneumonia and LRTI. This may partly be explained 
by the non-specificity of pneumonia and LRTI aetiology to these vaccines among the study 
population. However, enhanced vaccines (for example, using adjuvants) and schedules (for 
example, annual pneumococcal vaccination) may improve vaccine effectiveness, and 
should be explored for this high-risk population.  
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11.7 Personal learning 
Preparing this thesis has been an opportunity for me to reflect on my personal learning. 
The course of my studies has not always been efficient. For example, the identification and 
classification of Read codes for chronic renal diseases was time-consuming. This code list is 
now a resource available to other researchers, but an earlier assessment of their strengths 
and weaknesses relative to the completeness of serum creatinine testing might have 
allowed me to describe CKD status more quickly.  
I have gained new knowledge and skills during my studies. Practically, I have developed 
improved data management skills, learned to conduct data analyses which were new to me 
and responded to some analytical challenges, such as developing an approach to non-
converging models when calculate mortality risk ratios. I have also gained a better 
theoretical understanding of the challenges of handling, analysing and interpreting 
routinely-collected electronic health records. In particular, developing detailed study design 
and data analysis plans for each study objective required me to move from identifying bias 
in studies to managing it as far as possible.  
I have been fortunate to have my studies funded by Kidney Research UK. Attending the 
annual KRUK Fellows’ Days, I have been struck by how widely the scope of kidney research 
ranges: in discipline from epigenetics and immunology to epidemiology; in aim from 
behaviour change for CKD prevention to refining dialysis delivery arrangements; in scale 
from studies of muscle-cell models to interactions of CKD with the cardiovascular system. 
Patients have generously shared their stories of living with the psychological, as well as 
physical, demands of kidney disease. Homer W. Smith argued that it was the kidney’s salt 
and water regulation that had won humankind the freedom from the sea to become 
philosophers rather than fish.1 From my contact with the Kidney Research UK community, I 
have gained some appreciation of the nuanced and pervasive roles of the kidney in 
supporting wellbeing, and learned to see the kidney as more than a physiologically 
impressive organ working in isolation from the rest of the person. 
                                                          
1 A quote from Homer W. Smith’s book, ‘From Fish to Philosopher’ (1953) appears on page 3 of this 
thesis. 
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11.8 Conclusions 
Electronic health records facilitate fast, large, low-cost observational studies. They also 
raise challenging methodological issues, such as how to identify health status from a wealth 
of data collected for the purposes of routine care with varying validity. This is a particular 
challenge for CKD, as a silent disease.  
The population of older people with diabetes has a high burden of morbidity and mortality 
from community-acquired infections, and among this population, CKD is associated at early 
stages with an increased risk of infection incidence and, at later stages, with short-term 
mortality post-infection.  
There has traditionally been some hesitancy in diagnosing early stages of CKD among older 
people. The relevance of CKD is increasingly accepted as extending beyond the risk of 
progression to end-stage renal failure. Early stages of CKD are now recognised as important 
risk markers for cardiovascular and cerebrovascular events, and are used to prompt 
aggressive management of cardio- and cerebrovascular risk factors. A parallel relationship 
appears to exist between CKD and community-acquired infection incidence, and I hope that 
this thesis adds detail to that picture. 
Several major causes of CKD (diabetes, hypertension and smoking) are modifiable: CKD is 
predominantly a preventable disease. It is to be hoped that this further evidence of the 
systemic importance of early CKD will contribute another element to recognition of the 
burden of morbidity and mortality associated with even early stages of CKD, and the 
potential benefits of CKD prevention. 
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Appendix A: Supplementary material for Paper 1 - Chronic 
kidney disease as a risk factor for acute community-acquired 
infections in high-income countries: a systematic review 
This appendix contains the supplementary material referred to in the systematic review 
presented in Chapter 2. It comprises: full Medline, Embase and Cochrane search strategies 
(Tables 1–3); inclusion and exclusion criteria used to determine study eligibility (Table 4); 
details of the quality assessment of each study (Table 5); and a funnel plot showing the 
relationship between relative risk and standard error for the 17 estimates from all 12 
studies considered for meta-analysis (Figure 1). 
Table A 1 Medline search strategy 
 Search Results 
1 (sepsis* or septic?emia or bacter?emia or fung?emia or pneumonia* or 
bronchopneumonia* or pleuropneumonia* or LRTI or empy?ema or 
influenza* or legionell* or bacteriuri* or pyelonephriti* or cystitis* or 
pyelocystitis* or pyelitis* or urethriti* or UTI or meningiti* or 
meningococc* or encephaliti* or poliomyeliti* or septic shock).tw. 
343181  
2 (CNS adj4 infection*).tw. 2545  
3 (central nervous adj4 infection*).tw. 3805  
4 exp cerebral phaeohyphomycosis/ or central nervous system infections/ or 
exp brain abscess/ or exp toxoplasmosis, cerebral/ or central nervous 
system bacterial infections/ or exp empyema, subdural/ or exp epidural 
abscess/ or exp lyme neuroborreliosis/ or exp meningitis, bacterial/ or exp 
meningitis, escherichia coli/ or exp meningitis, haemophilus/ or exp 
meningitis, listeria/ or exp meningitis, meningococcal/ or exp meningitis, 
pneumococcal/ or exp central nervous system fungal infections/ or exp 
meningitis, fungal/ or exp meningitis, cryptococcal/ or exp 
neuroaspergillosis/ or central nervous system viral diseases/ or exp 
encephalitis/ or exp encephalitis, viral/ or exp encephalitis, arbovirus/ or 
exp encephalitis, california/ or exp encephalitis, japanese/ or exp 
"encephalitis, st. louis"/ or exp encephalitis, tick-borne/ or exp west nile 
fever/ or exp encephalitis, herpes simplex/ or exp encephalitis, varicella 
zoster/ or exp encephalomyelitis, equine/ or exp meningitis, viral/ or exp 
lymphocytic choriomeningitis/ or exp meningitis, aseptic/ or exp 
paraparesis, tropical spastic/ or poliomyelitis/ or exp poliomyelitis, bulbar/ 
or exp encephalomyelitis/ or exp meningitis/ 
102876  
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5 exp endocarditis, bacterial/ or exp endocarditis, subacute bacterial/ or exp 
pneumococcal infections/ or catheter-related infections/ or exp 
coinfection/ or communicable diseases/ or exp community-acquired 
infections/ or exp sepsis/ or exp bacteremia/ or exp hemorrhagic 
septicemia/ or exp fungemia/ or exp shock, septic/ or exp empyema/ or 
exp viremia/ or exp parasitemia/ 
139752  
6 ((renal or kidney) adj4 chronic adj4 failure*).tw. 21053  
7 ((renal or kidney) adj4 chronic adj4 disease*).tw. 15978  
8 ((renal or kidney) adj4 chronic adj4 insufficienc*).tw. 4448  
9 ((renal or kidney) adj4 chronic adj4 injury).tw. 454  
10 ((renal or kidney) adj4 chronic adj4 impairment*).tw. 336  
11 (creatinine* or GFR or eGFR or albuminuri* or proteinuri* or 
microalbuminuri* or nephropath* or glomerulo* or nephr#ti* or nephrosi* 
or ur?emia or ESRD or CKD or cardio-renal or Kimmelstiel-Wilson).tw. 
194742  
12 Creatinine/bl [Blood] 25724  
13 Kidney Diseases/co, ep [Complications, Epidemiology] 11809  
14 exp diabetic nephropathies/ or exp hypertension, renal/ or exp nephritis/ 
or exp anti-glomerular basement membrane disease/ or exp 
glomerulonephritis, iga/ or exp glomerulonephritis, 
membranoproliferative/ or exp glomerulonephritis, membranous/ or exp 
lupus nephritis/ or exp nephrosclerosis/ or exp nephrosis/ or exp renal 
insufficiency/ or exp cardio-renal syndrome/ or exp uremia/ or exp 
azotemia/ or exp proteinuria/ 
234481  
15 kidney function tests/ or exp glomerular filtration rate/ 44837  
16 Animals/ 4889105  
17 Humans/ 12139628  
18 16 not (16 and 17) 3594930  
19 Adult/ 3567838  
20 exp child/ or exp child, preschool/ or exp infant/ 1849722  
21 20 not (19 and 20) 1265383  
22 Case reports/ 1557478  
23 developing countries/ or exp africa/ or cuba/ or dominica/ or dominican 
republic/ or grenada/ or guadeloupe/ or haiti/ or jamaica/ or exp central 
america/ or "gulf of mexico"/ or latin america/ or exp south america/ or 
exp asia, central/ or borneo/ or cambodia/ or east timor/ or indonesia/ or 
laos/ or malaysia/ or mekong valley/ or myanmar/ or philippines/ or 
thailand/ or vietnam/ or bangladesh/ or india/ or afghanistan/ or iran/ or 
iraq/ or jordan/ or lebanon/ or syria/ or turkey/ or yemen/ or nepal/ or 
620630  
232
[233]  
 
pakistan/ or sri lanka/ or exp china/ or "democratic people's republic of 
korea"/ or mongolia/ or albania/ or latvia/ or lithuania/ or bosnia-
herzegovina/ or bulgaria/ or "republic of belarus"/ or romania/ or exp 
russia/ or serbia/ or ukraine/ or yugoslavia/ or exp transcaucasia/ or exp 
indian ocean islands/ or fiji/ or papua new guinea/ or vanuatu/ or palau/ or 
hawaii/ 
24 developed countries/ or bahamas/ or barbados/ or netherlands antilles/ or 
puerto rico/ or "trinidad and tobago"/ or "virgin islands of the united 
states"/ or canada/ or greenland/ or united states/ or brunei/ or 
singapore/ or bahrain/ or israel/ or kuwait/ or oman/ or qatar/ or saudi 
arabia/ or united arab emirates/ or hong kong/ or macau/ or exp japan/ or 
"republic of korea"/ or bermuda/ or exp australia/ or andorra/ or austria/ 
or belgium/ or estonia/ or croatia/ or czech republic/ or hungary/ or 
poland/ or slovakia/ or slovenia/ or finland/ or exp france/ or exp germany/ 
or gibraltar/ or exp great britain/ or greece/ or iceland/ or ireland/ or exp 
italy/ or liechtenstein/ or luxembourg/ or cyprus/ or malta/ or monaco/ or 
netherlands/ or portugal/ or san marino/ or exp scandinavia/ or spain/ or 
switzerland/ or new zealand/ or new caledonia/ or guam/ 
1800832  
25 23 not (23 and 24) 556094  
26 Postoperative complications.sh. 263650  
27 (incidence* or odds ratio or risk ratio or risk factor or relative risk).tw. 608698  
28 (respiratory adj3 infection*).tw. 28563  
29 (lower respiratory adj3 infection*).tw. 4633  
30 (urinary adj3 infection*).tw. 28333  
31 (upper urinary adj3 infection*).tw. 312  
32 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 366856  
33 (exp incidence/ or exp multivariate analysis/ or exp odds ratio/ or exp 
logistic models/ or exp risk factors/ or exp epidemiologic studies/).sh. 
1799348  
34 (exp pyelitis/ or exp pyelocystitis/ or exp pyelonephritis/ or exp urethritis/ 
or cystitis or urinary tract infections or exp pyuria/).sh. 
50526  
35 (respiratory tract infections or exp bronchiolitis/ or exp bronchiolitis, viral/ 
or empyema, pleural or exp influenza, human/ or exp legionellosis/ or exp 
legionnaires' disease/ or exp lung abscess/ or exp lung diseases, fungal/ or 
exp lung diseases, parasitic/ or exp pneumonia/ or exp 
bronchopneumonia/ or exp pleuropneumonia/ or exp pneumonia, 
bacterial/ or exp chlamydial pneumonia/ or exp pneumonia, mycoplasma/ 
or exp pneumonia, pneumococcal/ or exp pneumonia, rickettsial/ or exp 
pneumonia, staphylococcal/ or exp pneumonia, pneumocystis/ or exp 
155035  
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pneumonia, viral/ or exp severe acute respiratory syndrome/ or exp 
tracheitis/ or exp whooping cough/).sh. 
36 1 or 2 or 3 or 4 or 5 or 28 or 29 or 30 or 31 or 34 or 35 585963  
37 27 or 33 2098986  
38 32 and 36 and 37 5940  
39 38 not 18 not 21 not 22 not 25 not 26 3514  
40 limit 39 to (english or french or german) 3163  
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Table A 2 Embase search strategy 
 Search Results 
1 kidney failure/co, ep [Complication, Epidemiology] 13218  
2 chronic kidney failure/co, ep [Complication, Epidemiology] 10827  
3 exp proteinuria/co, ep [Complication, Epidemiology] 5456  
4 uremia/co, ep [Complication, Epidemiology] 3030  
5 glomerulus filtration rate/ 43185  
6 creatinine clearance/ 17973  
7 glomerulosclerosis/co, ep [Complication, Epidemiology] 450  
8 kidney disease/co, ep [Complication, Epidemiology] 10406  
9 analgesic nephropathy/co, ep [Complication, Epidemiology] 39  
10 chronic kidney disease/co, ep [Complication, Epidemiology] 1733  
11 diabetic nephropathy/co, ep [Complication, Epidemiology] 9683  
12 allergic glomerulonephritis/co, ep [Complication, Epidemiology] 109  
13 immune complex nephritis/co, ep [Complication, Epidemiology] 77  
14 immunoglobulin A nephropathy/co, ep [Complication, Epidemiology] 678  
15 kidney amyloidosis/co, ep [Complication, Epidemiology] 228  
16 nephritis/co, ep [Complication, Epidemiology] 1053  
17 glomerulitis/ 456  
18 Goodpasture syndrome/co, ep [Complication, Epidemiology] 31  
19 immune complex nephritis/co, ep [Complication, Epidemiology] 77  
20 interstitial nephritis/co, ep [Complication, Epidemiology] 901  
21 lupus erythematosus nephritis/co, ep [Complication, Epidemiology] 850  
22 nephrosis/co, ep [Complication, Epidemiology] 189  
23 nephrotic syndrome/co, ep [Complication, Epidemiology] 2133  
24 exp glomerulopathy/co, ep [Complication, Epidemiology] 5475  
25 exp glomerulonephritis/co, ep [Complication, Epidemiology] 4296  
26 exp kidney dysfunction/co, ep [Complication, Epidemiology] 1322  
27 (creatinine* or GFR or eGFR or albuminuri* or proteinuri* or 
microalbuminuri* or nephropath* or glomerulo* or nephr#ti* or nephrosi* 
or ur?emia or ESRD or CKD or cardio-renal or Kimmelstiel-Wilson).tw. 
282722  
28 ((renal or kidney) adj4 chronic adj4 failure*).tw. 28639  
29 ((renal or kidney) adj4 chronic adj4 disease*).tw. 23893  
30 ((renal or kidney) adj4 chronic adj4 insufficienc*).tw. 6425  
31 ((renal or kidney) adj4 chronic adj4 injury).tw. 631  
32 ((renal or kidney) adj4 chronic adj4 impairment*).tw. 501  
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33 exp infectious pneumonia/ or bacterial pneumonia/ or chlamydial 
pneumonia/ or group b streptococcal pneumonia/ or legionnaire disease/ or 
mycoplasma pneumonia/ or pneumocystis pneumonia/ or pulmonary 
candidiasis/ or severe acute respiratory syndrome/ or staphylococcal 
pneumonia/ or virus pneumonia/ 
50671  
34 respiratory tract infection/ or exp influenza/ or laryngotracheobronchitis/ or 
lower respiratory tract infection/ or parainfluenza virus infection/ or 
respiratory syncytial virus infection/ or viral respiratory tract infection/ 
106624  
35 avian influenza/ 5081  
36 chest infection/ or pertussis/ 13997  
37 bronchiolitis/ or laryngotracheobronchitis/ or tracheobronchitis/ 10003  
38 pleura empyema/ 3703  
39 pyuria/ or urinary tract infection/ 66023  
40 candiduria/ or kidney infection/ 1502  
41 kidney abscess/ or pyonephrosis/ 1666  
42 cystitis/ 11865  
43 pyelonephritis/ or acute pyelonephritis/ 22138  
44 brain infection/ or brain abscess/ or herpes simplex encephalitis/ or herpes 
zoster encephalitis/ or subdural empyema/ or tick borne encephalitis/ or 
virus encephalitis/ 
24862  
45 central nervous system infection/ or epidural abscess/ or poliomyelitis/ 38386  
46 meningitis/ or bacterial meningitis/ or exp fungal meningitis/ or 
haemophilus meningitis/ or lymphocytic choriomeningitis/ or subdural 
empyema/ or virus meningitis/ 
57864  
47 encephalitis/ or brain ventriculitis/ or eastern equine encephalitis/ or 
encephalomyelitis/ or epidemic encephalitis/ or meningoencephalitis/ or 
panencephalitis/ or primary amebic meningoencephalitis/ 
47288  
48 exp meningococcosis/ 11231  
49 exp pneumococcal infection/ 5729  
50 exp group b streptococcal infection/ or group b streptococcal pneumonia/ 405  
51 exp bacteremia/ or staphylococcal bacteremia/ 29638  
52 bloodstream infection/ 2518  
53 candidemia/ 1358  
54 systemic mycosis/ or fungemia/ or invasive aspergillosis/ or invasive 
candidiasis/ 
5182  
55 sepsis/ or bacteremia/ or septic shock/ or septicemia/ or urosepsis/ 140091  
56 viremia/ 12287  
57 parasitemia/ 6918  
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58 (sepsis* or septic?emia or bacter?emia or fung?emia or pneumonia* or 
bronchopneumonia* or pleuropneumonia* or LRTI or empy?ema or 
influenza* or legionell* or bacteriuri* or pyelonephritis or cystitis or 
pyelocystitis or pyelitis or urethriti* or meningiti* or meningococc* or 
encephaliti* or poliomyeliti* or septic shock).tw. 
497436  
59 (CNS adj4 infection*).tw. 3591  
60 (central nervous adj4 infection*).tw. 4861  
61 UTI.tw. 6684  
62 bronchopneumonia/ 8394  
63 arachnoiditis/ or aseptic meningitis/ or epidemic meningitis/ or group b 
streptococcal meningitis/ or meningoencephalitis/ or pneumococcal 
meningitis/ 
21305  
64 exp epidemiology/ or exp incidence/ 1705072  
65 exp risk factor/ 513022  
66 exp attributable risk/ 1487  
67 exp hazard ratio/ 11362  
68 statistical model/ 87903  
69 (odds adj1 ratio).tw. 101865  
70 (relative adj2 ratio).tw. 2736  
71 case report/ 1892302  
72 developing country/ 71459  
73 developed country/ 25618  
74 postoperative complication/ or postoperative infection/ or surgical 
infection/ 
272218  
75 exp Africa/ 196804  
76 argentina/ or bolivia/ or brazil/ or chile/ or colombia/ or ecuador/ or french 
guiana/ or guyana/ or paraguay/ or peru/ or suriname/ or uruguay/ or 
venezuela/ 
98392  
77 exp Central America/ 15618  
78 china/ or mongolia/ or philippines/ 82530  
79 borneo/ or cambodia/ or indonesia/ or laos/ or malaysia/ or myanmar/ or 
papua new guinea/ or thailand/ or timor-leste/ or viet nam/ 
53670  
80 North Korea/ 237  
81 latvia/ or lithuania/ 3316  
82 albania/ or armenia/ or azerbaijan/ or belarus/ or "bosnia and herzegovina"/ 
or bulgaria/ or "georgia (republic)"/ or "macedonia (republic)"/ or romania/ 
or russian federation/ or serbia/ or ukraine/ 
83374  
83 USSR/ 50149  
237
[238]  
 
84 iran/ or iraq/ or jordan/ or lebanon/ or "turkey (republic)"/ or yemen/ 49920  
85 kazakhstan/ or kyrgyzstan/ or tajikistan/ or turkmenistan/ or uzbekistan/ 5682  
86 afghanistan/ or bangladesh/ or india/ or nepal/ or pakistan/ or sikkim/ or sri 
lanka/ 
105351  
87 cuba/ or dominica/ or dominican republic/ or grenada/ or guadeloupe/ or 
haiti/ or jamaica/ 
11346  
88 fiji/ or philippines/ or polynesia/ 8607  
89 exp Indian Ocean/ 2505  
90 Mexico/ 28748  
91 72 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 
87 or 88 or 89 or 90 
789122  
92 exp Western Europe/ 911511  
93 croatia/ or czech republic/ or hungary/ or poland/ or slovakia/ or slovenia/ 73494  
94 Estonia/ 2056  
95 canada/ or united states/ 1031054  
96 japan/ or macao/ 115065  
97 South Korea/ 4982  
98 bahrain/ or cyprus/ or israel/ or kuwait/ or oman/ or qatar/ or saudi arabia/ 
or united arab emirates/ 
37707  
99 exp "Australia and New Zealand"/ 129186  
100 brunei darussalam/ or hong kong/ or singapore/ 21427  
101 73 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 2259038  
102 91 not (91 and 101) 710496  
103 treatment outcome/ 579285  
104 editorial/ 438527  
105 embryo/ 177038  
106 infant/ 533322  
107 child/ 1295310  
108 preschool child/ 469034  
109 school child/ 217344  
110 adolescent/ 1180705  
111 adult/ 4186945  
112 105 or 106 or 107 or 108 or 109 or 110 2546570  
113 112 not (112 and 111) 1658687  
114 animal model/ 630310  
115 animal experiment/ 1606715  
116 nonhuman/ 3807183  
117 animal/ 1773703  
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118 human/ 13422168  
119 114 or 115 or 116 or 117 5921124  
120 119 not (119 and 118) 4747089  
121 pneumonia/ 97950  
122 lung infection/ or hantavirus pulmonary syndrome/ or lung abscess/ or viral 
bronchiolitis/ 
21795  
123 (respiratory adj3 infection*).tw. 43371  
124 (lower respiratory adj3 infection*).tw. 6553  
125 (urinary adj3 infection*).tw. 44177  
126 (upper urinary adj3 infection*).tw. 444  
127 (epidemiolog$ or incidence).tw. 878025  
128 (relative adj risk*).tw. 55195  
129 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 
16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 
29 or 30 or 31 or 32 
364340  
130 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 
46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 
59 or 60 or 61 or 62 or 63 or 121 or 122 or 123 or 124 or 125 or 126 
851259  
131 64 or 65 or 66 or 67 or 68 or 69 or 70 or 127 or 128 2659100  
132 129 and 130 and 131 7357  
133 132 not 120 not 113 not 104 not 71 not 74 not 102 4970  
134 limit 133 to (english or french or german) 4602  
135 limit 134 to embase 4247  
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Table A 3 Cochrane library search strategy 
 Search Results 
1 sepsis* or septic*mia or bacter*mia or fung*mia or pneumonia* or 
bronchopneumonia* or pleuropneumonia* or LRTI or empy*ma or influenza* 
or legionell* or bacteriuri* or pyelonephriti* or cystitis* or pyelocystitis* or 
pyelitis* or urethriti* or UTI or meningiti* or meningococc* or encephaliti* or 
poliomyeliti* or "septic shock" 
19098 
2 CNS near/4 infection* 47 
3 "central nervous" near/4 infection* 92 
4 [mh "cerebral phaeohyphomycosis"] or [mh ^"central nervous system 
infections"] or [mh "brain abscess"] or [mh "toxoplasmosis, cerebral"] or [mh 
^"central nervous system bacterial infections"] or [mh "empyema, subdural"] 
or [mh "epidural abscess"] or [mh "lyme neuroborreliosis"] or [mh 
"meningitis, bacterial"] or [mh "meningitis, escherichia coli"] or [mh 
"meningitis, haemophilus"] or [mh "meningitis, listeria"] or [mh "meningitis, 
meningococcal"] or [mh "meningitis, pneumococcal"] or [mh "central nervous 
system fungal infections"] or [mh "meningitis, fungal"] or [mh "meningitis, 
cryptococcal"] or [mh neuroaspergillosis] or [mh ^"central nervous system 
viral diseases"] or [mh encephalitis] or [mh "encephalitis, viral"] or [mh 
"encephalitis, arbovirus"] or [mh "encephalitis, california"] or [mh 
"encephalitis, japanese"] or [mh "encephalitis, st. louis"] or [mh "encephalitis, 
tick-borne"] or [mh "west nile fever"] or [mh "encephalitis, herpes simplex"] 
or [mh "encephalitis, varicella zoster"] or [mh "encephalomyelitis, equine"] or 
[mh "meningitis, viral"] or [mh "lymphocytic choriomeningitis"] or [mh 
"meningitis, aseptic"] or [mh "paraparesis, tropical spastic"] or [mh 
^poliomyelitis] or [mh "poliomyelitis, bulbar"] or [mh encephalomyelitis] or 
[mh meningitis] 
1015 
5 [mh "endocarditis, bacterial"] or [mh "endocarditis, subacute bacterial"] or 
[mh "pneumococcal infections"] or [mh ^"catheter-related infections"] or 
[mh coinfection] or [mh ^"communicable diseases"] or [mh "community-
acquired infections"] or [mh sepsis] or [mh bacteremia] or [mh "hemorrhagic 
septicemia"] or [mh fungemia] or [mh "shock, septic"] or [mh empyema] or 
[mh viremia] or [mh parasitemia] 
4033 
6 respiratory near/3 infection* 4398 
7 urinary near/3 infection* 3732 
8 [mh pyelitis] or [mh pyelocystitis] or [mh pyelonephritis] or [mh urethritis] or 
[mh ^cystitis] or [mh ^"urinary tract infections"] or [mh pyuria] 
2143 
9 [mh ^"respiratory tract infections"] or [mh bronchiolitis] or [mh 
"bronchiolitis, viral"] or [mh ^"empyema, pleural"] or [mh "influenza, 
human"] or [mh legionellosis] or [mh "legionnaires' disease"] or [mh "lung 
abscess"] or [mh "lung diseases, fungal"] or exp [mh "lung diseases, 
parasitic"] or [mh pneumonia] or [mh bronchopneumonia] or [mh 
pleuropneumonia] or [mh "pneumonia, bacterial"] or [mh "chlamydial 
pneumonia"] or [mh "pneumonia, mycoplasma"] or [mh "pneumonia, 
pneumococcal"] or [mh "pneumonia, rickettsial"] or [mh "pneumonia, 
staphylococcal"] or [mh "pneumonia, pneumocystis"] or [mh "pneumonia, 
viral"] or [mh "severe acute respiratory syndrome"] or [mh tracheitis] or [mh 
"whooping cough"] 
5402 
10 (renal or kidney) near/4 chronic near/4 failure* 4476 
11 (renal or kidney) near/4 chronic near/4 disease* 1647 
12 (renal or kidney) near/4 chronic near/4 insufficienc* 510 
13 (renal or kidney) near/4 chronic near/4 injury 29 
14 (renal or kidney) near/4 chronic near/4 impairment* 34 
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15 creatinine* or GFR or eGFR or albuminuri* or proteinuri* or 
microalbuminuri* or nephropath* or glomerulo* or nephr?ti* or nephrosi* or 
ur*mia or ESRD or CKD or cardio-renal or Kimmelstiel-Wilson 
16810 
16 [mh ^creatinine/BL] 2042 
17 [mh ^"kidney diseases"/CO,EP] 341 
18 [mh "diabetic nephropathies"] or [mh "hypertension, renal"] or [mh 
nephritis] or [mh "anti-glomerular basement membrane disease"] or [mh 
"glomerulonephritis, iga"] or [mh "glomerulonephritis, 
membranoproliferative"] or [mh "glomerulonephritis, membranous"] or [mh 
"lupus nephritis"] or [mh nephrosclerosis] or [mh nephrosis] or [mh "renal 
insufficiency"] or [mh "cardio-renal syndrome"] or [mh uremia] or [mh 
azotemia] or [mh proteinuria] 
7117 
19 [mh ^"kidney function tests"] or [mh "glomerular filtration rate"] 2417 
20 {or #1-#9} 25511 
21 [175-#19] 21120 
22 {and #20-#21} 1422 
23 incidence* or "odds ratio" or "risk ratio" or "risk factor" or "relative risk" 69239 
24 [mh incidence] or [mh "multivariate analysis"] or [mh "odds ratio"] or [mh 
"logistic models"] or [mh "risk factors"] or [mh "epidemiologic studies"] 
122866 
25 {or #23-#24} 165844 
26 {and #22, #25} 953 
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Table A 4 Inclusion and exclusion criteria for determining study eligibility 
 Included Excluded 
Participants Adult human participants. Populations exclusively of: 
- pregnant women; 
- kidney transplant recipients or  
patients receiving renal replacement 
therapy; 
- patient groups usually managed in 
secondary care unless this was for 
chronic kidney disease, or routinely 
treated with immunosuppressive 
medication. 
Study settings High income countries (World Bank 
classification). 
Community settings, including adults 
living in institutional care. 
 
Exposure of 
interest 
Chronic acquired kidney disease, 
indicated by any of the following: 
- medical diagnosis; 
- reduced estimated glomerular 
filtration rate; 
- reduced creatinine clearance; 
- elevated creatinine; 
- proteinuria, micro- or macro-
albuminuria; 
- renal structural abnormalities. 
 
Where there was no ‘unexposed’ group 
without kidney disease, comparison 
between stages 1-2 and stages 3-5 CKD 
was accepted. 
 
Outcomes of 
interest 
Incidence rate ratio, risk ratio or odds 
ratio estimates of the effect of kidney 
disease on any of the following 
community-acquired acute infections: 
- lower respiratory tract infections;  
- urinary tract infections (UTIs); 
- central nervous system infections;  
- sepsis. 
 
Urinary catheter-associated UTIs from 
community settings, and incidence of 
severe disease (such as hospitalisation 
for infection) were accepted. 
Outcomes not accepted: 
- infection prevalence; 
- hospital-associated infection rates; 
- post-operative follow up 
outcomes; 
- incidence of infection-related 
mortality; 
- prognosis among infected patients. 
Study 
methodology 
Trials, case-control studies, cohort 
studies or other observational study 
designs containing original data.  
 
Relevant review articles without original 
data were identified for reference list 
screening. 
Case reports.  
Descriptive studies without a 
comparison group. 
 
Studies with fewer than 30 
participants in either the exposed or 
unexposed categories. 
Publication 
details 
Any publication date.  
Languages: English, German, French. 
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 c
la
im
s 
O
b
se
rv
er
 b
ia
s 
10
 
U
n
ce
rt
ai
n
: 
st
an
d
ar
d
 
d
ef
in
it
io
n
 o
f 
A
P
N
 is
 v
ag
u
e 
an
d
 n
o
t 
re
p
o
rt
ed
 
w
h
et
h
er
 a
n
y 
o
b
se
rv
er
 
b
lin
d
ed
 t
o
 r
en
al
 
st
at
u
s 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
ch
o
ic
e 
o
f 
h
o
sp
it
al
 
d
ia
gn
o
si
s 
co
d
e 
fo
r 
se
ve
re
 
o
u
tc
o
m
e 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
ch
o
ic
e 
o
f 
h
o
sp
it
al
 
d
ia
gn
o
si
s 
co
d
e 
fo
r 
se
ve
re
 
o
u
tc
o
m
e 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
ch
o
ic
e 
o
f 
h
o
sp
it
al
 
d
ia
gn
o
si
s 
co
d
e 
fo
r 
se
ve
re
 
o
u
tc
o
m
e 
Lo
w
: o
b
je
ct
iv
e 
d
ef
in
it
io
n
 o
f 
o
u
tc
o
m
e 
in
d
ep
en
d
en
t 
o
f 
ex
p
o
su
re
 s
ta
tu
s 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
ch
o
ic
e 
o
f 
h
o
sp
it
al
 
d
ia
gn
o
si
s 
co
d
e 
fo
r 
se
ve
re
 
o
u
tc
o
m
e 
Lo
w
: C
K
D
 s
ta
tu
s 
u
n
lik
el
y 
to
 
se
ve
re
ly
 a
ff
ec
t 
ap
p
lic
at
io
n
 o
f 
cl
ea
r 
cr
it
er
ia
 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 
st
ro
n
gl
y 
in
fl
u
en
ce
 
d
ia
gn
o
si
s 
o
f 
U
TI
 
at
 a
ge
 8
6
-8
9
 
ye
ar
s,
 g
iv
en
 c
as
e 
cr
it
er
ia
 in
cl
u
d
e 
sy
m
p
to
m
s 
an
d
 
u
ri
n
ar
y 
an
al
ys
is
 
Lo
w
: o
b
je
ct
iv
e 
cr
it
er
ia
 f
o
r 
ca
se
s 
o
n
ce
 t
es
te
d
 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
ch
o
ic
e 
o
f 
h
o
sp
it
al
 
d
ia
gn
o
si
s 
co
d
e 
fo
r 
se
ve
re
 
o
u
tc
o
m
e 
245
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6
] 
  
A
sc
er
ta
in
m
en
t1
1
 
U
n
ce
rt
ai
n
: 
m
et
h
o
d
s 
fo
r 
as
ce
rt
ai
n
in
g 
in
fe
ct
io
n
 n
o
t 
re
p
o
rt
ed
 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
d
ia
gn
o
si
s 
o
f 
se
ve
re
 o
u
tc
o
m
e 
w
it
h
 w
id
el
y 
ac
ce
p
te
d
 c
lin
ic
al
 
cr
it
er
ia
 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
h
o
sp
it
al
 
at
te
n
d
an
ce
 w
it
h
 
se
ve
re
 o
u
tc
o
m
e 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
h
o
sp
it
al
 
at
te
n
d
an
ce
 w
it
h
 
se
ve
re
 o
u
tc
o
m
e 
Lo
w
: s
en
d
in
g 
o
f 
b
lo
o
d
 c
u
lt
u
re
 
u
n
lik
el
y 
to
 b
e
 
in
fl
u
en
ce
d
 b
y 
ki
d
n
ey
 d
is
ea
se
 
in
 c
o
n
te
xt
 o
f 
se
ve
re
 il
ln
es
s 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
d
ia
gn
o
si
s 
o
f 
se
ve
re
 o
u
tc
o
m
e 
w
it
h
 w
id
el
y 
ac
ce
p
te
d
 c
lin
ic
al
 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
h
o
sp
it
al
 
at
te
n
d
an
ce
 w
it
h
 
se
ve
re
 o
u
tc
o
m
e 
U
n
ce
rt
ai
n
: 
ki
d
n
ey
 d
is
ea
se
 
st
at
u
s 
m
ay
 
af
fe
ct
 
h
ea
lt
h
ca
re
 
at
te
n
d
an
ce
 f
o
r 
m
in
o
r 
ill
n
es
s 
su
ch
 a
s 
U
TI
 
U
n
ce
rt
ai
n
: 
se
n
d
in
g 
o
f 
P
C
R
 
te
st
 d
u
ri
n
g 
in
fl
u
en
za
 
p
an
d
em
ic
 
vu
ln
er
ab
le
 t
o
 b
e 
in
fl
u
en
ce
d
 b
y 
co
m
o
rb
id
it
ie
s 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
u
n
lik
el
y 
to
 a
ff
ec
t 
h
o
sp
it
al
 
at
te
n
d
an
ce
 w
it
h
 
se
ve
re
 o
u
tc
o
m
e 
C
o
n
fo
u
n
d
in
g 
12
 
H
ig
h
: 
u
n
ad
ju
st
ed
 
es
ti
m
at
e.
 In
 
p
ar
ti
cu
la
r,
 h
ig
h
 
im
m
u
n
o
su
p
p
re
s
sa
n
t 
u
se
 a
m
o
n
g 
th
e 
st
u
d
y 
p
o
p
u
la
ti
o
n
 
Lo
w
: a
d
ju
st
ed
 
fo
r 
ag
e,
 s
ex
, 
n
at
u
re
 o
f 
in
d
ex
 
ev
en
t,
 c
h
ar
ls
o
n
 
in
d
ex
, 
h
ea
lt
h
ca
re
 u
se
, 
an
d
 o
th
er
 
co
m
o
rb
id
it
ie
s 
Lo
w
: a
d
ju
st
ed
 
fo
r 
ag
e,
 s
ex
, 
ra
ce
, s
m
o
ki
n
g,
 
B
M
I,
 d
ia
b
et
es
 
m
el
lit
u
s,
 a
n
d
 
m
u
lt
ip
le
 c
o
-
m
o
rb
id
it
ie
s.
 
H
ig
h
: n
o
 
ad
ju
st
m
en
t 
fo
r 
se
x 
16
 
Lo
w
:  
ad
ju
st
ed
 
fo
r 
ag
e,
 s
ex
, 
d
ia
b
et
es
, 
co
m
o
rb
id
it
y 
sc
o
re
, c
ar
e 
in
 a
 
d
ed
ic
at
ed
 r
en
al
 
cl
in
ic
 
Lo
w
: a
d
ju
st
ed
 
fo
r 
ag
e,
 s
ex
, 
so
ci
o
-e
co
n
o
m
ic
 
st
at
u
s,
 e
th
n
ic
it
y,
 
d
ia
b
et
es
 
m
el
lit
u
s,
 
C
h
ar
ls
o
n
 
co
m
o
rb
id
it
y 
sc
o
re
 
H
ig
h
: a
d
ju
st
ed
 
fo
r 
ag
e,
 s
ex
, 
al
co
h
o
l, 
sm
o
ki
n
g 
an
d
 
d
em
o
gr
ap
h
ic
 
fa
ct
o
rs
 b
u
t 
n
o
 
co
m
o
rb
it
id
ie
s.
 
H
ig
h
: n
o
 
ad
ju
st
m
en
t 
fo
r 
se
x 
o
r 
d
ia
b
et
es
 
17
 
H
ig
h
: a
d
ju
st
ed
 
fo
r 
ag
e 
o
n
ly
 
 
H
ig
h
: 
u
n
ad
ju
st
ed
 1
9
 
R
e
ve
rs
e
 
ca
u
sa
ti
o
n
 1
8  
U
n
ce
rt
ai
n
: 
Ti
m
in
g 
o
f 
cr
ea
ti
n
in
e 
m
ea
su
re
m
en
t 
re
la
ti
ve
 t
o
 
in
fe
ct
io
n
s 
n
o
t 
sp
ec
if
ie
d
 
Lo
w
: c
h
ro
n
ic
 
re
n
al
 f
ai
lu
re
 
sh
o
u
ld
 n
o
t 
b
e
 
d
ia
gn
o
se
d
 
w
it
h
in
 o
n
e 
h
o
sp
it
al
 e
p
is
o
d
e 
fo
r 
in
fe
ct
io
n
 
Lo
w
: b
as
el
in
e 
se
ru
m
 c
ys
ta
ti
n
 C
 
u
se
d
 
Lo
w
: s
er
u
m
 
b
io
ch
em
is
tr
y 
te
st
ed
 a
t 
sc
re
en
in
g 
Lo
w
:  
b
as
el
in
e 
cr
ea
ti
n
in
e 
u
se
d
 
Lo
w
: o
n
ly
 
fo
llo
w
ed
 t
o
 f
ir
st
 
o
u
tc
o
m
e 
ev
en
t,
 
cr
ea
ti
n
in
e 
re
su
lt
 
p
re
d
at
es
 
q
u
al
if
yi
n
g 
in
fe
ct
io
n
 
Lo
w
: 
b
as
el
in
e 
cr
ea
ti
n
in
e 
u
se
d
 
Lo
w
: b
as
el
in
e 
cr
ea
ti
n
in
e 
u
se
d
 
Lo
w
: p
re
-
ex
is
ti
n
g 
ki
d
n
e
y 
d
is
ea
se
 r
ep
o
rt
ed
 
at
 t
im
e 
o
f 
in
fe
ct
io
n
 
Lo
w
: k
id
n
ey
 
d
is
ea
se
 s
ta
tu
s 
es
ta
b
lis
h
ed
 in
 
ye
ar
 p
ri
o
r 
to
 
st
u
d
y 
*T
h
e 
u
n
u
su
al
 d
e
si
gn
 o
f 
th
e 
ar
ti
fi
ci
al
 c
o
h
o
rt
 s
tu
d
y 
b
y 
C
am
p
b
el
l e
t 
a
l. 
is
 w
o
rt
h
 c
la
ri
fi
ca
ti
o
n
. D
u
ri
n
g 
th
e
 2
0
0
9
–2
0
1
0
 in
fl
u
en
za
 p
an
d
em
ic
, h
o
sp
it
al
is
ed
 c
as
es
 o
f 
la
b
o
ra
to
ry
 c
o
n
fi
rm
ed
 p
an
d
em
ic
 in
fl
u
en
za
 A
 
(H
1
N
1
) 
w
er
e 
re
p
o
rt
ed
 b
y 
a 
la
b
o
ra
to
ry
-b
as
ed
 n
at
io
n
al
 s
u
rv
ei
lla
n
ce
 s
ys
te
m
. T
h
e 
su
rv
ei
lla
n
ce
 r
ep
o
rt
, c
o
m
p
le
te
d
 b
y 
th
e 
m
ic
ro
b
io
lo
gi
st
, a
sk
ed
 w
h
e
th
er
 t
h
e 
ca
se
 h
ad
 a
 d
ia
gn
o
si
s 
o
f 
C
K
D
. D
en
o
m
in
at
o
rs
 f
o
r 
in
fe
ct
io
n
 r
at
e
s 
w
er
e 
o
b
ta
in
ed
 f
ro
m
 p
ri
m
ar
y 
ca
re
 r
eg
is
te
rs
 o
f 
p
at
ie
n
ts
 e
lig
ib
le
 f
o
r 
p
an
d
em
ic
 in
fl
u
e
n
za
 v
ac
ci
n
at
io
n
 b
y 
vi
rt
u
e 
o
f 
a 
C
K
D
 d
ia
gn
o
si
s 
(f
o
r 
C
K
D
):
 a
n
d
 f
ro
m
 t
h
e 
n
at
io
n
al
 c
en
su
s 
(f
o
r 
n
o
n
-
C
K
D
).
[1
7
6
] 
Th
e 
ef
fe
ct
 o
f 
C
K
D
 o
n
 in
fl
u
e
n
za
 m
ay
 b
e 
o
ve
re
st
im
at
ed
 in
 t
h
is
 s
tu
d
y,
 b
ec
au
se
 C
K
D
 w
as
 a
d
ve
rt
is
e
d
 a
s 
a 
p
o
ss
ib
le
 r
is
k 
fa
ct
o
r 
fo
r 
p
an
d
em
ic
 in
fl
u
e
n
za
 t
o
 e
n
co
u
ra
ge
 v
ac
ci
n
e 
u
p
ta
ke
 a
m
o
n
g 
th
is
 
gr
o
u
p
, a
n
d
 p
at
ie
n
ts
 w
it
h
 f
lu
-l
ik
e 
sy
m
p
to
m
s 
co
u
ld
 h
av
e 
b
ee
n
 m
o
re
 li
ke
ly
 t
o
 a
tt
en
d
 h
o
sp
it
al
 o
r 
b
e 
te
st
ed
 f
o
r 
p
an
d
em
ic
 in
fl
u
en
za
 A
 (
H
1
N
1
) 
if
 t
h
ey
 h
ad
 a
 d
ia
gn
o
si
s 
o
f 
C
K
D
. 
1
. H
ig
h
 r
is
k:
 p
ro
b
ab
ili
ty
 o
f 
se
le
ct
io
n
 a
s 
a 
co
n
tr
o
l l
ik
el
y 
to
 b
e 
af
fe
ct
ed
 b
y 
ki
d
n
ey
 d
is
ea
se
 s
ta
tu
s 
(k
n
o
w
n
 o
r 
u
n
kn
o
w
n
).
  
Lo
w
 r
is
k:
 c
o
n
tr
o
ls
 s
el
ec
te
d
 u
si
n
g 
ra
n
d
o
m
 s
am
p
lin
g 
(o
r 
o
th
er
 s
ys
te
m
 u
n
lik
el
y 
to
 b
e 
b
ia
se
d
 b
y 
ki
d
n
ey
 d
is
ea
se
 s
ta
tu
s)
 f
ro
m
 t
h
e 
p
o
p
u
la
ti
o
n
 f
ro
m
 w
h
ic
h
 t
h
e 
ca
se
s 
ar
o
se
. 
2
. L
o
w
 r
is
k:
 (
1
) 
au
to
m
at
ed
 p
ar
ti
ci
p
at
io
n
 (
e.
g.
 m
ed
ic
al
 r
ec
o
rd
 r
ev
ie
w
),
 o
r 
(2
) 
≥8
0
%
 p
ar
ti
ci
p
at
io
n
, o
r 
(3
) 
7
0
-8
0
%
 p
ar
ti
ci
p
at
io
n
 w
it
h
 a
 c
o
m
p
ar
is
o
n
 (
m
in
 a
ge
, s
ex
, d
ea
th
/m
o
rb
id
it
y)
 s
h
o
w
in
g 
si
m
ila
r 
ch
ar
ac
te
ri
st
ic
s 
b
et
w
ee
n
 t
h
o
se
 in
cl
u
d
e
d
 a
n
d
 t
h
o
se
 n
o
t 
in
cl
u
d
ed
 in
 t
h
e 
st
u
d
y.
 
3
. L
o
w
 r
is
k:
 (
1
) 
au
to
m
at
ed
 f
o
llo
w
 u
p
 (
e.
g.
 t
h
ro
u
gh
 r
ec
o
rd
 li
n
ka
ge
),
 o
r 
(2
) 
≥8
0
%
 f
o
llo
w
 u
p
, o
r 
(3
) 
7
0
-8
0
%
 f
o
llo
w
 u
p
 w
it
h
 a
 c
o
m
p
ar
is
o
n
 (
m
in
 a
ge
, s
e
x,
 d
ea
th
/m
o
rb
id
it
y)
 s
h
o
w
in
g 
si
m
ila
r 
ch
ar
ac
te
ri
st
ic
s 
b
et
w
ee
n
 t
h
o
se
 in
cl
u
d
ed
 a
n
d
 t
h
o
se
 n
o
t 
in
cl
u
d
ed
 in
 t
h
e 
st
u
d
y.
 
4
. H
ig
h
 r
is
k:
 a
llo
ca
ti
o
n
 o
f 
ki
d
n
e
y 
d
is
ea
se
 s
ta
tu
s 
re
lie
s 
o
n
 e
xi
st
in
g 
ki
d
n
ey
 d
is
ea
se
 h
av
in
g 
b
ee
n
 d
ia
gn
o
se
d
 a
s 
p
ar
t 
o
f 
ro
u
ti
n
e 
m
ed
ic
al
 c
ar
e.
  
Lo
w
 r
is
k:
 A
ll 
m
em
b
er
s 
o
f 
st
u
d
y 
as
se
ss
ed
 f
o
r 
ki
d
n
ey
 d
is
ea
se
 a
t 
b
as
el
in
e.
 
5
.  
H
ig
h
 r
is
k:
 k
id
n
ey
 d
is
ea
se
 s
ta
tu
s 
d
ef
in
ed
 b
y 
p
at
ie
n
t 
re
ca
ll 
o
f 
C
K
D
 d
ia
gn
o
si
s 
in
 c
o
n
te
xt
 o
f 
re
ce
n
t 
in
fe
ct
io
n
.  
6
. H
ig
h
 r
is
k:
 k
id
n
ey
 d
is
ea
se
 s
ta
tu
s 
d
ef
in
ed
 b
y 
o
b
se
rv
er
 u
n
b
lin
d
ed
 t
o
 c
as
e 
st
at
u
s,
 w
it
h
o
u
t 
cl
ea
r 
o
b
je
ct
iv
e 
cr
it
er
ia
 t
o
 a
p
p
ly
. 
7
. H
ig
h
 r
is
k:
 p
ar
ti
ci
p
an
ts
 w
it
h
 in
fe
ct
io
n
s 
ar
e 
m
o
re
 o
r 
le
ss
 li
ke
ly
 t
o
 b
e 
te
st
ed
 f
o
r 
ki
d
n
ey
 d
is
e
as
e.
 
8
. L
o
w
 r
is
k:
 A
ct
iv
e 
sc
re
en
in
g 
fo
r 
in
fe
ct
io
n
, o
r 
se
ve
re
 o
u
tc
o
m
e 
u
n
lik
el
y 
to
 b
e 
m
is
se
d
 o
r 
p
re
se
n
ts
 v
al
id
at
io
n
 r
es
u
lt
s 
o
f 
>7
0
%
 s
e
n
si
ti
vi
ty
 a
n
d
 s
p
ec
if
ic
it
y 
246
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9
. H
ig
h
 r
is
k:
 in
fe
ct
io
n
 s
ta
tu
s 
d
ef
in
ed
 b
y 
p
at
ie
n
t 
re
ca
ll 
o
f 
in
fe
ct
io
n
 in
 c
o
n
te
xt
 o
f 
ki
d
n
ey
 d
is
ea
se
 e
.g
. p
ar
ti
ci
p
an
ts
 w
it
h
 k
id
n
ey
 d
is
ea
se
 a
sk
ed
 t
o
 r
ec
al
l i
n
fe
ct
io
n
s 
w
h
ile
 a
t 
re
n
al
 c
lin
ic
. 
1
0
. H
ig
h
 r
is
k:
 in
fe
ct
io
n
 s
ta
tu
s 
d
ef
in
ed
 b
y 
o
b
se
rv
e
r 
in
 c
o
n
te
xt
 li
ke
ly
 t
o
 b
e 
in
fl
u
en
ce
d
 b
y 
ki
d
n
ey
 d
is
ea
se
 s
ta
tu
s 
(a
ss
u
m
e
d
 t
h
at
 c
lin
ic
al
 d
ia
gn
o
si
s 
o
f 
se
ve
re
 in
fe
ct
io
n
s 
w
as
 u
n
lik
el
y 
to
 b
e 
st
ro
n
gl
y 
in
fl
u
en
ce
d
 
b
y 
aw
ar
en
es
s 
o
f 
C
K
D
 a
s 
a 
co
m
o
rb
id
it
y 
b
u
t 
th
at
 le
ss
 s
ev
er
e 
in
fe
ct
io
n
s 
m
ay
 b
e 
in
fl
u
e
n
ce
d
 b
y 
th
is
 in
 t
h
e 
ab
se
n
ce
 o
f 
cl
ea
r 
d
ia
gn
o
st
ic
 c
ri
te
ri
a)
. 
1
1
. H
ig
h
 r
is
k:
 a
sc
er
ta
in
m
en
t 
o
f 
in
fe
ct
io
n
s 
lik
e
ly
 t
o
 b
e 
in
fl
u
e
n
ce
d
 b
y 
ki
d
n
ey
 d
is
ea
se
 s
ta
tu
s 
(a
ss
u
m
e
d
 t
h
at
 a
tt
en
d
an
ce
 t
o
 h
ea
lt
h
ca
re
 f
ac
ili
ty
 f
o
r 
se
ve
re
 in
fe
ct
io
n
s 
w
as
 u
n
lik
el
y 
to
 b
e 
st
ro
n
gl
y 
in
fl
u
e
n
ce
d
 b
y 
aw
ar
en
es
s 
o
f 
C
K
D
 a
s 
a 
co
m
o
rb
id
it
y 
b
u
t 
th
at
 a
tt
en
d
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Figure A 1 Funnel plot showing the relationship between relative risk and 
standard error for the 17 estimates from all 12 studies considered for meta-
analysis (all infections combined) 
 
UTI = urinary tract infection LRTI= lower respiratory tract infections 
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Appendix B: Codelists for identifying diabetes mellitus 
This appendix contains the Read codes used to identify a definite or possible diagnosis of 
diabetes mellitus, and the medication codes used to identify insulin and oral antidiabetes 
medications. 
Table B 1 Read codes used to identify a ‘definite’ diagnosis of diabetes 
mellitus  
Compiled by Sara Thomas.  
Read code Read term 
R054200 [D]Gangrene of toe in diabetic 
R054300 [D]Widespread diabetic foot gangrene 
ZV6DA00 [V]Admitted for commencement of insulin 
ZV6DB00 [V]Admitted for conversion to insulin 
ZV65312 [V]Dietary counselling in diabetes mellitus 
U602312 [X] Adverse reaction to insulins 
U602311 [X] Adverse reaction to insulins and antidiabetic agents 
U60231E [X] Adverse reaction to insulins and antidiabetic agents NOS 
Cyu2.00 [X]Diabetes mellitus 
Kyu0300 [X]Glomerular disorders in diabetes mellitus 
Cyu2000 [X]Other specified diabetes mellitus 
Cyu2300 [X]Unspecified diabetes mellitus with renal complications 
F372000 Acute painful diabetic neuropathy 
8H2J.00 Admit diabetic emergency 
F420300 Advanced diabetic maculopathy 
F420500 Advanced diabetic retinal disease 
TJ23000 Adverse reaction to insulins 
TJ23.00 Adverse reaction to insulins and antidiabetic agents 
TJ23z00 Adverse reaction to insulins and antidiabetic agents NOS 
66AT.00 Annual diabetic blood test 
F372200 Asymptomatic diabetic neuropathy 
9OLH.00 Attended DAFNE diabetes structured education programme 
9OLG.00 Attended XPERT diabetes structured education programme 
9NM0.00 Attending diabetes clinic 
F171100 Autonomic neuropathy due to diabetes 
F420000 Background diabetic retinopathy 
66AJ100 Brittle diabetes 
C350011 Bronzed diabetes 
M037200 Cellulitis in diabetic foot 
F372100 Chronic painful diabetic neuropathy 
7L10000 Continuous subcutaneous infusion of insulin 
66AH000 Conversion to insulin 
ZRB4.11 CSQ - Diabetes clinic satisfaction questionnaire 
C10N100 Cystic fibrosis related diabetes mellitus 
9OLJ.00 DAFNE diabetes structured education programme completed 
66AN.00 Date diabetic treatment start 
889A.00 Diab mellit insulin-glucose infus acute myocardial infarct 
66AU.00 Diabetes care by hospital only 
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8CS0.00 Diabetes care plan agreed 
ZRB4.00 Diabetes clinic satisfaction questionnaire 
8CR2.00 Diabetes clinical management plan 
66AR.00 Diabetes management plan given 
8B3l.00 Diabetes medication review 
C104z00 Diabetes mellitis with nephropathy NOS 
C10..00 Diabetes mellitus 
C10C.00 Diabetes mellitus autosomal dominant 
C10D.00 Diabetes mellitus autosomal dominant type 2 
C102z00 Diabetes mellitus NOS with hyperosmolar coma 
C101z00 Diabetes mellitus NOS with ketoacidosis 
C103z00 Diabetes mellitus NOS with ketoacidotic coma 
C106z00 Diabetes mellitus NOS with neurological manifestation 
C100z00 Diabetes mellitus NOS with no mention of complication 
C105z00 Diabetes mellitus NOS with ophthalmic manifestation 
C10yz00 Diabetes mellitus NOS with other specified manifestation 
C107z00 Diabetes mellitus NOS with peripheral circulatory disorder 
C10zz00 Diabetes mellitus NOS with unspecified complication 
C107.11 Diabetes mellitus with gangrene 
C102.00 Diabetes mellitus with hyperosmolar coma 
C101.00 Diabetes mellitus with ketoacidosis 
C103.00 Diabetes mellitus with ketoacidotic coma 
C106.00 Diabetes mellitus with neurological manifestation 
C106.12 Diabetes mellitus with neuropathy 
C100.00 Diabetes mellitus with no mention of complication 
C105.00 Diabetes mellitus with ophthalmic manifestation 
C10y.00 Diabetes mellitus with other specified manifestation 
C107.00 Diabetes mellitus with peripheral circulatory disorder 
C106.13 Diabetes mellitus with polyneuropathy 
C104.00 Diabetes mellitus with renal manifestation 
C10z.00 Diabetes mellitus with unspecified complication 
C106100 Diabetes mellitus, adult onset, + neurological manifestation 
C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation 
C10z100 Diabetes mellitus, adult onset, + unspecified complication 
C100100 Diabetes mellitus, adult onset, no mention of complication 
C102100 Diabetes mellitus, adult onset, with hyperosmolar coma 
C101100 Diabetes mellitus, adult onset, with ketoacidosis 
C103100 Diabetes mellitus, adult onset, with ketoacidotic coma 
C104100 Diabetes mellitus, adult onset, with renal manifestation 
C107200 Diabetes mellitus, adult with gangrene 
C10y100 Diabetes mellitus, adult, + other specified manifestation 
C107100 Diabetes mellitus, adult, + peripheral circulatory disorder 
C107000 Diabetes mellitus, juvenile +peripheral circulatory disorder 
C105000 Diabetes mellitus, juvenile type, + ophthalmic manifestation 
C10z000 Diabetes mellitus, juvenile type, + unspecified complication 
C100000 Diabetes mellitus, juvenile type, no mention of complication 
C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma 
C101000 Diabetes mellitus, juvenile type, with ketoacidosis 
C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma 
C104000 Diabetes mellitus, juvenile type, with renal manifestation 
C106000 Diabetes mellitus, juvenile, + neurological manifestation 
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ZRB5.00 Diabetes treatment satisfaction questionnaire 
3883 Diabetes treatment satisfaction questionnaire 
66An.00 Diabetes type 1 review 
66Ao.00 Diabetes type 2 review 
3882 Diabetes well being questionnaire 
ZRB6.00 Diabetes wellbeing questionnaire 
C107.12 Diabetes with gangrene 
66AP.00 Diabetes: practice programme 
66AQ.00 Diabetes: shared care programme 
66AK.00 Diabetic - cooperative patient 
66AM.00 Diabetic - follow-up default 
66AI.00 Diabetic - good control 
66AJ.00 Diabetic - poor control 
66AJz00 Diabetic - poor control NOS 
66Ai.00 Diabetic 6 month review 
F381311 Diabetic amyotrophy 
C106.11 Diabetic amyotrophy 
66AS.00 Diabetic annual review 
F464000 Diabetic cataract 
N030100 Diabetic Charcot arthropathy 
N030000 Diabetic cheiroarthropathy 
N030011 Diabetic cheiropathy 
8A12.00 Diabetic crisis monitoring 
68AB.00 Diabetic digital retinopathy screening offered 
66AG.00 Diabetic drug side effects 
66Ab.00 Diabetic foot examination 
8I3W.00 Diabetic foot examination declined 
8I6G.00 Diabetic foot examination not indicated 
66AW.00 Diabetic foot risk assessment 
66Aq.00 Diabetic foot screen 
F440700 Diabetic iritis 
F420400 Diabetic maculopathy 
F345000 Diabetic mononeuritis multiplex 
F35z000 Diabetic mononeuritis NOS 
F3y0.00 Diabetic mononeuropathy 
C104.11 Diabetic nephropathy 
F372.12 Diabetic neuropathy 
66A3.00 Diabetic on diet only 
66A5.00 Diabetic on insulin 
66AV.00 Diabetic on insulin and oral treatment 
66A4.00 Diabetic on oral treatment 
9OLD.00 Diabetic patient unsuitable for digital retinal photography 
G73y000 Diabetic peripheral angiopathy 
66Ac.00 Diabetic peripheral neuropathy screening 
F372.11 Diabetic polyneuropathy 
6761 Diabetic pre-pregnancy counselling 
F420.00 Diabetic retinopathy 
8HBG.00 Diabetic retinopathy 12 month review 
8HBH.00 Diabetic retinopathy 6 month review 
F420z00 Diabetic retinopathy NOS 
68A7.00 Diabetic retinopathy screening 
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8I6F.00 Diabetic retinopathy screening not indicated 
68A9.00 Diabetic retinopathy screening offered 
8I3X.00 Diabetic retinopathy screening refused 
8A13.00 Diabetic stabilisation 
66AH.00 Diabetic treatment changed 
13AC.00 Diabetic weight reducing diet 
66AL.00 Diabetic-uncooperative patient 
8HLE.00 Diabetology D.V. done 
8HKE.00 Diabetology D.V. requested 
9NiC.00 Did not attend DAFNE diabetes structured education programme 
9N4p.00 Did not attend diabetic retinopathy clinic 
9NiE.00 Did not attend XPERT diabetes structured education programme 
8I82.00 Did not complete DAFNE diabetes structured education program 
8I84.00 Did not complete XPERT diabetes structured education program 
ZC2C800 Dietary advice for diabetes mellitus 
ZC2C900 Dietary advice for type I diabetes 
ZC2CA00 Dietary advice for type II diabetes 
ZLD7500 Discharge by diabetic liaison nurse 
8Hg4.00 Discharged from care of diabetes specialist nurse 
ZRB5.11 DTSQ - Diabetes treatment satisfaction questionnaire 
ZRB6.11 DWBQ - Diabetes wellbeing questionnaire 
2G5C.00 Foot abnormality - diabetes related 
2G51000 Foot abnormality - diabetes related 
14F4.00 H/O: Admission in last year for diabetes foot problem 
14P3.00 H/O: insulin therapy 
42W..00 Hb. A1C - diabetic control 
42WZ.00 Hb. A1C - diabetic control NOS 
42c..00 HbA1 - diabetic control 
F420800 High risk non proliferative diabetic retinopathy 
F420700 High risk proliferative diabetic retinopathy 
C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
C110000 Iatrogenic hyperinsulinism 
C108.11 IDDM-Insulin dependent diabetes mellitus 
9M00.00 Informed consent for diabetes national audit 
9M10.00 Informed dissent for diabetes national audit 
66AA.11 Injection sites - diabetic 
C110.11 Insulin coma 
C108900 Insulin dependant diabetes maturity onset 
C108800 Insulin dependant diabetes mellitus - poor control 
C108J00 Insulin dependent diab mell with neuropathic arthropathy 
C108G00 Insulin dependent diab mell with peripheral angiopathy 
C10E912 Insulin dependent diabetes maturity onset 
C100011 Insulin dependent diabetes mellitus 
C108.00 Insulin dependent diabetes mellitus 
C10E.12 Insulin dependent diabetes mellitus 
C10E812 Insulin dependent diabetes mellitus - poor control 
C108H00 Insulin dependent diabetes mellitus with arthropathy 
C108F00 Insulin dependent diabetes mellitus with diabetic cataract 
C10EF12 Insulin dependent diabetes mellitus with diabetic cataract 
C108600 Insulin dependent diabetes mellitus with gangrene 
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C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma 
C108B00 Insulin dependent diabetes mellitus with mononeuropathy 
C10E312 Insulin dependent diabetes mellitus with multiple complicat 
C108300 Insulin dependent diabetes mellitus with multiple complicatn 
C108D00 Insulin dependent diabetes mellitus with nephropathy 
C108C00 Insulin dependent diabetes mellitus with polyneuropathy 
C10EC12 Insulin dependent diabetes mellitus with polyneuropathy 
C108700 Insulin dependent diabetes mellitus with retinopathy 
C10E712 Insulin dependent diabetes mellitus with retinopathy 
C108500 Insulin dependent diabetes mellitus with ulcer 
C10E512 Insulin dependent diabetes mellitus with ulcer 
66Am.00 Insulin dose changed 
9kL..00 Insulin initiation - enhanced services administration 
M21yC00 Insulin lipohypertrophy 
66Ag.00 Insulin needles changed daily 
66Ah.00 Insulin needles changed for each injection 
66Aj.00 Insulin needles changed less than once a day 
M21yC11 Insulin site lipohypertrophy 
8I3k.00 Insulin therapy declined 
C109J11 Insulin treated non-insulin dependent diabetes mellitus 
C10FJ00 Insulin treated Type 2 diabetes mellitus 
C109J00 Insulin treated Type 2 diabetes mellitus 
C109J12 Insulin treated Type II diabetes mellitus 
C10FJ11 Insulin treated Type II diabetes mellitus 
66Ap.00 Insulin treatment initiated 
C108200 Insulin-dependent diabetes mellitus with neurological comps 
C108100 Insulin-dependent diabetes mellitus with ophthalmic comps 
C10E112 Insulin-dependent diabetes mellitus with ophthalmic comps 
C108000 Insulin-dependent diabetes mellitus with renal complications 
C108A00 Insulin-dependent diabetes without complication 
C10EA12 Insulin-dependent diabetes without complication 
M271000 Ischaemic ulcer diabetic foot 
C10ER00 Latent autoimmune diabetes mellitus in adult 
C10M.00 Lipoatrophic diabetes mellitus 
8HME.00 Listed for Diabetology admissn 
C100111 Maturity onset diabetes 
C10C.11 Maturity onset diabetes in youth 
C10C.12 Maturity onset diabetes in youth type 1 
C10D.11 Maturity onset diabetes in youth type 2 
M271200 Mixed diabetic ulcer - foot 
F381300 Myasthenic syndrome due to diabetic amyotrophy 
K01x100 Nephrotic syndrome in diabetes mellitus 
M271100 Neuropathic diabetic ulcer - foot 
C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
F420600 Non proliferative diabetic retinopathy 
C109E00 Non-insulin depend diabetes mellitus with diabetic cataract 
C109700 Non-insulin dependent diabetes mellitus - poor control 
C109H00 Non-insulin dependent d m with neuropathic arthropathy 
C100112 Non-insulin dependent diabetes mellitus 
C109.00 Non-insulin dependent diabetes mellitus 
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C109G00 Non-insulin dependent diabetes mellitus with arthropathy 
C109500 Non-insulin dependent diabetes mellitus with gangrene 
C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma 
C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy 
C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy 
C109400 Non-insulin dependent diabetes mellitus with ulcer 
C109F00 Non-insulin-dependent d m with peripheral angiopath 
C109300 Non-insulin-dependent diabetes mellitus with multiple comps 
C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps 
C109000 Non-insulin-dependent diabetes mellitus with renal comps 
C109600 Non-insulin-dependent diabetes mellitus with retinopathy 
C109900 Non-insulin-dependent diabetes mellitus without complication 
8H3O.00 Non-urgent diabetic admission 
2BBL.00 O/E - diabetic maculopathy present both eyes 
2G5W.00 O/E - left chronic diabetic foot ulcer 
2G5L.00 O/E - Left diabetic foot - ulcerated 
2G5K.00 O/E - Left diabetic foot at high risk 
2G5I.00 O/E - Left diabetic foot at low risk 
2G5J.00 O/E - Left diabetic foot at moderate risk 
2G5B.00 O/E - Left diabetic foot at risk 
2BBQ.00 O/E - left eye background diabetic retinopathy 
2BBX.00 O/E - left eye diabetic maculopathy 
2BBS.00 O/E - left eye preproliferative diabetic retinopathy 
2BBV.00 O/E - left eye proliferative diabetic retinopathy 
2BBl.00 O/E - left eye stable treated prolif diabetic retinopathy 
2G5V.00 O/E - right chronic diabetic foot ulcer 
2G5H.00 O/E - Right diabetic foot - ulcerated 
2G5G.00 O/E - Right diabetic foot at high risk 
2G5E.00 O/E - Right diabetic foot at low risk 
2G5F.00 O/E - Right diabetic foot at moderate risk 
2G5A.00 O/E - Right diabetic foot at risk 
2BBP.00 O/E - right eye background diabetic retinopathy 
2BBW.00 O/E - right eye diabetic maculopathy 
2BBR.00 O/E - right eye preproliferative diabetic retinopathy 
2BBT.00 O/E - right eye proliferative diabetic retinopathy 
2BBk.00 O/E - right eye stable treated prolif diabetic retinopathy 
2BBo.00 O/E - sight threatening diabetic retinopathy 
7276 Pan retinal photocoagulation for diabetes 
93C4.00 Patient consent given for addition to diabetic register 
9360 Patient held diabetic record issued 
8BL2.00 Patient on maximal tolerated therapy for diabetes 
ZRbH.00 Perceived control of insulin-dependent diabetes 
F372.00 Polyneuropathy in diabetes 
L180500 Pre-existing diabetes mellitus, insulin-dependent 
L180600 Pre-existing diabetes mellitus, non-insulin-dependent 
L180X00 Pre-existing diabetes mellitus, unspecified 
F420200 Preproliferative diabetic retinopathy 
F420100 Proliferative diabetic retinopathy 
8H7r.00 Refer to diabetic foot screener 
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8Hl1.00 Referral for diabetic retinopathy screening 
8Hj3.00 Referral to DAFNE diabetes structured education programme 
8HTk.00 Referral to diabetic eye clinic 
8HHy.00 Referral to diabetic register 
8Hj5.00 Referral to XPERT diabetes structured education programme 
2BBF.00 Retinal abnormality - diabetes related 
C10G.00 Secondary pancreatic diabetes mellitus 
C10G000 Secondary pancreatic diabetes mellitus without complication 
9N1v.00 Seen in diabetic eye clinic 
9N1i.00 Seen in diabetic foot clinic 
7L19800 Subcutaneous injection of insulin 
8CP2.00 Transition of diabetes care options discussed 
C10E.00 Type 1 diabetes mellitus 
C108.12 Type 1 diabetes mellitus 
C10E800 Type 1 diabetes mellitus - poor control 
C108812 Type 1 diabetes mellitus - poor control 
C10E900 Type 1 diabetes mellitus maturity onset 
C108912 Type 1 diabetes mellitus maturity onset 
C10EH00 Type 1 diabetes mellitus with arthropathy 
C10EF00 Type 1 diabetes mellitus with diabetic cataract 
C10EP00 Type 1 diabetes mellitus with exudative maculopathy 
C10E600 Type 1 diabetes mellitus with gangrene 
C10EQ00 Type 1 diabetes mellitus with gastroparesis 
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma 
C108E12 Type 1 diabetes mellitus with hypoglycaemic coma 
C10EM00 Type 1 diabetes mellitus with ketoacidosis 
C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
C10EB00 Type 1 diabetes mellitus with mononeuropathy 
C10E300 Type 1 diabetes mellitus with multiple complications 
C10ED00 Type 1 diabetes mellitus with nephropathy 
C10E200 Type 1 diabetes mellitus with neurological complications 
C108212 Type 1 diabetes mellitus with neurological complications 
C108J12 Type 1 diabetes mellitus with neuropathic arthropathy 
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy 
C10E100 Type 1 diabetes mellitus with ophthalmic complications 
C10EG00 Type 1 diabetes mellitus with peripheral angiopathy 
C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
C10EC00 Type 1 diabetes mellitus with polyneuropathy 
C108012 Type 1 diabetes mellitus with renal complications 
C10E000 Type 1 diabetes mellitus with renal complications 
C10E700 Type 1 diabetes mellitus with retinopathy 
C108712 Type 1 diabetes mellitus with retinopathy 
C10E500 Type 1 diabetes mellitus with ulcer 
C108512 Type 1 diabetes mellitus with ulcer 
C10EA00 Type 1 diabetes mellitus without complication 
C10F.00 Type 2 diabetes mellitus 
C109.12 Type 2 diabetes mellitus 
C10F700 Type 2 diabetes mellitus - poor control 
C109712 Type 2 diabetes mellitus - poor control 
C109G12 Type 2 diabetes mellitus with arthropathy 
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C10FG00 Type 2 diabetes mellitus with arthropathy 
C109E12 Type 2 diabetes mellitus with diabetic cataract 
C10FE00 Type 2 diabetes mellitus with diabetic cataract 
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
C10F500 Type 2 diabetes mellitus with gangrene 
C109512 Type 2 diabetes mellitus with gangrene 
C10FR00 Type 2 diabetes mellitus with gastroparesis 
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
C109D12 Type 2 diabetes mellitus with hypoglycaemic coma 
C10FN00 Type 2 diabetes mellitus with ketoacidosis 
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C10F300 Type 2 diabetes mellitus with multiple complications 
C10FC00 Type 2 diabetes mellitus with nephropathy 
C109C12 Type 2 diabetes mellitus with nephropathy 
C10F200 Type 2 diabetes mellitus with neurological complications 
C109212 Type 2 diabetes mellitus with neurological complications 
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
C10F100 Type 2 diabetes mellitus with ophthalmic complications 
C109112 Type 2 diabetes mellitus with ophthalmic complications 
C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
C109F12 Type 2 diabetes mellitus with peripheral angiopathy 
C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
C10FB00 Type 2 diabetes mellitus with polyneuropathy 
C109012 Type 2 diabetes mellitus with renal complications 
C10F000 Type 2 diabetes mellitus with renal complications 
C10F600 Type 2 diabetes mellitus with retinopathy 
C109612 Type 2 diabetes mellitus with retinopathy 
C10F400 Type 2 diabetes mellitus with ulcer 
C109412 Type 2 diabetes mellitus with ulcer 
C10F900 Type 2 diabetes mellitus without complication 
C10E.11 Type I diabetes mellitus 
C108.13 Type I diabetes mellitus 
C108811 Type I diabetes mellitus - poor control 
C108911 Type I diabetes mellitus maturity onset 
C10E911 Type I diabetes mellitus maturity onset 
C108H11 Type I diabetes mellitus with arthropathy 
C108F11 Type I diabetes mellitus with diabetic cataract 
C10EP11 Type I diabetes mellitus with exudative maculopathy 
C108E11 Type I diabetes mellitus with hypoglycaemic coma 
C10EM11 Type I diabetes mellitus with ketoacidosis 
C10EN11 Type I diabetes mellitus with ketoacidotic coma 
C108B11 Type I diabetes mellitus with mononeuropathy 
C10E311 Type I diabetes mellitus with multiple complications 
C108D11 Type I diabetes mellitus with nephropathy 
C108211 Type I diabetes mellitus with neurological complications 
C108J11 Type I diabetes mellitus with neuropathic arthropathy 
C10E111 Type I diabetes mellitus with ophthalmic complications 
C10EC11 Type I diabetes mellitus with polyneuropathy 
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C108011 Type I diabetes mellitus with renal complications 
C108711 Type I diabetes mellitus with retinopathy 
C10E711 Type I diabetes mellitus with retinopathy 
C108511 Type I diabetes mellitus with ulcer 
C10E511 Type I diabetes mellitus with ulcer 
C10EA11 Type I diabetes mellitus without complication 
C108A11 Type I diabetes mellitus without complication 
C109.13 Type II diabetes mellitus 
C10F.11 Type II diabetes mellitus 
C109711 Type II diabetes mellitus - poor control 
C10F711 Type II diabetes mellitus - poor control 
C109G11 Type II diabetes mellitus with arthropathy 
C109E11 Type II diabetes mellitus with diabetic cataract 
C10FE11 Type II diabetes mellitus with diabetic cataract 
C109511 Type II diabetes mellitus with gangrene 
C109D11 Type II diabetes mellitus with hypoglycaemic coma 
C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
C109A11 Type II diabetes mellitus with mononeuropathy 
C10FA11 Type II diabetes mellitus with mononeuropathy 
C10F311 Type II diabetes mellitus with multiple complications 
C109C11 Type II diabetes mellitus with nephropathy 
C109211 Type II diabetes mellitus with neurological complications 
C10F211 Type II diabetes mellitus with neurological complications 
C109H11 Type II diabetes mellitus with neuropathic arthropathy 
C109111 Type II diabetes mellitus with ophthalmic complications 
C10F111 Type II diabetes mellitus with ophthalmic complications 
C109F11 Type II diabetes mellitus with peripheral angiopathy 
C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
C10FL11 Type II diabetes mellitus with persistent proteinuria 
C109B11 Type II diabetes mellitus with polyneuropathy 
C10FB11 Type II diabetes mellitus with polyneuropathy 
C109011 Type II diabetes mellitus with renal complications 
C10F011 Type II diabetes mellitus with renal complications 
C10F611 Type II diabetes mellitus with retinopathy 
C109611 Type II diabetes mellitus with retinopathy 
C109411 Type II diabetes mellitus with ulcer 
C10F411 Type II diabetes mellitus with ulcer 
C10F911 Type II diabetes mellitus without complication 
9NND.00 Under care of diabetic foot screener 
9NN8.00 Under care of diabetologist 
C108z00 Unspecified diabetes mellitus with multiple complications 
66AJ.11 Unstable diabetes 
C108400 Unstable insulin dependant diabetes mellitus 
C10E412 Unstable insulin dependent diabetes mellitus 
C10E400 Unstable type 1 diabetes mellitus 
C108412 Unstable type 1 diabetes mellitus 
C10E411 Unstable type I diabetes mellitus 
C108411 Unstable type I diabetes mellitus 
9OLL.00 XPERT diabetes structured education programme completed 
2BBr.00 Impaired vision due to diabetic retinopathy 
C10E611 Type I diabetes mellitus with gangrene 
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C10E212 Insulin-dependent diabetes mellitus with neurological comps 
C10ED12 Insulin dependent diabetes mellitus with nephropathy 
C10FC11 Type II diabetes mellitus with nephropathy 
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Table B 2 Read codes used to identify a 'possible' diagnosis of diabetes 
mellitus 
Compiled by Sara Thomas.  
Read code Read term 
9OLB.00 Attended diabetes structured education programme 
9OL1.00 Attends diabetes monitoring 
9OLK.00 DESMOND diabetes structured education programme completed 
9OL..11 Diabetes clinic administration 
9OLA.00 Diabetes monitor. check done 
9OL8.00 Diabetes monitor.phone invite 
9OL7.00 Diabetes monitor.verbal invite 
9OLA.11 Diabetes monitored 
9OL4.00 Diabetes monitoring 1st letter 
9OL5.00 Diabetes monitoring 2nd letter 
9OL6.00 Diabetes monitoring 3rd letter 
9OL..00 Diabetes monitoring admin. 
9OLZ.00 Diabetes monitoring admin.NOS 
9OL3.00 Diabetes monitoring default 
9OL9.00 Diabetes monitoring deleted 
9OLF.00 Diabetes structured education programme completed 
9OLM.00 Diabetes structured education programme declined 
13B1.00 Diabetic diet 
66AY.00 Diabetic diet - good compliance 
66Aa.00 Diabetic diet - poor compliance 
13AB.00 Diabetic lipid lowering diet 
66A..00 Diabetic monitoring 
66Al.00 Diabetic monitoring - higher risk albumin excretion 
66Ak.00 Diabetic monitoring - lower risk albumin excretion 
66AZ.00 Diabetic monitoring NOS 
66b1.00 Diabetic monitoring not required 
9NiD.00 Did not attend DESMOND diabetes structured education program 
9NiA.00 Did not attend diabetes structured education programme 
8I83.00 Did not complete DESMOND diabetes structured educat program 
8I81.00 Did not complete diabetes structured education programme 
9N4I.00 DNA - Did not attend diabetic clinic 
3881 Education score - diabetes 
ZRBa.00 Education score - diabetes 
9h41.00 Excepted from diabetes qual indicators: Patient unsuitable 
9h42.00 Excepted from diabetes quality indicators: Informed dissent 
9h4..00 Exception reporting: diabetes quality indicators 
66A2.00 Follow-up diabetic assessment 
66AD.00 Fundoscopy - diabetic check 
44V3.00 Glucose tol. test diabetic 
66A8.00 Has seen dietician - diabetes 
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66A1.00 Initial diabetic assessment 
2BBM.00 O/E - diabetic maculopathy absent both eyes 
2BBK.00 O/E - no left diabetic retinopathy 
2BBJ.00 O/E - no right diabetic retinopathy 
C103y00 Other specified diabetes mellitus with coma 
C101y00 Other specified diabetes mellitus with ketoacidosis 
C108y00 Other specified diabetes mellitus with multiple comps 
C106y00 Other specified diabetes mellitus with neurological comps 
C105y00 Other specified diabetes mellitus with ophthalmic complicatn 
C10yy00 Other specified diabetes mellitus with other spec comps 
C104y00 Other specified diabetes mellitus with renal complications 
C10zy00 Other specified diabetes mellitus with unspecified comps 
66Af.00 Patient diabetes education review 
8I57.00 Patient held diabetic record declined 
679R.00 Patient offered diabetes structured education programme 
8HVU.00 Private referral to diabetologist 
8CA4100 Pt advised re diabetic diet 
8H7C.00 Refer, diabetic liaison nurse 
8Hl4.00 Referral to community diabetes specialist nurse 
8Hj4.00 Referral to DESMOND diabetes structured education programme 
8H7f.00 Referral to diabetes nurse 
ZL62500 Referral to diabetes nurse 
8HTe.00 Referral to diabetes preconception counselling clinic 
8H4e.00 Referral to diabetes special interest general practitioner 
8Hj0.00 Referral to diabetes structured education programme 
ZL62600 Referral to diabetic liaison nurse 
8H4F.00 Referral to diabetologist 
8HTi.00 Referral to multidisciplinary diabetic clinic 
9OL2.00 Refuses diabetes monitoring 
ZLA2500 Seen by diabetic liaison nurse 
9N2i.00 Seen by diabetic liaison nurse 
9N2d.00 Seen by diabetologist 
9Nl4.00 Seen by general practitioner special interest in diabetes 
9N0n.00 Seen in community diabetes specialist clinic 
9N0o.00 Seen in community diabetic specialist nurse clinic 
9N1Q.00 Seen in diabetic clinic 
9N0m.00 Seen in diabetic nurse consultant clinic 
9N1o.00 Seen in multidisciplinary diabetic clinic 
9NN9.00 Under care of diabetes specialist nurse 
ZL22500 Under care of diabetic liaison nurse 
66A9.00 Understands diet - diabetes 
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Table B 3 Medication product codes identifying insulin prescriptions 
Product 
code 
Product name 
22823 INSULIN ISOPHANE (PURIFIED) 100 I/U INJ 
24722 INSULIN ISOPHANE 50%/NEUTRAL 50% 100 I/U INJ 
9079 INSULIN SOLUBLE 100 I/U INJ 
20196 INSULIN SOLUBLE 40 I/U INJ 
26784 INSULIN ZINC SEMILENTE SUSP BP 100 I/U INJ 
20195 INSULIN BOVINE PROTAMINE ZINC 40 I/U INJ 
24866 INSULIN INSULATARD (LEO RETARD) 40 I/U INJ 
23003 INSULIN ISOPHANE (NPH) 40 I/U 
24845 INSULIN PUR-IN ISOPHANE 100 I/U INJ 
28978 INSULIN PUR-IN MIX 15/85 100 I/U INJ 
31267 INSULIN PUR-IN MIX 50/50 100 I/U INJ 
7861 INSULIN HUMULIN S (NEUTRAL) CARTRIDGE 100 I/U 
8646 INSULIN ZINC CRYSTALLINE susp 100 I/U INJ 
7765 INSULIN NEUTRAL (HUMAN) 100 I/U INJ 
10566 INSULIN HUMULIN M CARTRIDGE 100 I/U 
12060 INSULIN QUICKSOL (SOLUBLE NEUTRAL) 100 I/U INJ 
12244 INSULIN ZINC BOVINE susp 100 I/U INJ 
15624 INSULIN ISOPHANE (HIGHLY PURIFIED) 100 I/U INJ 
15040 INSULIN MONOPHANE (ISOPHANE) 100 I/U INJ 
18645 INSULIN NEUTRAL (PURIFIED) 100 I/U INJ 
4248 INSULIN NOVO ULTRATARD MC 100 I/U INJ 
1839 INSULIN HUMULIN I (ISOPHANE) 100 I/U INJ 
2373 INSULIN HUMAN VELOSULIN 100 I/U INJ 
14504 INSULIN HYPURIN PROTAMINE ZINC 100 I/U INJ 
10546 INSULIN HUMULIN M4 100 I/U INJ 
10691 INSULIN ISOPHANE (NPH) 100 I/U INJ 
8354 INSULIN ISOPHANE 70%/NEUTRAL 30% 100 I/U INJ 
14506 INSULIN BOVINE PROTAMINE ZINC 100 I/U INJ 
8839 INSULIN SEMITARD 100 I/U INJ 
10545 INSULIN HUMULIN M4 CARTRIDGE 100 I/U 
13550 INSULIN BP 100 I/U 
2808 INSULIN LENTARD INJ 
8838 INSULIN SEMITARD 40 I/U INJ 
7959 INSULIN MIXTARD 30/70 40 I/U INJ 
7757 INSULIN NEULENTE (ZINC SUSP)(PURIFIED) 100 I/U INJ 
7763 INSULIN NEUPHANE (ISOPHANE)(PURIFIED) 100 I/U INJ 
1645 INSULIN NOVO ACTRAPID MC 100 I/U INJ 
321 INSULIN HUMAN ACTRAPID (NEUTRAL) 40 I/U INJ 
16209 INSULIN HYPURIN SOLUBLE 100 I/U INJ 
7764 INSULIN NEUSULIN (NEUTRAL)(PURIFIED) 100 I/U INJ 
1643 INSULIN NOVO MONOTARD MC 100 I/U INJ 
18301 INSULIN SOLUBLE INJ I/U^2 
8376 INSULIN ISOPHANE 100 I/U 
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7783 INSULIN ISOPHANE (HUMAN) 100 I/U INJ 
20672 INSULIN HUM/ACTRAPID 
20671 INSULIN HUM/ACTRAPHANE 
27911 INSULIN HUMAN ACTRAPID PENFILL 
25006 INSULIN HUMAN ACTRAPID (NEUTRAL) 
19707 INSULIN HUMULIN S (NEUTRAL SOLUBLE) 
22161 INSULIN HUMULIN M1 VIAL 
22094 INSULIN HUMULIN M2 VIAL 
21945 INSULIN PORK INSULATARD 
19829 INSULIN NOVO MONOTARD MC 
28723 INSULIN ZINC BOVINE SUSPENSION 
24485 INSULIN ZINC ANIMAL SUSPENSION 
30861 INSULIN ZINC HUMAN SUSPENSION 
22496 INSULIN ZINC LENTE PURIFIED SUSPENSION 
22806 INSULIN PORK ACTRAPID 
32053 INSULIN HUMALOG MIX 25 
6209 NOVORAPID VIAL injection solution 100 units/ml [NOVO] 
5021 NOVORAPID PENFILL injection solution 100 units/ml [NOVO] 
11337 NOVORAPID NOVOLET injection 100 iu/ml [NOVO] 
5892 NOVORAPID FLEXPEN injection solution 100 units/ml [NOVO] 
6447 insulin aspart human pyr injection 100 iu/ml  
322 HUMALOG injection 100 iu/ml [LILLY]  
5214 insulin lispro human prb injection 100 iu/ml  
28442 insulin glulisine injection solution 100 units/ml   
19491 APIDRA VIAL injection solution 100 units/ml [SANOFI/AVE]  
14345 APIDRA CARTRIDGE injection solution 100 units/ml [SANOFI/AVE]  
29567 insulin aspart vial injection solution 100 units/ml   
16142 insulin aspart cartridge injection solution 100 units/ml   
19877 insulin aspart disposable pen injection solution 100 units/ml   
26060 insulin lispro vial injection solution 100 units/ml   
14313 insulin lispro cartridge injection solution 100 units/ml   
14362 insulin lispro disposable pen injection solution 100 units/ml   
18224 HUMALOG VIAL injection solution 100 units/ml [LILLY]  
7318 HUMALOG CARTRIDGE injection solution 100 units/ml [LILLY]  
10264 HUMALOG DISPOSABLE PEN injection solution 100 units/ml [LILLY]  
28101 insulin glulisine vial injection solution 100 units/ml   
14299 insulin glulisine cartridge injection solution 100 units/ml   
21583 APIDRA OPTISET injection solution 100 units/ml [SANOFI/AVE]  
21590 insulin glulisine disposable pen injection solution 100 units/ml   
36355 insulin human powder for inhalation 1mg   
36356 insulin human powder for inhalation 3mg   
31465 EXUBERA powder for inhalation 1mg [PFIZER]  
31467 EXUBERA powder for inhalation 3mg [PFIZER]  
29953 APIDRA OPTICLIK injection solution 100 units/ml [SANOFI/AVE]  
36920 APIDRA SOLOSTAR injection solution 100 units/ml [SANOFI/AVE]  
38986 HUMALOG KWIKPEN injection solution 100 units/ml [LILLY]  
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1587 MONOTARD injection 100 units/ml [NOVO]  
4760 HUMULIN I injection 100 units/ml [LILLY]  
8895 INITARD 50/50 injection 100 units/ml [NOVO]  
1843 PORK INSULATARD VIAL injection suspension 100 units/ml [NOVO]  
4784 LENTARD MC injection 100 units/ml [NOVO]  
2459 PORK MIXTARD 30 VIAL injection suspension 100 units/ml [NOVO]  
34031 MONOTARD MC injection 100 units/ml [NOVO]  
4163 RAPITARD MC injection 100 units/ml [NOVO]  
12299 SEMITARD MC injection 100 units/ml [NOVO]  
4715 HUMALOG MIX 25 injection 25:75; 100 units/ml [LILLY]  
7537 HUMULIN ZN injection 100 units/ml [LILLY]  
41834 INSULIN ZINC SUSPENSION LENTE injection 100 iu/ml [CELLTECH]  
16682 TEMPULIN injection 100 units/ml [KNOLL]  
7772 HUMAN PROTAPHANE injection 100 units/ml [NOVO]  
7771 HUMAN PROTAPHANE PENFILL 100 units/ml [NOVO]  
1844 ULTRATARD injection 100 units/ml [NOVO]  
33966 INSULATARD injection 100 units/ml [NOVO]  
1886 INSULATARD ge injection 100 iu/ml [NOVO]  
1593 INSULATARD PENFILL 100 iu/ml [NOVO]  
1805 MIXTARD 30/70 injection 100 units/ml [NOVO]  
34097 HUMAN INITARD 50/50 injection 100 units/ml [NOVO]  
38422 ISOPHANE injection 100 iu/ml [CELLTECH]  
5501 INSUMAN BASAL injection 100 iu/ml [AVENTIS]  
9503 HYPURIN BOVINE PROTAMINE ZINC VIAL injection suspension 100 units/ml [CP 
PHARM] 
 
17712 HYPURIN BOVINE LENTE VIAL injection suspension 100 units/ml [CP PHARM]  
13516 HYPURIN BOVINE ISOPHANE injection 100 units/ml [CP PHARM]  
1649 HUMAN ACTRAPHANE injection 100 iu/ml [NOVO]  
10547 HUMULIN LENTE injection 100 units/ml [LILLY]  
4199 HUMULIN M1 injection 100 units/ml [LILLY]  
4093 HUMULIN M2 injection 100 units/ml [LILLY]  
4198 HUMULIN M3 injection 100 units/ml [LILLY]  
11107 HUMULIN M4 injection 100 units/ml [LILLY]  
8841 HUMULIN M5 injection 100 units/ml [LILLY]  
13416 insulin biphasic injection 100 units/ml   
16700 insulin zinc mixed bovine vial injection suspension 100 units/ml   
8322 insulin zinc suspension mixed human pyr injection 100 units/ml   
9376 insulin zinc suspension crystalline human pyr - long acting injection 100 units/ml   
18931 insulin zinc suspension crystalline human prb - intermediate acting injection 100 
units/ml  
 
15484 insulin isophane bovine injection 100 units/ml   
4247 insulin isophane porcine injection 100 units/ml   
14619 insulin biphasic isophane porcine injection 30:70; 100 units/ml   
14505 insulin protamine zinc bovine vial injection suspension 100 units/ml   
12035 insulin zinc lente bovine vial injection suspension 100 units/ml   
30236 isophane insulin injection 100 iu/ml   
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8203 PENMIX 50/50 PENFILL injection 100 iu/ml [NOVO]  
10887 PENMIX 40/60 PENFILL injection 100 iu/ml [NOVO]  
27614 PENMIX 30/70 injection 100 iu/ml [NOVO]  
10484 PENMIX 20/80 PENFILL PENFILL [NOVO]  
15961 insulin isophane human crb injection 100 iu/ml   
3396 PENMIX 10/90 PENFILL PENFILL [NOVO]  
26403 PUR-IN MIX 25/75 injection [CP PHARM]  
22058 PUR-IN MIX 15/85 injection [CP PHARM]  
1806 PENMIX 30/70 PENFILL injection 100 iu/ml [NOVO]  
3439 PENMIX 10/90 pen [NOVO]  
2220 PENMIX 20/80 pen [NOVO]  
21347 PENMIX 40/60 injection 100 iu/ml [NOVO]  
17731 PENMIX 50/50 injection 100 iu/ml [NOVO]  
6057 LANTUS injection 100 iu/ml [AVENTIS]  
33167 insulin biphasic isophane human crb injection 25:75; 100 units/ml   
33232 insulin biphasic isophane human crb injection 50:50; 100 units/ml   
10001 HUMALOG MIX 50 DISPOSABLE PEN injection suspension 100 units/ml [LILLY]  
5953 insulin glargine injection 100 iu/ml   
15199 INSUMAN COMB 25 injection 100 iu/ml [AVENTIS]  
21554 INSUMAN COMB 50 injection 100 iu/ml [AVENTIS]  
5891 INSULATARD FLEXPEN injection 100 iu/ml [NOVO]  
1595 INSULATARD NOVOLET 100 iu/ml [NOVO]  
5255 MIXTARD 10 PENFILL 100 iu/ml [NOVO]  
2456 MIXTARD 10 NOVOLET 100 iu/ml [NOVO]  
3551 MIXTARD 20 PENFILL 100 iu/ml [NOVO]  
2455 MIXTARD 20 NOVOLET 100 iu/ml [NOVO]  
2454 MIXTARD 30 PENFILL 100 iu/ml [NOVO]  
2221 MIXTARD 30 NOVOLET 100 iu/ml [NOVO]  
2929 MIXTARD 30 ge injection 100 iu/ml [NOVO]  
3550 MIXTARD 40 PENFILL 100 iu/ml [NOVO]  
2812 MIXTARD 40 NOVOLET 100 iu/ml [NOVO]  
4790 MIXTARD 50 PENFILL 100 iu/ml [NOVO]  
5933 MIXTARD 50 NOVOLET 100 iu/ml [NOVO]  
12818 MIXTARD 50 injection 50:50; 100 units/ml [NOVO]  
20422 INSUMAN COMB 15 injection 100 iu/ml [AVENTIS]  
8118 HUMAJECT I pen 100 iu/ml [LILLY]  
10915 HUMAJECT M1 pen 100 iu/ml [LILLY]  
10910 HUMAJECT M2 pen 100 iu/ml [LILLY]  
7793 HUMAJECT M3 pen 100 iu/ml [LILLY]  
17809 HUMAJECT M4 pen 100 iu/ml [LILLY]  
22155 HUMAJECT M5 pen 100 iu/ml [LILLY]  
44251 insulin zinc suspension mixed porcine injection 100 units/ml   
26498 insulin zinc suspension mixed bovine and porcine injection 100 units/ml   
13837 insulin biphasic isophane human prb injection 10:90; 100 units/ml   
14644 insulin biphasic isophane human prb injection 20:80; 100 units/ml   
9341 insulin biphasic isophane human prb injection 30:70; 100 units/ml   
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10175 insulin isophane human pyr injection 100 iu/ml   
11080 insulin isophane human prb injection 100 iu/ml   
13729 insulin isophane human emp injection 100 units/ml   
18461 insulin zinc suspension mixed human prb injection 100 units/ml   
14649 insulin biphasic isophane human pyr injection 10:90; 100 units/ml   
11055 insulin biphasic isophane human pyr injection 20:80; 100 units/ml   
11056 insulin biphasic isophane human pyr injection 30:70; 100 units/ml   
21395 insulin biphasic isophane human pyr injection 40:60; 100 units/ml   
22697 insulin biphasic isophane human pyr injection 50:50; 100 units/ml   
21374 insulin biphasic isophane human prb injection 40:60; 100 units/ml   
21110 insulin biphasic isophane human prb injection 50:50; 100 units/ml   
5845 MIXTARD 30 INNOLET injection suspension 30:70; 100 units/ml [NOVO]  
9737 INSULATARD INNOLET injection 100 iu/ml [NOVO]  
5250 insulin biphasic lispro human prb injection 25:75; 100 units/ml   
27177 insulin biphasic lispro human prb injection 50:50; 100 units/ml   
10067 insulin biphasic aspart human pyr injection 30:70; 100 units/ml   
6061 NOVOMIX 30 injection 30:70; 100 units/ml [NOVO]  
13819 HYPURIN PORCINE ISOPHANE injection 100 units/ml [CP PHARM]  
9618 HYPURIN PORCINE 30/70 MIX injection 100 iu/ml [CP PHARM]  
29837 insulin biphasic isophane human prb injection 25:75; 100 units/ml   
10184 insulin detemir injection solution 100 iu/ml   
6965 LEVEMIR PENFILL injection solution 100 units/ml [NOVO]  
6958 LEVEMIR FLEXPEN injection solution 100 units/ml [NOVO]  
25736 insulin biphasic isophane human cartridge injection suspension 10:90; 100 units/ml  
10245 MIXTARD 10 PENFILL injection suspension 100 units/ml [NOVO]  
25735 insulin biphasic isophane human cartridge injection suspension 20:80; 100 units/ml  
7319 MIXTARD 20 PENFILL injection suspension 100 units/ml [NOVO]  
16152 insulin biphasic isophane human cartridge injection suspension 30:70; 100 units/ml  
21232 insulin biphasic isophane human vial injection suspension 30:70; 100 units/ml   
19878 insulin biphasic isophane human disposable pen injection suspension 30:70; 100 
units/ml  
7231 MIXTARD 30 PENFILL injection suspension 100 units/ml [NOVO]  
10277 HUMULIN M3 CARTRIDGE injection suspension 100 units/ml [LILLY]  
19513 HUMULIN M3 VIAL injection suspension 100 units/ml [LILLY]  
16160 HUMULIN M3 DISPOSABLE PEN injection suspension 100 units/ml [LILLY]  
21422 insulin biphasic isophane human cartridge injection suspension 40:60; 100 units/ml  
10244 MIXTARD 40 PENFILL injection suspension 100 units/ml [NOVO]  
28096 insulin biphasic isophane human cartridge injection suspension 50:50; 100 units/ml  
41120 insulin biphasic isophane human disposable pen injection suspension 50:50; 100 
units/ml  
35253 INSUMAN COMB 50 CARTRIDGE injection suspension 100 units/ml [AVENTIS]  
31205 INSUMAN COMB 50 OPTISET injection suspension 100 units/ml [AVENTIS]  
30819 INSUMAN COMB 15 OPTISET injection suspension 100 units/ml [AVENTIS]  
42954 insulin biphasic isophane human vial injection suspension 25:75; 100 units/ml   
36194 insulin biphasic isophane human cartridge injection suspension 25:75; 100 units/ml  
44378 insulin biphasic isophane human disposable pen injection suspension 25:75; 100 
units/ml  
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24002 INSUMAN COMB 25 VIAL injection suspension 100 units/ml [AVENTIS]  
24993 INSUMAN COMB 25 CARTRIDGE injection suspension 100 units/ml [AVENTIS]  
25133 INSUMAN COMB 25 OPTISET injection suspension 100 units/ml [AVENTIS]  
14925 insulin isophane human vial injection suspension 100 units/ml   
10207 insulin isophane human cartridge injection suspension 100 units/ml   
25812 insulin isophane human disposable pen injection suspension 100 units/ml   
10225 LANTUS OPTICLIK injection solution 100 units/ml [AVENTIS]  
14918 HUMULIN I VIAL injection suspension 100 units/ml [LILLY]  
14357 HUMULIN I CARTRIDGE injection suspension 100 units/ml [LILLY]  
10229 HUMULIN I DISPOSABLE PEN injection suspension 100 units/ml [LILLY]  
27461 INSUMAN BASAL CARTRIDGE injection suspension 100 units/ml [AVENTIS]  
35468 INSUMAN BASAL VIAL injection suspension 100 units/ml [AVENTIS]  
23992 INSUMAN BASAL OPTISET injection suspension 100 units/ml [AVENTIS]  
24795 insulin biphasic aspart cartridge injection suspension 30:70; 100 units/ml   
23099 insulin biphasic aspart disposable pen injection suspension 30:70; 100 units/ml   
7267 NOVOMIX 30 PENFILL injection suspension 100 units/ml [NOVO]  
7228 NOVOMIX 30 FLEXPEN injection suspension 100 units/ml [NOVO]  
28185 insulin biphasic lispro cartridge injection suspension 25:75; 100 units/ml   
31258 insulin biphasic lispro disposable pen injection suspension 25:75; 100 units/ml   
10243 HUMALOG MIX 25 CARTRIDGE injection suspension 100 units/ml [LILLY]  
14270 HUMALOG MIX 25 DISPOSABLE PEN injection suspension 100 units/ml [LILLY]  
14301 insulin detemir cartridge injection solution 100 units/ml   
14330 insulin detemir disposable pen injection solution 100 units/ml   
10259 insulin glargine vial injection solution 100 units/ml   
7400 insulin glargine disposable pen injection solution 100 units/ml   
7393 insulin glargine cartridge injection solution 100 units/ml   
7402 LANTUS VIAL injection solution 100 units/ml [AVENTIS]  
7237 LANTUS OPTISET injection solution 100 units/ml [AVENTIS]  
7266 LANTUS CARTRIDGE injection solution 100 units/ml [AVENTIS]  
7350 insulin isophane porcine vial injection suspension 100 units/ml   
30686 insulin isophane porcine cartridge injection suspension 100 units/ml   
28183 HYPURIN PORCINE ISOPHANE VIAL injection suspension 100 units/ml [CP PHARM] 
14933 HYPURIN PORCINE ISOPHANE CARTRIDGE injection suspension 100 units/ml [CP 
PHARM] 
27280 insulin biphasic isophane porcine vial injection suspension 30:70; 100 units/ml   
36031 insulin biphasic isophane porcine cartridge injection suspension 30:70; 100 
units/ml  
24800 HYPURIN PORCINE 30/70 MIX VIAL injection suspension 100 units/ml [CP PHARM] 
20995 HYPURIN PORCINE 30/70 MIX CARTRIDGE injection suspension 100 units/ml [CP 
PHARM] 
18590 insulin isophane bovine vial injection suspension 100 units/ml   
36066 insulin isophane bovine cartridge injection suspension 100 units/ml   
14340 HYPURIN BOVINE ISOPHANE VIAL injection suspension 100 units/ml [CP PHARM] 
28588 HYPURIN BOVINE ISOPHANE CARTRIDGE injection suspension 100 units/ml [CP 
PHARM] 
13277 MIXTARD 50 PENFILL injection suspension 100 units/ml [NOVO]  
14290 INSULATARD PENFILL injection suspension 100 units/ml [NOVO]  
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14928 INSULATARD VIAL injection suspension 100 units/ml [NOVO]  
10208 INSULATARD INNOLET injection suspension 100 units/ml [NOVO]  
7300 MIXTARD 30 VIAL injection suspension 100 units/ml [NOVO]  
35701 insulin biphasic lispro disposable pen injection suspension 50:50; 100 units/ml   
36146 insulin biphasic lispro cartridge injection suspension 50:50; 100 units/ml   
18593 HUMALOG MIX 50 CARTRIDGE injection suspension 100 units/ml [LILLY]  
35260 LEVEMIR INNOLET injection solution 100 units/ml [NOVO]  
36853 LANTUS SOLOSTAR injection solution 100 units/ml [SANOFI/AVE]  
39086 HUMALOG MIX 50 KWIKPEN injection suspension 100 units/ml [LILLY]  
39006 HUMALOG MIX 25 KWIKPEN injection suspension 100 units/ml [LILLY]  
43953 insulin biphasic lispro vial injection suspension 25:75; 100 units/ml   
42395 HUMALOG MIX 25 VIAL injection suspension 100 units/ml [LILLY]  
43991 HUMULIN M3 KWIKPEN injection suspension 100 units/ml [LILLY]  
43950 HUMULIN I KWIKPEN injection suspension 100 units/ml [LILLY]  
44480 INSUMAN COMB 25 SOLOSTAR injection suspension 100 units/ml [AVENTIS]  
45158 INSUMAN COMB 15 CARTRIDGE injection suspension 100 units/ml [AVENTIS]  
1588 ACTRAPID injection 100 iu/ml [NOVO]  
1840 HUMULIN S injection 100 units/ml [LILLY]  
1842 PORK VELOSULIN injection 100 units/ml [NOVO]  
30209 ACTRAPID MC injection 100 units/ml [ARUN]  
4706 VELOSULIN VIAL injection solution 100 units/ml [NOVO]  
12297 HYPURIN BOVINE NEUTRAL injection 100 units/ml [CP PHARM]  
1592 ACTRAPID PENFILL 100 iu/ml [NOVO]  
1594 ACTRAPID NOVOLET 100 iu/ml [NOVO]  
10572 insulin soluble bovine injection 100 units/ml   
24593 neutral insulin bovine injection 100 iu/ml   
36513 VELOSULIN CARTRIDGE injection 100 units/ml [NOVO]  
17336 NOVOPEN injection device 100 units/ml [NOVO]  
41959 PENJECT injection device 100 units/ml [HYPOGUARD]  
4129 insulin soluble porcine injection 100 units/ml   
24846 PUR-IN NEUTRAL injection 100 units/ml [CP PHARM]  
9565 HUMAJECT S DISPOSABLE PEN injection solution 100 units/ml [LILLY]  
12638 insulin soluble human pyr injection 100 units/ml   
15710 insulin soluble human emp injection 100 units/ml   
12654 insulin soluble human prb injection 100 units/ml   
13622 HYPURIN PORCINE NEUTRAL injection 100 units/ml [CP PHARM]  
22945 INSUMAN RAPID injection 100 iu/ml [AVENTIS]  
9521 PORK ACTRAPID VIAL injection solution 100 units/ml [NOVO]  
26621 insulin soluble human crb injection 100 iu/ml   
27402 insulin soluble human vial injection solution 100 units/ml   
36430 insulin soluble human disposable pen injection solution 100 units/ml   
16129 insulin soluble human cartridge injection solution 100 units/ml   
21235 HUMULIN S VIAL injection solution 100 units/ml [LILLY]  
14944 HUMULIN S CARTRIDGE injection solution 100 units/ml [LILLY]  
22983 INSUMAN RAPID CARTRIDGE injection solution 100 units/ml [AVENTIS]  
23993 INSUMAN RAPID OPTISET injection solution 100 units/ml [AVENTIS]  
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7349 ACTRAPID VIAL injection solution 100 units/ml [NOVO]  
27396 insulin soluble porcine vial injection solution 100 units/ml   
25479 insulin soluble porcine cartridge injection solution 100 units/ml   
26098 HYPURIN PORCINE NEUTRAL VIAL injection solution 100 units/ml [CP PHARM]  
14930 HYPURIN PORCINE NEUTRAL CARTRIDGE injection solution 100 units/ml [CP 
PHARM] 
18592 insulin soluble bovine vial injection solution 100 units/ml   
14938 insulin soluble bovine cartridge injection solution 100 units/ml   
23231 HYPURIN BOVINE NEUTRAL CARTRIDGE injection solution 100 units/ml [CP 
PHARM] 
14339 HYPURIN BOVINE NEUTRAL VIAL injection solution 100 units/ml [CP PHARM]  
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Table B 4 Product codes identifying oral antidiabetes medication 
prescriptions 
Product 
code Product name Drug substance 
9108 TOLBUTAMIDE 250 MG TAB  
16211 TOLBUTAMIDE 100 MG TAB  
22636 TOLBUTAMIDE 1 GM TAB  
41898 GLIBENCLAMIDE  
1254 glibenclamide tablets 5mg  glibenclamide 
2219 glibenclamide tablets 2.5mg  glibenclamide 
4862 DIABETAMIDE tablets 2.5mg [ASHBOURNE] glibenclamide 
7744 DAONIL tablets 5mg [AVENTIS] glibenclamide 
7912 SEMI-DAONIL tablets 2.5mg [AVENTIS] glibenclamide 
8976 EUGLUCON tablets 2.5mg [AVENTIS] glibenclamide 
13331 EUGLUCON tablets 5mg [AVENTIS] glibenclamide 
16602 CALABREN tablets 2.5mg [BERK] glibenclamide 
21424 glibenclamide oral suspension 5mg/5ml  glibenclamide 
21832 DIABETAMIDE tablets 5mg [ASHBOURNE] glibenclamide 
25636 LIBANIL tablets 2.5mg [APS] glibenclamide 
26218 CALABREN tablets 5mg [BERK] glibenclamide 
28708 MALIX tablets 2.5mg [LAGAP] glibenclamide 
30460 MALIX tablets 5mg [LAGAP] glibenclamide 
31474 LIBANIL tablets 5mg [APS] glibenclamide 
34507 GLIBENCLAMIDE tablets 2.5mg [CP PHARM] glibenclamide 
34563 GLIBENCLAMIDE tablets 5mg [CP PHARM] glibenclamide 
34676 GLIBENCLAMIDE tablets 2.5mg [HILLCROSS] glibenclamide 
34706 GLIBENCLAMIDE tablets 2.5mg [IVAX] glibenclamide 
41558 GLIBENCLAMIDE tablets 5mg [TEVA] glibenclamide 
41559 GLIBENCLAMIDE tablets 5mg [HILLCROSS] glibenclamide 
41593 GLIBENCLAMIDE tablets 2.5mg [TEVA] glibenclamide 
32 gliclazide tablets 80mg  gliclazide 
1964 DIAMICRON tablets 80mg [SERVIER] gliclazide 
5627 gliclazide modified release tablet 30mg  gliclazide 
11695 DIAMICRON MR tablets 30mg [SERVIER] gliclazide 
15374 gliclazide oral suspension 40mg/5ml  gliclazide 
17343 GLICLAZIDE tablets 80mg [HILLCROSS] gliclazide 
21564 GLICLAZIDE tablets 80mg [WOCKHARDT] gliclazide 
21892 DIAGLYK tablets 80mg [ASHBOURNE] gliclazide 
29939 GLICLAZIDE tablets 80mg [GEN (UK)] gliclazide 
31212 GLICLAZIDE tablets 80mg [ACTAVIS] gliclazide 
33562 DUCLAZIDE tablets 80mg [DUMEX] gliclazide 
34399 GLICLAZIDE tablets 80mg [IVAX] gliclazide 
34932 GLICLAZIDE tablets 80mg [GENUS] gliclazide 
36856 GLICLAZIDE tablets 80mg [SANDOZ] gliclazide 
40425 NAZDOL MR tablets 30mg [TEVA] gliclazide 
42790 GLICLAZIDE tablets 80mg [MERCK-GEN] gliclazide 
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43065 gliclazide tablets 40mg  gliclazide 
43465 ZICRON tablets 40mg [BRISTOL LB] gliclazide 
44473 EDICIL MR tablets 30mg [RATIOPHARM] gliclazide 
45215 GLICLAZIDE tablets 80mg [NEOLAB] gliclazide 
5276 glimepiride tablets 1mg  glimepiride 
5316 glimepiride tablets 4mg  glimepiride 
5353 glimepiride tablets 2mg  glimepiride 
6337 glimepiride tablets 3mg  glimepiride 
7284 AMARYL tablets 2mg [AVENTIS] glimepiride 
7332 AMARYL tablets 1mg [AVENTIS] glimepiride 
7409 AMARYL tablets 3mg [AVENTIS] glimepiride 
11284 AMARYL tablets 4mg [AVENTIS] glimepiride 
40365 GLIMEPIRIDE tablets 1mg [ACTAVIS] glimepiride 
44738 NIDDARYL tablets 1mg [DEE] glimepiride 
547 glipizide tablets 2.5mg  glipizide 
5636 glipizide tablets 5mg  glipizide 
12513 GLIBENESE tablets 5mg [PFIZER] glipizide 
17698 MINODIAB tablets 5mg [PHARMACIA] glipizide 
17706 MINODIAB tablets 2.5mg [PHARMACIA] glipizide 
29326 GLIPIZIDE tablets 5mg [GEN (UK)] glipizide 
34802 GLIPIZIDE tablets 5mg [IVAX] glipizide 
1965 tolbutamide tablets 500mg  tolbutamide 
11946 tolbutamide injection 50mg/ml  tolbutamide 
12455 RASTINON tablets 500mg [HOECHSTMAR] tolbutamide 
33673 TOLBUTAMIDE tablets 500mg [ACTAVIS] tolbutamide 
34957 TOLBUTAMIDE tablets 500mg [HILLCROSS] tolbutamide 
44304 GLYCONON tablets 500mg [DDSA] tolbutamide 
35144 BYETTA injection 5 micrograms [LILLY] exenatide 
35149 exenatide injection 10micrograms  exenatide 
35150 BYETTA injection 10micrograms [LILLY] exenatide 
35251 exenatide injection 5 micrograms  exenatide 
40642 VICTOZA injection 18mg/3ml [NOVO] liraglutide 
40693 liraglutide injection 18mg/3ml  liraglutide 
5678 nateglinide tablets 120mg  nateglinide 
5989 nateglinide tablets 180mg  nateglinide 
11483 nateglinide tablets 60mg  nateglinide 
15955 STARLIX tablets 120mg [NOVARTIS] nateglinide 
23945 STARLIX tablets 60mg [NOVARTIS] nateglinide 
27125 STARLIX tablets 180mg [NOVARTIS] nateglinide 
548 pioglitazone tablets 15mg  
pioglitazone 
hydrochloride 
9699 pioglitazone tablets 30mg  
pioglitazone 
hydrochloride 
10051 pioglitazone tablets 45mg  
pioglitazone 
hydrochloride 
19472 ACTOS tablets 45mg [TAKEDA] 
pioglitazone 
hydrochloride 
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20287 ACTOS tablets 15mg [TAKEDA] 
pioglitazone 
hydrochloride 
20889 ACTOS tablets 30mg [TAKEDA] 
pioglitazone 
hydrochloride 
9707 repaglinide tablets 1mg  repaglinide 
9748 repaglinide tablets 2mg  repaglinide 
9865 repaglinide tablets 500 micrograms  repaglinide 
11316 NOVONORM tablets 500 micrograms [NOVO] repaglinide 
11321 NOVONORM tablets 1mg [NOVO] repaglinide 
11366 NOVONORM tablets 2mg [NOVO] repaglinide 
35561 PRANDIN tablets 2mg [NOVO] repaglinide 
36774 PRANDIN tablets 1mg [NOVO] repaglinide 
36948 PRANDIN tablets 500 micrograms [NOVO] repaglinide 
41204 saxagliptin tablets 5mg  
saxagliptin 
hydrochloride 
41431 ONGLYZA tablets 5mg [BMS] 
saxagliptin 
hydrochloride 
35022 sitagliptin tablets 100mg  
sitagliptin phosphate 
monohydrate 
35462 JANUVIA tablets 100mg [M S D] 
sitagliptin phosphate 
monohydrate 
37875 vildagliptin tablets 50mg  vildagliptin 
39149 GALVUS tablets 50mg [NOVARTIS] vildagliptin 
43619 sitagliptin with metformin tablets 50mg + 1000mg  
metformin 
hydrochloride/sitaglipti
n phosphate 
monohydrate 
43684 JANUMET tablets 50mg + 1000mg [M S D] 
metformin 
hydrochloride/sitaglipti
n phosphate 
monohydrate 
37874 vildagliptin with metformin tablets 50mg + 850mg  
metformin 
hydrochloride/vildaglipt
in 
37902 vildagliptin with metformin tablets 50mg + 1000mg  
metformin 
hydrochloride/vildaglipt
in 
38551 EUCREAS tablets 50mg + 1000mg [NOVARTIS] 
metformin 
hydrochloride/vildaglipt
in 
39203 EUCREAS tablets 50mg + 850mg [NOVARTIS] 
metformin 
hydrochloride/vildaglipt
in 
18220 pioglitazone with metformin tablets 15mg + 850mg  metformin/pioglitazone 
30316 metformin with pioglitazone tablets 850mg + 15mg  metformin/pioglitazone 
31077 COMPETACT film coated tablets [TAKEDA] metformin/pioglitazone 
2928 METFORMIN HCl 850 MG TAB  
3252 METFORMIN HCl 500 MG TAB  
7815 METFORMIN 800 MG TAB  
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16213 METFORMIN 250 MG TAB  
20810 METFORMIN  
23 metformin tablets 500mg  
metformin 
hydrochloride 
93 metformin tablets 850mg  
metformin 
hydrochloride 
735 metformin oral suspension 100mg/ml  
metformin 
hydrochloride 
7048 metformin modified release tablet 500mg  
metformin 
hydrochloride 
7166 GLUCOPHAGE tablets 500mg [MERCK SER] 
metformin 
hydrochloride 
7610 GLUCOPHAGE tablets 850mg [MERCK SER] 
metformin 
hydrochloride 
11990 metformin oral solution 500mg/5ml  
metformin 
hydrochloride 
16044 GLUCOPHAGE SR tablets 500mg [MERCK SER] 
metformin 
hydrochloride 
25678 GLUCAMET tablets 500mg [OPUS] 
metformin 
hydrochloride 
26258 GLUCAMET tablets 850mg [OPUS] 
metformin 
hydrochloride 
27501 ORABET tablets 500mg [LAGAP] 
metformin 
hydrochloride 
31146 METSOL oral solution 500mg/5ml [ORBIS] 
metformin 
hydrochloride 
33087 METFORMIN tablets 500mg [ACTAVIS] 
metformin 
hydrochloride 
33674 METFORMIN tablets 850mg [HILLCROSS] 
metformin 
hydrochloride 
34004 METFORMIN tablets 500mg [IVAX] 
metformin 
hydrochloride 
34020 METFORMIN tablets 850mg [IVAX] 
metformin 
hydrochloride 
34135 METFORMIN tablets 500mg [M&A PHARM] 
metformin 
hydrochloride 
34323 METFORMIN tablets 500mg [HILLCROSS] 
metformin 
hydrochloride 
34504 METFORMIN tablets 500mg [WOCKHARDT] 
metformin 
hydrochloride 
34598 METFORMIN tablets 500mg [GEN (UK)] 
metformin 
hydrochloride 
34697 METFORMIN tablets 850mg [WOCKHARDT] 
metformin 
hydrochloride 
34742 METFORMIN tablets 850mg [TEVA] 
metformin 
hydrochloride 
34836 METFORMIN tablets 850mg [ACTAVIS] 
metformin 
hydrochloride 
34917 METFORMIN tablets 500mg [TEVA] 
metformin 
hydrochloride 
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38355 metformin modified release tablet 750mg  
metformin 
hydrochloride 
38400 GLUCOPHAGE SR tablets 750mg [MERCK SER] 
metformin 
hydrochloride 
39560 BOLAMYN SR tablets 500mg [TEVA] 
metformin 
hydrochloride 
39598 metformin modified release tablet 1000mg  
metformin 
hydrochloride 
39729 GLUCOPHAGE SR tablets 1000mg [MERCK SER] 
metformin 
hydrochloride 
39988 metformin oral powder 500mg  
metformin 
hydrochloride 
40007 GLUCOPHAGE sachets 1000mg [MERCK SER] 
metformin 
hydrochloride 
40110 GLUCOPHAGE sachets 500mg [MERCK SER] 
metformin 
hydrochloride 
40233 metformin oral powder 1000mg  
metformin 
hydrochloride 
42161 ORABET tablets 500mg [SANDOZ] 
metformin 
hydrochloride 
43270 
METFORMIN sugar free oral solution 500mg/5ml 
[ROSEMONT] 
metformin 
hydrochloride 
44250 METFORMIN oral solution 500mg/5ml [HILLCROSS] 
metformin 
hydrochloride 
45581 METABET SR tablets 500mg [MORNINGSID] 
metformin 
hydrochloride 
22858 acetohexamide tablets 500mg  acetohexamide 
26118 DIMELOR tablets 500mg [LILLY] acetohexamide 
1253 chlorpropamide tablets 100mg  chlorpropamide 
1847 chlorpropamide tablets 250mg  chlorpropamide 
8034 DIABINESE tablets 100mg [PFIZER] chlorpropamide 
8168 DIABINESE tablets 250mg [PFIZER] chlorpropamide 
27969 GLYMESE tablets 250mg [DDSA] chlorpropamide 
12245 GLUTRIL tablets 25mg [ROCHE] glibornuride 
12259 glibornuride tablets 25mg  glibornuride 
8390 gliquidone tablets 30mg  gliquidone 
19658 GLURENORM tablets 30mg [SANOFI S] gliquidone 
10427 tolazamide tablets 250mg  tolazamide 
19336 tolazamide tablets 100mg  tolazamide 
21489 TOLANASE tablets 250mg [PHARMACIA] tolazamide 
22145 TOLANASE tablets 100mg [PHARMACIA] tolazamide 
13628 ROMOZIN tablets 400mg [GLAXO] troglitazone 
24848 glymidine sodium tablets 500mg  glymidine sodium 
469 rosiglitazone tablets 4mg  rosiglitazone maleate 
5227 rosiglitazone tablets 8mg  rosiglitazone maleate 
9662 AVANDIA tablets 4mg [GLAXSK PHA] rosiglitazone maleate 
15232 AVANDIA tablets 8mg [GLAXSK PHA] rosiglitazone maleate 
37617 rosiglitazone tablets 2mg  rosiglitazone maleate 
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6855 AVANDAMET tablets 2mg + 500mg [GLAXSK PHA] 
metformin 
hydrochloride/rosiglitaz
one maleate 
7325 AVANDAMET tablets 4mg + 1000mg [GLAXSK PHA] 
metformin 
hydrochloride/rosiglitaz
one maleate 
7375 rosiglitazone with metformin tablets 4mg + 1000mg  
metformin 
hydrochloride/rosiglitaz
one maleate 
11601 rosiglitazone with metformin tablets 2mg + 500mg  
metformin 
hydrochloride/rosiglitaz
one maleate 
11604 rosiglitazone with metformin tablets 1mg + 500mg  
metformin 
hydrochloride/rosiglitaz
one maleate 
11609 metformin with rosiglitazone tablets 500mg + 1mg  
metformin 
hydrochloride/rosiglitaz
one maleate 
11610 metformin with rosiglitazone tablets 500mg + 2mg  
metformin 
hydrochloride/rosiglitaz
one maleate 
11717 rosiglitazone with metformin tablets 2mg + 1000mg  
metformin 
hydrochloride/rosiglitaz
one maleate 
11737 metformin with rosiglitazone tablets 1000mg + 4mg  
metformin 
hydrochloride/rosiglitaz
one maleate 
11760 metformin with rosiglitazone tablets 1000mg + 2mg  
metformin 
hydrochloride/rosiglitaz
one maleate 
14164 AVANDAMET tablets 2mg + 1000mg [GLAXSK PHA] 
metformin 
hydrochloride/rosiglitaz
one maleate 
17580 AVANDAMET tablets 1mg + 500mg [GLAXSK PHA] 
metformin 
hydrochloride/rosiglitaz
one maleate 
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Appendix C: Codelists for identifying diagnoses of infection 
This Appendix contains the Read codes and ICD-10 codes used to identify diagnoses of 
acute, community-acquired lower respiratory tract infections (and the subset of these 
which identified a pneumonia diagnosis), sepsis, and urinary tract infections. 
Table C 1 Read codes identifying a diagnosis of lower respiratory tract 
infection but not pneumonia 
Read code Read term 
16L..00 Influenza-like symptoms 
1J72.00 Suspected influenza A virus subtype H1N1 infection 
1J72.11 Suspected swine influenza 
1W0..00 Possible influenza A virus H1N1 subtype 
43jQ.00 Avian influenza virus nucleic acid detection 
43jx.00 Parainfluenza type 1 nucleic acid detection 
43jy.00 Parainfluenza type 2 nucleic acid detection 
43jz.00 Parainfluenza type 3 nucleic acid detection 
4J3L.00 Influenza A virus H1N1 subtype detected 
4JU0.00 Influenza H1 virus detected 
4JU2.00 Influenza H3 virus detected 
4JU3.00 Influenza H5 virus detected 
4JU4.00 Influenza A virus, other or untyped strain detected 
4JU5.00 Influenza B virus detected 
4JUF.00 Human parainfluenza virus detected 
4JUK.00 Mycoplasma pneumoniae detected 
65VA.00 Notification of whooping cough 
A33..00 Whooping cough 
A330.00 Bordetella pertussis 
A331.00 Bordetella parapertussis 
A33y.00 Whooping cough - other specified organism 
A33yz00 Other whooping cough NOS 
A33z.00 Whooping cough NOS 
A39y000 Pulmonary nocardiosis 
A3BXA00 Mycoplasma pneumoniae [PPLO] cause/dis classifd/oth chaptr 
A3By100 Eaton's agent infection 
A3By400 Pleuropneumonia-like organism (PPLO) infection 
AB40600 Acute pulmonary histoplasmosis capsulati 
AB42.00 Pulmonary histoplasmosis 
Ayu3A00 [X]Whooping cough, unspecified 
G520300 Acute myocarditis - influenzal 
H04..00 Acute laryngitis and tracheitis 
H041.00 Acute tracheitis 
H041000 Acute tracheitis without obstruction 
H041100 Acute tracheitis with obstruction 
H041z00 Acute tracheitis NOS 
H042.00 Acute laryngotracheitis 
H042.11 Laryngotracheitis 
H042000 Acute laryngotracheitis without obstruction 
H042100 Acute laryngotracheitis with obstruction 
H042z00 Acute laryngotracheitis NOS 
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H04z.00 Acute laryngitis and tracheitis NOS 
H052.00 Pharyngotracheitis 
H053.00 Tracheopharyngitis 
H06..00 Acute bronchitis and bronchiolitis 
H060.00 Acute bronchitis 
H060.11 Acute wheezy bronchitis 
H060300 Acute purulent bronchitis 
H060400 Acute croupous bronchitis 
H060500 Acute tracheobronchitis 
H060600 Acute pneumococcal bronchitis 
H060700 Acute streptococcal bronchitis 
H060800 Acute haemophilus influenzae bronchitis 
H060900 Acute neisseria catarrhalis bronchitis 
H060A00 Acute bronchitis due to mycoplasma pneumoniae 
H060B00 Acute bronchitis due to coxsackievirus 
H060C00 Acute bronchitis due to parainfluenza virus 
H060D00 Acute bronchitis due to respiratory syncytial virus 
H060E00 Acute bronchitis due to rhinovirus 
H060F00 Acute bronchitis due to echovirus 
H060v00 Subacute bronchitis unspecified 
H060w00 Acute viral bronchitis unspecified 
H060x00 Acute bacterial bronchitis unspecified 
H060z00 Acute bronchitis NOS 
H061.00 Acute bronchiolitis 
H061000 Acute capillary bronchiolitis 
H061200 Acute bronchiolitis with bronchospasm 
H061300 Acute exudative bronchiolitis 
H061500 Acute bronchiolitis due to respiratory syncytial virus 
H061600 Acute bronchiolitis due to other specified organisms 
H061z00 Acute bronchiolitis NOS 
H062.00 Acute lower respiratory tract infection 
H06z.00 Acute bronchitis or bronchiolitis NOS 
H06z000 Chest infection NOS 
H06z011 Chest infection 
H06z100 Lower resp tract infection 
H06z112 Acute lower respiratory tract infection 
H06z200 Recurrent chest infection 
H07..00 Chest cold 
H24..11 Chest infection with infectious disease EC 
H27..00 Influenza 
H271.00 Influenza with other respiratory manifestation 
H271000 Influenza with laryngitis 
H271100 Influenza with pharyngitis 
H271z00 Influenza with respiratory manifestations NOS 
H27y.00 Influenza with other manifestations 
H27y000 Influenza with encephalopathy 
H27y100 Influenza with gastrointestinal tract involvement 
H27yz00 Influenza with other manifestations NOS 
H27z.00 Influenza NOS 
H27z.11 Flu like illness 
H27z.12 Influenza like illness 
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H29..00 Avian influenza 
H2A..00 Influenza due to Influenza A virus subtype H1N1 
H2A..11 Influenza A (H1N1) swine flu 
H2y..00 Other specified pneumonia or influenza 
H2z..00 Pneumonia or influenza NOS 
H30..11 Chest infection - unspecified bronchitis 
H3y0.00 Chronic obstruct pulmonary dis with acute lower resp infectn 
H50..00 Empyema 
H500.00 Empyema with fistula 
H500000 Empyema with bronchocutaneous fistula 
H500100 Empyema with bronchopleural fistula 
H500400 Empyema with pleural fistula NOS 
H501.00 Empyema with no fistula 
H501000 Pleural abscess 
H501200 Pleural empyema 
H501300 Lung empyema NOS 
H501400 Purulent pleurisy 
H501500 Pyopneumothorax 
H501600 Pyothorax 
H50z.00 Empyema NOS 
H510900 Pneumococcal pleurisy 
H510A00 Staphylococcal pleurisy 
H510B00 Streptococcal pleurisy 
H511.00 Bacterial pleurisy with effusion 
H511000 Pneumococcal pleurisy with effusion 
H511100 Staphylococcal pleurisy with effusion 
H511z00 Bacterial pleurisy with effusion NOS 
Hyu0400 [X]Flu+oth respiratory manifestations,'flu virus identified 
Hyu0500 [X]Influenza+other manifestations,influenza virus identified 
Hyu0600 [X]Influenza+oth respiratory manifestatns,virus not identifd 
Hyu0700 [X]Influenza+other manifestations, virus not identified 
Hyu1.00 [X]Other acute lower respiratory infections 
Hyu1000 [X]Acute bronchitis due to other specified organisms 
Hyu1100 [X]Acute bronchiolitis due to other specified organisms 
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Table C 2 Read codes identifying a diagnosis of lower respiratory tract 
infection and a diagnosis of pneumonia 
Read code H262.00 ‘Postoperative pneumonia’ identified a post-operative pneumonia. 
Episodes of pneumonia which included this code were classified as hospital-acquired 
infections. 
Read code Read term 
A022200 Salmonella pneumonia 
A203.00 Primary pneumonic plague 
A205.00 Pneumonic plague, unspecified 
A521.00 Varicella pneumonitis 
A54x400 Herpes simplex pneumonia 
A551.00 Postmeasles pneumonia 
A730.00 Ornithosis with pneumonia 
A785000 Cytomegaloviral pneumonitis 
A789300 HIV disease resulting in Pneumocystis carinii pneumonia 
AB24.11 Pneumonia - candidal 
AB40500 Histoplasma capsulatum with pneumonia 
AB41500 Histoplasma duboisii with pneumonia 
AD04.00 Toxoplasma pneumonitis 
AD63.00 Pneumocystosis 
H2...00 Pneumonia and influenza 
H20..00 Viral pneumonia 
H20..11 Chest infection - viral pneumonia 
H200.00 Pneumonia due to adenovirus 
H201.00 Pneumonia due to respiratory syncytial virus 
H202.00 Pneumonia due to parainfluenza virus 
H20y.00 Viral pneumonia NEC 
H20y000 Severe acute respiratory syndrome 
H20z.00 Viral pneumonia NOS 
H21..00 Lobar (pneumococcal) pneumonia 
H21..11 Chest infection - pneumococcal pneumonia 
H22..00 Other bacterial pneumonia 
H22..11 Chest infection - other bacterial pneumonia 
H220.00 Pneumonia due to klebsiella pneumoniae 
H221.00 Pneumonia due to pseudomonas 
H222.00 Pneumonia due to haemophilus influenzae 
H222.11 Pneumonia due to haemophilus influenzae 
H223.00 Pneumonia due to streptococcus 
H223000 Pneumonia due to streptococcus, group B 
H224.00 Pneumonia due to staphylococcus 
H22y.00 Pneumonia due to other specified bacteria 
H22y000 Pneumonia due to escherichia coli 
H22y011 E.coli pneumonia 
H22y100 Pneumonia due to proteus 
H22y200 Pneumonia - Legionella 
H22yX00 Pneumonia due to other aerobic gram-negative bacteria 
H22yz00 Pneumonia due to bacteria NOS 
H22z.00 Bacterial pneumonia NOS 
H23..00 Pneumonia due to other specified organisms 
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H23..11 Chest infection - pneumonia organism OS 
H230.00 Pneumonia due to Eaton's agent 
H231.00 Pneumonia due to mycoplasma pneumoniae 
H232.00 Pneumonia due to pleuropneumonia like organisms 
H233.00 Chlamydial pneumonia 
H23z.00 Pneumonia due to specified organism NOS 
H24..00 Pneumonia with infectious diseases EC 
H240.00 Pneumonia with measles 
H241.00 Pneumonia with cytomegalic inclusion disease 
H242.00 Pneumonia with ornithosis 
H243.00 Pneumonia with whooping cough 
H243.11 Pneumonia with pertussis 
H246.00 Pneumonia with aspergillosis 
H247000 Pneumonia with candidiasis 
H247z00 Pneumonia with systemic mycosis NOS 
H24y.00 Pneumonia with other infectious diseases EC 
H24y000 Pneumonia with actinomycosis 
H24y100 Pneumonia with nocardiasis 
H24y200 Pneumonia with pneumocystis carinii 
H24y300 Pneumonia with Q-fever 
H24y400 Pneumonia with salmonellosis 
H24y500 Pneumonia with toxoplasmosis 
H24y600 Pneumonia with typhoid fever 
H24y700 Pneumonia with varicella 
H24yz00 Pneumonia with other infectious diseases EC NOS 
H24z.00 Pneumonia with infectious diseases EC NOS 
H25..00 Bronchopneumonia due to unspecified organism 
H25..11 Chest infection - unspecified bronchopneumonia 
H26..00 Pneumonia due to unspecified organism 
H26..11 Chest infection - pnemonia due to unspecified organism 
H260.00 Lobar pneumonia due to unspecified organism 
H260000 Lung consolidation 
H261.00 Basal pneumonia due to unspecified organism 
H270.00 Influenza with pneumonia 
H270.11 Chest infection - influenza with pneumonia 
H270000 Influenza with bronchopneumonia 
H270100 Influenza with pneumonia, influenza virus identified 
H270z00 Influenza with pneumonia NOS 
H28..00 Atypical pneumonia 
H530200 Gangrenous pneumonia 
H530300 Abscess of lung with pneumonia 
H540000 Hypostatic pneumonia 
H540100 Hypostatic bronchopneumonia 
H564.00 Bronchiolitis obliterans organising pneumonia 
Hyu0800 [X]Other viral pneumonia 
Hyu0A00 [X]Other bacterial pneumonia 
Hyu0B00 [X]Pneumonia due to other specified infectious organisms 
Hyu0D00 [X]Pneumonia in viral diseases classified elsewhere 
Hyu0H00 [X]Other pneumonia, organism unspecified 
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Table C 3 ICD-10 codes identifying a diagnosis of lower respiratory tract 
infection but not pneumonia 
ICD-10 
code 
Diagnostic name 
A37 Whooping cough 
A37.0 Whooping cough due to Bordetella pertussis 
A37.1 Whooping cough due to Bordetella parapertussis 
A37.8 Whooping cough due to other Bordetella species 
A37.9 Whooping cough, unspecified 
B96.0 Mycoplasma pneumoniae as cause dis class oth chaps 
J04.1 Acute tracheitis 
J04.2 Acute laryngotracheitis 
J09 Influenza due to other identified influenza virus 
J10 Influenza due to identified influenza virus 
J10.1 Influenza with oth resp manifest influenza virus identified 
J10.8 Influenza with other manifest influenza virus identified 
J11 Influenza, virus not identified 
J11.1 Influenza with oth resp manifestation virus not identified 
J11.8 Influenza with other manifestations, virus not identified 
J20 Acute bronchitis 
J20.0 Acute bronchitis due to Mycoplasma pneumoniae 
J20.1 Acute bronchitis due to Haemophilus influenzae 
J20.2 Acute bronchitis due to streptococcus 
J20.3 Acute bronchitis due to coxsackievirus 
J20.4 Acute bronchitis due to parainfluenza virus 
J20.5 Acute bronchitis due to respiratory syncytial virus 
J20.6 Acute bronchitis due to rhinovirus 
J20.7 Acute bronchitis due to echovirus 
J20.8 Acute bronchitis due to other specified organisms 
J20.9 Acute bronchitis, unspecified 
J21 Acute bronchiolitis 
J21.0 Acute bronchiolitis due to respiratory syncytial virus 
J21.8 Acute bronchiolitis due to other specified organisms 
J21.9 Acute bronchiolitis, unspecified 
J22 Unspecified acute lower respiratory infection 
J44.0 Chronic obstructive pulmonary disease with acute lower respiratory 
infection 
J86 Pyothorax 
J86.0 Pyothorax with fistula 
J86.9 Pyothorax without fistula 
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Table C 4 ICD-10 codes identifying a diagnosis of lower respiratory tract 
infection and pneumonia 
ICD-10 
code 
Diagnostic name 
B01.2 Varicella pneumonia 
B05.2 Measles complicated by pneumonia 
B20.6 HIV disease resulting in Pneumocystis carinii pneumonia 
B25.0 Cytomegaloviral pneumonitis 
J10.0 Influenza with pneumonia, influenza virus identified 
J11.0 Influenza with pneumonia, virus not identified 
J12 Viral pneumonia, not elsewhere classified 
J12.0 Adenoviral pneumonia 
J12.1 Respiratory syncytial virus pneumonia 
J12.2 Parainfluenza virus pneumonia 
J12.8 Other viral pneumonia 
J12.9 Viral pneumonia, unspecified 
J13 Pneumonia due to Streptococcus pneumoniae 
J14 Pneumonia due to Haemophilus influenzae 
J15 Bacterial pneumonia, not elsewhere classified 
J15.0 Pneumonia due to Klebsiella pneumoniae 
J15.1 Pneumonia due to Pseudomonas 
J15.2 Pneumonia due to staphylococcus 
J15.3 Pneumonia due to streptococcus, group B 
J15.4 Pneumonia due to other streptococci 
J15.5 Pneumonia due to Escherichia coli 
J15.6 Pneumonia due to other aerobic Gram-negative bacteria 
J15.7 Pneumonia due to Mycoplasma pneumoniae 
J15.8 Other bacterial pneumonia 
J15.9 Bacterial pneumonia, unspecified 
J16 Pneumonia due to other infectious organisms NEC 
J16.0 Chlamydial pneumonia 
J16.8 Pneumonia due to other specified infectious organisms 
J17 Pneumonia in diseases classified elsewhere 
J17.0 Pneumonia in bacterial diseases classified elsewhere 
J17.1 Pneumonia in viral diseases classified elsewhere 
J17.2 Pneumonia in mycoses 
J17.3 Pneumonia in parasitic diseases 
J17.8 Pneumonia in other diseases classified elsewhere 
J18 Pneumonia, organism unspecified 
J18.0 Bronchopneumonia, unspecified 
J18.1 Lobar pneumonia, unspecified 
J18.2 Hypostatic pneumonia, unspecified 
J18.8 Other pneumonia, organism unspecified 
J18.9 Pneumonia, unspecified 
J85.1 Abscess of lung with pneumonia 
U04 Severe acute respiratory syndrome [SARS] 
U04.9 Severe acute respiratory syndrome, unspecified 
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Table C 5 Read codes identifying a diagnosis of sepsis 
Read codes SP20000 ‘Postoperative endotoxic shock’, SP20100 ‘Postoperative septic shock’, 
SP25400 ‘Postoperative septicaemia’ and SP38000 ‘Septic shock due to transfusion’ 
identified sepsis with an iatrogenic source, and episodes of sepsis which contained any 
instances of these codes would have been classified as hospital-acquired infections. 
Read code Read term 
A271100 Erysipelothrix septicaemia 
A384100 Haemophilus influenzae septicaemia 
A384400 Serratia septicaemia 
A3Ay100 Toxic shock syndrome 
A545.00 Herpes simplex septicaemia 
AB2y300 Candidal septicaemia 
R106.00 [D]Unspecified bacteraemia 
R107.00 [D]Unspecified viraemia 
A021.00 Salmonella septicaemia 
A202.00 Septicaemic plague 
A270100 Listeria septicaemia 
A362.00 Meningococcal septicaemia 
A365.00 Meningococcal meningitis with acute meningococcal septicaem 
A366.00 Meningococcal meningitis with meningococcal septicaemia 
A38..00 Septicaemia 
A380.00 Streptococcal septicaemia 
A380000 Septicaemia due to streptococcus group A 
A380100 Septicaemia due to streptococcus group B 
A380300 Septicaemia due to streptococcus pneumoniae 
A380400 Septicaemia due to enterococcus 
A380500 Vancomycin resistant enterococcal septicaemia 
A381.00 Staphylococcal septicaemia 
A381000 Septicaemia due to Staphylococcus aureus 
A381100 Septicaemia due to coagulase-negative staphylococcus 
A382.00 Pneumococcal septicaemia 
A383.00 Septicaemia due to anaerobes 
A384.00 Septicaemia due to other gram negative organisms 
A384000 Gram negative septicaemia NOS 
A384200 Escherichia coli septicaemia 
A384211 E.coli septicaemia 
A384300 Pseudomonas septicaemia 
A384z00 Other gram negative septicaemia NOS 
A38y.00 Other specified septicaemias 
A38z.00 Septicaemia NOS 
A38z.11 Sepsis 
A98yz12 Gonococcal septicaemia 
Ayu3E00 [X]Other streptococcal septicaemia 
Ayu3F00 [X]Streptococcal septicaemia unspecified 
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Ayu3G00 [X]Septicaemia due to other gram-negative organisms 
Ayu3H00 [X]Other specified septicaemia 
Ayu3J00 [X]Septicaemia unspecified 
H5y0100 Tracheostomy sepsis 
J666.00 Biliary sepsis 
R055200 [D]Endotoxic shock 
R055300 [D]Gram-negative shock 
R055500 [D]Septic shock 
R055511 [D]Septicaemic shock 
A362000 Acute meningococcaemia 
A98yz11 Gonococcaemia NOS 
AB25.00 Disseminated, systemic candida 
Ayu3B00 [X]Meningococcaemia, unspecified 
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Table C 6 ICD-10 codes used to identify diagnoses of sepsis 
In addition to these codes, any instances of A49.9 ‘Bacterial infection, unspecified’ or B24.9 
‘Viral infection, unspecified’ with hospital admission date on the same day as a Read code 
for a diagnosis of sepsis in CPRD would have been taken as confirming the primary care 
diagnosis of sepsis on that day. 
ICD-10 code ICD-10 diagnostic name 
A02.1 Salmonella septicaemia 
A20.7 Septicaemic plague 
A22.7 Anthrax septicaemia 
A24.1 Acute and fulminating melioidosis 
A26.7 Erysipelothrix septicaemia 
A32.7 Listerial septicaemia 
A39.1 Waterhouse-Friderichsen syndrome 
A39.2 Acute meningococcaemia 
A39.4 Meningococcaemia, unspecified 
A40.0 Septicaemia due to streptococcus, group A 
A40.1 Septicaemia due to streptococcus, group B 
A40.2 Septicaemia due to streptococcus, group D 
A40.3 Septicaemia due to Streptococcus pneumoniae 
A40.8 Other streptococcal septicaemia 
A40.9 Streptococcal septicaemia, unspecified 
A41.0 Septicaemia due to Staphylococcus aureus 
A41.1 Septicaemia due to other specified staphylococcus 
A41.2 Septicaemia due to unspecified staphylococcus 
A41.3 Septicaemia due to Haemophilus influenzae 
A41.4 Septicaemia due to anaerobes 
A41.5 Septicaemia due to other Gram-negative organisms 
A41.8 Other specified septicaemia 
A41.9 Septicaemia, unspecified 
A42.7 Actinomycotic septicaemia 
A48.3 Toxic shock syndrome 
B00.7 Disseminated herpesviral disease 
B37.7 Candidal septicaemia 
R57.2 Septic shock 
R57.8 Other shock 
R65.0 Systemic Inflammatory response syndrome of infectious origin without 
organ failure 
R65.1 Systemic Inflammatory response syndrome of infectious origin with organ 
failure 
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Table C 7 Read codes used to identify a diagnosis of urinary tract infection 
Read code K190200 ‘Post operative urinary tract infection’ was used to identify episodes 
containing a postoperative urinary tract infection. Any episodes containing this code were 
classified as a hospital-acquired infection. 
Read codes 1J4..00 ‘Suspected UTI’ was used to link other UTI Read codes within a single 
episode, but did not on its own define a UTI. 
Read code Read term 
1AG..00 Recurrent urinary tract infections 
K190.00 Urinary tract infection, site not specified 
K190.11 Recurrent urinary tract infection 
K190300 Recurrent urinary tract infection 
K190311 Recurrent UTI 
K190500 Urinary tract infection 
K190z00 Urinary tract infection, site not specified NOS 
A32y300 Diphtheritic cystitis 
A981100 Acute gonococcal cystitis 
A981111 Bladder gonorrhoea - acute 
K15..00 Cystitis 
K150.00 Acute cystitis 
K152000 Subacute cystitis 
K154500 Cystitis in gonorrhoea 
K154600 Cystitis in moniliasis 
K154700 Cystitis in trichomoniasis 
K155.00 Recurrent cystitis 
K15y200 Abscess of bladder 
K15z.00 Cystitis NOS 
K213.00 Prostatocystitis 
K101.00 Acute pyelonephritis 
K101000 Acute pyelonephritis without medullary necrosis 
K101200 Acute pyelitis 
K101300 Acute pyonephrosis 
K101z00 Acute pyelonephritis NOS 
K102.00 Renal and perinephric abscess 
K102000 Renal abscess 
K102100 Perinephric abscess 
K102200 Renal carbuncle 
K102z00 Renal and perinephric abscess NOS 
K104.00 Xanthogranulomatous pyelonephritis 
K10y.00 Pyelonephritis and pyonephrosis unspecified 
K10y000 Pyelonephritis unspecified 
K10y100 Pyelitis unspecified 
K10y200 Pyonephrosis unspecified 
K10y300 Pyelonephritis in diseases EC 
K10y400 Pyelitis in diseases EC 
K10yz00 Unspecified pyelonephritis NOS 
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Table C 8 Read codes for urethritis used to exclude proteinuria records from 
defining CKD status 
The codes in Table C 7, including Read code K190200 ‘Post operative urinary tract infection’ 
and 1J4..00 ‘Suspected UTI’, together with the following codes for urethritis, were all used 
to exclude proteinuria records from defining CKD status. 
Read code Read term 
A980100 Acute gonococcal urethritis 
A994.00 Nonspecific urethritis 
AD10200 Trichomonal urethritis 
K17..00 Urethritis due to non venereal causes 
K17..11 Periurethritis 
K170.00 Urethral and periurethral abscess 
K170.11 Urethral abscess 
K170000 Urethral abscess unspecified 
K170111 Cowper's gland abscess 
K170200 Urethral gland abscess 
K170300 Periurethral cellulitis 
K170311 Periurethritis 
K170400 Periurethral abscess 
K170z00 Urethral abscess NOS 
K172.00 Candidal urethritis 
K17y.00 Other urethritis 
K17y000 Urethritis unspecified 
K17y100 Urethral syndrome NOS 
K17y200 Skene's glands adenitis 
K17y300 Cowperitis 
K17y600 Verumontanitis 
K17z.00 Urethritis due to non venereal cause NOS 
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Table C 9 ICD-10 codes used to identify a diagnosis of urinary tract infection 
ICD-10 
Code 
Name 
WHO guidance for use (selected)  
N10 Acute tubulo-interstitial nephritis  
Incl.:  Acute: 
 infectious interstitial nephritis 
 pyelitis 
 pyelonephritis 
Use additional code (B95-B97), if desired, to identify infectious agent. 
N12 Tubulo-interstitial nephritis not spec as acute or chronic 
Incl.:Interstitial nephritis NOS 
    Pyelitis NOS 
    Pyelonephritis NOS 
Excl.: calculous pyelonephritis (N20.9) 
N136 Pyonephrosis  
Conditions in N13.0-N13.5 with infection 
Obstructive uropathy with infection 
N151 Renal and perinephric abscess 
N159 Renal tubulo-interstitial disease, unspecified 
Infection of kidney NOS 
Excl.: urinary tract infection NOS (N39.0) 
N300 Acute cystitis 
Use additional code, if desired, to identify infectious agent (B95-B97) or 
responsible external agent (Chapter XX). 
Excl.: prostatocystitis (N41.3) 
N308 Other cystitis 
Abscess of bladder 
N309 Cystitis, unspecified 
N390 Urinary tract infection, site not specified 
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Appendix D: Codelists for identifying chronic kidney 
disease 
This appendix includes Read and ICD-10 codes identifying renal replacement therapy 
(kidney transplant or dialysis), Read codes used to identify proteinuria status, and Read 
codes identifying staged CKD status. 
Table D 1 Read codes identifying renal replacement therapy 
Read code Read term 
14S2.00 H/O: kidney recipient 
7B00.00 Transplantation of kidney 
7B00100 Transplantation of kidney from live donor 
7B00111 Allotransplantation of kidney from live donor 
7B00200 Transplantation of kidney from cadaver 
7B00211 Allotransplantation of kidney from cadaver 
7B00300 Allotransplantation of kidney from cadaver  heart-beating 
7B00400 Allotransplantation kidney from cadaver  heart non-beating 
7B00y00 Other specified transplantation of kidney 
7B00z00 Transplantation of kidney NOS 
7B01511 Excision of rejected transplanted kidney 
7B06300 Exploration of renal transplant 
7B0F.00 Interventions associated with transplantation of kidney 
7B0F100 Pre-transplantation of kidney work-up  recipient 
7B0F200 Pre-transplantation of kidney work-up  live donor 
7B0F400 Post-transplantation of kidney examination  live donor 
8L50.00 Renal transplant planned 
K0B5.00 Renal tubulo-interstitial disordrs in transplant rejectn 
Kyu1C00 [X]Renal tubulo-interstitial disorders/transplant rejection 
SP08011 Det.ren.func.after ren.transpl 
SP08300 Kidney transplant failure and rejection 
TB00100 Kidney transplant with complication  without blame 
TB00111 Renal transplant with complication  without blame 
ZV42000 [V]Kidney transplanted 
14V2.00 H/O: renal dialysis 
14V2.11 H/O: kidney dialysis 
7A60600 Creation of graft fistula for dialysis 
7L1A.00 Compensation for renal failure 
7L1A.11 Dialysis for renal failure 
7L1A000 Renal dialysis 
7L1A011 Thomas intravascular shunt for dialysis 
7L1A100 Peritoneal dialysis 
7L1A200 Haemodialysis NEC 
7L1A300 Haemofiltration 
7L1A400 Automated peritoneal dialysis 
7L1A500 Continuous ambulatory peritoneal dialysis 
7L1A600 Peritoneal dialysis NEC 
7L1Ay00 Other specified compensation for renal failure 
7L1Az00 Compensation for renal failure NOS 
7L1B.00 Placement ambulatory apparatus compensation renal failure 
7L1B.11 Placement ambulatory dialysis apparatus - compens renal fail 
288
[289]  
 
7L1B000 Insertion of ambulatory peritoneal dialysis catheter 
7L1B100 Removal of ambulatory peritoneal dialysis catheter 
7L1By00 Placement ambulatory apparatus- compensate renal failure OS 
7L1C.00 Placement other apparatus for compensation for renal failure 
7L1C000 Insertion of temporary peritoneal dialysis catheter 
7L1Cz00 Placement other apparatus- compensate for renal failure NOS 
TA02000 Accid cut puncture perf h'ge - kidney dialysis 
TA02z00 Accid cut puncture perf h'ge - perfusion NOS 
TA22.00 Failure of sterile precautions during perfusion 
TA22000 Failure of sterile precautions during kidney dialysis 
TB11.00 Kidney dialysis with complication  without blame 
TB11.11 Renal dialysis with complication  without blame 
U612200 [X]Failure sterile precautions dur kidney dialys/other perf 
ZV45100 [V]Renal dialysis status 
ZV56.00 [V]Aftercare involving intermittent dialysis 
ZV56011 [V]Aftercare involving renal dialysis NOS 
ZVu3G00 [X]Other dialysis 
 
Table D 2 ICD-10 codes identifying renal replacement therapy 
ICD-10 code ICD-10 diagnostic name 
T86.1 Kidney transplant failure and rejection 
Z94.0 Kidney transplant status 
Y84.1 Kidney dialysis 
Z49.0 Preparatory care for dialysis 
Z49.1 Extracorporeal dialysis 
Z49.2 Other dialysis 
Z99.2 Dependence on renal dialysis 
 
Table D 3 Read codes identifying a positive test for proteinuria (defined 
proteinuria if no concurrent urinary tract infection) 
Read 
code 
Quality 
Outcomes 
Framework* 
Read term 
4674  Urine protein test = + 
4675  Urine protein test = ++ 
4676  Urine protein test = +++ 
4677  Urine protein test = ++++ 
4678  Proteinuria 
46W0.00  Urine microalbumin positive 
R110.00 Yes [D]Proteinuria 
R110000 Yes [D]Albuminuria 
R110200  [D]Exercise proteinuria 
R110300 Yes [D]Microalbuminuria 
R110z00 Yes [D]Proteinuria NOS 
* The Quality Outcomes Framework financially incentivises recording of these codes 
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Table D 4 Read codes identifying persistent proteinuria or proteinuric disease 
(defined proteinuria irrespective of urinary tract infections) 
Read 
code 
Quality 
Outcomes 
Framework* 
Read term 
1Z17.00  Chronic kidney disease stage 1 with proteinuria 
1Z17.11  CKD stage 1 with proteinuria 
1Z19.00  Chronic kidney disease stage 2 with proteinuria 
1Z19.11  CKD stage 2 with proteinuria 
1Z1B.00 Yes Chronic kidney disease stage 3 with proteinuria 
1Z1B.11 Yes CKD stage 3 with proteinuria 
1Z1D.00 Yes Chronic kidney disease stage 3A with proteinuria 
1Z1D.11 Yes CKD stage 3A with proteinuria 
1Z1F.00 Yes Chronic kidney disease stage 3B with proteinuria 
1Z1F.11 Yes CKD stage 3B with proteinuria 
1Z1H.00 Yes Chronic kidney disease stage 4 with proteinuria 
1Z1H.11 Yes CKD stage 4 with proteinuria 
1Z1K.00 Yes Chronic kidney disease stage 5 with proteinuria 
1Z1K.11 Yes CKD stage 5 with proteinuria 
A844100  Plasmodium malariae malaria with nephropathy 
C10EK00  Type 1 diabetes mellitus with persistent proteinuria 
C10EL00  Type 1 diabetes mellitus with persistent microalbuminuria 
C10EL11  Type I diabetes mellitus with persistent microalbuminuria 
C10FL00  Type 2 diabetes mellitus with persistent proteinuria 
C10FL11  Type II diabetes mellitus with persistent proteinuria 
C10FM00  Type 2 diabetes mellitus with persistent microalbuminuria 
C10FM11  Type II diabetes mellitus with persistent microalbuminuria 
C373600  Nephropathic amyloidosis 
D011100  Vit B12 defic anaemia due to malabsorption with proteinuria 
K00..00  Acute glomerulonephritis 
K00..12  Bright's disease 
K000.00  Acute proliferative glomerulonephritis 
K001.00  Acute nephritis with lesions of necrotising glomerulitis 
K00y.00  Other acute glomerulonephritis 
K00y000  Acute glomerulonephritis in diseases EC 
K00yz00  Other acute glomerulonephritis NOS 
K00z.00  Acute glomerulonephritis NOS 
K01..00  Nephrotic syndrome 
K010.00  Nephrotic syndrome with proliferative glomerulonephritis 
K011.00  Nephrotic syndrome with membranous glomerulonephritis 
K012.00  Nephrotic syndrome+membranoproliferative 
glomerulonephritis 
K013.00  Nephrotic syndrome with minimal change glomerulonephritis 
K013.11  Lipoid nephrosis 
K013.12  Steroid sensitive nephrotic syndrome 
K014.00  Nephrotic syndrome, minor glomerular abnormality 
K015.00  Nephrotic syndrome, focal and segmental glomerular lesions 
K016.00  Nephrotic syndrome, diffuse membranous 
glomerulonephritis 
K017.00  Nephrotic syn difus mesangial prolifertiv glomerulonephritis 
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K018.00  Nephrotic syn,difus endocapilary proliftv glomerulonephritis 
K019.00  Nephrotic syn,diffuse mesangiocapillary glomerulonephritis 
K01A.00  Nephrotic syndrome, dense deposit disease 
K01B.00  Nephrotic syndrome, diffuse crescentic glomerulonephritis 
K01x000  Nephrotic syndrome in amyloidosis 
K01x100  Nephrotic syndrome in diabetes mellitus 
K01x200  Nephrotic syndrome in malaria 
K01x300  Nephrotic syndrome in polyarteritis nodosa 
K01x400  Nephrotic syndrome in systemic lupus erythematosus 
K01x411  Lupus nephritis 
K01y.00  Nephrotic syndrome with other pathological kidney lesions 
K01z.00  Nephrotic syndrome NOS 
K020.00  Chronic proliferative glomerulonephritis 
K021.00  Chronic membranous glomerulonephritis 
K022.00  Chronic membranoproliferative glomerulonephritis 
K023.00  Chronic rapidly progressive glomerulonephritis 
K02y.00  Other chronic glomerulonephritis 
K02y000  Chronic glomerulonephritis + diseases EC 
K02y200  Chronic focal glomerulonephritis 
K02y300  Chronic diffuse glomerulonephritis 
K02yz00  Other chronic glomerulonephritis NOS 
K02z.00  Chronic glomerulonephritis NOS 
K030.00  Proliferative nephritis unspecified 
K031.00  Membranous nephritis unspecified 
K032.00  Membranoproliferative nephritis unspecified 
K032000  Focal membranoproliferative glomerulonephritis 
K032300  Anaphylactoid glomerulonephritis 
K032400  Familial glomerulonephritis in Alport's syndrome 
K032500  Other familial glomerulonephritis 
K032600  Berger's IgA or IgG nephropathy 
K032y00  Nephritis unsp+OS membranoprolif glomerulonephritis lesion 
K032y11  Hypocomplementaemic persistent glomerulonephritis NEC 
K032y13  Mesangioproliferative glomerulonephritis NEC 
K032y14  Mesangiocapillary glomerulonephritis NEC 
K032y15  Mixed membranous and proliferative glomerulonephritis NEC 
K032z00  Nephritis unsp+membranoprolif glomerulonephritis lesion 
NOS 
K033.00  Rapidly progressive nephritis unspecified 
K03T.00  Tubulo-interstit nephritis, not specif as acute or chron 
K03U.00  Unspecif nephr synd, diff concentric glomerulonephritis 
K03V.00  Unspecified nephritic syndrome, dense deposit disease 
K03W.00  Unsp nephrit synd, diff endocap prolif glomerulonephritis 
K03X.00  Unsp nephrit synd, diff mesang prolif glomerulonephritis 
K03y200  Other interstitial nephritis 
K03z.00  Unspecified glomerulonephritis NOS 
K072.00  Glomerulosclerosis 
K08y500  Acute interstitial nephritis 
K0A..00  Glomerular disease 
K0A0.00  Acute nephritic syndrome 
K0A0000  Acute nephritic syndrome  minor glomerular abnormality 
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K0A0100  Acute nephritic syndrome, focal+segmental glomerular 
lesions 
K0A0200  Acute nephritic syn, diffuse membranous glomerulonephritis 
K0A0300  Acut neph syn, diffuse mesangial prolifrative glomnephritis 
K0A0400  Ac neph syn difus endocaplry prolifrative glomerulonephritis 
K0A0500  Acute neph syn, diffuse mesangiocapillary glomerulonephritis 
K0A0600  Acute nephritic syndrome  dense deposit disease 
K0A0700  Acute nephrotic syndrm diffuse crescentic glomerulonephritis 
K0A1.00  Rapidly progressive nephritic syndrome 
K0A1100  Rapid progres nephritic syn focal+segmental glomerulr lesion 
K0A1200  Rapid progres neph syn diffuse membranous 
glomerulonephritis 
K0A1300  Rpd prog neph syn df mesangial prolifratv glomerulonephritis 
K0A1600  Rapid progressive nephritic syndrome, dense deposit disease 
K0A1700  Rapid progres nephritic syn df crescentic glomerulonephritis 
K0A2100  Recur+persist haematuria, focal+segmental glomerular 
lesions 
K0A2200  Recur+persist haematuria difus membranous 
glomerulonephritis 
K0A2300  Recur+persist haemuria df mesangial prolif glomerulnephritis 
K0A2500  Recur+persist hmuria df mesangiocapilary glomerulonephritis 
K0A2700  Recur+persist haematuria difus crescentic glomerulonephritis 
K0A3.00  Chronic nephritic syndrome 
K0A3000  Chronic nephritic syndrome, minor glomerular abnormality 
K0A3100  Chronic nephritic syndrm focal+segmental glomerular lesions 
K0A3200  Chron nephritic syndrom difuse membranous 
glomerulonephritis 
K0A3300  Chron neph syn difus mesangial prolifrtiv glomerulonephritis 
K0A3500  Chronic neph syn difus mesangiocapillary glomerulonephritis 
K0A3600  Chronic nephritic syndrome, dense deposit disease 
K0A3700  Chronic nephritic syn diffuse crescentic glomerulonephritis 
K0A4.00  Isolated proteinuria with specified morphological lesion 
K0A4100  Isolatd proteinur/specifd morphlgcl les foc+seg glom lesn 
K0A4200  Isolatd proteinur/specfd morphlgcl les df membrn glomneph 
K0A4300  Isoltd prteinur/spcfd morph lesn df mesngl prolf glomneph 
K0A4500  Isoltd prteinur+specfd morph les df mesangiocap glomnephr 
K0A4W00  Isolated proteinuria  with unspecified morpholog changes 
K0A4X00  Isolated proteinuria  with oth specif morpholog changes 
K0A5000  Hereditary nephropathy NEC, minor glomerular abnormality 
K0A5100  Hereditary nephropathy NEC,focal+segmnt glomerular lesion 
K0A5200  Hereditry nephropathy NEC,difus membran glomerulnephritis 
K0A5300  Heredtry nephrpthy NEC difus mesangial prolif glomnephrit 
K0A5600  Hereditary nephropathy, NEC, dense deposit disease 
K136.00  Benign postural proteinuria 
K136.11  Orthostatic proteinuria 
K190X00  Persistent proteinuria, unspecified 
Kyu0900  [X]Unsp nephrit synd, diff mesang prolif glomerulonephritis 
Kyu5G00  [X]Persistent proteinuria, unspecified 
* The Quality Outcomes Framework financially incentivises recording of these codes 
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Table D 5 Read codes identifying chronic kidney disease by stage 
Read code 
Quality 
Outcomes 
Framework* Read term 
1Z10.00  Chronic kidney disease stage 1 
1Z18.00  Chronic kidney disease stage 1 without proteinuria 
1Z17.00  Chronic kidney disease stage 1 with proteinuria 
1Z17.11  CKD stage 1 with proteinuria 
1Z11.00  Chronic kidney disease stage 2 
1Z1A.00  Chronic kidney disease stage 2 without proteinuria 
1Z19.00  Chronic kidney disease stage 2 with proteinuria 
1Z19.11  CKD stage 2 with proteinuria 
1Z1A.11  CKD stage 2 without proteinuria 
1Z1F.11 Yes CKD stage 3B with proteinuria 
1Z12.00 Yes Chronic kidney disease stage 3 
1Z1C.00 Yes Chronic kidney disease stage 3 without proteinuria 
1Z1E.00 Yes Chronic kidney disease stage 3A without proteinuria 
1Z15.00 Yes Chronic kidney disease stage 3A 
1Z16.00 Yes Chronic kidney disease stage 3B 
1Z1G.00 Yes Chronic kidney disease stage 3B without proteinuria 
1Z1B.00 Yes Chronic kidney disease stage 3 with proteinuria 
1Z1D.00 Yes Chronic kidney disease stage 3A with proteinuria 
1Z1F.00 Yes Chronic kidney disease stage 3B with proteinuria 
1Z1C.11 Yes CKD stage 3 without proteinuria 
1Z1B.11 Yes CKD stage 3 with proteinuria 
1Z1E.11 Yes CKD stage 3A without proteinuria 
1Z1D.11 Yes CKD stage 3A with proteinuria 
1Z1G.11 Yes CKD stage 3B without proteinuria 
1Z13.00 Yes Chronic kidney disease stage 4 
1Z1J.00 Yes Chronic kidney disease stage 4 without proteinuria 
1Z1H.00 Yes Chronic kidney disease stage 4 with proteinuria 
1Z1H.11 Yes CKD stage 4 with proteinuria 
1Z1J.11 Yes CKD stage 4 without proteinuria 
1Z14.00 Yes Chronic kidney disease stage 5 
1Z1K.00 Yes Chronic kidney disease stage 5 with proteinuria 
1Z1L.00 Yes Chronic kidney disease stage 5 without proteinuria 
1Z1K.11 Yes CKD stage 5 with proteinuria 
1Z1L.11 Yes CKD stage 5 without proteinuria 
K05..12  End stage renal failure 
K050.00  End stage renal failure 
K0D..00  End-stage renal disease 
* The Quality Outcomes Framework financially incentivises recording of these codes 
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Appendix E. Supplementary analyses to Paper 3, examining 
the association of CKD with incidence of community-
acquired infections  
This appendix presents sensitivity analyses of the association of CKD with incidence of 
community-acquired infection as discussed in Chapter 8.  
Tables E1 and E2 present an exploration of whether there was interaction between (1) and 
and eGFR or (2) proteinuria and eGFR in the models of LRTI and pneumonia incidence.  
Table E 1 Association of estimated glomerular filtration rate (eGFR) with 
infection incidence among different categories of age and proteinuria status 
 eGFR Age (years) History of proteinuria 
  <75 
IRR (95% CI) 
≥75 
IRR (95% CI) 
No 
IRR (95% CI) 
Yes 
IRR (95% CI) 
LRTI     
 <15 1.54 (1.31–1.81) 1.51 (1.34–1.70) 1.81 (1.55–2.12) 1.37 (1.21–1.55) 
 15-29 1.08 (1.01–1.17) 1.27 (1.22–1.33) 1.27 (1.21–1.33) 1.17 (1.11–1.24) 
 30-44 1.11 (1.07–1.15) 1.12 (1.09–1.15) 1.12 (1.09–1.16) 1.09 (1.05–1.13) 
 45-59 1.06 (1.03–1.08) 1.03 (1.01–1.06) 1.05 (1.03–1.07) 1.03 (1.00–1.06) 
 ≥60 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
P (interaction)* <0.001 0.02 
Pneumonia     
 <15 2.92 (1.79–4.76) 3.62 (2.79–4.69) 5.13 (3.61–7.29) 2.72 (2.02–3.67) 
 15-29 2.22 (1.78–2.78) 2.06 (1.85–2.29) 2.27 (1.99–2.58) 1.92 (1.66–2.21) 
 30-44 1.54 (1.33–1.78) 1.37 (1.27–1.48) 1.41 (1.30–1.54) 1.39 (1.24–1.55) 
 45-59 1.05 (0.94–1.17) 1.02 (0.95–1.10) 1.02 (0.95–1.10) 1.06 (0.95–1.17) 
 ≥60 1 (reference) 1 (reference) 1 (reference) 1 (reference) 
P (interaction)* 0.56 0.03 
eGFR, estimated glomerular filtration rate (ml/min/1.73m2); IRR incidence rate ratio; 95% CI 95% confidence 
interval 
* P (interaction) is a likelihood ratio test with the null hypothesis that there is no interaction between the two 
relevant variables 
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Table E 2 Effect of age and proteinuria with infection incidence among 
difference categories of estimated glomerular filtration rate (eGFR) 
 eGFR Age (years) History of proteinuria 
  <75 
IRR (95% CI) 
≥75 
IRR (95% CI) 
No 
IRR (95% CI) 
Yes 
IRR (95% CI) 
LRTI     
 <15 1 (reference) 1.07 (0.88–1.30) 1 (reference) 0.83 (0.68–1.00) 
 15-29 1 (reference) 1.28 (1.18–1.38) 1 (reference) 1.01 (0.95–1.08) 
 30-44 1 (reference) 1.10 (1.05–1.15) 1 (reference) 1.06 (1.02–1.10) 
 45-59 1 (reference) 1.07 (1.04–1.10) 1 (reference) 1.07 (1.04–1.11) 
 ≥60 1 (reference) 1.09 (1.07–1.11) 1 (reference) 1.09 (1.07–1.12) 
Pneumonia     
 <15 1 (reference) 2.74 (1.59–4.72) 1 (reference) 0.68 (1.43–1.06) 
 15-29 1 (reference) 2.05 (1.62–2.59) 1 (reference) 1.08 (0.91–1.28) 
 30-44 1 (reference) 1.96 (1.70–2.28) 1 (reference) 1.26 (1.12–1.41) 
 45-59 1 (reference) 2.16 (1.93–2.41) 1 (reference) 1.32 (1.20–1.46) 
 ≥60 1 (reference) 2.21 (2.06–2.38) 1 (reference) 1.28 1.18–
1.38) 
eGFR, estimated glomerular filtration rate (ml/min/1.73m2); IRR incidence rate ratio; 95% CI 95% confidence 
interval 
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Table E 3 Sensitivity analysis of the association between markers of chronic 
kidney disease and infection incidence limited to patients with HES linkage 
 Infections 
n 
Person 
years 
Minimally 
adjusted rate 
ratio (95% CI)1 
Fully adjusted 
rate ratio (95% 
CI) 2 
 
P value 3 
 
Lower respiratory tract infection (LRTI) n=113,085 
eGFR  
<15 342 1,387 1.84 (1.61–2.10) 1.45 (1.28–1.66) <0.0001 
15-29 3,155 14,594 1.45 (1.38–1.53) 1.20 (1.14–1.26) 
30-44 10,036 56,525 1.22 (1.18–1.26) 1.09 (1.06–1.12) 
45-59 18,166 123,818 1.06 (1.03–1.08) 1.12 (0.99–1.04) 
60+ 38,162 288,786 1 (reference) 1 (reference) 
Proteinuria  
Yes 19,053 118,201 1.13 (1.11–1.16) 1.08 (1.05–1.11) <0.0001 
No 50,808 366,908 1 (reference) 1 (reference) 
Total 69,861 485,109  
Pneumonia n=113,105  
eGFR  
<15 75 1,404 5.26 (3.98–6.95) 3.61 (2.75–4.75) <0.0001 
15-29 474 14,784 2.46 (2.18–2.78) 1.84 (1.63–2.07) 
30-44 1,085 57,164 1.45 (1.33–1.57) 1.21 (1.11–1.32) 
45-59 1,406 125,061 1.00 (0.93–1.07) 0.94 (0.87–1.01) 
60+ 2,593 291,457 1 (reference) 1 (reference) 
Proteinuria  
Yes 1,890 119,452 1.39 (1.30–1.49) 1.28 (1.20–1.37) <0.0001 
No 3,743 370,418 1 (reference) 1 (reference) 
Total 5,633 489,871  
Sepsis n=113,106  
eGFR  
<15 19 1,406 6.55 (3.91–10.98) 4.82 (2.88–8.08) <0.0001 
15-29 117 14,796 3.71 (2.95–4.68) 2.78 (2.20–3.53) 
30-44 229 57,204 1.82 (1.52–2.16) 1.52 (1.27–1.82) 
45-59 287 125,116 1.51 (0.99–1.34) 1.07 (0.92–1.25) 
60+ 499 291,568 1 (reference) 1 (reference) 
Proteinuria  
Yes 380 119,518 1.29 (1.13–1.48) 1.20 (1.04–1.37) 0.01 
No 771 370,572 1 (reference) 1 (reference) 
Total 1,151 490,090  
HES, Hospital Episode Statistics; 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate 
(ml/min/1.73m2) 
1. Adjusted for age, sex, practice IMD, and calendar year pre/post 2004 
2. Adjusted for age, sex, practice IMD, calendar year pre/post 2004, comorbidities (updated), smoking 
(baseline), and characteristics of diabetes (baseline) 
3. Likelihood ratio test 
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Table E 4 Sensitivity analysis of the association between markers of chronic 
kidney disease and infection incidence limited to first occurrence of each infection 
only 
 Infections 
n 
Person 
years 
Minimally 
adjusted rate 
ratio (95% CI)1 
Fully adjusted 
rate ratio (95% 
CI) 2 
 
P value 
3 
 
Lower respiratory tract infection (LRTI) n=191,672 
eGFR  
<15 269 1,752 2.06 (1.79–2.38) 1.64 (1.42–1.88) <0.0001 
15-29 2,185 17,473 1.56 (1.48–1.65) 1.26 (1.19–1.32) 
30-44 7,311 71,741 1.23 (1.20–1.27) 1.08 (1.05–1.11) 
45-59 14,335 160,949 1.08 (1.05–1.10) 1.02 (1.00–1.04) 
60+ 31,976 390,543 1 (reference) 1 (reference) 
Proteinuria  
Yes 13,649 149,771 1.15 (1.12–1.18) 1.09 (1.07–1.12) <0.0001 
No 42,427 492,687 1 (reference) 1 (reference) 
Total 56,076 642,457  
Pneumonia n= 191,706  
eGFR  
<15 90 2,488 3.68 (2.94–4.51) 3.17 (2.50–4.01) <0.0001 
15-29 586 24,690 2.15 (1.95–2.38) 1.77 (1.59–1.96) 
30-44 1,365 95,568 1.29 (1.29–1.48) 1.20 (1.12–1.29) 
45-59 1,795 204,579 1.01 (0.95–1.07) 0.95 (0.90–1.01) 
60+ 3,259 479,906 1 (reference) 1 (reference) 
Proteinuria  
Yes 2,365 201,310 1.32 (1.25–1.40) 1.29 (1.21–1.36) <0.0001 
No 4,730 605,921 1 (reference) 1 (reference) 
Total 7,095 807,231  
Sepsis n= 191,708  
eGFR  
<15 39 2,535 7.58 (5.20–11.04) 6.27 (4.25–9.27) <0.0001 
15-29 180 25,195 3.30 (2.71–4.02) 2.67 (2.19–3.26) 
30-44 372 96,908 1.80 (1.57–2.07) 1.54 (1.34–1.77) 
45-59 78 206,365 1.19 (1.06–1.34) 1.11 (0.99–1.26) 
60+ 833 483,174 1 (reference) 1 (reference) 
Proteinuria  
Yes 681 203,904 1.45 (1.30–1.62) 1.38 (1.24–1.55) <0.0001 
No 1,221 610,272 1 (reference) 1 (reference) 
Total 1,902 814,176  
95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate (ml/min/1.73m2) 
1. Adjusted for age, sex, practice IMD, and calendar year pre/post 2004 
2. Adjusted for age, sex, practice IMD, calendar year pre/post 2004, comorbidities (updated), smoking 
(baseline), and characteristics of diabetes (baseline) 
3. Likelihood ratio test 
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Table E 5 Sensitivity analysis of the association between markers of chronic 
kidney disease and infection incidence limited to time from 1 April 2004 onwards 
 Infections 
n 
Person 
years 
Minimally adjusted 
rate ratio (95% CI)1 
Fully adjusted 
rate ratio (95% 
CI) 2 
 
P3 
 
Lower respiratory tract infection (LRTI) n=173,152 
eGFR  
<15 461 1,935 1.71 (1.52–1.92) 1.44 (1.29–1.61) <0.0001 
15-29 3,952 19,375 1.35 (1.52–1.92) 1.17 (1.12–1.22) 
30-44 12,345 73,044 1.16 (1.13–1.42) 1.05 (1.03–1.08) 
45-59 21,785 151,508 1.05 (1.03–1.07) 1.02 (1.00–1.04) 
60+ 49,265 373,352 1 (reference) 1 (reference) 
Proteinuria  
Yes 26,562 171,338 1.12 (1.09–1.14) 1.06 (1.0–1.09) <0.0001 
No 61,246 447,877 1 (reference) 1 (reference) 
Total 87,808 619,215  
Pneumonia n=173,181  
eGFR  
<15 74 1,965 3.82 (2.01–.03) 2.83 (2.16–3.70) <0.0001 
15-29 487 19,642 2.07 (1.84–2.32) 1.63 (1.45–1.83) 
30-44 1,156 73,897 1.33 (1.22–1.44) 1.13 (1.05–1.23) 
45-59 1,469 153,084 0.95 (0.89–1.02) 0.91 (0.85–0.97) 
60+ 2,943 376,967 1 (reference) 1 (reference) 
Proteinuria  
Yes 2,259 173,216 1.40 (1.32–1.49) 1.29 (1.21–1.37) <0.0001 
No 3,870 452,339 1 (reference) 1 (reference) 
Total 6,129 625,555  
Sepsis n=173,185  
eGFR  
<15 34 1,966 7.87 (5.30–11.69) 5.99 (4.03–8.90) <0.0001 
15-29 143 19,657 3.06 (2.50–3.75) 2.38 (1.94–2.93) 
30-44 303 73,939 1.75 (1.51–2.04) 1.49 (1.28–1.74) 
45-59 380 153,143 1.16 (1.02–1.33) 1.10 (0.96–1.25) 
60+ 702 377,089 1 (reference) 1 (reference) 
Proteinuria  
Yes 606 173,294 1.43 (1.28–1.60) 1. 32 (1.18–1.48) <0.0001 
No 956 452,499 1 (reference) 1 (reference) 
Total 1,562 625,793  
95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate (ml/min/1.73m2) 
1. Adjusted for age, sex, practice IMD, and calendar year pre/post 2004 
2. Adjusted for age, sex, practice IMD, calendar year pre/post 2004, comorbidities (updated), smoking 
(baseline), and characteristics of diabetes (baseline) 
3. Likelihood ratio test 
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